0001839998-23-000007.txt : 20231114 0001839998-23-000007.hdr.sgml : 20231114 20231114172846 ACCESSION NUMBER: 0001839998-23-000007 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: American Oncology Network, Inc. CENTRAL INDEX KEY: 0001839998 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40177 FILM NUMBER: 231408127 BUSINESS ADDRESS: STREET 1: 14543 GLOBAL PKWY #110 CITY: FORT MYERS STATE: FL ZIP: 33913 BUSINESS PHONE: 833-886-1725 MAIL ADDRESS: STREET 1: 14543 GLOBAL PKWY #110 CITY: FORT MYERS STATE: FL ZIP: 33913 FORMER COMPANY: FORMER CONFORMED NAME: Digital Transformation Opportunities Corp. DATE OF NAME CHANGE: 20210111 10-Q 1 aonc-20230930.htm 10-Q aonc-20230930
00018399982023Q312-31FALSEhttp://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrentP60MP10YP5D00018399982023-01-012023-09-300001839998us-gaap:CommonClassAMember2023-01-012023-09-300001839998us-gaap:WarrantMember2023-01-012023-09-300001839998us-gaap:CommonClassAMember2023-11-09xbrli:shares0001839998us-gaap:CommonClassBMember2023-11-0900018399982023-09-30iso4217:USD00018399982022-12-310001839998us-gaap:SeriesAPreferredStockMember2023-09-30iso4217:USDxbrli:shares0001839998us-gaap:CommonClassAMember2023-09-300001839998us-gaap:CommonClassBMember2023-09-300001839998us-gaap:CapitalUnitClassAMember2023-09-300001839998us-gaap:CapitalUnitClassAMember2022-12-310001839998aonc:CapitalUnitClassA1Member2023-09-300001839998aonc:CapitalUnitClassA1Member2022-12-310001839998us-gaap:CapitalUnitClassBMember2023-09-300001839998us-gaap:CapitalUnitClassBMember2022-12-310001839998us-gaap:RelatedPartyMember2023-09-300001839998us-gaap:RelatedPartyMember2022-12-310001839998aonc:PatientServiceMember2023-07-012023-09-300001839998aonc:PatientServiceMember2022-07-012022-09-300001839998aonc:PatientServiceMember2023-01-012023-09-300001839998aonc:PatientServiceMember2022-01-012022-09-300001839998us-gaap:ProductAndServiceOtherMember2023-07-012023-09-300001839998us-gaap:ProductAndServiceOtherMember2022-07-012022-09-300001839998us-gaap:ProductAndServiceOtherMember2023-01-012023-09-300001839998us-gaap:ProductAndServiceOtherMember2022-01-012022-09-3000018399982023-07-012023-09-3000018399982022-07-012022-09-3000018399982022-01-012022-09-300001839998us-gaap:RelatedPartyMember2023-07-012023-09-300001839998us-gaap:RelatedPartyMember2022-07-012022-09-300001839998us-gaap:RelatedPartyMember2023-01-012023-09-300001839998us-gaap:RelatedPartyMember2022-01-012022-09-3000018399982023-06-300001839998us-gaap:MemberUnitsMemberus-gaap:CapitalUnitClassAMember2023-06-300001839998aonc:CapitalUnitClassA1Memberus-gaap:MemberUnitsMember2023-06-300001839998us-gaap:CapitalUnitClassBMemberus-gaap:MemberUnitsMember2023-06-300001839998us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300001839998us-gaap:NoncontrollingInterestMember2023-06-300001839998us-gaap:RetainedEarningsMember2023-06-300001839998aonc:CapitalUnitClassA1Memberus-gaap:MemberUnitsMember2023-07-012023-09-300001839998us-gaap:RetainedEarningsMember2023-07-012023-09-300001839998us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-07-012023-09-300001839998us-gaap:CapitalUnitClassBMemberus-gaap:MemberUnitsMember2023-07-012023-09-300001839998us-gaap:MemberUnitsMemberaonc:CapitalUnitClassB1Member2023-07-012023-09-300001839998us-gaap:NoncontrollingInterestMember2023-07-012023-09-3000018399982023-09-212023-09-300001839998us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-09-212023-09-300001839998us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-09-212023-09-300001839998us-gaap:MemberUnitsMemberus-gaap:CapitalUnitClassAMember2023-09-212023-09-300001839998aonc:CapitalUnitClassA1Memberus-gaap:MemberUnitsMember2023-09-212023-09-300001839998us-gaap:CapitalUnitClassBMemberus-gaap:MemberUnitsMember2023-09-212023-09-300001839998us-gaap:MemberUnitsMemberaonc:CapitalUnitClassB1Member2023-09-212023-09-300001839998us-gaap:AdditionalPaidInCapitalMember2023-09-212023-09-300001839998us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-09-212023-09-300001839998us-gaap:RetainedEarningsMember2023-09-212023-09-300001839998us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-09-300001839998us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-09-300001839998us-gaap:CapitalUnitClassBMemberus-gaap:MemberUnitsMember2023-09-300001839998us-gaap:AdditionalPaidInCapitalMember2023-09-300001839998us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-09-300001839998us-gaap:NoncontrollingInterestMember2023-09-300001839998us-gaap:RetainedEarningsMember2023-09-300001839998us-gaap:MemberUnitsMemberus-gaap:CapitalUnitClassAMember2022-12-310001839998aonc:CapitalUnitClassA1Memberus-gaap:MemberUnitsMember2022-12-310001839998us-gaap:CapitalUnitClassBMemberus-gaap:MemberUnitsMember2022-12-310001839998us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001839998us-gaap:RetainedEarningsMember2022-12-3100018399982023-01-012023-09-200001839998us-gaap:RetainedEarningsMember2023-01-012023-09-200001839998aonc:CapitalUnitClassA1Memberus-gaap:MemberUnitsMember2023-01-012023-09-200001839998us-gaap:NoncontrollingInterestMember2023-01-012023-09-200001839998us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-09-200001839998us-gaap:CapitalUnitClassBMemberus-gaap:MemberUnitsMember2023-01-012023-09-200001839998us-gaap:MemberUnitsMemberaonc:CapitalUnitClassB1Member2023-01-012023-09-200001839998us-gaap:MemberUnitsMemberus-gaap:CapitalUnitClassAMember2022-06-300001839998aonc:CapitalUnitClassA1Memberus-gaap:MemberUnitsMember2022-06-300001839998us-gaap:CapitalUnitClassBMemberus-gaap:MemberUnitsMember2022-06-300001839998us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001839998us-gaap:RetainedEarningsMember2022-06-3000018399982022-06-300001839998us-gaap:RetainedEarningsMember2022-07-012022-09-300001839998us-gaap:CapitalUnitClassBMemberus-gaap:MemberUnitsMember2022-07-012022-09-300001839998us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001839998us-gaap:MemberUnitsMemberus-gaap:CapitalUnitClassAMember2022-09-300001839998aonc:CapitalUnitClassA1Memberus-gaap:MemberUnitsMember2022-09-300001839998us-gaap:CapitalUnitClassBMemberus-gaap:MemberUnitsMember2022-09-300001839998us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001839998us-gaap:RetainedEarningsMember2022-09-3000018399982022-09-300001839998us-gaap:MemberUnitsMemberus-gaap:CapitalUnitClassAMember2021-12-310001839998aonc:CapitalUnitClassA1Memberus-gaap:MemberUnitsMember2021-12-310001839998us-gaap:CapitalUnitClassBMemberus-gaap:MemberUnitsMember2021-12-310001839998us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001839998us-gaap:RetainedEarningsMember2021-12-3100018399982021-12-310001839998us-gaap:RetainedEarningsMember2022-01-012022-09-300001839998us-gaap:CapitalUnitClassBMemberus-gaap:MemberUnitsMember2022-01-012022-09-300001839998us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300001839998us-gaap:SeriesAPreferredStockMember2023-01-012023-09-300001839998us-gaap:SeriesAPreferredStockMember2022-01-012022-09-30aonc:practiceaonc:state0001839998aonc:AONLLCMember2023-09-20xbrli:pure0001839998aonc:DigitalTransformationOpportunitiesCorpDTOCMemberus-gaap:CommonClassBMember2023-09-200001839998us-gaap:CommonClassAMember2023-09-202023-09-200001839998aonc:LegacyAONShareholdersMemberaonc:AONLLCMember2023-09-200001839998aonc:NewAONAONIncMemberaonc:AONLLCMember2023-09-200001839998aonc:NewAONAONIncMemberus-gaap:SeriesAPreferredStockMemberaonc:AONLLCMember2023-09-200001839998us-gaap:CommonClassAMemberaonc:AONLLCMember2023-09-200001839998us-gaap:CommonClassAMemberaonc:DTOCUnredeemedShareholdersMember2023-09-200001839998us-gaap:CommonClassAMemberaonc:DTOCSponsorMember2023-09-200001839998aonc:LegacyAONShareholdersMemberus-gaap:CommonClassBMember2023-09-200001839998us-gaap:SeriesAPreferredStockMemberaonc:AEAGrowthManagementLPMember2023-09-200001839998aonc:ClassBPrefundedWarrantsMemberaonc:LegacyAONShareholdersMember2023-09-200001839998aonc:SponsorEarnoutSharesMember2023-09-202023-09-200001839998aonc:SponsorEarnoutSharesMember2023-09-200001839998aonc:DTOCSponsorMemberaonc:PublicWarrantMember2023-09-200001839998us-gaap:CommonClassAMemberaonc:DTOCSponsorMemberaonc:PublicWarrantMember2023-09-200001839998aonc:DTOCSponsorMemberaonc:PublicWarrantMember2023-09-202023-09-200001839998aonc:DTOCSponsorMemberaonc:PrivatePlacementWarrantsMember2023-09-200001839998aonc:ClassBPrefundedWarrantsMemberaonc:AONLLCMember2023-09-200001839998aonc:ClassBPrefundedWarrantsMemberus-gaap:CommonClassBMemberaonc:AONLLCMember2023-09-200001839998us-gaap:CommonClassBMemberaonc:AONLLCMember2023-09-200001839998aonc:AONLLCMember2023-07-012023-09-300001839998aonc:AONLLCMember2023-01-012023-09-300001839998aonc:TemporaryEquityMemberaonc:AONLLCMember2023-01-012023-09-300001839998aonc:AONLLCMember2022-12-310001839998aonc:AONLLCMember2022-07-012022-09-300001839998aonc:AONLLCMember2022-01-012022-09-300001839998aonc:ParticipatingThreshold1Member2023-09-300001839998aonc:ParticipatingThreshold2Member2023-09-300001839998aonc:ParticipatingThreshold3Member2023-09-300001839998us-gaap:SeriesAPreferredStockMemberaonc:AONLLCMember2023-09-300001839998aonc:AONLLCMemberaonc:NewAONAONIncMember2023-09-212023-09-300001839998aonc:LegacyAONShareholdersMemberaonc:AONLLCMember2023-09-212023-09-300001839998aonc:LegacyAONShareholdersMemberaonc:AONLLCMember2023-01-012023-09-200001839998aonc:LegacyAONShareholdersMemberaonc:AONLLCMember2022-01-012022-09-300001839998aonc:MIBAMember2023-05-012023-05-31aonc:segment0001839998aonc:PatientVisitsMember2023-07-012023-09-300001839998aonc:PatientVisitsMember2022-07-012022-09-300001839998aonc:PatientVisitsMember2023-01-012023-09-300001839998aonc:PatientVisitsMember2022-01-012022-09-300001839998aonc:ClinicalTrialsMember2023-07-012023-09-300001839998aonc:ClinicalTrialsMember2022-07-012022-09-300001839998aonc:ClinicalTrialsMember2023-01-012023-09-300001839998aonc:ClinicalTrialsMember2022-01-012022-09-300001839998aonc:OCPManagementArizonaLLPMember2023-01-012023-01-310001839998aonc:OCPManagementArizonaLLPMember2023-01-310001839998us-gaap:PreferredClassAMember2023-01-012023-09-300001839998us-gaap:SeriesCPreferredStockMember2023-06-072023-06-070001839998us-gaap:SeriesCPreferredStockMember2023-06-070001839998us-gaap:SeriesCPreferredStockMember2023-01-012023-09-300001839998us-gaap:ProfessionalMalpracticeLiabilityMember2023-01-012023-09-300001839998us-gaap:DirectorsAndOfficersLiabilityInsuranceMember2023-01-012023-09-300001839998aonc:PublicWarrantMember2023-09-300001839998aonc:PrivatePlacementWarrantsMember2023-09-300001839998aonc:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-09-300001839998us-gaap:MeasurementInputPriceVolatilityMemberaonc:PrivatePlacementWarrantsMember2023-09-300001839998aonc:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-09-300001839998aonc:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2023-09-300001839998aonc:AONIncMember2023-09-30aonc:person0001839998aonc:AONCommonUnitholdersMember2023-09-3000018399982023-09-202023-09-200001839998aonc:PublicAndPrivateWarrantsMember2023-09-212023-09-300001839998aonc:AONCentralMemberaonc:PhysiciansMember2023-01-012023-09-300001839998aonc:AONCentralMember2023-01-012023-09-300001839998aonc:MIBAMember2023-04-012023-06-300001839998aonc:MIBAMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-04-012023-06-300001839998us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-09-300001839998us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-12-310001839998aonc:NorthernArizonaHematologyAndOncologyMember2022-01-012022-01-010001839998aonc:NorthernArizonaHematologyAndOncologyMember2023-09-300001839998aonc:NorthernArizonaHematologyAndOncologyMember2022-12-310001839998us-gaap:FairValueInputsLevel1Memberaonc:OvernightRepurchaseAgreementsMember2023-09-300001839998us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-09-300001839998us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-09-300001839998us-gaap:FairValueInputsLevel1Member2023-09-300001839998us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2023-09-300001839998us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-09-300001839998us-gaap:FairValueInputsLevel2Member2023-09-300001839998us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-12-310001839998us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2022-12-310001839998us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2022-12-310001839998us-gaap:FairValueInputsLevel2Member2022-12-310001839998aonc:IntravenousDrugsMember2023-09-300001839998aonc:IntravenousDrugsMember2022-12-310001839998aonc:OralPharmaceuticalsMember2023-09-300001839998aonc:OralPharmaceuticalsMember2022-12-310001839998us-gaap:LeaseholdImprovementsMember2023-09-300001839998us-gaap:LeaseholdImprovementsMember2022-12-310001839998aonc:FurnitureFixturesAndEquipmentMember2023-09-300001839998aonc:FurnitureFixturesAndEquipmentMember2022-12-310001839998aonc:MedicalEquipmentMember2023-09-300001839998aonc:MedicalEquipmentMember2022-12-310001839998us-gaap:ComputerEquipmentMember2023-09-300001839998us-gaap:ComputerEquipmentMember2022-12-310001839998aonc:SignsMember2023-09-300001839998aonc:SignsMember2022-12-310001839998us-gaap:AutomobilesMember2023-09-300001839998us-gaap:AutomobilesMember2022-12-310001839998us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-09-300001839998us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-12-310001839998us-gaap:ConstructionInProgressMember2023-09-300001839998us-gaap:ConstructionInProgressMember2022-12-310001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2023-09-300001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2022-12-310001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2021-04-302021-04-300001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMemberaonc:AlternateBaseRateMember2021-04-302021-04-300001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2021-04-300001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMemberaonc:DebtInstrumentThresholdLimitPeriodOneMember2021-04-302021-04-300001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMemberaonc:DebtInstrumentThresholdLimitPeriodTwoMember2021-04-302021-04-300001839998us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMember2021-04-300001839998us-gaap:LineOfCreditMemberaonc:LondonInterbankOfferedRateLIBOR1Memberus-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMember2021-04-302021-04-300001839998us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberaonc:AlternateBaseRateMemberaonc:PNCLineOfCreditMember2021-04-302021-04-300001839998us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMember2021-04-302021-04-300001839998us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMember2023-01-012023-09-300001839998us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMember2022-01-012022-12-310001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2021-07-290001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2022-02-140001839998us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMember2022-02-140001839998us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMemberaonc:BloombergShortTermBankYieldIndexMember2022-02-142022-02-140001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2022-02-142022-02-140001839998us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMember2022-08-150001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMemberaonc:DebtInstrumentThresholdLimitPeriodOneMember2023-09-302023-09-30aonc:lease0001839998aonc:A2024NotesReceivableNote2Member2023-09-300001839998aonc:A2024NotesReceivableNote2Member2022-12-310001839998aonc:A2024NotesReceivableNote2Member2019-05-010001839998aonc:A2024NotesReceivableNote3Member2023-09-300001839998aonc:A2024NotesReceivableNote3Member2022-12-310001839998aonc:A2024NotesReceivableNote3Member2019-06-010001839998aonc:A2023NotesReceivableNote6Member2023-09-300001839998aonc:A2023NotesReceivableNote6Member2022-12-310001839998aonc:A2023NotesReceivableNote6Member2020-05-220001839998aonc:A2025NotesReceivableNote8Member2023-09-300001839998aonc:A2025NotesReceivableNote8Member2022-12-310001839998aonc:A2025NotesReceivableNote8Member2020-05-010001839998aonc:A2023NotesReceivableNote9Member2023-09-300001839998aonc:A2023NotesReceivableNote9Member2022-12-310001839998aonc:A2023NotesReceivableNote9Member2022-01-24aonc:office0001839998us-gaap:RelatedPartyMemberaonc:SubsidiaryUnderCommonControlOfClassA1MemberMember2023-07-012023-09-300001839998us-gaap:RelatedPartyMemberaonc:SubsidiaryUnderCommonControlOfClassA1MemberMember2022-07-012022-09-300001839998us-gaap:RelatedPartyMemberaonc:SubsidiaryUnderCommonControlOfClassA1MemberMember2023-01-012023-09-300001839998us-gaap:RelatedPartyMemberaonc:SubsidiaryUnderCommonControlOfClassA1MemberMember2022-01-012022-09-300001839998us-gaap:RelatedPartyMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsTotalMemberaonc:SubsidiaryUnderCommonControlOfClassA1MemberMember2023-07-012023-09-300001839998us-gaap:RelatedPartyMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsTotalMemberaonc:SubsidiaryUnderCommonControlOfClassA1MemberMember2022-07-012022-09-300001839998us-gaap:RelatedPartyMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsTotalMemberaonc:SubsidiaryUnderCommonControlOfClassA1MemberMember2023-01-012023-09-300001839998us-gaap:RelatedPartyMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsTotalMemberaonc:SubsidiaryUnderCommonControlOfClassA1MemberMember2022-01-012022-09-300001839998us-gaap:RelatedPartyMemberaonc:SubsidiaryUnderCommonControlOfClassA1MemberMember2023-09-300001839998us-gaap:RelatedPartyMemberaonc:SubsidiaryUnderCommonControlOfClassA1MemberMember2022-12-310001839998us-gaap:RelatedPartyMemberus-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberaonc:SubsidiaryUnderCommonControlOfClassA1MemberMember2022-01-012022-12-310001839998us-gaap:RelatedPartyMemberus-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberaonc:SubsidiaryUnderCommonControlOfClassA1MemberMember2023-01-012023-09-300001839998aonc:AONLLCMemberus-gaap:CommonClassAMember2022-12-310001839998aonc:CommonClassA1Memberaonc:AONLLCMember2022-12-310001839998us-gaap:CommonClassBMemberaonc:AONLLCMember2022-12-310001839998us-gaap:CommonClassBMemberaonc:AONLLCMember2022-01-012022-12-310001839998us-gaap:CommonClassAMember2023-06-300001839998us-gaap:CommonClassAMember2022-06-300001839998us-gaap:CommonClassAMember2022-12-310001839998us-gaap:CommonClassAMember2021-12-310001839998us-gaap:CommonClassAMember2023-07-012023-09-300001839998us-gaap:CommonClassAMember2022-07-012022-09-300001839998us-gaap:CommonClassAMember2023-01-012023-09-300001839998us-gaap:CommonClassAMember2022-01-012022-09-300001839998us-gaap:CommonClassAMember2023-09-300001839998us-gaap:CommonClassAMember2022-09-300001839998aonc:CommonClassA1Member2023-06-300001839998aonc:CommonClassA1Member2022-06-300001839998aonc:CommonClassA1Member2022-12-310001839998aonc:CommonClassA1Member2021-12-310001839998aonc:CommonClassA1Member2023-07-012023-09-300001839998aonc:CommonClassA1Member2022-07-012022-09-300001839998aonc:CommonClassA1Member2023-01-012023-09-300001839998aonc:CommonClassA1Member2022-01-012022-09-300001839998aonc:CommonClassA1Member2023-09-300001839998aonc:CommonClassA1Member2022-09-300001839998us-gaap:CommonClassBMember2023-06-300001839998us-gaap:CommonClassBMember2022-06-300001839998us-gaap:CommonClassBMember2022-12-310001839998us-gaap:CommonClassBMember2021-12-310001839998us-gaap:CommonClassBMember2023-07-012023-09-300001839998us-gaap:CommonClassBMember2022-07-012022-09-300001839998us-gaap:CommonClassBMember2023-01-012023-09-300001839998us-gaap:CommonClassBMember2022-01-012022-09-300001839998us-gaap:CommonClassBMember2023-09-300001839998us-gaap:CommonClassBMember2022-09-300001839998aonc:CommonStockClassB1Member2023-06-012023-07-310001839998aonc:CommonStockClassB1Member2023-07-012023-09-300001839998us-gaap:SeriesAPreferredStockMemberaonc:AEAGrowthManagementLPMember2023-09-202023-09-200001839998us-gaap:CommonClassCMember2023-01-012023-09-300001839998us-gaap:CommonClassCMember2023-06-072023-06-070001839998us-gaap:CommonClassCMember2023-06-300001839998aonc:OptionFeatureMember2023-07-012023-09-300001839998us-gaap:SeriesAPreferredStockMember2023-09-202023-09-200001839998aonc:StockholdersMember2023-09-300001839998us-gaap:SeriesAPreferredStockMemberaonc:StockholdersMember2023-09-300001839998us-gaap:SeriesAPreferredStockMemberaonc:StockholdersMember2023-01-012023-09-300001839998aonc:NewAONAONIncMember2023-09-300001839998aonc:NewAONAONIncMember2023-01-012023-09-300001839998aonc:DividendsPaidEventPriorToJune72024Memberus-gaap:SeriesAPreferredStockMember2023-01-012023-09-300001839998us-gaap:SeriesAPreferredStockMemberaonc:DividendsPaidEventPriorToJune72025AfterJune72024Member2023-01-012023-09-300001839998aonc:DividendsPaidEventPriorToJune72026AfterJune72025Memberus-gaap:SeriesAPreferredStockMember2023-01-012023-09-300001839998us-gaap:SeriesAPreferredStockMemberaonc:DividendsPaidEventPriorToJune72027AfterJune72026Member2023-01-012023-09-300001839998us-gaap:SeriesAPreferredStockMemberaonc:DividendsPaidEventPriorToJune72028AfterJune72027Member2023-01-012023-09-300001839998aonc:DividendsPaidEventAfterJune72028Memberus-gaap:SeriesAPreferredStockMember2023-01-012023-09-300001839998us-gaap:CommonClassAMember2020-03-042020-03-040001839998aonc:CommonClassA1Member2020-03-042020-03-040001839998us-gaap:CommonClassAMember2023-06-072023-06-070001839998aonc:CommonClassA1Member2023-06-072023-06-070001839998aonc:AntiDilutionFeatureMember2023-07-012023-09-300001839998aonc:AntiDilutionFeatureMember2023-01-012023-09-300001839998aonc:CommonClassA1Member2023-09-212023-09-210001839998us-gaap:CommonClassAMember2023-06-070001839998us-gaap:CommonClassAMember2023-09-210001839998aonc:CommonClassA1Member2023-09-202023-09-200001839998aonc:CommonClassA1Member2023-06-072023-09-200001839998us-gaap:SeriesAPreferredStockMember2023-01-012023-09-300001839998us-gaap:CommonClassBMember2023-01-012023-09-300001839998aonc:ClassBPrefundedWarrantsMember2023-01-012023-09-300001839998aonc:PublicAndPrivateWarrantsMember2023-01-012023-09-300001839998aonc:LegacyAONShareholdersMemberaonc:AONLLCMember2023-09-300001839998aonc:LegacyAONShareholdersMemberaonc:AONLLCMember2023-01-012023-09-300001839998us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001839998us-gaap:RetainedEarningsMember2023-01-012023-09-300001839998aonc:AONLLCMemberaonc:NewAONAONIncMember2023-09-200001839998aonc:LegacyAONShareholdersMemberaonc:AONLLCMember2023-09-200001839998aonc:AONLLCMember2023-09-200001839998aonc:AONLLCMemberaonc:NewAONAONIncMember2023-09-300001839998aonc:AONLLCMember2023-09-300001839998aonc:AONLLCMember2023-09-212023-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
or
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number 001-04321
American Oncology Network, Inc.
(Exact name of registrant as specified in its charter)
Delaware85-3984427
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
14543 Global Parkway, Suite 110, Fort Myers, Florida
33913
(Address of Principal Executive Offices)(Zip Code)
(833) 886-1725
Registrant's telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Class A common stock, par value $0.0001, per shareAONCThe Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per shareAONCWThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.:
Large accelerated fileroAccelerated filero
Non-accelerated filerxSmaller reporting companyx
Emerging growth companyx
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x
As of November 9, 2023, the registrant had outstanding 9,550,099 shares of Class A common stock, inclusive of the Sponsor Earnout shares, and 25,109,551 shares of Class B common stock.

TABLE OF CONTENTS
Page

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “Form 10-Q”), including, without limitation, statements under the headings “Management's Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, including statements about the financial condition, results of operations, earnings outlook and prospects of American Oncology Network, Inc. (“AON”, “New AON”, “AON Inc.”, or the “Company”). Any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements are based on current expectations and projections about future events and various assumptions. AON cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on AON’s forward-looking statements.

These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of AON), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in AON’s filings with the Securities and Exchange Commission, including “Risk Factors” in the Company’s most recent proxy statement, prospectus, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The risks described in the “Risk Factors” sections are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can AON assess the impact of all such risk factors on the business of AON, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statement. The statements made herein are made as of the date of this press release and, except as may be required by law, AON undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.

Part I - Financial Information
Item 1. Financial Statements

American Oncology Network, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
($ in thousands, except share and per share data)
As of September 30,
2023		As of December 31,
2022
Assets
Current assets
Cash and cash equivalents$51,653 $26,926 
Short-term marketable securities26,034 9,851 
Patient accounts receivable, net141,039 136,098 
Inventories37,844 36,476 
Other receivables36,747 28,201 
Prepaid expenses and other current assets3,445 2,670 
Current portion of notes receivable - related parties1,630 1,797 
Total current assets298,392 242,019 
Property and equipment, net36,240 31,980 
Operating lease right-of-use assets, net (1)46,138 43,724 
Notes receivable - related parties1,504 2,076 
Other assets7,055 5,199 
Goodwill and intangibles, net1,230 1,230 
Deferred tax asset, net3,455 - 
Total assets$394,014 $326,228 
Liabilities, Mezzanine Equity, and Stockholders' Equity
Current liabilities
Accounts payable (2)$120,383 $106,495 
Accrued compensation related costs16,210 7,466 
Accrued other22,977 17,800 
Income tax payable1,211 - 
Current portion of operating lease liabilities (3)7,123 9,177 
Total current liabilities167,904 140,938 
Long-term debt, net80,425 80,301 
Long-term operating lease liabilities (4)42,261 37,224 
Other long-term liabilities10,333 5,749 
Total liabilities300,923 264,212 
Mezzanine equity
Series A convertible preferred stock; $0.0001 par value; 7,500,000 shares authorized; 6,651,610 issued and outstanding at September 30, 2023, with an aggregate liquidation preference of $66,649,130 at September 30, 2023.
64,986 - 
Redeemable noncontrolling interest369,329 -
Stockholders' equity
Class A Common Stock; $0.0001 par value; 200,000,000 shared authorized; 9,453,604 shares issued and outstanding at September 30, 2023
1 - 
Class B Common Stock; $0.0001 par value; 100,000,000 shared authorized; 25,109,551 shares issued and outstanding at September 30, 2023
3 - 
Class A Units; 0 Units outstanding at September 30, 2023 and 19,495,376 Units outstanding at December 31, 2022
- 7,725 
Class A-1 Units; 0 Units outstanding at September 30, 2023 and 1,842,520 Units outstanding at December 31, 2022
- 28,500 
Class B Units; 0 Units outstanding at September 30, 2023 and 4,703,628 Units outstanding at December 31, 2022
- 80 
Additional paid-in capital- - 
Accumulated other comprehensive income (loss)21 (117)
Retained earnings (deficit)(341,357)25,828 
Total stockholders' equity(341,332)62,016 
 Noncontrolling interest108 - 
Total liabilities, mezzanine equity, and stockholders' equity$394,014 $326,228 
(1)Includes related party operating right-of-use assets, net of $11,476 and $13,077 at September 30, 2023 and December 31, 2022, respectively
(2)Includes amounts due to related party of $112,740 and $102,113 at September 30, 2023 and December 31, 2022, respectively
(3)Includes related party current portion of operating lease liabilities of $1,912 and $1,836 at September 30, 2023 and December 31, 2022, respectively
(4)Includes related party long-term operating lease liabilities of $9,994 and $11,631 at September 30, 2023 and December 31, 2022, respectively
The accompanying notes are an integral part of these condensed consolidated financial statements.
1
American Oncology Network, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
($ in thousands, except share and per share data)
Three Months Ended September 30,Nine Months Ended
September 30,
2023202220232022
Revenue
Patient service revenue, net$332,195 $293,612 $945,681 $840,507 
Other revenue4,110 3,712 9,322 8,765 
Total revenue336,305 297,324 955,003 849,272 
Costs and expenses
Cost of revenue (1)310,894 267,647 880,827 780,658 
General and administrative expenses (2)25,199 23,432 72,831 66,155 
Transaction expenses24,603 151 29,886 151 
Total costs and expenses360,696 291,230 983,544 846,964 
Income (loss) from operations(24,391)6,094 (28,541)2,308 
Other income (expense)
Interest expense(1,532)(924)(4,500)(2,034)
Interest income373 49 499 104 
Other (expense) income, net(3,309)388 (7,689)849 
Income (loss) before income taxes, equity loss in affiliate, and noncontrolling interest(28,859)5,607 (40,231)1,227 
Income tax expense315 - 315 - 
Income (loss) before equity loss in affiliate and noncontrolling interest(29,174)5,607 (40,546)1,227 
Equity in loss of affiliate(31)- (251)- 
Net income (loss) before noncontrolling interest (29,205)5,607 (40,797)1,227 
Net income (loss) and noncontrolling interest attributable to Legacy AON Shareholders prior to the reverse recapitalization(15,489)5,607 (27,081)1,227 
Net loss attributable to noncontrolling interest(11,924)- (11,924)- 
Net loss attributable to Class A Common Stockholders$(1,792)$- $(1,792)$- 
Loss per share of Class A Common Stock:
Basic$(0.61)$- $(0.61)$- 
Diluted$(0.61)$- $(0.61)$- 
Weighted average shares of Class A Common Stock Outstanding:
Basic6,614,229 - 6,614,229 - 
Diluted6,614,229 - 6,614,229 - 
Other comprehensive income (loss):
Unrealized gains (losses) on marketable securities102 (77)190 (161)
Other comprehensive gain (loss)102 (77)190 (161)
Comprehensive income (loss)$(29,103)$5,530 $(40,607)$1,066 
Other comprehensive income (loss) attributable to Legacy AON Shareholders(15,398)5,530 (26,902)1,066 
Other comprehensive loss attributable to noncontrolling interests
(11,915)— (11,915)— 
Total comprehensive loss attributable to Class A Common Stockholders
$(1,790)$— $(1,790)$— 
2

(1)Includes related party inventory expense of $271,790 and $236,077 and $777,478 and $682,671 for the three and nine months ended September 30, 2023 and 2022, respectively.
(2)Includes related party rent of $679 and $655 and $2,037 and $2,037 for the three and nine months ended September 30, 2023 and 2022, respectively.
The accompanying notes are an integral part of these condensed consolidated financial statements. 
3
American Oncology Network, Inc.
Condensed Consolidated Statements of Mezzanine and Stockholders’ Equity
(Unaudited)
($ in thousands, except share and per share data)
Mezzanine Equity - Class C Units exchanged for Series A Preferred Stock (2)
NCI(1)
Class A Common
 Stock		Class B Common StockClass A
Units		Class A-1
Units		Class B UnitsClass B-1 Units
In thousands (including share and per share data)Stock$Stock$Stock$Units$Units$Units$Units$
APIC(1)
AOCI(1)
Noncontrolling InterestRetained
Earnings (Deficit)		Total
Equity (Deficit)
Three Months Ended September 30, 2023
Balances at June 30, 20236,50062,897- ----19,4957,725 2,28231,040 4,70480 - - - (29)134 5,803 $44,753 
Activity prior to reverse recapitalization
Issuance of additional Class A-1 Units pursuant to the Anti-Dilution Feature--- ------ 7197,185 - - - - - - - - $7,185 
Tax distributions--- ------ -- - - - - - - (1,045)$(1,045)
Capital contribution from noncontrolling interest member-------- -- - - - - - - - $- 
Accumulated Other Comprehensive Income--- ------ -- - - - - 90 - - $90 
Equity based compensation--- ------ -- 91110 1,047 4,864 - - - - $4,874 
Net loss-------- -- - - - - - - (26)(15,464)$(15,490)
Reverse Recapitalization, net1522,089 36,873 6,6141 25,1103 (19,495)(7,725)(3,000)(38,225)(5,615)(90)(1,047)(4,864)17,602 (42)- (2,089)$(35,429)
Activity after reverse recapitalization
Other comprehensive income-- 9 ------ -- - - - - - 2 - - $2 
Net loss after the reverse recapitalization-- (11,924)------ -- - - - - - - - (1,792)$(1,792)
Fair value adjustment to redeemable noncontrolling interest--344,371 ------------(17,602)--(326,769)$(344,371)
Balances at September 30, 20236,652$64,986 $369,329 6,614 $1 25,110 $3 -$- -$- - $- - $- $- $21 $108 $(341,356)$(341,223)
(1) The acronyms in the tables above are defined as follows:
APIC - Accumulated paid in capital
AOCI - Accumulated other comprehensive income
NCI - Mezzanine equity classified noncontrolling interest
(2) This activity reflects the issuance of the AON LLC Class C Units, the conversion of AON LLC Class C Units to AON LLC Series A Preferred Units, and the exchange of AON LLC Series A Preferred Units for Series A Preferred Stock, in accordance with the Business Combination. Refer to Note - 1 for the description of the Business Combination and Note 12 for the summary of equity instruments. .

The accompanying notes are an integral part of these condensed consolidated financial statements. 
4
Mezzanine Equity - Class C Units exchanged for Series A Preferred Stock (2)
NCI(1)
Class A Common
 Stock		Class B Common StockClass A
Units		Class A-1
Units		Class B UnitsClass B-1 Units
In thousands (including share and per share data)Stock$Stock$Stock$Units$Units$Units$Units$
APIC(1)
AOCI(1)
Noncontrolling InterestRetained
Earnings (Deficit)		Total
Equity (Deficit)
Nine Months Ended September 30, 2023
Balances at December 31, 2022--- ----19,4957,725 1,84328,500 4,70480 - - - (117)- 25,828 $62,016 
Activity prior to reverse recapitalization
Issuance of Class C Units, net of offering costs6,50062,897- - - - - - - - - - - - - - - - - $- 
Class A and A-1 preferred returns--- ------ -- - - - - - - - (8,174)$(8,174)
Issuance of additional Class A-1 Units pursuant to the Anti-Dilution Feature--- ------ 1,1589,725 - - - - - - - - $9,725 
Tax distributions--- ------ -- - - - - - - (1,305)$(1,305)
Capital contribution from noncontrolling interest member-------- -- - - - - - 134 - $134 
Accumulated Other Comprehensive Income--- ------ -- - - - - 178 - - $178 
Equity based compensation--- ------ -- 91110 1,047 4,864 - - - - $4,874 
Net loss-------- -- - - - - - - (26)(27,055)$(27,081)
Reverse Recapitalization, net1522,08936,873 6,6141 25,1103 (19,495)(7,725)(3,000)(38,225)(5,615)(90)(1,047)(4,864)17,602 (42)- (2,089)$(35,429)
Activity after reverse recapitalization
Other comprehensive income--9 ------ -- - - - - - 2 - - $2 
Net loss after the reverse recapitalization--(11,924)------ -- - - - - - - - (1,792)$(1,792)
Fair value adjustment to redeemable noncontrolling interest--344,371------------(17,602)--(326,769)$(344,371)
Balances at September 30, 20236,652$64,986 $369,329 6,614 $1 25,110 $3 -$- -$- - $- - $- $- $21 $108 $(341,356)$(341,223)
(1) The acronyms in the tables above are defined as follows:
APIC - Accumulated paid in capital
AOCI - Accumulated other comprehensive income
NCI - Mezzanine equity classified noncontrolling interest
(2) This activity reflects the issuance of the AON LLC Class C Units, the conversion of AON LLC Class C Units to AON LLC Series A Preferred Units, and the exchange of AON LLC Series A Preferred Units for Series A Preferred Stock, in accordance with the Business Combination. Refer to Note - 1 for the description of the Business Combination and Note 12 for the summary of equity instruments. .

The accompanying notes are an integral part of these condensed consolidated financial statements. 
5
In thousands (including share and unit data)Class AClass A-1Class B
Three Months Ended September 30, 2022Units$Units$$
AOCI(1)
Retained
Earnings		Total
Equity
Balances at June 30, 202219,495$7,725 1,843$28,500 $90 $(84)$18,859 $55,090 
Activity prior to reverse recapitalization
Net Income attributable to Legacy AON Shareholders-- -- - - 5,607 5,607 
Equity-based compensation attributable to Legacy AON Shareholders-- -- 5 - - 5 
Other comprehensive income attributable to Legacy AON Shareholders-- -- - (77)- (77)
Balances at September 30, 202219,495$7,725 1,843$28,500 $95 $(161)$24,466 $60,625 
Class AClass A-1Class B
In thousands (including share and unit data)Units$Units$$
AOCI(1)
Retained
Earnings		Total
Equity
Nine Months Ended September 30, 2022
Balances at December 31, 202119,495$7,725 1,843$28,500 $80 $- $23,239 $59,544 
Activity prior to reverse recapitalization
Net Income attributable to Legacy AON Shareholders-- -- - - 1,227 1,227 
Equity-based compensation attributable to Legacy AON Shareholders-- -- 15 - - 15 
Other comprehensive income attributable to Legacy AON Shareholders-- -- - (161)- (161)
Balances at September 30, 202219,495$7,725 1,843$28,500 $95 $(161)$24,466 $60,625 
(1) The acronyms in the table above are defined as follows:
AOCI - Accumulated other comprehensive loss
The accompanying notes are an integral part of these condensed consolidated financial statements. 
6
American Oncology Network, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
($ in thousands, except share and per share data)
Nine Months Ended
September 30,
20232022
Cash flows from operating activities
Net income (loss)$(40,797)$1,227 
Adjustments to reconcile net income (loss) to net cash provided by operating activities
Depreciation and amortization6,368 5,318 
Amortization of debt issuance costs570 458 
Deferred income taxes75 - 
Amortization of operating right-of-use assets (1)6,194 7,766 
Changes in fair value adjustments of warrants and derivative liabilities9,334 - 
Equity-based compensation4,875 15 
Equity in loss of affiliate251 - 
Gain on sale of property and equipment(2)- 
Changes in operating assets and liabilities, net of reverse recapitalization:
Patient accounts receivable, net(4,941)(15,223)
Inventories (2)(1,367)876 
Prepaid expenses and other current assets(775)641 
Other receivables(8,546)(211)
Other assets(2,107)(376)
Accounts payable (3)13,889 9,586 
Accrued compensation related costs8,744 4,456 
Accrued other6,290 (1,563)
Operating lease liabilities (4)(5,625)(8,252)
Medicare advance payments- (3,742)
Other long-term liabilities1,410 654 
Net cash (used) provided by operating activities(6,160)1,630 
Cash flows from investing activities
Purchases of property and equipment(9,527)(5,051)
Proceeds from disposals of property and equipment5 1,137 
Purchases of marketable securities(20,824)(11,949)
Proceeds from sales of marketable securities4,933 1,956 
Issuance of notes receivable - related parties- (243)
Collections on notes receivable - related parties740 1,091 
Net cash used in investing activities(24,673)(13,059)
Cash flows from financing activities
Borrowings on long-term debt- 16,250 
Issuance of redeemable convertible Class C Units64,996 - 
Cash paid for offering costs on issuance of Class A Common Stock- - 
Class A and A-1 preferred returns and tax distributions(9,481)- 
Cash paid for offering costs on reverse recapitalization- - 
Repayments on finance lease liabilities(387)(321)
Contribution from noncontrolling interest134 - 
Cash paid for debt financing costs(446)(171)
Cash paid for offering costs on issuance of Class C Units(750)- 
Proceeds from reverse recapitalization1,494 - 
Net cash provided by financing activities55,560 15,758 
Net increase (decrease) in cash and cash equivalents24,727 4,329 
Cash and cash equivalents
Beginning of period26,926 32,354 
End of period$51,653 $36,683 
Supplemental noncash investing and financing activities
Unpaid offering costs relating to the reverse recapitalization$2,745 $- 
Right-of-use assets and lease liabilities removed in termination of lease$1,254 $- 
Deemed divided for Series A Preferred Stock extinguishment$2,089 $- 
Changes in accounts payable for capital additions to property and equipment$- $159 
Disposal of property and equipment in exchange for reduction in finance lease liability$- $72 
(1)Includes related party amortization of operating right-of-use assets of $1,601 and $1,536 for the nine months ended September 30, 2023 and 2022, respectively.
(2)Includes changes in related party balances of ($1,299) and $832 for the nine months ended September 30, 2023 and 2022, respectively.
(3)Includes changes in related party balances of $10,627 and $23,309 for the nine months ended September 30, 2023 and 2022, respectively.
(4)Includes changes in related party balances of ($1,835) and ($1,446) for the nine months ended September 30, 2023 and 2022, respectively.
The accompanying notes are an integral part of these condensed consolidated financial statements.
7
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
1.Business

American Oncology Network, Inc. (“AON”, “New AON”, “AON Inc.”, or the “Company”), through its subsidiary companies and variable interest entities (together, “its subsidiaries”), is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services across 33 oncology practices located in nineteen states (Arizona, Arkansas, Florida, Georgia, Iowa, Idaho, Indiana, Louisiana, Maryland, Missouri, Michigan, North Carolina, Nevada, Nebraska, Ohio, South Carolina, Texas, Virginia and Washington). The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services, clinical research, radiation oncology, and imaging. During the nine months ended September 30, 2023 and 2022, the Company entered into affiliation agreements with or acquired the following oncology practices.
Nine Months Ended September 30, 2022Nine Months Ended September 30, 2023
StateState
Arizona
Texas(a)
Georgia(a)
Florida(a)
Louisiana(a)
Arkansas(a)
Georgia(a)
Georgia(a)
Georgia(a)
(a)The Company entered into affiliation agreements with the physicians for these respective practices. The Company evaluated each of the affiliation agreements and determined that the transactions did not represent a business combination.
The operations of the practices that were acquired have been included in the Company’s condensed consolidated financial statements since the date of acquisition. The Company intends to continue to pursue additional purchases of physician practices in addition to seeking out new affiliation relationships.
Business Combination Agreements

Digital Transformation Opportunities Corp. (“DTOC”), American Oncology Network, LLC (“AON LLC”), GEF AON Holdings Corp. (“AON Class C Preferred Investor”), and DTOC Merger Sub, Inc., a direct, wholly owned subsidiary of DTOC (“Merger Sub”) entered into a Business Combination Agreement (the “Business Combination Agreement”), dated as of June 14, 2023 (which further amended and restated the Business Combination Agreement entered into by DTOC and AON as of October 5, 2022, and amended and restated on January 6, 2023, and April 27, 2023), pursuant to which, among other transactions, on September 20, 2023 (the “Closing Date”), DTOC and AON undertook a series of transactions (the “Business Combination”) resulting in the organization of the combined post-business combination company as an umbrella partnership C corporation, in which substantially all of the assets and the business of the combined company are held by AON LLC, and DTOC became a member of AON LLC. In connection with the closing of the Business Combination (“the Closing”), DTOC changed its name to “American Oncology Network, Inc.”. The Business Combination was completed on September 20, 2023.

As a result of, and in connection with, the Closing, among other things, (i) AON LLC amended and restated its operating agreement (the “Amended and Restated AON LLC Agreement”) to reclassify its existing Class A units, Class A-1 units and Class B units into a single class of AON LLC common units (“AON LLC Common Units”) that can be exchanged on a one-to-one basis for shares of New AON Class A common stock (“New AON Class A Common Stock”) and its existing AON LLC Class C units into AON LLC Series A preferred units (AON LLC Series A Preferred Units”); (ii) AON LLC converted profit pool units of certain of AON LLC’s subsidiaries into an equal number of AON LLC Common Units and shares of New AON Class B common stock (“New AON Class B Common Stock”), which together are exchangeable into shares of New AON Class A Common Stock (together with the New AON Class B Common Stock, the “New AON Common Stock”); (iii) New AON amended and
8
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
restated its charter (the “Charter”) to provide for (a) the conversion of all existing shares of DTOC Class B common stock into shares of New AON Class A Common Stock on a one-to-one basis, (b) amendment of the terms
of New AON Class B Common Stock to provide holders voting rights but no economic rights and (c) designation of a new series of New AON preferred stock as Series A convertible preferred stock (the “New AON Series A
Preferred Stock” or “Series A Preferred Stock") with such rights and preferences as provided for in the certificate of designation of the New Aon Series A Preferred Stock (the “New AON Series A Certificate of Designation”); and (iv) among other things, (a) AON LLC issued common units to New AON in exchange for a combination of cash and shares of New AON Class B Common Stock and warrants to acquire shares of New AON Class B Common Stock (the “Class B Prefunded Warrants”), (b) New AON was admitted as a member of AON LLC, (c) AON LLC distributed shares of New AON Class B common stock or Class B Prefunded Warrants, as applicable, to AON LLC equity holders, (d) New AON reserved a specified number of additional shares of New AON Class A Common Stock after the Closing for issuance to eligible participants, (e) Merger Sub merged with and into the AON Class C Preferred Investor whereby the separate existence of Merger Sub ceased and New AON issued a number of shares of New AON Series A Preferred Stock equal to the number of AON LLC Series A preferred units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor (the “First Step”), (f) promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON LLC Series A preferred units and (g) from and after the Closing (but subject to lock-up restrictions), the AON LLC common equity holders (other than New AON), referred to herein as “Legacy AON Shareholders” (former AON LLC Class A, Class A-1, and Class B unit holders), will have the right (but not the obligation) to exchange AON LLC Common Units together with an equal number of shares of New AON Class B Common Stock (whether held directly or indirectly through Class B Prefunded Warrants) for shares of New AON Class A Common Stock.

In addition, in connection with the Closing, DTOC completed the offer to the holders of AON LLC Class B-1 units to exchange their AON LLC Class B-1 units for such number of newly issued shares of New AON Class A Common Stock equal to the ratio set forth in the Business Combination Agreement (such offer, the “Exchange Offer”). DTOC and AON LLC solicited consents from the holders of AON LLC Class B-1 units to make certain amendments to the terms of the awards and the unit grant agreements pursuant to which the AON LLC Class B-1 units were granted, which provided for the automatic exchange, as of immediately prior to the adoption of the Amended and Restated AON LLC Agreement, of all outstanding AON LLC Class B-1 units into shares of New AON Class A Common Stock (collectively, the “Proposed Amendments”). The requisite number of holders of Class B-1 units provided their consent to the Proposed Amendments, and as a result, in connection with the Closing, all AON LLC Class B-1 units were exchanged for an aggregate of 1,047,343 shares of New AON Class A Common Stock.

Upon the consummation of the Business Combination, the outstanding membership units in AON LLC and the outstanding shares in AON Inc. (New AON) are as follows:
•AON LLC Common Units held by the Legacy AON Shareholders - 28,109,796
•AON LLC Common Units held by New AON - 9,532,354
•AON LLC Series A Preferred Units held by New AON - 6,651,610

•Class A Common Stock held by the former AON LLC Class B-1 unit holders - 1,047,343
•Class A Common Stock held by the DTOC unredeemed shareholders - 147,511
•Class A Common Stock held by the DTOC Sponsor and their permitted transferees - 5,419,375(a)
•Class B Common Stock held by Legacy AON Shareholders - 25,109,551(b)
•New AON Series A Preferred Stock held by AEA Growth Management LP - 6,651,610

(a) Sponsor Earnout Shares of 2,839,375 are subject to vesting and forfeiture provisions and are not outstanding for GAAP purposes as of the Closing Date.

(b) Certain Legacy AON Shareholders hold 3,000,245 Class B Prefunded Warrants, which underlying shares of Class B common stock are not outstanding as of the Closing Date.
9
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)


Accounting Treatment for the Business Combination

As AON LLC does not meet any of the characteristics of a VIE under ASC 810, the Business Combination was evaluated under ASC 805, Business Combinations. Notwithstanding the legal form of the Business Combination pursuant to the Business Combination Agreement, the Business Combination was accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, DTOC was treated as the acquired company and AON LLC was considered the acquirer for financial statement reporting purposes. AON LLC was determined to be the accounting acquirer based on, in summary, an evaluation of the following primary facts and circumstances:

•AON LLC’s directors will represent a majority of the board seats for New AON’s board of directors;

•AON LLC’s senior management will be the senior management of the combined company;

•AON LLC’s operations comprising the ongoing operations of the post-combination company; and

•AON LLC’s relative size (i.e., assets, revenues, and earnings) is significantly larger compared to DTOC.

Accordingly, for accounting purposes, the financial statements of the post-combination entity will represent a continuation of the financial statements of AON LLC with the acquisition being treated as the equivalent of AON LLC issuing stock for the net assets of DTOC, accompanied by a recapitalization. The net assets of DTOC are stated at historical cost, with no goodwill or other intangible assets recorded. Refer to Note 3 for additional information.

Accounting for the Earnout Shares

Following the Closing and for five years thereafter, the DTOC Sponsor agreed to subject 35%, or 2,839,375 shares of New AON Class A common stock held by it as of the Closing (the “Sponsor Earnout Shares”) to the following vesting and forfeiture provisions:

•the Sponsor Earnout Shares will vest when the volume-weighted average price of the New AON Class A common stock equals or exceeds $13.50 per share for any 20 trading days within any 30 trading day period beginning after the Closing and ending 60 months following the Closing;

•the Sponsor Earnout Shares will be released immediately upon the consummation of a change of control transaction within the 60-month period following the Closing; and

•if the Sponsor Earnout Shares are not released pursuant to the foregoing provisions on or before the date that is 60 months after the Closing, then the Sponsor Earnout Shares will be forfeited immediately following such date.

As the Business Combination was accounted for as a reverse recapitalization, the issuance of the Sponsor Earnout Shares to the Company’s existing shareholders will be accounted for as an equity transaction. The accounting for the Sponsor Earnout Shares was evaluated under ASC Topic 480, Distinguishing Liabilities from Equity, and ASC Subtopic 815-40, Derivatives and Hedging — Contracts in Entity’s Own Equity, to determine if the Sponsor Earnout Shares should be classified as a liability or within equity. As part of that analysis, it was determined that the Sponsor Earnout Shares are freestanding, do not meet the criteria within ASC 480 to be classified as a liability, and meet the criteria in ASC 815-40 to be considered indexed to the post-combination entity’s common stock and classified within equity.


10
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)


Warrants

As of the Closing Date, New AON assumed the outstanding warrants (Public Warrants and Private Placement Warrants) that were issued by DTOC as part of DTOC’s IPO. Further, New AON issued the Class B Prefunded Warrants to former Class A-1 unit holders, in lieu of New AON Class B Common Stock. The accounting treatment for the Public Warrants, the Private Placement Warrants, and the Class B Prefunded Warrants, collectively referred to as “the Warrants”, is disclosed in Note 2.

Public Warrants

As of the Closing Date, New AON assumed 8,337,500 public warrants (the “Public Warrants”) issued by DTOC in its IPO. Each whole warrant entitles the holder to purchase one share of New AON Class A Common Stock at a price of $11.50 per share, subject to adjustment. The warrants will become exercisable on the later of 12 months from the closing of the DTOC Initial Public Offering or 30 days after the completion of its initial business combination and will expire five years after the Closing of the Business Combination, or earlier upon redemption or liquidation.

Private Warrants

As of the Closing Date, New AON assumed 6,113,333 Private Placement Warrants held by the DTOC Sponsor (the “Private Placement Warrants” or “Private Warrants”). The Private Placement Warrants will be non-redeemable in certain circumstances so long as they are held by the Sponsor or its permitted transferees. The Private Placement Warrants may also be exercised by the Sponsor and its permitted transferees for cash or on a cashless basis. Otherwise, the Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants, including as to exercise price, exercisability, and exercise period.

Class B Prefunded Warrants

As of the Closing Date, New AON issued 3,000,245 of Class B Prefunded Warrants to former AON Class A-1 unitholders. Because the Class B Warrants are prefunded, there was not any cash consideration exchanged as part of the Class B Warrant issuance. Each Class B Prefunded Warrant entitles the holder to purchase one share of New AON Class B common stock at a price of $0.01 per share. The exercise term of the Class B Warrant shall continue indefinitely so long as the holder of the Class B Warrant is also the holder of an AON LLC Common Unit, provided that the number of shares of Common Stock that this Warrant is exercisable for shall not exceed the number of AON LLC Common Units held by holder.


Transaction Expenses

In connection with the Reverse Recapitalization, AON LLC incurred costs of $24.6 million and $30.6 million during the three and nine months ended September 30, 2023, respectively. Of the total costs incurred during the three months ended September 30, 2023, $24.6 million were reported as transaction expenses in the condensed consolidated statements of operations and comprehensive loss. Of the total costs incurred during the nine months ended September 30, 2023, $29.8 million were reported as transaction expenses in the condensed consolidated statements of operations and comprehensive loss and $0.8 million were reported as a reduction of Series A Preferred Stock presented as mezzanine equity on the condensed consolidated balance sheet at September 30, 2023. At December 31, 2022, the Company had accrued $0.3 million of transaction costs related to the Reverse Recapitalization, which were reported as other assets on the condensed consolidated balance sheet. AON LLC recorded $0.2 million of transaction expenses in connection with the Reverse Recapitalization during the three and nine months September 30, 2022, which were reported as transaction expenses in the condensed consolidated statements of operations and comprehensive loss.
11
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
2.Basis of Presentation and Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of the Company were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. Management believes the unaudited condensed consolidated financial statements for the interim periods presented contain all necessary adjustments, of a normal recurring nature, to state fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. These condensed consolidated financial statements were prepared on the same basis as and should be read in conjunction with the Company’s annual consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with such audited consolidated financial statements and related notes thereto of AON LLC and its wholly-owned subsidiaries, included in the proxy statement/prospectus of Digital Transformation Opportunities Corp., dated July 18, 2023 (the “Proxy Statement/Prospectus"). Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results the Company expects for the entire year.

For the three and nine months ended September 30, 2023, these unaudited condensed consolidated financial statements reflect the consolidated results of operations, comprehensive income (loss), cash flows and changes in equity of AON LLC and its wholly-owned subsidiaries for the period of January 1, 2023 through September 20, 2023, the Closing Date of the Reverse Recapitalization, and the consolidated results of operations, comprehensive income (loss), cash flows and changes in stockholders’ equity of AON Inc. and its consolidated subsidiaries, including AON LLC, for the period of September 21, 2023 through September 30, 2023. The condensed consolidated balance sheet at September 30, 2023 presents the financial condition of AON Inc. and its consolidated subsidiaries, including AON LLC, and reflects the initial recording of the assets and liabilities of AON Inc. at their historical cost (see Note 3). All intercompany balances and transactions of AON LLC prior to the Reverse Recapitalization have been eliminated. All intercompany balances and transactions of AON Inc. after the Reverse Recapitalization have been eliminated.

For the three and nine months ended September 30, 2022, these unaudited condensed consolidated financial statements present the consolidated results of operations, comprehensive income (loss), cash flows and changes in equity of AON LLC. The condensed consolidated balance sheet as of December 31, 2022 presents the financial condition of AON LLC and its wholly-owned subsidiaries. All intercompany balances and transactions of AON LLC have been eliminated.

In accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, the historical equity of AON LLC has been recasted in all periods up to the Closing Date, to reflect the number of shares of New AON’s Class A Common Stock and Class B Common Stock issued to Legacy AON Shareholders in connection with the Reverse Recapitalization. The Company recasted the units outstanding related to the historical AON LLC Class A, Class A-1, and Class B units prior to the Reverse Recapitalization (“Historical AON LLC Equity”) as common equity of New AON, equal to the Per Company Class Unit Exchange Ratio, pursuant to the Business Combination Agreement.

The Per Company Unit Exchange Ratio at which AON LLC Class A units and Class A-1 units were reclassified is equal to 2,524 AON Common Units. The Per Company Unit Exchange Ratio at which AON LLC Class B units were reclassified varied depending on participation threshold, and is equal to 2,524, 2,453, or 1,976, AON Common Units. The Per Company Unit Exchange Ratio at which Class C units were reclassified is equal to 2,705 AON LLC Series A Preferred Units.

12
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
The condensed consolidated financial statements and related notes thereto give effect to the conversion for all periods presented, without any change to par value or per unit amounts. The condensed consolidated financial statements do not necessarily represent the capital structure of New AON had the Reverse Recapitalization occurred in prior periods. The Company has not made retroactive adjustments related to the historical book values of Historical AON LLC Equity as the adjustments were considered immaterial.

For both the three and nine months ended September 30, 2023, $1.7 million of the consolidated net loss of AON LLC were attributable to the Class A Common Stockholders, and reflects the Class A Common Stockholders’ absorption of 19.0% of the consolidated net loss of AON LLC for the period of September 21, 2023 through September 30, 2023. For both the three and nine months ended September 30, 2023, $11.9 million of the consolidated net losses of AON LLC were attributable to the noncontrolling interest, and reflects the Legacy AON Shareholders’ absorption of 81.0% of the consolidated net losses of AON LLC for the period of September 21, 2023 through September 30, 2023. For the three and nine months ended September 30, 2023, $15.5 million and $27.0 million of the consolidated net losses of AON LLC were attributable to the Legacy AON Shareholders, respectively, to reflect their absorption of 100% of the consolidated net losses of AON LLC pertaining to the days prior to the Reverse Recapitalization. For the three and nine months ended September 30, 2022, net income of $5.6 million and $1.2 million were attributable to the Legacy AON Shareholders, respectively, to reflect their absorption of 100% of AON LLC’s net income pertaining to the periods prior to the Reverse Recapitalization.


Principles of Consolidation
For the period of September 21, 2023 through September 30, 2023, the condensed consolidated financial statements include the accounts of the Company, AON, Inc., American Oncology Network, LLC (“AON LLC”) and its wholly owned subsidiary American Oncology Management Company, LLC (“AOMC”), and its consolidated variable interest entities (“VIEs”) American Oncology Partners, P.A. (“AON Partners”), American Oncology Partners of Maryland, P.A. (“Partners of Maryland”), AON Central Services, LLC (“AON Central Services”), and Meaningful Insights Biotech Analytics, LLC (“MIBA”). All intercompany accounts and transactions between the entities have been eliminated in consolidation.

Refer to Note 1 for the accounting treatment of the Business Combination.

For the periods prior to the Reverse Recapitalization, the consolidated financial statements of the Company comprise the accounts of AON LLC and its wholly-owned subsidiaries. All intercompany accounts and transactions among AON LLC and its consolidated subsidiaries were eliminated.
The Company accounts for American Oncology Network, LLC, AON Partners, Partners of Maryland, AON Central Services, and MIBA in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, Consolidations. The Company determines whether it has a controlling financial interest in an entity by first evaluating whether the entity is a VIE. A VIE is broadly defined as an entity that has any of the following three characteristics: (i) the equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (ii) substantially all of the entity’s activities either involve or are conducted on behalf of an investor that has disproportionately few voting rights; or (iii) the equity investors as a group lack any of the following, the power through voting or similar rights to direct the activities of the entity that most significantly impact the entity’s economic performance, the obligation to absorb the expected losses of the entity, or the right to receive the expected residual returns of the entity. The Company consolidates a VIE if it has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and an obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively, if any.

AON LLC has contractual relationships with AON Partners, Partners of Maryland and AON Central Services and the physician owners through management service agreements (“MSAs”) and other contractual agreements to
13
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
provide all practice management services outside of medical services provided by the physicians. In addition, despite not being required by the contractual relationships, AON LLC regularly provides funding to support AON Partners and Partners of Maryland’s operations and acquisitions of physician practices. AON Central Services was formed July 15, 2022 and, effective January 1, 2023, entered into an agreement with AOMC to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. MIBA was established during the first quarter of 2023 for the purpose of developing intellectual property to synergize the collection, de-identification, and dissemination of the Company’s patient data for sale to external parties for research, development, and clinical decisions. In May 2023, the Company contributed $0.2 million for a 56% interest in the equity of MIBA. As of September 30, 2023, MIBA had no significant operating activity. The Company concluded that AON LLC had a controlling financial interest in MIBA and has consolidated the entity at September 30, 2023 and recorded the noncontrolling interest in equity. 
The Company has concluded that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all VIEs in which AON LLC has the characteristics of a controlling financial interest and is deemed to be the primary beneficiary. The variable interest subjects AON LLC to all potential losses in the entities and, therefore, requires AON LLC, and in turn AON Inc., to consolidate the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA in its condensed consolidated financial statements. 
Refer to Note 4 for further information on the VIEs. Refer to Note 1 for the accounting treatment of the Reverse Recapitalization.
Significant Accounting Policies
The accounting policies included below should be read in conjunction with the annual consolidated financial statements.
Accounting Estimates and Assumptions
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Segments
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the “CODM”). The Company’s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company’s performance. The Company has one operating segment and one reportable segment that are structured around the organizational management of oncology practice operations. All revenue and assets are in the United States. 
Revenue Recognition
Revenue is recognized under Accounting Standards Update (“ASU”) 2014-09 Revenue from Contracts with Customers (“Topic 606”). The Company determines the transaction price based upon standard charges for goods and services with anticipated consideration due from patients, third-party payors (including health insurers and government agencies) and others. The Company’s revenue is primarily derived from patient service revenues, which encompass oncology services provided during patient visits and shipments of pharmacy prescriptions. Performance obligations for the Company’s services provided to patients and most procedures, are satisfied over the time of visit which is the same day services are performed. Performance obligations relating to pharmacy revenue are considered fully satisfied at a point in time upon the customer receiving delivery of the prescription. Accordingly, the Company does not anticipate a significant amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods, and any such revenue recognized during the three and nine month periods ended September 30, 2023 and 2022 was immaterial. Additionally, the Company does not expect to recognize material revenue in the future related to performance obligations that are unsatisfied (or partially
14
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
satisfied) as of September 30, 2023 and December 31, 2022. Approximately $238.9 million and $213.8 million and $678.1 million and $606.0 million of the Company’s revenues are generated from services performed during patient visits with the remainder primarily generated from shipments of pharmacy prescriptions for the three and nine month periods ended September 30, 2023 and 2022, respectively.
As services are performed and prescriptions are shipped, timely billing occurs for services rendered and prescriptions shipped less discounts provided to uninsured patients and contractual adjustments to third-party payors based upon prospectively determined rates and discounted charges. Payment is requested at the time of service for self-paying patients and for patients covered by third-party payors that are responsible for paying deductibles and coinsurance.
The Company monitors revenue and receivables to prepare estimated contractual allowances for the anticipated differences between billed and reimbursed amounts. Payments from third-party payors and Government programs including Medicare and Medicaid may be subject to audit and other retrospective adjustments. Such amounts are considered on an estimated basis when net patient revenue is recorded and are adjusted as final adjustments are determined. For the three and nine month periods ended September 30, 2023 and 2022, such resulting historic adjustments have been immaterial to the condensed consolidated financial statements. 
In assessing who is the principal in providing patient services and pharmacy prescriptions, the Company considered who controls the provision of services and prescriptions. The Company has determined they are acting as a principal in these relationships. 
In April 2022, the Company entered into a long-term arrangement to sponsor and manage a clinical trial. The Company subsequently contracted with a third-party to provide the clinical research services and is the principal in this arrangement. The performance of clinical research services are considered a single performance obligation because the Company provides a highly-integrated service. Revenue is recognized for the single performance obligation over time due to the Company’s right to payment for work performed to date. The contract provides for invoices based on predetermined milestones. 

The Company uses the cost-to-cost measure of progress for the Company’s contract because it best depicts the transfer of control to the customer as the performance obligation is fulfilled. For this method, the Company compares the contract costs incurred to date to the estimated total contract costs through completion. As part of the client proposal and contract negotiation process, the Company develops a detailed project budget for the direct costs and reimbursable costs based on the scope of the work, the complexity of the study, the geographical location involved and the Company’s historical experience. The estimated total contract costs at the project level are reviewed and revised periodically throughout the life of the contract, with adjustments to revenue resulting from such revisions being recorded on a cumulative basis in the period in which the revisions are identified. Contract costs consist primarily of direct labor and other reimbursable project-related costs such as travel, third-party vendor costs and investigator fees. The Company establishes pricing based on the Company’s internal pricing guidelines, discount agreements, if any, and negotiations with the client. The transaction price is the contractually defined amount. Revenue related to the clinical trial, which is included within other revenue, was $2.2 million and $1.0 million and $3.7 million and $3.1 million for the three and nine months ended September 30, 2023 and 2022, respectively. 
The Company has a system and estimation process for recording Medicare net patient service revenue and estimated recoupments as it relates to value-based care (“VBC”) revenue included in patient service revenue in the condensed consolidated statements of operations and comprehensive loss. The Company’s VBC revenue is primarily generated through its participation in the CMS Oncology Care Model (“OCM”) which is an episode-based payment model to promote high-quality cancer care. Participants enter six-month episode periods, and the Company bills a monthly fee during the six-month period based on a fixed rate per participant per month and the total number of participants. Certain quality and compliance metrics are tracked as part of the program and submitted to CMS at the end of the episode period which may result in recoupment of funds. The Company estimates the recoupment amount by developing a recoupment percentage for each period based on historical known recoupment from CMS and applies the recoupment percentage against total fees for the period. Based on the
15
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
estimate, the Company accrues a liability representing the expected final recoupments based on historical settlement trends.
Short-term Marketable Securities 
Investments in marketable securities consist of corporate bonds and U.S. Treasury securities.
Management determines the appropriate classification of investments at the time of purchase and reevaluates such determination at each balance sheet date. Marketable securities are classified as available-for-sale and are carried at fair value in the consolidated balance sheets. The marketable securities are classified as short-term based on management’s intent to convert such securities within one year and the ability to convert them within two to three days.
Certain of our available-for-sale securities are debt securities. For an available-for-sale debt security with an amortized cost that exceeds its fair value, the Company first determines if it intends to sell or will more-likely-than-not be required to sell the security before the expected recovery of its amortized cost. If it intends to sell or will more-likely-than-not be required to sell the security, then the Company recognizes the impairment as a credit loss in the condensed consolidated statements of operations and comprehensive loss by writing down the security’s amortized cost to its fair value. If it does not intend to sell or it is not more-likely-than-not that it will be required to sell the security before the expected recovery of its amortized cost, the Company recognizes the portion of the impairment that is due to a credit loss, if any, in the condensed consolidated statements of operations and comprehensive loss through an allowance. The portion of the impairment that is due to factors other than a credit loss is recognized in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss as an unrealized loss.
Equity Investment in Affiliate
In January 2023, the Company contributed noncash consideration, with a fair value of approximately $2.3 million, in return for a 49% equity interest in OCP Management Arizona, LLP. Investments in entities over which the Company has the ability to exercise significant influence but does not control the entity are accounted for using the equity method. Equity method investments are included with other assets in the condensed consolidated balance sheets. The carrying amount of the investment is adjusted to reflect the Company’s proportionate share of the net earnings or losses and reduced by any dividends received. The Company’s share of income or loss related to this investment is reported as an equity in loss of affiliate in the condensed consolidated statements of operations and comprehensive loss.
Noncontrolling Interests
The Company consolidates the results of entities in which it has a controlling financial interest. Refer to Note 14 for additional considerations and presentation for noncontrolling interest.
Mezzanine Equity

New AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which is outside of the Company’s control). As a result, Management has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity. As of September 30, 2023, the Preferred Stock are recorded at their initial carrying value, net of offering costs of $0.8 million. The Series A Preferred Stock are not being accreted to redemption value, as the redemption is not probable. The Series A Preferred Stock are classified outside of members’ equity on the consolidated balance sheets. Refer to Note 14 for mezzanine equity presentation considerations for redeemable noncontrolling interest.
Business Combinations
The Company evaluates acquired practices in accordance with ASU 2017-01, Business Combinations (Topic 805)-Clarifying the Definition of a Business. This standard clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or
16
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
disposals of assets or businesses. Because substantially all of the value of each acquired practice did not relate to a similar group of assets and as each acquired practice contained both inputs and processes necessary to provide economic benefits to the Company, it was determined that each acquisition represents a business combination. Therefore, the transactions have been accounted for using the acquisition method of accounting, which requires, with limited exceptions, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Any excess of the consideration transferred over the estimated fair values of the net assets acquired is recorded as goodwill. Transaction costs related to business combinations are expensed in the period in which they are incurred.
Offering Costs
The Company defers specific incremental costs directly attributable to proposed offerings of securities. These costs consist of legal, accounting, and other similar expenses incurred through the balance sheet date that are directly related to a potential offering. If the offering is completed, these costs will be charged against the gross proceeds of the offering. These offering costs will be allocated to the separable financial instruments issued in the transaction on a relative fair value basis of the securities issued, compared to total proceeds received. Offering costs associated with any instruments classified as liabilities will be expensed as incurred, presented as non-operating expenses in the condensed consolidated statement of operations and comprehensive loss.
During the nine months ended September 30, 2023, the Company incurred additional deferred offering costs of approximately $0.8 million which were recorded as an offset to the net proceeds of the AON LLC Class C Units (discussed below) in mezzanine equity on the condensed consolidated balance sheet at September 30, 2023. At December 31, 2022, the Company had incurred approximately $0.3 million of offering costs, which are included in other assets in the accompanying condensed consolidated balance sheets.

As discussed in Note 1, on June 7, 2023, AON LLC issued Redeemable Convertible Preferred Class C Units (“Class C Units” or “AON LLC Class C Units”) for net proceeds of approximately $64.5 million ($65.0 million in gross proceeds, net of $0.5 million in offering costs). The Company determined that an additional $0.3 million of costs incurred through June 7, 2023 related to the process of raising the proceeds generated by the issuance of the Class C Units. Accordingly, these deferred offering costs have been reclassified from other assets to mezzanine equity, for a total of $0.8 million in Class C Unit offering costs. The Class C Units were subsequently converted to AON LLC Series A Preferred Units upon the Closing of the Business Combination, which were subsequently exchanged for Series A Preferred Stock.
Professional Liability
The Company maintains insurance policies for exposure to professional malpractice insurance risk. The limits of malpractice insurance provide each physician/advanced practice provider with a dedicated $1.0 million limit per claim and a $3.0 million limit in the aggregate per policy period – on a first dollar basis, as no deductible applies. The policy further then extends coverage to the Company, by providing a $2.0 million limit per claim and a $4.0 million limit in the aggregate per policy period - on a first dollar basis, additionally, as no deductible applies. Reserves are established for estimates of the loss that will ultimately be incurred on claims that have been reported but not paid and claims that have been incurred but not reported. These reserves are established based on consultation with a third-party actuary. The actuarial valuations consider a number of factors, including historical claims payment patterns, changes in case reserves and the assumed rate of increase in healthcare costs. Management believes the use of actuarial methods to account for these reserves provides a consistent and effective way to measure these subjective accruals. However, due to the sensitive nature of this estimation technique, recorded reserves could differ from ultimate costs related to these claims due to changes in claims reporting, claims payment and settlement practices and differences in assumed future cost increases. Accrued unpaid claims and expenses that are expected to be paid within the next twelve months are classified as current liabilities and included in accrued other. All other accrued unpaid claims and expenses are classified as long-term liabilities and included in other long-term liabilities. Insurance recoveries associated with the unpaid claims are classified as long-term assets included in other assets.
17
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
Fair Value of Financial Instruments
Fair value is the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.
Accounting guidance establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:
Level 1Inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.
Level 2Inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.
Level 3Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. 
Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement of assets and liabilities being measured within the fair value hierarchy.
Our financial instruments include cash, short-term marketable securities, accounts receivable, notes receivable, accounts payable, accrued expenses, long-term debt and contractual agreements that resulted in derivative liabilities. Our nonfinancial assets such as property and equipment are not measured at fair value on a recurring basis; however, they are subject to fair value adjustments in certain circumstances, such as when there is evidence that impairment may exist.
The carrying amounts of cash, accounts receivable, accounts payable, notes receivable, and accrued expenses approximate their fair value because of the short-term maturity and highly liquid nature of these instruments. We determine the fair value of long-term debt and marketable securities based on various factors including maturity schedules and current market rates.
See Note 6 for a discussion of the Company’s Level 1 and Level 2 Marketable Securities as of September 30, 2023. See below for a discussion of the Company’s Level 1 and Level 3 warrant liabilities as of September 30, 2023. As of December 31, 2022, there were no Level 3 financial instruments. There were no transfers between any levels of the hierarchy during any periods presented.

Warrant Liabilities

The Company evaluated the Public Warrants and Private Placement Warrants and the Class B Prefunded Warrants, collectively referred to herein as “Warrants”, in accordance with ASC 815-40, “Derivatives and Hedging —- Contracts in Entity’s Own Equity”, and concluded that a provision in the warrant agreements related to potential net cash settlement of the warrants upon an exchange or tender offer that may not result in a change in control of the entity precludes the warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as long term liabilities on the condensed consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive loss in the period of change.
18
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)

As of September 30, 2023, the Public Warrants were trading separately from the Class A Common Stock and the quoted market price was used to establish fair value. As such, the Public Warrants fair value was determined using a Level 1 input. The fair value of the Public Warrants is $1.4 million and recorded in other long-term liabilities on the condensed consolidated balance sheets.

Management has utilized the public warrant price to value the private warrants and believes the public and private warrants have materially consistent fair values given the existence of the make-whole redemption feature. As of September 30, 2023, a valuation of the private warrants was performed which confirmed the private warrant value was materially consistent with the public warrants. The details of this valuation are included in the paragraph below.

The fair value of the Private Placement warrants was determined using Level 3 inputs. As of September 30, 2023, the fair value of the Private Placement Warrants was estimated to be $1.0 million and recorded in other long-term liabilities on the condensed consolidated balance sheets. The fair value was estimated at September 30, 2023, using the Black-Scholes Option Pricing model using the following assumptions:
Expected annual dividend yield – 0.0%
                Expected volatility – 0.75%
                Risk-free rate of return – 4.60%
                Expected Option Term – 5.0
                
The AON Class B Prefunded Warrants are exercisable into one share of New AON Class B Common Stock. A share of New AON Class B Common Stock, together with an AON LLC Common Unit, may be exchanged for one share of New AON Class A Common Stock. Considering New AON Class B Common Stock has no economic rights and limited liquidity or value if the holder does not also possess an AON LLC Common Unit, and because the AON Class B Prefunded Warrants are exercisable into New AON Class B Common Stock, the Company has estimated fair value of the Class B Prefunded Warrants to be immaterial.
Earnings Per Share

The Company recast Historical AON LLC Equity as AON Inc. common equity for all periods prior to the Reverse Recapitalization, refer to Note 2. However, as 100% of the net losses of AON LLC prior to the Reverse Recapitalization were absorbed by the Legacy AON Shareholders, basic and diluted earnings (loss) per share is zero for the three and nine months ended September 30, 2022 and basic and diluted earnings (loss) per share for the three and nine months ended September 30, 2023 represents only the period from September 21, 2023 to September 30, 2023, the period where the Company had earnings (loss) attributable to Class A Common Stockholders. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted earnings (loss) per share. As such, basic and diluted earnings (loss) per share of Class B Common Stock has not been presented.

As discussed in Note 1, the Company has issued and outstanding Sponsor Earnouts, which are subject to forfeiture if the achievement of certain stock price thresholds are not met. In accordance with ASC Topic 260, “Earnings Per Share,” the Sponsor Earnouts are excluded from weighted-average shares outstanding to calculate basic earnings (loss) per share as they are considered contingently issuable shares due to their potential forfeiture. Sponsor Earnouts will be included in weighted-average shares outstanding to calculate basic earnings (loss) per share as of the date of their stock price thresholds are met and they are no longer subject to forfeiture.

Basic and diluted earnings (loss) per share is computed by use of the two-class method as a result of outstanding Series A Preferred Stock, which accrue dividends at the annual rate of 8% of the original price per share, participate with common stock on all other dividends, and accordingly have participation rights in undistributed earnings as if all such earnings had been distributed during the period (see Note 12). Under such method income available to common shareholders is computed by deducting both dividends declared or, if not declared,
19
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
accumulated on Series A Preferred Stock from net income. Loss attributable to common shareholders is computed by increasing net loss by such dividends. Since the participating Series A Preferred Stock has no contractual obligation to share in the losses of the Company, there is no loss allocation between Class A Common Stock and Series A Preferred Stock.

Basic earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock used for the basic earnings (loss) per share calculation, adjusted for the dilutive effect of the Public and Private Warrants and Sponsor Earnout, if any, using the “treasury stock” method and the convertible Series A Preferred Stock and, exchangeable Class B Common Stock and Class B Prefunded Warrants, if any, using the “if-converted” method. Net earnings (loss) for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net earnings (loss), net of AON Inc. taxes, after giving effect to the Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock, to the extent it is dilutive.
Recently Adopted Accounting Pronouncements 
In June 2016, the FASB issued ASU 2016-13, ‘‘Financial instruments-Credit Losses’’ (“ASU 2016- 13”). ASU 2016-13 requires entities to report ‘‘expected’’ credit losses on financial instruments and other commitments to extend credit rather than the current ‘‘incurred loss’’ model. These expected credit losses for financial assets held at the reporting date are to be based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU will also require enhanced disclosures relating to significant estimates and judgments used in estimating credit losses, as well as the credit quality. ASU 2016-13 is effective for the Company for annual reporting periods beginning after December 15, 2022. ASU 2016-13 was adopted by the Company effective January 1, 2023 with no material impact on the Company’s consolidated financial statements and related disclosures. 
Recently Issued Accounting Pronouncements
In October 2021, the FASB issued ASU 2021-08, “Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”, which provides that an acquirer must recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606. The guidance is effective for the Company for annual reporting periods beginning after December 15, 2023, with early adoption permitted. The Company does not expect the adoption of this standard to have a material impact on the Company’s consolidated financial statements and related disclosures.
3.Reverse Recapitalization

As discussed in Note 1, AON LLC merged with DTOC, with AON LLC surviving the Merger. AON LLC is governed by a board of managers composed of three (3) persons that were designated by New AON and two (2) persons that were designated by holders of a majority of the AON LLC Common Units, held by members of AON LLC other than New AON. Management determined AON LLC was not a variable interest entity (Refer to Note 2), and as result, identified AON LLC as the accounting acquirer of the Merger in accordance ASC Topic 805. Management concluded that AON LLC was the accounting acquirer due to (i) the Legacy AON Shareholders, defined as the former AON Class A, Class A-1, and Class B unit holders, receiving the largest portion of the voting rights in the combined company, New AON, (ii) significantly all of the Legacy AON Shareholders retained their equity interest as stockholders in New AON, (iii) AON LLC’s operations prior to the Reverse Recapitalization comprising the only ongoing operations of New AON, (iv) the Legacy AON Shareholders have the right to appoint a majority of the directors of New AON, (v) the executive management of AON LLC will become the executive management of New AON and (vi) AON LLC is significantly larger than New AON in terms of revenue, total assets, and employees. Therefore, the Merger was accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded, in accordance with ASC Topic 805. New AON was treated as the “acquired” company for financial reporting purposes, and for accounting purposes, the Reverse Recapitalization was treated as the equivalent of AON LLC issuing stock for the net assets of New AON, accompanied by a recapitalization. The net assets of New AON were recorded at historical cost on the condensed consolidated balance sheet as of
20
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
September 20, 2023, the Closing Date of the Reverse Recapitalization, with no goodwill or other intangible assets recorded. For additional information on the capitalization of New AON and AON LLC immediately following the Closing of the Reverse Recapitalization, see Note 1.

The following table provides the historical cost of assets and liabilities of AON Inc. as of September 20, 2023.

As of September 30,
2023
Cash and Cash Equivalents$1,493 
Current Liabilities(13,295)
Long Term Liabilities(6,791)
Total Net Liabilities$(18,593)

The Company recorded a Day 1 expense as of the Closing of the Business Combination equal to $18.2 million. Of that total amount, $13.0 million was recorded in transaction expenses on the condensed consolidated statement of operations and comprehensive loss. The remaining $5.2 million was recorded in other income (expense) net on the condensed consolidated statement of operations and comprehensive loss. This amount represented the loss on the issuance of Public and Private Warrants, as of the Closing, net of cash received. The Company also recorded a $4.3 million gain in other income (expense), net related to the change in the fair value of the Public and Private Warrants during the period of September 21, 2023 through September 30, 2023.
4.Variable Interest Entities
AOMC is a wholly owned subsidiary of AON LLC and neither AOMC nor AON LLC has ownership interest in AON Partners and Partners of Maryland. Both AON Partners and Partners of Maryland are fully owned by physicians. AON LLC operates its physician practices through the MSAs and other contractual agreements between AOMC, AON Partners, and Partners of Maryland. The responsibilities of AOMC include, but are not limited to, negotiating provider and payor contracts, employment and compensation decisions, billing and collections, furnishing all supplies and equipment necessary for the respective practice’s operations as well as, necessary real estate, contracting on behalf of AON Partners and Partners of Maryland, entering into leases, holding a power of attorney to perform the above activities, preparing, maintaining and administering all accounting records (including financial reporting), expense payment, and maintenance of all information systems/software. AON LLC is paid a management fee to compensate AOMC for the services provided. AON Central Services is 80% physician owned and 20% owned by AON LLC. AOMC entered into an agreement with AON Central Services, effective January 1, 2023, to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. AOMC pays a monthly management fee to AON Central Services equal to the aggregate cost of compensation, benefits and all other costs related to these employees. AON LLC invested $0.2 million in MIBA, a newly formed LLC, during the second quarter of 2023 in exchange for 56% equity ownership. The Company evaluated AON LLC’s relationship with MIBA under the VIE model and determined it was a VIE and the Company is the primary beneficiary based on its financial controlling interest.

Based on various quantitative and qualitative factors, including assessment of certain services performed and relationships held above, management has determined that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all variable interest entities and AOMC is the primary beneficiary who holds the decision-making rights over the activities that most significantly impact the economic performance of AON Partners, Partners of Maryland, AON Central Services, and MIBA through the MSAs and other contractual agreements. Accordingly, the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA have been consolidated with the Company for the three and nine month periods ended September 30, 2023 and 2022.
21
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
The assets of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of September 30, 2023 and December 31, 2022, are as follows:
As of September 30,
2023		As of December 31,
2022
Assets
Cash and cash equivalents$33,083 $26,844 
Accounts receivable141,039 136,098 
Inventories37,844 36,476 
Prepaid expenses and other current assets869 846 
Goodwill and intangibles, net180 180 
Other receivables36,294 28,139 
Other assets2,014 1,489 
Total assets$251,323 $230,072 
The liabilities of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of September 30, 2023 and December 31, 2022, are as follows:
As of September 30,
2023		As of December 31,
2022
Liabilities
Accounts payable$114,779 $102,783 
Accrued compensation and benefits22,747 6,021 
Accrued other16,038 15,926 
Other long-term liabilities137 452 
Due to AON LLC and subsidiaries, net134,344 128,204 
Total liabilities$288,045 $253,386 
All intercompany transactions and balances with the VIEs are eliminated in consolidation.
5.Business Combinations
2022 Acquisitions
During the nine months ended September 30, 2022, the Company entered into a purchase agreement acquiring control of Northern Arizona Hematology and Oncology on January 1, 2022 for an aggregate purchase price of less than $0.1 million. Because the acquisition of Northern Arizona Hematology and Oncology was on the first day of the fiscal period, the Company’s results for the three and nine months ended September 30, 2022 include the results of the acquired practice.
In connection with each of the Company’s business combinations (the “Transactions”), the Company executed employment agreements with the selling physicians to become employees of AON Partners and/or Partners of Maryland. Additionally, for each transaction the Company and selling physicians entered into a separate unwind agreement granting each other a unilateral option that may be exercised by either party and effectively returns the acquired business to the selling physicians if exercised. In the event the Company or seller exercise their unwind rights, the selling physicians are required to repay the original purchase price for the assets that were sold in the Transaction plus any assets that were acquired after the Transaction, less any accumulated depreciation or amortization with respect to the assets. The selling physicians are also required to assume all contracts associated with their practice. Additionally, in the event of unwind, the selling physicians are entitled to any severance
22
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
amounts that are due to them under their employment agreement with AON Partners and their employment is terminated on the unwind date. As of September 30, 2023 and December 31, 2022, no liability has been recorded related to the unwind agreements as neither the Company nor any selling physicians have exercised their unwind rights and therefore no payments are considered probable to the selling physicians.
6.Marketable Securities
The following table summarizes the Company’s marketable securities financial assets that are measured at fair value on a recurring basis:
As of September 30, 2023
Amortized
Cost		Gross Unrealized
Gains		Gross Unrealized
Losses		Estimated Fair
Value
Cash equivalents (1)
Level 1:
Overnight repurchase agreements (2)$28,272 $- $- $28,272 
Money market funds773 - - 773 
U.S. Treasury Bills18,606 - - 18,606 
Level 1 total$47,651 $— $— $47,651 
Marketable securities
Level 2:
Corporate bonds13,980 62 (38)14,004 
U.S. Treasury securities11,981 52 (4)12,029 
Level 2 total25,961 114 (42)26,033 
Total$73,612 $114 $(42)$73,684 
As of December 31, 2022
Amortized
Cost		Gross Unrealized
Gains		Gross Unrealized
Losses		Estimated Fair
Value
Cash equivalents (1)
Level 1:
Money market funds$109 $- $- $109 
Marketable securities
Level 2:
Corporate bonds7,742 6 (125)7,623 
U.S. Treasury securities2,226 6 (4)2,228 
Level 2 total9,968 12 (129)9,851 
Total$10,077 $12 $(129)$9,960 
(1)Included in cash and cash equivalents in the Consolidated Balance Sheets at September 30, 2023 and December 31, 2022.
(2)Cash equivalents as of September 30, 2023 included U.S. Treasury Bills with an initial maturity of 3 months or less and overnight repurchase agreements in which cash from the Company's main operating checking account is invested overnight in highly liquid, short-term investments sponsored by a large financial institution. The company had no such investments as of December 31, 2022.
23
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
The Company uses quoted prices in active markets for identical assets to determine the fair value of its Level 1 investments. The fair value of the Company’s Level 2 investments is determined using pricing based on quoted market prices or alternative market observable inputs. 
The fair value of the Company’s marketable securities as of September 30, 2023, by remaining contractual maturities, were as follows:
Corporate BondsU.S. TreasuriesTotal
Due in one year or less$4,805 $8,385 $13,190 
Due in one to five years9,199 3,644 12,843 
Total$14,004 $12,029 $26,033 
7. Supplemental Condensed Balance Sheet Information
Other receivables
Other receivables consisted of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December 31,
2022
Rebates receivable$36,556 $27,955 
Other191 246 
Total other receivables$36,747 $28,201 
Inventory
Inventory consisted of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December
31, 2022
Intravenous drugs$27,508 $25,674 
Oral pharmaceuticals10,336 10,802 
Total inventories$37,844 $36,476 
24
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
Property and Equipment, net
Property and equipment, net consisted of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December 31,
2022
Leasehold improvements$30,078 $26,076 
Furniture, fixtures and equipment2,722 2,669 
Medical equipment12,659 11,003 
Computer equipment3,325 3,115 
Signs147 129 
Automobiles59 69 
Software4,412 4,834 
Construction-in-progress6,150 1,433 
Property and equipment, gross59,552 49,328 
Accumulated depreciation and amortization(23,312)(17,348)
Property and equipment, net$36,240 $31,980 
Accrued Other
Accrued other consisted of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December 31,
2022
Refund liability$14,521 $14,544 
Deferred social security taxes - COVID- 378 
Excise taxes payable2,700 - 
Current portion of finance lease liabilities630 425 
Other5,126 2,453 
Total accrued other$22,977 $17,800 

8. Long-term Debt
Debt consisted of the following at September 30, 2023 and December 31, 2022: 
As of September 30,
2023		As of December
31, 2022
PNC Facility$81,250 $81,250 
Total81,250 81,250 
Unamortized debt issuance costs(825)(949)
Total debt$80,425 $80,301 
Credit Facilities
On April 30, 2021, the Company entered into a Loan Facility with PNC (“PNC Loan Facility”) collateralized by the Company’s assets and outstanding patient accounts receivable. The PNC Loan Facility is guaranteed on a limited basis by the Company and shareholder of AON Partners and Partners of Maryland. $34.6 million of
25
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
proceeds from the PNC Loan Facility was used to pay off the Company’s previous term loans and revolver with Truist Bank. The remaining funds were made available for working capital and acquisition of additional physician practices.
The PNC Loan Facility is interest-only with total principal due at maturity on April 30, 2024. Interest originally accrued at one-month LIBOR or an alternate base rate plus 1.45%. The maximum balance of the PNC Loan Facility (“Borrowing Base”) is limited to the lesser of the Facility Limit ($65.0 million) or the fair value of the Company’s patient accounts receivable. The Company must maintain a balance of the lesser of the Borrowing Base or 65% of the Facility Limit in the first year and 75% of the Facility Limit in subsequent years (“minimum funding threshold”). The Company can repay the PNC Loan Facility up to the minimum funding threshold at any time without penalty. In accordance with the PNC Loan Facility, the Company pledged $10.0 million of collateral as restricted cash to be released quarterly in increments of $2.5 million. The restricted cash was fully released as of September 30, 2023 and December 31, 2022.
On April 30, 2021, the Company entered into a $5.0 million revolving line of credit agreement (“PNC Line of Credit”). The PNC Line of Credit has an expiration date of April 30, 2024 and originally bore interest at a rate per annum equal to the sum of the daily LIBOR rate plus 1.65% or an alternate base rate plus 0.65% and is due on the first day of each month beginning June 1, 2021. Any outstanding principal and accrued interest will be due on the expiration date. Beginning July 1, 2021, quarterly bank fees equal to 1.65% per day per annum are due in arrears and will continue on the first day of each quarter thereafter. All debt related to the PNC Line of Credit is collateralized by the Company’s assets. As of September 30, 2023 and December 31 2022, no draws had been made on the PNC Line of Credit. The Company is also subject to a 0.20% unused line fee calculated per annum on the unused balance of the PNC Line of Credit. 
On July 29, 2021, the Company amended the PNC Loan Facility increasing the Facility Limit to $75.0 million. On February 14, 2022, the Company further amended the PNC Loan Facility and Line of Credit agreements. The primary changes included an increase of the Facility limit from $75.0 million to $125.0 million, an increase of the PNC Line of Credit availability from $5.0 million to $10.0 million, interest charges to be calculated based on the Bloomberg Short-Term Bank Yield Index plus 1.65% and certain financial covenants. As part of the amendment, the Company drew an additional $16.3 million in proceeds under the Loan Facility. On August 15, 2022, the PNC Loan Facility and Line of Credit agreements were amended again to reduce the availability under the PNC Line of Credit from $10.0 million to $1.0 million. 
Effective November 23, 2022, the Company entered into Waiver and Amendment No. 6 (“Waiver and Amendment”) under its PNC Loan Facility as the Company was not in compliance with the Delinquency Ratio financial covenant for the period ending October 31, 2022 and the requirement to provide certain annual financial statements. The Waiver and Amendment waives each event of default and also revised future delinquency percentages and financial statement requirements. 
On June 30, 2023, the Company entered into Amendment No. 7 (“Amendment 7”) to its PNC Loan Facility which extended the maturity date from April 30, 2024 to June 30, 2026. In connection with Amendment 7, the Company paid additional debt issuance costs of $0.4 million which will be amortized over the revised remaining life of the Loan Facility. In addition, Amendment 7 revised the definition of the minimum funding threshold to limit the threshold multiplier to 65% of the Facility Limit. 
The PNC Loan Facility and PNC Line of Credit nonfinancial covenants include restrictions related to unpermitted property liens and the requirement of audited financial statements. Both agreements also contain several financial covenants, including the following ratios: accounts receivable default, delinquency, dilution, days sales outstanding, leverage, and fixed charge coverage. As of September 30, 2023, the Company was in compliance with all financial and nonfinancial debt covenants as required by both loan agreements.
26
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)

9. Income Taxes

The Company is a member of American Oncology Network, LLC, which is treated as a partnership for U.S. federal and certain state and local income taxes. As a partnership, American Oncology Network, LLC is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by American Oncology Network, LLC is passed through to and included in the taxable income or loss of its members, including the Company, on a pro-rata basis.

The Company is subject to U.S. federal income taxes, in addition to state and local income taxes with respect to the allocable share of any taxable income of American Oncology Network, LLC. Additionally, other corporate entities within the Company's structure are subject to income taxes. These corporate entities continue to generate losses and continue to maintain a valuation allowance against their net deferred tax assets.

The Company’s effective income tax rate was (1.1)% and —% for the three months ended September 30, 2023 and 2022, respectively. The provision for income taxes was $315 and $0 for the three months ended September 30, 2023 and 2022, respectively.

The Company’s effective income tax rate was (0.8)% and —% for the nine months ended September 30, 2023 and 2022, respectively. The provision for income taxes was $315 and $0 for the nine ended September 30, 2023 and 2022, respectively.

The change to the income tax provision for the three and nine months ended September 30, 2023 compared to the income tax provision for the three and nine months ended September 30, 2022 was primarily a result of the transaction closing on September 20, 2023, resulting in a portion of the Company's consolidated pre-tax earnings, which were previously not subject to income taxes, flowing into a taxable corporation included in the Company's post transaction structure.

The effective income tax rate for the three and nine months ended September 30, 2023 and 2022 differed from the federal statutory rate primarily due to certain legal entities in the Company's structure being treated as partnerships for income tax purposes and, therefore, a significant portion of its income not being subject to income tax. Additionally, certain corporate entities within the Company's structure continue to maintain a full valuation allowance against their net deferred tax assets.


27
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)

10. Leases
The Company currently leases office facilities and equipment for its practices under noncancelable operating and finance lease agreements expiring on various dates through 2038. Certain of the leases contain renewal options which are exercisable at the Company’s discretion. These renewal options are considered in determining the lease term if it is reasonably certain that the Company will exercise such options. Additionally, the Company leases certain other office and medical equipment under month-to-month lease agreements. 
Right-of-use assets and lease liabilities consist of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December 31,
2022
Assets
Operating lease right-of-use assets, net$46,138 $43,724 
Finance lease right-of-use assets, net (included in property and equipment, net)2,791 1,998 
Total right-of-use assets$48,929 $45,722 
Liabilities
Current
Current portion of operating lease liabilities$7,123 $9,177 
Current portion of finance lease liabilities (included in accrued other)630 425 
Long-term7,753 9,602 
Long-term operating lease liabilities42,261 37,224 
Long-term finance lease liabilities (included in other long-term liabilities)2,126 1,619 
Total lease liabilities$52,140 $48,445 
The components of lease costs recognized in the condensed consolidated statements of operations and comprehensive loss consist of the following for the three and nine month periods ended September 30, 2023 and 2022 and are included in selling, general, and administrative expenses unless otherwise noted:
Three Months Ended September 30,Nine Months Ended
September 30,
2023202220232022
Operating lease costs$2,820 $3,161 $8,361 $9,297 
Finance lease costs
Amortization of finance lease right-of-use assets122185354 413 
Interest on finance lease liabilities (included in interest expense)351979 60 
Variable lease costs5608621,742 2,232 
Total lease costs$3,537 $4,227 $10,536 $12,002 
28
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of September 30, 2023:
Operating
Lease		Finance
Leases
2023 (remainder of year after September 30, 2023)$1,679 $188 
202410,940 753 
20259,830 731 
20269,413 492 
20278,194 428 
Thereafter24,154 528 
Total lease payments64,210 3,120 
Less: amount representing interest(14,826)(364)
Present value of lease liabilities49,384 2,756 
Less: current portion of lease liabilities(7,123)(630)
Long-term lease liabilities, net of current portion$42,261 $2,126 
The weighted-average remaining lease term as of September 30, 2023 and December 31, 2022 was 7.01 years and 5.68 years for operating leases and 5.00 years and 5.37 years for finance leases, respectively. The weighted-average discount rate as of September 30, 2023 and December 31, 2022 was 6.56% and 4.88% for operating leases and 5.12% and 3.60% for finance leases, respectively.
The cash paid for amounts included in the measurement of lease liabilities for the nine months ended September 30, 2023 and 2022 is as follows:
Nine Months Ended
September 30,
20232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$7,678 $9,788 
Operating cash flows from finance leases79 60 
Financing cash flows from finance leases387 321 
ROU assets obtained in exchange for new operating lease liabilities9,862 9,771 
ROU assets obtained in exchange for new finance lease liabilities1,103 - 
At September 30, 2023, the Company had entered into two sixty-month finance leases for medical equipment that had not yet commenced. The future commitments related to these leases are approximately $3.8 million and the Company expects to take control of the leased assets early in the fourth quarter.
29
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)

11. Related Parties
Transactions Notes Receivable
The Company enters into promissory notes with physicians of the Company. The notes receivable balances are satisfied through cash payments or settlements through the physicians’ compensation as part of their employee agreement. The notes receivable are amortized over a 60-month period as a reduction of compensation. The notes bear interest at the Company’s incremental borrowing rate (7.14% at September 30, 2023 and 1.57% at December 31, 2022, respectively).
As of September 30,
2023		As of
December 31,
2022		Original
Principal		Issue
Date		Maturity
Date
Notes receivable
Note 2$1,027 $1,057 $5,355 5/1/20194/30/2024
Note 342 119 491 6/1/20195/31/2024
Note 6- 351 1,111 5/22/20205/22/2023
Note 82,065 2,221 2,816 5/1/20205/1/2025
Note 9- 125 125 1/24/20226/30/2023
Total notes receivables3,134 3,873 
Less:  Current portion of notes receivable$(1,630)(1,797)
Notes receivable, less current portion$1,504 $2,076 
Leases
The Company has operating leases for ten of the office facilities owned by employees of the Company. Total cash was approximately $0.6 million and $1.9 million paid for leases to related parties for the both the three and nine months ended September 30, 2023 and 2022, respectively.
Inventory Purchases/Concentration Risk
The Company purchases the majority of pharmaceuticals inventory from a subsidiary under common control of a Legacy AON Shareholder. During the three and nine months ended September 30, 2023 and 2022, the Company purchased from the related party approximately $268.0 million and $239.0 million and $774.0 million and $682.0 million, respectively. These purchases were approximately 86% and 89% and 88% and 86% as a percentage of cost of revenue for the three and nine months ended September 30, 2023 and 2022, respectively. At September 30, 2023 and December 31, 2022, the Company had $113.0 million and $102.1 million, respectively, included in accounts payable for invoices from the related party, representing 94% of accounts payable at each period-end.

12. Equity

Prior Period Presentation

For periods prior to the Reverse Recapitalization, AON LLC had equity and stock-based compensation described below authorized, issued and outstanding. As discussed in Note 1, upon the Closing of the Business Combination, Legacy AON Shareholders received Class A Common Stock, Class B Common Stock, or Class B Prefunded Warrants and AON LLC reclassified their existing Class A, Class A-1, and Class B Units into AON LLC Common Units, pursuant to the terms of the Business Combination Agreement.

30
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)



The Company recasted Historical AON LLC Equity outstanding for the periods prior to the Reverse Recapitalization, equal to the Per Company Unit Exchange Ratio, pursuant to the Business Combination, that was applied to the Class A, Class A-1, and Class B Units. The historical AON LLC units disclosed in this note give effect to the conversion for all periods presented, as follows.

Class A Units

AON LLC had authorized 19,495,376 units of Class A Units, of which 19,495,376 units were issued and were outstanding as of December 31, 2022.

Class A-1 Units

AON LLC had authorized 3,000,245 units of Class A-1 Units, of which 1,842,520 units were issued and were outstanding as of December 31, 2022.

Class B Units (Profit Interest)

The Class B units were issued through the 2017 Profits Interest Plan adopted by the Company in October 2017. The Class B Units represented a non-voting equity interest in AON LLC that entitled the holder to appreciation in the equity value of AON LLC arising after the date of grant and after such time as an applicable hurdle amount is met. AON LLC recognized the cost of services received in exchange for Class B Units based on the grant-date fair value. That cost was recognized over the period during which the service provider is required to provide service in exchange for the award over the requisite service period or based on performance. AON LLC used the Black-Scholes-Merton pricing model to estimate the fair value of profits interest unit awards. On an as converted basis, as of December 31, 2022, AON LLC issued 5,614,176 Class B Units, of which 4,703,628 were vested and outstanding; the remaining 910,548 of Class B units vested upon consummation of the Business Combination. The stock compensation expense that was recognized for the vesting of the Class B Units was less than $0.1 million.

The following table summarizes the changes to AON LLC’s Class A, Class A-1, and Class B Units for the three and nine months ended September 30, 2023, and 2022.


in thousands, except for share and per share amountsThree Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Class A Units, value
Beginning of Period$7,725 $7,725 $7,725 $7,725 
Issuance of Units— — — — 
Impact of the Reverse Recapitalization(7,725)— (7,725)— 
End of Period$— $7,725 $— $7,725 
Class A Units, units
Beginning of Period19,495,376 19,495,376 19,495,376 19,495,376 
Issuance of Units— — — — 
Impact of the Reverse Recapitalization(19,495,376)— (19,495,376)— 
End of Period— 19,495,376 — 19,495,376 
31
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
in thousands, except for share and per share amountsThree Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Class A-1 Units, value
Beginning of Period$31,040 $28,500 $28,500 $28,500 
Issuance of Units7,185 — 9,725 — 
Impact of the Reverse Recapitalization(38,225)— (38,225)— 
End of Period$— $28,500 $— $28,500 
Class A-1 Units, units
Beginning of Period2,281,696 1,842,520 1,842,520 1,842,520 
Issuance of Units718,549 1,157,725 
Impact of the Reverse Recapitalization(3,000,245)(3,000,245)
End of Period— 1,842,520 — 1,842,520 
in thousands, except for share and per share amountsThree Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Class B Units, value
Beginning of Period$80 $90 $80 $80 
Equity based compensation10 5 10 15 
Impact of the Reverse Recapitalization(90)— (90)
End of Period$— $95 $— $95 
Class B Units, units
Beginning of Period4,703,628 4,703,628 4,703,628 4,703,628 
Units Vested910,548 — 910,548 — 
Impact of the Reverse Recapitalization(5,614,176)— (5,614,176)— 
End of Period— 4,703,628 — 4,703,628 

Class B-1 Units

In June and July of 2023, the Company granted a total of 415 AON LLC Class B-1 Units to certain employees under the 2017 Profits Interest Plan (the “Plan”). The Class B-1 Units vested upon the consummation of the Business Combination, therefore, $4.9 million of expense has been recognized in the condensed consolidated statement of operations and comprehensive loss for the three months ended September 30, 2023. Upon the closing of the Business Combination, the vested Class B-1 Units were reclassified to AON LLC Common Units and exchanged for newly issued shares of Class A Common Stock equal to the Per Company Unit Exchange Ratio, pursuant to the Business Combination Agreement, which resulted in the issuance of 1,047,343 shares of New AON Class A Common Stock.

Mezzanine Equity Class C Units

32
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
As described in Note 1, the AON LLC Class C Units were converted into AON LLC Series A Preferred Units as of the Closing Date. Concurrently, New AON issued a number of shares of New AON Series A Preferred Stock equal to the number of AON LLC Series A Preferred Units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor. Promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON LLC Series A Preferred Units. On an as converted basis, as of September 20, 2023, 6,651,610 Series A Preferred Stock were issued to AEA Growth Management LP.

The AON LLC Class C Units were contingently redeemable convertible preferred units and classified as mezzanine equity on the condensed consolidated balance sheet as of June 30, 2023 because the units were redeemable five years from the issuance date, at the option of the holder. As of June 30, 2023, the AON LLC Class C Units were recorded at their initial carrying value, net of offering costs. The Class C Units were not being accreted to redemption value, as the redemption was not probable due to the removal of the redemption right pursuant to the Business Combination. See discussion below.

The Class C Units had materially the same rights as the Series A Preferred Stock issued by the Company to AEA Growth Management LP, the parent of the AON Class C Preferred Investor, with the exception of the “AON LLC Class C Unit Redemption Right” and the “Class C Option to Purchase Additional Shares”, discussed below. Further, the Class C Units did not contain a mandatory conversion feature that allowed AON LLC to force the Class C Investor to convert the Class C Units into another equity unit in AON LLC and the Class C Units did not have a one time conversion price adjustment.

Class C Unit Redemption Right

After the fifth anniversary of the Effective Date (June 7, 2028), the holders of a majority of the Class C Units had the right to cause the Company to redeem all of the Class C Units. The redemption price per Class C Unit was equal to the greater of (i) the Class C Liquidation Preference and (ii) the Fair Market Value of a Class C Unit (the “Class C Redemption Price”). The Class C Liquidation Preference is defined as an amount equal to the sum of (a) the Class C Preferred Return of such Class C Member and (b) the amount of such Class C Member’s Net Invested Capital Contributions of $65.0 million. The Class C Unit Preferred Return is defined as the cumulative, semiannually-compounded return of 8% per annum based on the original Net Invested Capital Contributions of $65.0 million. The Class C Unit Redemption Right was removed as of the Closing of the Business Combination.

Class C Unit Option to Purchase Additional Units

In accordance with the terms of the Amended and Restated Class C Convertible Preferred Unit Purchase Agreement dated June 7, 2023, the Class C Preferred Investor had an option to purchase an additional 378 AON Class C Units until the Closing of the Business Combination at a purchase price of $26,423 per Unit (“Option Feature”). The Company determined that this Option Feature was required to be accounted for as a derivative in accordance with ASC 815. The fair value of the derivative was estimated to be $1.4 million as of June 30, 2023. The Class C Preferred Investor did not exercise this option prior to the Closing of the Business Combination. As a result, the Company recognized a gain of $1.4 million in other (expense) income, net in the condensed consolidated statements of operations and comprehensive loss for the three months ended September 30, 2023. The Class C Unit Option expired as of the Closing of the Business Combination.


Series A Preferred Stock (Mezzanine Equity)

New AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which outside of the Company’s control). As a result, the Company has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity. At the closing of the Business Combination, the Company exchanged existing AON LLC Class C Units for Series A Preferred Stock in the Company. Based on the qualitative changes to the instrument, this exchange is
33
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
considered an extinguishment for accounting purposes, with the Company recording a deemed dividend of $2.1 million to account for the difference between the carrying value of the Class C Units and the fair value of the Series A Preferred Stock at the transaction date. This amount is reflected in the condensed consolidated statements of mezzanine and stockholders’ equity as part of the reverse recapitalization, net. See further discussion on the PIK Dividend discussed below.

The Series A Preferred Stock are not being accreted to redemption value, as the Series A Preferred Stock are not redeemable, nor are they probable of becoming redeemable.

Dividends

The Series A Preferred Stock accrue dividends at a cumulative, semiannually-compounded return of 8% per annum based on the original Net Invested Capital Contributions from the Class C Units of $65.0 million. These dividends may be paid in cash or accumulate into the Accrued Value at the option of New AON. The accrual shall be calculated on June 30 and December 31 and with respect to the semiannually-compounded return, no interest is required to be paid on any present or future Series A Preferred Stock accrued dividends. The Series A Preferred Stock also participate in distributions with the Class A Common stockholders.

On September 20, 2023, the Company issued 6,651,610 Series A Preferred Stock to AEA Growth Management LP. The number of Series A Preferred Stock shares issued at the Closing of the Business Combination was equal to the aggregate Class C Liquidation Preference pursuant to the Business Combination Agreement. As a result, the issuance of the Series A Preferred Stock effectively included an in-kind payout (“PIK”) of the accrued dividend since the calculation of the amount issued was based on the Class C Liquidation Preference. As of the Closing, the Company recorded a dividend of 151,610 Series A Preferred Stock PIK shares with respect to the accrued dividends on the Series A Preferred Stock (the "PIK Dividend").

Voting

The holders of the Preferred Stock are entitled to elect and appoint one of the directors (“Series A Director”) to the Board of Directors. All other directors are appointed by the Class A and Class B Common stockholders. There are no restrictions on which matters the Series A Preferred stockholders are entitled to vote. The Series A Preferred stockholders are entitled to the number of votes equal to the number of shares of Common Stock into which the Series A Preferred Stock would be convertible on the record date of the vote.

Conversion Rights

The Series A Preferred Stock is convertible, at the option of the holder, at any time, and without the payment of additional consideration by the holder, into such number of fully-paid Class A Common Stock as is determined by dividing the Accrued Value by the Conversion Price in effect at the time of conversion (“Conversion Ratio”). The Accrued Value is the Original Issue Price (which is $10.00 per share of Preferred Stock, as adjusted for any stock split, stock dividend, combination, or other recapitalization) plus any unpaid dividends, compounded semi-annually. The Conversion Price is initially $10.00 per Preferred Share subject to adjustment for dilutive issuances of additional shares, dividends to common stockholders, stock splits, mergers, and a five-year anniversary special adjustment based on the volume weighted average price of the common stock. These dividends may be paid in cash or accumulate into the Accrued Value, at the option of New AON, on June 30 and December 31 of each year. The Conversion Rights shall terminate at the close of business on the day prior to the date of a Change of Control.

If at any time on or after the 30th day after the five-year anniversary of the issue date, any of the Series A Preferred Stock remain outstanding and the 30-Day VWAP of the Common Stock is less than $10.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification), then the Conversion Price shall be adjusted to the greater of (x) the 30-Day VWAP on such date of determination and (y) $5.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification).

34
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
New AON also has the right on or after the third-year anniversary of the date of issuance to cause all (but not less than all) of the outstanding shares of Series A Preferred Stock to be converted into shares of Class A Common Stock for each share of Series A Preferred Stock at the Conversion Ratio detailed above. The Company may only convert shares of Series A Preferred Stock into shares of Common Stock if the 30-Day VWAP of the Common Stock immediately prior to the Company Conversion Date is greater than $16.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization).

Liquidation Preferences

In the event of voluntary or involuntary liquidation, dissolution or winding up of the Company or an Initial Public Offering (IPO) or Exit Event, the Series A Preferred Stock have preferential liquidation rights. If a Deemed Liquidation Event were to occur, each Series A Preferred stockholder is entitled to be paid out of the assets of the Company available for distribution, equal to the greater of the following:

(i) The Original Issue Price of $10 per Series A Preferred Stock multiplied by the Applicable Percentage plus any Accrued Dividends on such share of Series A Preferred Stock; or

(ii) Such amount per share as would have been payable had all shares of Series A Preferred Stock been converted into Common Stock immediately prior to such Deemed Liquidation Event.

The Series A Preferred Stock Applicable Percentage is defined as a percentage equal to (a) one hundred twenty-five percent (125%) if an Exit Event, dissolution, liquidation, or winding-up occurs prior to June 7, 2024, (b) one hundred twenty percent (120%) if an Exit Event, dissolution, liquidation, or winding up occurs after June 7, 2024, but prior to June 7, 2025, (c) one hundred fifteen percent (115%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2025, but prior to June 7, 2026, (d) one hundred ten percent (110%) if an Exit Event, dissolution, liquidation, or winding up occurs after June 7, 2026, but prior to June 7, 2027, (e) one hundred five percent (105%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2027, but prior to June 7, 2028, (f) one hundred percent (100%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2028.

Distributions to Class A and Class A-1 Members

On March 4, 2020, the AON LLC entered into the Second Amended and Restated Limited Liability Agreement (“Second Operating Agreement”) which established another class of equity, Class A-1 Units. The Second Operating Agreement provided, among other things, that the Class A and A-1 Units would receive a cumulative, annually-compounded, preferred return of 8.0% and 4.0%, respectively, on capital contributions when and if distributions are declared by the Board of the Company.

Prior to the issuance of the Class C Units on June 7, 2023 as discussed above, the Class A and A-1 unitholders were paid a cash distribution of $4.0 million and $4.1 million, respectively, representing the cumulative accrued preferred return to June 7, 2023.

On June 7, 2023, in connection with the issuance of the Class C Units, AON LLC entered into the Third Amended and Restated Limited Liability Agreement (“Third Operating Agreement”) which, among other things, eliminated any provisions for future preferred returns on Class A and A-1 units.

Class A-1 Anti-Dilution Feature

Prior to the Closing, in the event AON LLC, prior to a Qualified IPO, issued additional membership equity (“Additional Issuance”) at a valuation that represents a purchase price that is less than the New Unit Purchase Price, as defined, AON LLC was obligated to issue additional Class A-1 Units, for no consideration, such that the Class A-1 unitholder maintains the same percentage ownership as prior to the Additional Issuance (“Anti-Dilution Feature”).

35
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
The Company determined that the Anti-Dilution Feature met the definition of a derivative in accordance with ASC 815. The total loss on derivatives for the three months and nine months ended September 30, 2023 relating to this feature is $4.7 million and $9.8 million, respectively, and was recorded in other (expense) income, net in the condensed consolidated statements of operations and comprehensive loss.

As a result of the Anti-Dilution Feature, upon the issuance of the Class C Units on June 7, 2023 and the Closing of the Business Combination on September 20, 2023, the Company issued an additional 174 and 284 Class A-1 Units, that were subsequently converted into 439,176 and 718,549 AON Common Units using the Per Company Unit Exchange Ratio, pursuant to the Business Combination Agreement. The total fair value of the issuance of additional Class A-1 shares on June 7, 2023 and September 20, 2023 was $2.5 million and $7.2 million, respectively, for a cumulative $9.7 million recorded as Class A-1 member equity in the condensed consolidated statements of mezzanine and stockholders’ equity. Upon the Closing of the Business Combination, the Class A-1 Anti-dilution Feature was eliminated and the derivative liability was fully extinguished.


13. Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share of Class A Common Stock and represents the period from September 21, 2023 to September 30, 2023, the period where the Company had Class A and Class B common stock outstanding. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted loss per share. As such, basic and diluted loss per share of Class B Common Stock has not been presented. Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As such, basic and diluted loss per share is computed using the two-class method. For additional information, see Notes 1 and 2.

Basic loss per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted loss per share is based on the weighted-average number of shares of Class A Common Stock used for the basic loss per share calculation, adjusted for the dilutive effect of Public and Private Warrants and Sponsor Earnouts, if any, using the “treasury stock” method and the convertible Series A Preferred Stock, Class B Common Stock, and Class B Prefunded Warrants, if any, using the “if-converted” method. Net loss for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net loss, net of AON Inc. taxes, after giving effect to Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock that accrue dividends, to the extent it is dilutive.


Net loss attributable to Class A Common Stockholders for basic and diluted loss per share $ (1,791,768)
Series A Deemed Dividend (2,089,000)
Series A Preferred Cumulative Dividends (133,032)
Undistributed Net Loss attributable to Class A Common Stockholders $ (4,013,000)

                        
Weighted-average shares for basic and diluted loss per share 6,614,229
Basic & Diluted loss per share of Class A Common Stock $ (0.61)


The following table details the securities that have been excluded from the calculation of weighted-average shares for diluted loss per share for the period presented as they were anti-dilutive. Note that the Sponsor Earnouts are excluded from the calculation of weighted-average shares for diluted loss per share as the contingency had not been met as of the period end.

Series A Preferred Stock                                  6,651,610
36
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
Class B Common Stock                             25,109,551
Class B Prefunded Warrants                         3,000,245
Public and Private Warrants                         14,450,883


14. Redeemable Noncontrolling Interest

Legacy AON Shareholders own 28,109,796 AON LLC Common Units, equal to a 67.9% of the economic interest in AON LLC. Legacy AON Shareholders also own 25,109,551 shares of Class B Common Stock and 3,000,245 Class B Prefunded Warrants, which, together with the AON LLC Common Units, may be redeemed at the option of the Legacy AON Shareholder on a one-for-one basis for shares of Class A Common Stock or the cash equivalent thereof (based on the market price of the shares of Class A Common Stock at the time of redemption) as determined by New AON. If New AON elects the redemption to be settled in cash, the cash used to settle the redemption must be funded through a private or public offering of Class A Common Stock no later than ten (10) business days after the redemption notice date. Upon the redemption of the AON LLC Common Units and Class B
Common Stock for shares of Class A Common Stock or the equivalent thereof, all redeemed shares of Class B Common Stock will be cancelled. The redemption value is determined based on a five-day volume weighted average price (”VWAP”) of the Class A common shares, subject to customary conversion rate adjustments for share splits, share dividends, and similar events affecting Class A Common Stock.

When applying SEC guidance concerning mezzanine classification, the Company understands that due to the NCI holders having control of the Board, if there is a sequence of remotely possible events that could trigger a redemption, this requires the instrument to be classified as temporary equity, without any regard to probability. Accordingly, though the redemption would require such a remotely possible sequence of events, and such remote sequence of events would also require, in management’s view, the Company to take extraordinary actions in order to allow such sequence of events to be remotely possible, the noncontrolling interest is currently classified as temporary equity. In the event that the Legacy AON Shareholders own less than 50% of the outstanding economic interest in AON LLC Common Units due to future redemptions, the noncontrolling interest will be presented as permanent equity.

The redeemable noncontrolling interest is recognized at the greater of (1) its initial fair value plus accumulated earnings/(losses) associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At September 30, 2023, the redeemable noncontrolling interest was recorded based on its redemption value of $369.3 million which exceeded its carrying value by $344.3 million. This measurement adjustment decreased additional paid in capital by $17.6 million and retained earnings (deficit) by $326.7 million.

The following table summarizes the economic ownership of AON LLC, for the period beginning September 20, 2023, the Closing Date of the Reverse Recapitalization, and ending September 30, 2023 (Refer to Note 1).

37
American Oncology Network, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
($ in thousands, except share and per share data)
 Period beginning September 20, 2023 and ending September 30, 2023
AON LLC Units
AON Inc.Legacy AON ShareholdersTotal
Beginning of Period— — — 
Common Units Issued(1)
6,614,229 28,109,796 34,724,025 
Series A Preferred Units Issued6,651,610 — 6,651,610 
Total Units Issued13,265,839 28,109,796 41,375,635 
End of Period13,265,839 28,109,796 41,375,635 
Allocation of income to controlling and noncontrolling interests
32.1 %67.9 %100 %
Allocation of losses to controlling and noncontrolling interests(2)
19.0 %81.0 %100 %
(1) The 6,614,229 of AON Inc. Common Units excludes 2,839,375 units, which is equivalent to the number of Sponsor Earnout Shares, that do not participate in profits and losses and are not included in the controlling interest percentage.

(2) As discussed in Note 13, Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As a result, the consolidated net loss of AON LLC, during the period of September 21, 2023 through September 30, 2023, were allocated to the NCI to reflect the absorption of the Legacy AON Shareholders to a portion of the consolidated net loss of AON LLC. Net losses were not attributed to Series A Preferred Stock.
38
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis provides information which AON’s management believes is relevant to an assessment and understanding of AON’s results of operations and financial condition. You should read the following discussion and analysis of AON’s financial condition and results of operations together with AON’s condensed consolidated unaudited financial statements as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 that are included in this Quarterly Report, and its audited consolidated financial statements as of and for the years ended December 31, 2022 and 2021, together with the related notes thereto, included in the proxy statement/prospectus of Digital Transformation Opportunities Corp., dated July 18, 2023, which is available on the SEC’s website at www.sec.gov (the “Proxy Statement/Prospectus"). This discussion and analysis should also be read together with the description of AON’s business in the section entitled “Information About AON” in the proxy statement/prospectus.

In addition, the following discussion and analysis of AON Inc.’s financial condition and results of operations also contains forward-looking statements that involve risks, uncertainties and assumptions. Actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. The following should be read in conjunction with the sections titled “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors.”
Unless otherwise indicated or the context otherwise requires, references in this AON Management’s Discussion and Analysis of Financial Condition and Results of Operations section to “AON,”, “AON, Inc.”, “New AON”, “we,” “us,” “our,” the “Company,” and other similar terms refers to American Oncology Network, Inc., its consolidated subsidiaries and variable interest entities.
Overview
Since its inception in 2018, AON has offered an innovative model of physician-led, community-based oncology management. AON preserves and elevates community oncology by helping its physicians navigate the complex healthcare landscape, providing them an efficient platform to work autonomously and thrive, and most importantly, improving the quality of patient care that is being delivered. We are an alliance of physicians and veteran healthcare leaders partnering to ensure the long-term success and viability of oncology diagnosis and treatment in community-based settings. As of September 30, 2023, we have approximately 109 physicians and 95 advanced practice providers across 85 locations in 19 states and the District of Columbia. Our robust platform provides oncology practices with comprehensive support, access to revenue- diversifying adjacent services and practice management expertise to empower physicians to make cancer care better for every patient.
Our mission is to provide high quality, cost effective cancer care close to where patients live and work. We believe the key to accessible and equitable healthcare lies in the strength of community healthcare practices and we are committed to closing the gap in cancer care to ensure every patient has access to the optimal, comprehensive care needed to help in their fight against cancer. To accomplish this, we have practices in some of the most densely populated cities as well as rural areas where medical resources are scarce. We deliver cancer care innovation by bringing new treatments to the forum and also by ensuring access to the necessary adjacent services to provide comprehensive quality cancer care and preserving the delivery of personalized cancer care in the community oncology setting.
Through access to care-enhancing patient services such as a centralized specialty pharmacy, wide ranging clinical lab and pathology services, clinical research, diagnostic imaging, a fully integrated technology platform anchored by an oncology- specific electronic medical record system, as well as a caring management team and a variety of financial assistance programs, our patients receive expert cancer care at each of our clinics.
We provide patients a variety of services to enhance patient care throughout the healthcare journey: high-quality and timely laboratory services for routine and specialized testing; in-house professional and technical pathology services providing complete, accurate and timely pathology reports; in-house specialty pharmacy with patient education, financial assistance, and 24/7 patient assistance; and care management support services including nutrition guidance.
As the future of healthcare continues to transition from volume to value, we are at the forefront of this initiative by ensuring we remain focused on care quality over care quantity and maintaining a patient-first mentality. Through an integrated system of seamless communication, coordination and patient care for better health outcomes, AON practices benefit from decreased expenditures through the implementation of centralized administrative services, processes, and technologies designed to support effective decision- making such as optimal pricing on drugs and medical supplies. Our patients benefit through our 24/7 clinical care support leading to a reduction in unnecessary emergency room visits and
39
admissions and enhanced care quality. Ultimately, the payors benefit from more efficient delivery of high-quality, comprehensive services comparable to any hospital system at a lower cost point.
Though our network spans the country, our clinicians are interconnected and focused on driving change not just at their local clinics, but throughout our network. Our Network Practices not only unite in collaboration through a physician advisory board, but they also remain at the forefront of new discoveries and findings by expanding and improving cancer treatment options for every patient through a Pharmacy and Therapeutics Committee that continuously updates its formulary in real time as advanced therapeutics come to market and through participating in clinical research to ensure we remain on the cutting edge of cancer protocols. Patients benefit from convenient access to clinical trials that we participate in without the need to travel to large cities or tertiary cancer care facilities, and personalized care by matching a patient’s cancer to a tailored therapy using molecular profiling.
We have invested significantly in a resilient, integrated technology platform to support the practices which includes a fully integrated electronic health record and a robust decision support tool and analytics engine. Our development of compliance materials ensures consistency and optimal patient experiences that meets or exceeds the Office of Inspector General (“OIG”) guidelines.
We believe that our position in the market and focus on elevating the state of oncology care with our affiliated providers bodes well for future growth. Our proprietary technology platform supports this growth and enables the Network Practices to standardize and deliver consistent care at scale. We believe that our model will support growth into new markets and allow us to continue to service more patients across the United States.

The Business Combination
Digital Transformation Opportunities Corp. (“DTOC”), American Oncology Network, LLC (“AON LLC”), GEF AON Holdings Corp. (“AON Class C Preferred Investor”), and DTOC Merger Sub, Inc., a direct, wholly owned subsidiary of DTOC (“Merger Sub”) entered into a Business Combination Agreement (the “Business Combination Agreement”), dated as of June 14, 2023 (which further amended and restated the Business Combination Agreement entered into by DTOC and AON as of October 5, 2022, and amended and restated on January 6, 2023, and April 27, 2023), pursuant to which, among other transactions, on September 20, 2023 (the “Closing Date”), DTOC and AON undertook a series of transactions (the “Business Combination”) resulting in the organization of the combined post-business combination company as an umbrella partnership C corporation, in which substantially all of the assets and the business of the combined company are held by AON LLC, and DTOC became a member of AON LLC. In connection with the closing of the Business Combination (“the Closing”), DTOC changed its name to “American Oncology Network, Inc.”. The Business Combination was completed on September 20, 2023.

As a result of, and in connection with, the Closing, among other things, (i) AON LLC amended and restated its operating agreement (the “Amended and Restated AON LLC Agreement”) to reclassify its existing Class A units, Class A-1 units and Class B units into a single class of AON LLC common units (“AON LLC Common Units”) that can be exchanged on a one-to-one basis for shares of New AON Class A common stock (“New AON Class A Common Stock”) and its existing AON LLC Class C units into AON LLC Series A preferred units (AON LLC Series A Preferred Units”); (ii) AON LLC converted profit pool units of certain of AON LLC’s subsidiaries into an equal number of AON LLC Common Units and shares of New AON Class B common stock (“New AON Class B Common Stock”), which together are exchangeable into shares of New AON Class A Common Stock (together with the New AON Class B Common Stock, the “New AON Common Stock”); (iii) New AON amended and restated its charter (the “Charter”) to provide for (a) the conversion of all existing shares of DTOC Class B common stock into shares of New AON Class A Common Stock on a one-to-one basis, (b) amendment of the terms of New AON Class B Common Stock to provide holders voting rights but no economic rights and (c) designation of a new series of New AON preferred stock as Series A convertible preferred stock (the “New AON Series A Preferred Stock” or “Series A Preferred Stock") with such rights and preferences as provided for in the certificate of designation of the New Aon Series A Preferred Stock (the “New AON Series A Certificate of Designation”); and (iv) among other things, (a) AON LLC issued common units to New AON in exchange for a combination of cash and shares of New AON Class B Common Stock and warrants to acquire shares of New AON Class B Common Stock (the “Class B Prefunded Warrants”), (b) New AON was admitted as a member of AON LLC, (c) AON LLC distributed shares of New AON Class B common stock or Class B Prefunded Warrants, as applicable, to AON LLC equity holders, (d) New AON reserved a specified number of additional shares of New AON Class A Common Stock after the Closing for issuance to eligible participants, (e) Merger Sub merged with and into the AON Class C Preferred Investor whereby the separate existence of Merger Sub ceased and New AON issued a number of shares of New AON Series A Preferred Stock equal to the number of AON LLC Series A preferred units held by the AON Class C Preferred Investor to
40
AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor (the “First Step”), (f) promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON LLC Series A preferred units and (g) from and after the Closing (but subject to lock-up restrictions), the AON LLC common equity holders (other than New AON), referred to herein as “Legacy AON Shareholders” (former AON LLC Class A, Class A-1, and Class B unit holders), will have the right (but not the obligation) to exchange AON LLC Common Units together with an equal number of shares of New AON Class B Common Stock (whether held directly or indirectly through Class B Prefunded Warrants) for shares of New AON Class A Common Stock.

In addition, in connection with the Closing, DTOC completed the offer to the holders of AON LLC Class B-1 units to exchange their AON LLC Class B-1 units for such number of newly issued shares of New AON Class A Common Stock equal to the ratio set forth in the Business Combination Agreement (such offer, the “Exchange Offer”). DTOC and AON LLC solicited consents from the holders of AON LLC Class B-1 units to make certain amendments to the terms of the awards and the unit grant agreements pursuant to which the AON LLC Class B-1 units were granted, which provided for the automatic exchange, as of immediately prior to the adoption of the Amended and Restated AON LLC Agreement, of all outstanding AON LLC Class B-1 units into shares of New AON Class A Common Stock (collectively, the “Proposed Amendments”). The requisite number of holders of Class B-1 units provided their consent to the Proposed Amendments, and as a result, in connection with the Closing, all AON LLC Class B-1 units were exchanged for an aggregate of 1,047,343 shares of New AON Class A Common Stock.
Basis of Presentation

For the three and nine months ended September 30, 2023, these unaudited condensed consolidated financial statements reflect the consolidated results of operations, comprehensive income (loss), cash flows and changes in equity of AON LLC and its wholly-owned subsidiaries for the period of January 1, 2023 through September 20, 2023, the Closing Date of the Reverse Recapitalization, and the consolidated results of operations, comprehensive income (loss), cash flows and changes in stockholders’ equity of AON Inc. and its consolidated subsidiaries, including AON LLC, for the period of September 21, 2023 through September 30, 2023. The condensed consolidated balance sheet at September 30, 2023 presents the financial condition of AON Inc. and its consolidated subsidiaries, including AON LLC, and reflects the initial recording of the assets and liabilities of AON Inc. at their historical cost. All intercompany balances and transactions of AON LLC prior to the Reverse Recapitalization have been eliminated. All intercompany balances and transactions of AON Inc. after the Reverse Recapitalization have been eliminated.

For the three and nine months ended September 30, 2022, these unaudited condensed consolidated financial statements present the consolidated results of operations, comprehensive income (loss), cash flows and changes in equity of AON LLC. The condensed consolidated balance sheet as of December 31, 2022 presents the financial condition of AON LLC and its wholly-owned subsidiaries. All intercompany balances and transactions of AON LLC have been eliminated.

For both the three and nine months ended September 30, 2023, $1.7 million of the consolidated net loss of AON LLC were attributable to the Class A Common Stockholders, and reflects the Class A Common Stockholders’ absorption of 19.0% of the consolidated net loss of AON LLC for the period of September 21, 2023 through September 30, 2023. For both the three and nine months ended September 30, 2023, $11.9 million of the consolidated net losses of AON LLC were attributable to the noncontrolling interest, and reflects the Legacy AON Shareholders’ absorption of 81.0% of the consolidated net losses of AON LLC for the period of September 21, 2023 through September 30, 2023. For the three and nine months ended September 30, 2023, $15.5 million and $27.0 million of the consolidated net losses of AON LLC were attributable to the Legacy AON Shareholders, respectively, to reflect their absorption of 100% of the consolidated net losses of AON LLC pertaining to the days prior to the Reverse Recapitalization. For the three and nine months ended September 30, 2022, net income of $5.6 million and $1.2 million were attributable to the Legacy AON Shareholders, respectively, to reflect their absorption of 100% of AON LLC’s net income pertaining to the periods prior to the Reverse Recapitalization.
41
Key Factors Affecting Performance & Non-GAAP Measures
Factors Affecting Our Revenues
There are many factors that drive patient service revenues; however, we focus on certain key metrics such as:
•Total patient encounters which include initial consultations and treatments, new patient encounters, recurring patient encounters and treatments, and cancer vs non cancer patients.
•Patient referrals which are also an important driver of patient service revenue; we manage the referral pipeline locally through the coordinated efforts of our physician liaisons working with our physicians to market our practices by visiting referral sources such as, primary care providers and other medical specialties.
Factors Affecting Our Operating Costs
Operating costs are primarily dependent upon factors such as:
•The cost of prescription drugs used in our treatment plans which include both intravenous and oral oncolytics. The management of these costs are a critical component of our business as it is our single largest expense. We manage this cost by strategic volume purchases and continuously evaluating the most clinically effective drug for cancer type through our Pharmaceutical and Therapeutics Committee.
•Clinical compensation and benefits, including non-medical personnel, represent our second largest operating expense. These costs are impacted by both micro and macro-economic factors as well as local competition for personnel that could impact costs associated with personnel. In particular, in all of our markets, we have seen significant increases in compensation for qualified nursing resources. We continuously monitor wages period over period to mitigate the impact of variations in industry and macro-economic labor conditions.
•We lease all of our facilities, therefore real-estate costs are a significant component of our operating costs. We continuously monitor local and national real estate conditions to actively manage our exposure to fluctuating occupancy costs.
Key Non-GAAP Financial Measures We Use to Evaluate Our Performance
Adjusted EBITDA
This filing includes the non-GAAP financial measure “Adjusted EBITDA”. Management views this metric as a useful way to look at the performance of our operations between periods and to exclude decisions on capital investment and financing that might otherwise impact the review of profitability of the business based on present market conditions. Management believes this measure provides an additional way of viewing aspects of the Company’s operations that, when viewed with the GAAP results, provides a more complete understanding of the Company’s results of operations and the factors and trends affecting the business.
Adjusted EBITDA is defined as net income prior to interest income, interest expense, income taxes, and depreciation and amortization, as adjusted to add back certain other non-cash charges that we may record each year, such as stock-compensation expense, as well as non-recurring charges such as expenses incurred related to major operational transitions and transaction costs. We believe these expenses and non-recurring charges are not considered an indicator of ongoing company performance. The measures are used as a supplement to GAAP results in evaluating certain aspects of our business, as described below. We believe Adjusted EBITDA is useful to investors in evaluating our performance because the measure considers the performance of our operations, excluding decisions made with respect to capital investment, financing, and other non-recurring charges as outlined above.
The Company includes Adjusted EBITDA because it is an important measure upon which our management uses to assess the results of operations, to evaluate factors and trends affecting the business, and to plan and budget future periods. However, non-GAAP financial measures should be considered a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Non-GAAP financial measures used by management may differ from the non-GAAP measures used by other companies, including the Company’s competitors. Management encourages investors and others to review the Company’s financial information in its entirety, and not to rely on any single financial measure. Adjusted EBITDA should not be considered as an alternative to net income as an indicator of our performance or as an alternative to any other measure prescribed by GAAP as there are limitations to using such non-GAAP measures. We compensate for these limitations by providing disclosure of the differences between Adjusted
42
EBITDA and GAAP results, including providing a reconciliation to GAAP results, to enable investors to perform their own analysis of our operating results.
Components of Results of Operations
Patient Service Revenue, net
The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) pharmacy benefit managers (“PBMs”); (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”); (iv) state governments under Medicaid and other programs, including managed Medicare and Medicaid; and (v) individual patients.
The primary elements of patient service revenue are from fee for service (“FFS”) revenue which includes revenue from required patient infusion and injection treatments, as well as oral prescription drugs. FFS revenue comprise revenues in which we bill and collect for medical services rendered by our physicians or nurse practitioners including office visits and consults. FFS revenue also includes infusion therapies and treatment. FFS revenue consists of fees for medical services provided to patients. Payments for services provided are generally less than billed charges. The Company records revenue net of an allowance for contractual adjustments, which represents the net revenue expected to be collected from third-party payors (including managed care, commercial, and governmental payors such as Medicare and Medicaid), and patients.
These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient’s healthcare plan, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries). The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on certain factors, such as, the proper completion of medical charts following a patient encounter, proper medical coding of the charts, and the verification and authorization of each patient’s eligibility at the time services are rendered as to the payor(s) responsible for payment of such services.
Oral prescription drugs comprise revenues from prescriptions written by our doctors to their patients which are dispensed directly by AON’s specialty pharmacy. Revenue for the oral prescription is based on fee schedules set by various PBMs and other third-party payors. The fee schedule is often subject to direct and indirect remuneration (“DIR”) fees, which are based primarily on adherence and other metrics. DIR fees may be significant and may be assessed in the periods after payments are received against future payments. The Company recognizes revenue, net of estimated DIR fees, at the time the patient takes possession of the oral drug.
Other Revenue
Other revenue is primarily generated from service arrangements with various hospitals systems and data contracts as well as through clinical trials.
Cost of Revenue
Cost of services primarily includes chemotherapy drug costs, clinician salaries and benefits, medical supplies, and clinical occupancy costs. Clinicians include oncologists, advanced practice providers such as physician assistants and nurse practitioners, and registered nurses. Specialty pharmacy costs primarily include the cost of oral medications dispensed from the specialty pharmacy including overhead costs for running a free-standing pharmacy and shipping costs to patients.
General and administrative
Our general and administrative expenses include corporate occupancy costs, technology infrastructure, operations, clinical and quality support, finance, legal, human resources, and business development. Depreciation and amortization expenses are also included in general and administrative expenses. The Company expects its general and administrative expenses to increase over time following the consummation of the Business Combination due to the additional legal, accounting, insurance, investor relations and other costs that the Company will incur as a public company, as well as other costs associated with continuing to grow the business. While we expect general and administrative expenses to increase in the foreseeable future, such expenses on average are expected to decrease as a percentage of revenue over the long term, as the company continues to scale its operations.

Transaction Expenses
43
Transaction expenses consist of legal services, professional fees and other due diligence expenses that were incurred in connection with the Business Combination. These transaction expenses are considered non-recurring and as a result are included as an add-back in the Company’s adjusted EBITDA calculation.

Results of Operations
Comparison of the Three Months and Nine Months Ended September 30, 2023 and 2022 Revenue
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
(dollars in thousands)20232022$%20232022$%
Patient service revenue, net$332,195 $293,612 $38,583 13.1 %$945,681 $840,507 $105,174 12.5 %
Other revenue4,110 3,712 398 10.7 %9,322 8,765 557 6.4 %
Total revenue$336,305 $297,324 $38,981 13.1 %$955,003 $849,272 $105,731 12.4 %
For the three months ended September 30, 2023 and 2022 revenue increased $39.0 million, or 13.1%, primarily due to a $38.6 million increase in patient service revenue and a $0.4 million increase in other revenue.

For the nine months ended September 30, 2023 and 2022 revenue increased by $105.7 million, or 12.4%, primarily due to a $105.1 million increase in patient service revenue and a $0.6 million increase in other revenue.
Patient service revenue, net
For the three months ended September 30, 2023 and 2022 the $38.6 million increase in revenue is attributable to organic growth seen between periods due to an increase of patient encounters of 6.0% driving $38.1 million of the revenue increase.

For the nine months ended September 30, 2023 and 2022 the $105.2 million increase in revenue is partially attributable to organic growth seen between periods due to an increase of patient encounters of 5.7% driving $86.0 million of the revenue increase. An additional $19.1 million increase in patient service revenue was due to the impact of one acquisition and five affiliate agreements in 2022 which are fully reflected in the nine months ended September 30, 2023 as well as three affiliate agreements entered into during the nine months ended September 30, 2023.
Other revenue
For the three months ended September 30, 2023 and 2022 other revenue increased $0.4 million primarily due to an increase in clinical trial revenue.

For the nine months ended September 30, 2023 and 2022 other revenue increased $0.6 million primarily due to an increase in clinical trial revenue.




44
Operating Expenses

Three Months Ended September 30,ChangeNine Months Ended September 30,Change
(dollars in thousands)20232022$%20232022$%
Cost of revenue$310,894 $267,647 $43,247 16.2 %$880,827 $780,658 $100,169 12.8 %
General and administrative expenses25,199 23,432 1,767 7.5 %72,831 66,155 6,676 10.1 %
Transaction expenses
24,603 151 24,452 *29,886 151 29,735 *
Total costs and expenses$360,696 $291,230 $69,466 23.9 %$983,544 $846,964 $136,580 16.1 %
* — % not meaningful
For the three months ended September 30, 2023 and 2022, operating expenses increased $55.0 million, or 18.9%, due to a $43.2 million increase in cost of revenue, a $1.8 million increase in general and administrative expenses and a $10.0 million increase in transaction expenses.

For the nine months ended September 30, 2023 and 2022, operating expenses increased $122.2 million, or 14.4%, due to a $100.2 million increase in cost of revenue, a $6.7 million increase in general and administrative expenses and a $15.3 million increase in transaction expenses.
Cost of revenue
For the three months ended September 30, 2023 and 2022, cost of revenue increased $43.2 million which was primarily driven by drug and medical supply costs, due to both increased patient encounters and cost per encounter. The volume of patient encounters at our practices increased cost of revenue by $13.4 million, and the cost per encounter drove a $24.2 million increase. The increased cost of patient encounters was driven by a combination of higher drug and supply costs as well as the drug and service mix patients required. Company also incurred a one time, non-recurring $4.8 million expense related to non-cash stock compensation as a result of closing of the transaction. The remaining increase of cost of revenue relates to drug and supply costs from two affiliate agreements entered into during the three months ended September 30, 2023.

For the nine months ended September 30, 2023 and 2022, cost of revenue increased $100.2 million which was primarily driven by drug and medical supply costs, due to both increased patient encounters and cost per encounter. The volume of patient encounters at our practices increased cost of revenue by $35.7 million, and the cost per encounter drove a $44.1 million increase. The increased cost of patient encounters was driven by a combination of higher drug and supply costs as well as the drug and service mix patients required. An additional $15.9 million of increase in cost of revenue relates to drug and supply costs from one acquisition and five affiliate agreements in 2022 which are fully reflected in the nine months ended September 30, 2023 as well as three affiliate agreements entered into during the nine months ended September 30, 2023. Company incurred a one time, non-recurring $4.8 million of non-cash stock compensation expense as a result of closing of the transaction.
General and administrative expense
For the three months ended September 30, 2023 and 2022, the $1.8 million increase in general and administrative expenses was driven by a $2.0 million increase in costs associated with the Company’s revenue cycle function.

For the nine months ended September 30, 2023 and 2022, the $6.7 million increase in general and administrative expenses was primarily driven by a $5.5 million increase in revenue cycle costs associated with the Company’s growth and optimization of our revenue cycle function. The remaining increase was driven by an increase in depreciation and amortization of $1.1 million.
Transaction expense
For the three months ended September 30, 2023 and 2022, the $24.5 million increase in transaction expenses was driven by the legal, accounting, and consulting fees incurred by the Company due to the Business Combination that closed in September of 2023.
45
For the nine months ended September 30, 2023 and 2022, the $29.7 million increase in transaction expenses was driven by the legal, accounting, and consulting fees incurred by the Company due to the Business Combination that closed in September of 2023.
Other Income (Expense)

Three Months Ended September 30,ChangeNine Months Ended September 30,Change
(dollars in thousands)20232022$%20232022$%
Interest expense$(1,532)$(924)$(608)65.8 %$(4,500)$(2,034)$(2,466)121.2 %
Interest income373 49 324 *499 104 395 *
Other (expense) income, net(3,309)388 (3,697)(952.8 %)(7,689)849 (8,538)(1005.7 %)
Total other expense$(4,468)$(487)$(3,981)817.4 %$(11,690)$(1,081)$(10,609)981.4 %
* — % not meaningful
Interest expense
The increase in interest expense for the three and nine months ended September 30, 2023 was due to an increase in interest rates resulting from an increase in the federal funds rate from 3.25% in the third quarter of 2022 to 5.50% in the third quarter of 2023.
Other (expense) income, net
For the three months ended September 30, 2023 and 2022 the increase in other expense is attributable to a non-cash charge of $3.3 million related to the fair value adjustment of the Class A-1 & Class C derivative liability, in addition to a non-cash charge of $0.2 million related to the fair value of the Public and Private Warrant liabilities.

For the nine months ended September 30, 2023 and 2022 the increase in other expense is attributable to a non-cash charge of $8.3 million related to the fair value adjustment of the Class A-1 & Class C derivative liability, in addition to a non-cash charge of $0.2 million related to the fair value of the Public and Private Warrant liabilities.
Income taxes
Three Months Ended September 30,
ChangeNine Months Ended September 30,Change
(dollars in thousands)20232022$%20232022$%
Provision for income taxes
$315 $— $315 *$315 $— $315 *
Effective tax rate
(1.1)%— %(0.8)%— %
* — % not meaningful
The Company’s effective income tax rate was (1.1)% and 0% for the three months ended September 30, 2023 and 2022, respectively and (0.8)% and 0% for the nine months ended September 30, 2023 and 2022 respectively. The effective income tax rate for the three and nine months ended September 30, 2023 and 2022 differed from the federal statutory rate primarily as a result of the Closing on September 20, 2023, resulting in a portion of the Company's consolidated pre-tax earnings, which were previously not subject to income taxes, flowing into a taxable corporation included in the Company's post transaction structure.
46

Our Adjusted EBITDA for recent comparative periods is presented as follows:
Comparison of the Three Months and Nine Months Ended September 30, 2023 and 2022
The following table provides a reconciliation of net income, the most closely comparable GAAP financial measure, to Adjusted EBITDA:
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
(dollars in thousands)20232022$%20232022$%
Net loss$(29,205)$5,607 $(34,812)(620.9 %)$(40,797)$1,227 $(42,024)(3424.9 %)
Interest expense, net1,159 875 284 32.5 %4,001 1,930 2,071 107.3 %
Depreciation and amortization2,060 2,159 (99)(4.6 %)6,368 5,318 1,050 19.7 %
Income tax expense
315 — 315 *315 — 315 *
Non-cash stock compensation
4,875 5 4,870 *4,875 15 4,860 *
Operational transformation (a)
— 235 (235)(100.0 %)— 1,409 (1,409)(100.0)%
Gain/loss on derivative liabilities3,316 — 3,316 *8,382 — 8,382 *
Transaction expenses (b)
24,603 151 24,452 *29,886 151 29,735 *
Adjusted EBITDA$7,123 $9,032 $(1,909)(21.1 %)$13,030 $10,050 $2,980 29.7 %
* — % not meaningful
(a) Personnel costs associated with rationalization of our central services cost structure
(b) Transaction expenses are one-time non-recurring and are a result of expenses incurred in connection with the Business Combination.
Adjusted Net Income
Management believes Adjusted Net Income is a useful non GAAP measure because it reflects the impact of non-recurring and recurring, non-cash gain/loss on derivatives and non-cash stock compensation related to the Class B-1 shares that vested in their entirety upon closing of the transaction on net income related to the closing of the Business Combination with DTOC. We define Adjusted Net Income as net income, plus (i) the mark to market charge on derivative liabilities that are (a) non-cash or (b) non-operating in nature, (ii) the mark to market, non-cash charge on the derivative related to the public and private warrants, and (iii) nonrecurring transaction costs incurred by the AON and DTOC in conjunction with the Business Combination. A reconciliation of Adjusted Net Income to net income/loss, its closes GAAP measure, is set forth in the table below.


47
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
(dollars in thousands)20232022$%20232022$%
Net loss$(29,205)$5,607 $(34,812)(620.9 %)$(40,797)$1,227 $(42,024)(3424.9 %)
Plus: Non-cash stock compensation
4,875 5 4,870 *4,875 15 4,860 *
Plus: Gain/loss on derivative liabilities
3,316 — 3,316 *8,382 — 8,382 *
Plus: Transaction expenses (a)
24,603 151 24,452 *29,886 151 29,735 *
Total Adjusted Net Income
$3,589 $5,763 $(2,174)(37.7 %)$2,346 $1,393 $953 68.4 %
* — % not meaningful
(a) Transaction expenses are one-time non-recurring and are a result of expenses incurred in connection with the Business Combination.
Liquidity and Capital Resources 
General
To date, the Company has financed its operations principally through the issuance of membership units and long-term debt, and to a lesser extent, cash flows from operations. As discussed below, on June 7, 2023, the Company entered into an agreement to issue Class C Preferred Units for net proceeds of approximately $64.5 million. As of September 30, 2023, the Company had $51.6 million of cash and cash equivalents, $26.0 million of short-term marketable securities, $81.3 million in outstanding long-term indebtedness, and $1.0 million of availability under its PNC Line of Credit. 
The Company may incur operating losses and generate negative cash flows from operations for the foreseeable future due to the investments management intends to continue making in expanding operations and sales and marketing and due to additional general and administrative expenses management expects to incur in connection with operating as a public company. As a result, the Company may require additional capital resources to execute strategic initiatives to grow the business.
Management believes that the cash on hand, cash proceeds from the Class C issuance, and additional cash from the Business Combination will be sufficient to fund the Company’s operating and capital needs for at least the next 12 months. The Company’s actual results may vary due to, and its future capital requirements will depend on, many factors, including its organic growth rate and the timing and extent of acquisitions of new clinics and expansion into new markets. The Company may in the future enter into arrangements to acquire or invest in complementary businesses. The Company could use its available capital resources sooner than management currently expects. The Company may be required to seek additional equity or debt financing. 

Reverse Recapitalization

The Company closed the Business Combination on September 20, 2023 (“the Closing” or the “Closing Date”). As of the Closing, the Company received $1.4 million of the remaining cash held in the Trust Account after all redemptions. On the Closing Date, the Company paid $7.1 million of DTOC transaction expenses incurred as a result of the Business Combination. The Company assumed an additional $6.1 million in liabilities, of which $3.4 million were related to an excise tax and $2.7 million related to unpaid transaction expenses incurred by DTOC as a result of the Business Combination.
Significant Financing Transactions
2022 Debt Financing Activity
In 2022, the Company amended the PNC Facility and Line of Credit agreements. The primary changes included an increase of the Facility limit from $75.0 million to $125.0 million, a decrease of the PNC Line of Credit amount from $5.0 million to $1.0 million, interest charges to be calculated based on the Bloomberg Short-Term Bank Yield Index plus 1.65%
48
and certain financial covenants. As part of the amendments, the Company drew an additional $16.3 million in proceeds under the Facility. 
The total amount outstanding under the PNC Facility as of September 30, 2023 and December 31, 2022 was $81.3 million, at an interest rate of 7.14% as of September 30, 2023. No amounts were drawn down on the PNC Line of Credit as of September 30, 2023 and December 31, 2022.
2023 Sale of Class C Equity
On April 27, 2023, AON LLC and the AON Class C Preferred Investor entered into a Unit Purchase Agreement, which they subsequently amended and restated on June 7, 2023 (as amended, the “Unit Purchase Agreement”), which provides for an investment of at least $65.0 million with an option to increase the investment to $75.0 million in connection with the issuance of AON Class C Convertible Preferred Units (“AON Class C Units”) to the AON Class C Preferred Investor.
Pursuant to the Unit Purchase Agreement, on June 7, 2023, the AON Class C Preferred Investor purchased, and AON LLC issued and sold to the AON Class C Preferred Investor, 2,459 AON Class C Units at an aggregate purchase price of $65.0 million. Under the Unit Purchase Agreement, the AON Class C Preferred Investor has an option to purchase an additional 378 AON LLC Class C Units until the closing of the Business Combination (the “Closing”), at a purchase price of $26,432 per Unit. This option was not exercised and expired as of the Closing of the Business Combination. In connection with the Class C Unit sale, AON LLC amended and restated its operating agreement, to among other things, authorize 2,837 AON LLC Class C Units of which 2,459 were outstanding as of June 30, 2023 to the AON Class C Preferred Investor. The AON LLC Class C Units were reclassified into AON LLC Series A Preferred Units as of September 20, 2023, the Closing Date. Concurrently, New AON issued a number of shares of New AON Series A Preferred Stock equal to the number of AON Series A Preferred Units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor. Promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON Series A Preferred Units.
2023 Debt Financing Activity
On June 30, 2023, AON entered into Amendment No. 7 to its PNC Loan Facility which primarily extended the maturity date of the Facility from April 30, 2024 to June 30, 2026.


Cash Flows
Historical information regarding sources of cash and capital expenditures in recent periods and analysis of those sources and uses is provided below.
Cash flows for the nine months ended September 30, 2023 and 2022 were as follows:
Nine Months Ended September 30,Change
(dollars in thousands)20232022$%
Net cash (used) provided by in operations
$(6,160)$1,630 $(7,790)(477.9)%
Net cash used in investing activities(24,673)(13,059)(11,614)88.9 %
Net cash provided by financing activities55,560 15,758 39,802 252.6 %
Cash flows from operating activities
Net cash used in operating activities was $6.2 million during the nine months ended September 30, 2023 compared to $1.6 million provided by operations for the comparable period for 2022. The $7.8 million period over period decrease in cash from operations was primarily attributable to:
•The operating cash flows period over period were positively impacted by a $16.4 million improvement in net changes to working capital components.
49
•The impacts from changes in the Medicare advance payments liability, which had no impact on cash flows in the nine month period ended September 30, 2023, but had a $3.7 negative impact in the nine-month period ended September 30, 2022.
•These improvements above were offset by a $28.0 million reduction in cash provided by net loss including the effects of non-cash reconciling items.
Cash flows from investing activities
Net cash used in investing activities was $24.7 million for the nine months ended September 30, 2023 compared to $13.1 million for the comparable period for 2022. The increase in cash used period over period was primarily attributable to the following:
•Purchases of marketable securities for the nine months ended September 30, 2023 of $20.8 million were offset by sales of marketable securities of $4.9 million. Purchases of marketable securities for the nine months ended September 30, 2022 were $11.9 million offset by sales of $2.0 million during this period. This difference resulted in a $6.0 million increase in cash used between periods.
•The $4.5 million increase in purchases of property and equipment during the nine months ended September 30, 2023 compared to 2022 further increased the cash used between periods. Proceeds from disposals of property in the prior period of $1.1 million also contributed to the increase in cash used between periods.
Cash flows from financing activities
Net cash provided by financing activities was $55.6 million for the nine months ended September 30, 2023 compared to net cash provided of $15.8 million for the comparable period for 2022. The period over period increase in cash flows from financing activities was primarily attributable to the issuance of Class C Units which resulted in net proceeds of $64.2 million and proceeds received from the Reverse Recapitalization of $1.5 million. This was offset by distributions to Class A and A-1 members of $9.5 million paid in connection with the Business Combination. The increase in 2023 was further offset by the reduction in borrowings on long-term debt, which were $16.3 million in the prior period and $0.0 during the nine months ended September 30, 2023. There were no debt repayments during the period ended September 30, 2023.

Off Balance Sheet Arrangements
As of the date of this Quarterly Report on Form 10-Q, AON does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with AON is a party, under which it has any obligation arising under a guarantee contract, derivative instrument or variable interest or a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.
AON does not engage in off-balance sheet financing arrangements.
Material Cash Requirements
Based on the Company’s borrowings under the long-term debt arrangement as of September 30, 2023, the Company expects future cash outflows related to interest expense (based on Bloomberg Short-Term Bank Yield Index rate of 7.14% as of September 30, 2023) of $1.4 million for the remainder of 2023 and $5.8 million in 2024.
The Company also expects a cash outflow of $81.3 million related to the repayment of principal when the PNC Loan Facility matures in June of 2026.
The Company expects the following cash flows related to operating leases with third parties: $1.0 million in 2023, $8.4 million in 2024, $7.4 million in 2025, $7.0 million in 2026, $5.8 million in 2027, and $21.1 million thereafter.
The Company expects the following cash flows related to operating leases with related parties: $0.6 million in 2023, $2.4 million in 2024, $2.3 million in 2025, $2.4 million in 2026, $2.3 million in 2027, and $3.0 million thereafter.
50
Cash outflows related to certain vendor contracts with committed expenditures are expected to total approximately $2.3 million. The timing of the expenditures is as follows: $0.8 million in 2023, and $1.5 million in 2024.
The Company does not have any significant supply or other arrangements which result in material cash requirements other than as described above.
Critical Accounting Policies and Estimates
The accompanying consolidated financial statements have been prepared in accordance with GAAP. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions are involved in the calculation of the Company’s allowance for contractual adjustments and allowances for uncollectible on accounts receivable, liabilities for provider compensation, and accrued insurance claim reserves. Actual results could differ from those estimates.

Private Warrants

The fair value of the Private Placement Warrants was determined using Level 3 inputs. The fair value of the Private Placement Warrants was estimated using the Black-Scholes Option Pricing model using the following inputs a) expected annual dividend b) expected volatility c) risk-free rate of return d) expected option term and e) underlying stock price.
Variable Interest Entities
AOMC is a wholly owned subsidiary of AON LLC and neither AOMC nor AON LLC has ownership interest in AON Partners and Partners of Maryland. Both AON Partners and Partners of Maryland are fully owned by physicians. AON LLC operates its physician practices through the MSAs and other contractual agreements between AOMC, AON Partners, and Partners of Maryland. The responsibilities of AOMC include, but are not limited to negotiating provider and payor contracts, employment and compensation decisions, billing and collections, furnishing all supplies and equipment necessary for the respective practice’s operations as well as, necessary real estate, contracting on behalf of AON Partners and Partners of Maryland, entering into leases, holding a power of attorney to perform the above activities, preparing, maintaining and administering all accounting records (including financial reporting), expense payment, and maintenance of all information systems/software. AON LLC is paid a management fee to compensate AOMC for the services provided. AON Central Services is 80% physician owned and 20% owned by AON LLC. AOMC entered into an agreement with AON Central Services, effective January 1, 2023, for AOMC to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. AOMC pays a monthly management fee to AON Central Services equal to the aggregate cost of compensation, benefits and all other costs related to these employees.
Based on various quantitative and qualitative factors, including assessment of certain services performed and relationships held above, management has determined that AON Partners, Partners of Maryland and AON Central Services are all variable interest entities and AOMC is the primary beneficiary who holds the decision-making rights over the activities that most significantly impact AON Partners, Partners of Maryland and AON Central Services’ economic performance through the MSAs and other contractual agreements. Accordingly, the results of AON Partners, Partners of Maryland and AON Central Services have been consolidated with the Company for all periods presented. During the first quarter of 2023, Meaningful Insights Biotech Analytics, LLC (“MIBA”) was established which is also considered a VIE; however, as of September 30, 2023, it had immaterial activity.
Segment Reporting
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the “CODM”). The Company’s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company’s performance. The Company has one operating segment and one reportable segment that are structured around the organizational management of oncology practice operations. All revenues and assets are in the United States.
Revenue Recognition
Revenue is recognized under Accounting Standards Update (“ASU”) 2014-09 Revenue from Contracts with Customers (“Topic 606”). The Company determines the transaction price based upon standard charges for goods and
51
services with anticipated consideration due from patients, third-party payors (including health insurers and government agencies) and others. The Company’s revenue is primarily derived from patient service revenues, which encompass oncology services provided during patient encounters and shipments of pharmacy prescriptions. Performance obligations for the Company’s services provided to patients and most procedures, are satisfied over the time of visit which is the same day services are performed. Performance obligations relating to pharmacy revenue are considered fully satisfied at a point in time upon the customer receiving delivery of the prescription. Accordingly, the Company does not anticipate a significant amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods.
As services are performed and prescriptions are shipped, timely billing occurs for services rendered and prescriptions shipped less discounts provided to uninsured patients and contractual adjustments to third-party payors based upon prospectively determined rates and discounted charges. Payment is requested at the time of service for self-paying patients and for patients covered by third-party payors that are responsible for paying deductibles and coinsurance.
The Company monitors revenue and receivables to prepare estimated contractual allowances for the anticipated differences between billed and reimbursed amounts. Payments from third-party payors and Government programs including Medicare and Medicaid may be subject to audit and other retrospective adjustments. Such amounts are considered on an estimated basis when net patient revenue is recorded and are adjusted as final adjustments are determined.
The Company has a system and estimation process for recording Medicare net patient service revenue and estimated recoupments as it relates to value-based care (“VBC”) revenue included in patient service revenue on the Consolidated Statements of Operations and Comprehensive Income (Loss). The Company’s VBC revenue is primarily generated through its participation in the Enhancing Oncology Model (“EOM”) which is an episode-based payment model to promote high-quality cancer care. Participants enter six-month episode periods, and the Company bills a monthly fee during the six-month period based on a fixed rate per participant per month and the total number of participants. Certain quality and compliance metrics are tracked as part of the program and submitted to CMS at the end of the episode period which may result in recoupment of funds. The Company estimates the recoupment amount by developing a recoupment percentage for each period based on historical known recoupment from CMS and applies the recoupment percentage against total fees for the period. Based on the estimate, the Company accrues a liability representing the expected final recoupments based on historical settlement trends.
Accounts Receivable
Accounts receivable from patients are carried at the original charge for the services provided, and an adjustment is made to the receivable in a contra account based on the historical collection rate for the provider and payor combination. This adjustment takes into consideration any allowance for doubtful accounts. Management determines the allowance for uncollectible accounts based on historical experience.
Business Combinations
The Company evaluates acquired practices in accordance with ASU 2017-01, Business Combinations (Topic 805) — Clarifying the Definition of a Business. This standard clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. Because substantially all of the value of each acquired practice did not relate to a similar group of assets and as each acquired practice contained both inputs and processes necessary to provide economic benefits to the Company, it was determined that each acquisition represents a business combination. Therefore, the transactions have been accounted for using the acquisition method of accounting, which requires, with limited exceptions, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Any excess of the consideration transferred over the estimated fair values of the net assets acquired is recorded as goodwill. Transaction costs related to business combinations are expensed in the period in which they are incurred.
Leases
The Company’s lease portfolio primarily consists of office and equipment leases for its practice facilities. The Company evaluates whether a contract is or contains a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As the Company’s operating leases do not generally provide an implicit rate, the incremental borrowing rate is used based on the information available at
52
commencement date in determining the present value of lease payments. The incremental borrowing rate for a lease is the rate of interest the Company would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The lease term for all of the Company’s operating leases include the noncancellable period of the lease plus any additional periods covered by either a lessee option to extend (or not to terminate) the lease that the lessee is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Lease payments included in the measurement of the operating lease right-of-use (“ROU”) assets and lease liabilities are comprised of fixed payments (including in- substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.
The operating lease ROU assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. The operating lease ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The operating lease liabilities are initially measured at the present value of the unpaid lease payments at the lease commencement date.
Professional Liability
The Company maintains an insurance policy for exposure to professional malpractice insurance risk beyond selected retention levels. Reserves are established for estimates of the loss that will ultimately be incurred on claims that have been reported but not paid and claims that have been incurred but not reported. These reserves are established based on consultation with a third-party actuary. The actuarial valuations consider a number of factors, including historical claims payment patterns, changes in case reserves and the assumed rate of increase in healthcare costs. Management believes the use of actuarial methods to account for these reserves provides a consistent and effective way to measure these subjective accruals. However, due to the sensitive nature of this estimation technique, recorded reserves could differ from ultimate costs related to these claims due to changes in claims reporting, claims payment and settlement practices and differences in assumed future cost increases. Accrued unpaid claims and expenses that are expected to be paid within the next twelve months are classified as current liabilities and included in accrued other. All other accrued unpaid claims and expenses are classified as long-term liabilities and included in other long-term liabilities. Insurance recoveries associated with the unpaid claims are classified as long-term assets included in other assets.
Fair Value of Financial Instruments
Fair value is the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.
Accounting guidance establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:
Level 1Inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.
Level 2Inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.
Level 3Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.
Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement of assets and liabilities being measured within the fair value hierarchy.
Our financial instruments include cash, short-term marketable securities, accounts receivable, notes receivable, accounts payable, accrued expenses, long-term debt and contractual agreements that resulted in derivative liabilities. Our
53
nonfinancial assets such as property and equipment are not measured at fair value on a recurring basis; however, they are subject to fair value adjustments in certain circumstances, such as when there is evidence that impairment may exist.
The carrying amounts of cash, accounts receivable, accounts payable, notes receivable, and accrued expenses approximate their fair value because of the short-term maturity and highly liquid nature of these instruments. We determine the fair value of long-term debt and marketable securities based on various factors including maturity schedules and current market rates.
The fair value of our derivative liabilities was determined using Level 1, Level 2, or Level 3 inputs. The fair value of derivatives that use Level 3 classified inputs was estimated using the Black-Scholes Option Pricing model. There were no transfers between any levels of the hierarchy during any periods presented.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure due to potential changes in inflation or interest rates. We do not hold financial instruments for trading purposes.
Interest Rate Risk
Certain of AON’s outstanding indebtedness bears interest at a floating rate. As a result, AON may be exposed to fluctuations in interest rates to the extent of its borrowings under these arrangements. AON does not currently engage in any hedging or derivative instruments to attempt to offset this risk. Based on the total amount of variable debt outstanding as of September 30, 2023, if the Bloomberg Short-Term Bank Yield Index increased by 1.0% due to normal market conditions, AON’s interest expense will increase by approximately $0.8 million per annum.
AON had $81.3 million of borrowings under loans with variable rates as of September 30, 2023.
Inflation Risk
The healthcare industry is very labor intensive and salaries and benefits are subject to inflationary pressures, as are drug and medical supplies costs, medical equipment and other costs. The nationwide shortage of nurses and other clinical staff and support personnel has been a significant operating issue facing us and other healthcare providers. In particular, like others in the healthcare industry, we have experienced a shortage of nurses and other clinical staff and support personnel in certain geographic areas, which was largely driven by the COVID-19 pandemic. Nationally, the increase demand for healthcare workers has in some regions, required us to offer one-time retention bonuses, pay premium wages above standard compensation for essential workers, and even utilize higher cost temporary labor. This staffing shortage may require us to further enhance wages and benefits to recruit and retain nurses and other clinical staff and support personnel or require us to hire expensive temporary personnel. We have also experienced cost increases related to the procurement of medical supplies and equipment as well as construction of new facilities and additional capacity added to existing facilities. Our ability to pass on increased costs associated with providing healthcare to Medicare and Medicaid patients is limited due to various federal, state and local laws which have been enacted that, in certain cases, limit our ability to increase prices.
We minimize the impact of inflation on our labor, drug, and supply costs primarily through maintaining strong relationship with our suppliers and GPO and renegotiated contracts with our payors. In addition, AOP has a Pharmacy and Therapeutics Committee (“P&T Committee”) that meets biweekly to evaluate and modify the preferred drug formulary. The P&T Committee considers the following in its formulary recommendations: 1) evidence-based research demonstrating favorable clinical outcomes of such treatment; 2) potential adverse events or side effects of such treatment; and 3) cost of such treatment to the applicable stakeholder (patient and payor).
Item 4. Controls and Procedures
Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2023. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s
54
rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company on the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including, our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgement in designing and evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as a result of material weaknesses identified in our internal control over financial reporting, as previously disclosed in our Registration Statement on Form S-1 (File No. 333-274975), our disclosure controls and procedures were not effective as of September 30, 2023. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting as defined under the Exchange Act and by the Public Company Accounting Oversight Board (United States), such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We are in the process of implementing measures designed to improve our internal control over financial reporting to remediate these material weaknesses.
Changes in Internal Control

There has been no change in our internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.


55
Part II - Other Information
Item 1. Legal Proceedings

None.
Item 1A. Risk Factors

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors disclosed in our prospectus dated and filed with the SEC on July 18, 2023, and the other reports that we have filed with the SEC. Any of the risks discussed in such reports, as well as additional risks and uncertainties not currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations, financial condition or prospects.

During the period covered by this Quarterly Report on Form 10-Q, other than the risk factors set forth below, there have been no material changes in our risk factors as previously disclosed.

Risks Relating to Our Common Stock and Warrants

We are obligated to register for resale a substantial amount of our securities in the public market (including the shares of Class A Common Stock issuable upon exercise of our warrants, conversion of our Class B Common Stock, or conversion of our Series A Preferred Stock), and the future resale of such securities or the perception that such sales may occur, may cause the market price of our securities to decline significantly.

We are obligated to register for resale a substantial amount of our securities in the public market and such securities will represent approximately 537% of total AON Class A Common Stock outstanding as of October 1, 2023 (assuming no exercise of any of our warrants). The amount of Class A Common Stock offered for resale will exceed the number of shares of Class A Common Stock currently outstanding because a significant portion of the shares of Class A Common Stock that will be registered and offered for resale is not currently outstanding and are issuable upon the exercise of warrants, conversion of our Class B Common Stock, or conversion of our Series A Preferred Stock. The sale of these securities in the public market, or the perception that holders of a large number of securities intend to sell their securities, could reduce the market price of our Class A Common Stock and public warrants.

Although (i) the AON LLC equityholders for whom 28,109,796 shares are registered for resale hereunder, are currently prohibited from transferring any of their shares of Class B Common Stock or from exchanging their Class B Common Stock together with an equal number of AON LLC common units for Class A Common Stock for a period of 6 months following the Closing Date, and (ii) the Sponsors and its permitted transferees for whom 14,450,833 shares are registered for resale hereunder, are currently prohibited from transferring any of their shares of Class A Common Stock for a period of 12 months following the Closing Date, once such resale restrictions end, the market price of our Class A Common Stock could decline if the holders of currently restricted shares sell them or are perceived by the market as intending to sell them.

Certain existing shareholders purchased our shares at a price below the current trading price of such shares, and may experience a positive rate of return based on the current trading price. Other investors and shareholders may not experience a similar rate of return.

The Sponsor paid the nominal price of $0.003 per share for the shares of Class A Common Stock held by it and $1.50 per private placement warrant. The shares held by the Sponsor and its permitted transferees (including 2,839,375 Earnout Shares, which are subject to vesting) represent approximately 87% of the total outstanding shares of the Company’s Class A Common Stock. As a result of these nominal prices compared with the market prices of our Class A Common Stock and public warrants, which as of November 1, 2023, were $5.89 per share and $0.16 per warrant, respectively, the Sponsor is likely to earn a positive return on its investment even if other holders of shares of Class A Common Stock, including our public stockholders, experience a negative return on their investment in the Company’s securities. As a result, the Sponsor and its permitted transferees may be incentivized to sell its securities when others are not. Other shareholders and investors may not experience a similar rate of return.

56
Because we do not anticipate paying any cash dividends in the foreseeable future, capital appreciation, if any, would be your sole source of gain.

We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of Class A Common Stock would be your sole source of gain on an investment in such shares for the foreseeable future.

A market for our securities may not continue, which would adversely affect the liquidity and price of its securities.

The price of our securities may continue to fluctuate significantly. An active trading market for our securities may never develop or, if developed, it may not be sustained. In addition, the price of our securities can vary due to general economic conditions and forecasts, our general business condition and the release of our financial reports. Additionally, if our securities are not listed on, or become delisted from Nasdaq for any reason, and are quoted on the OTC Bulletin Board, an inter-dealer automated quotation system for equity securities that is not a national securities exchange, the liquidity and price of our securities may be more limited than if we were quoted or listed on Nasdaq or another national securities exchange. You may be unable to sell your securities unless a market can be established or sustained.

Nasdaq may delist our securities from trading on its exchange, which could limit investors’ ability to make transactions in its securities and subject us to additional trading restrictions.

Currently, Class A Common Stock and public warrants are listed on Nasdaq under the symbols “AONC” and “AONCW.” In order to continue the list of these securities on Nasdaq, we are required to maintain certain financial, distribution and stock price levels. Generally, we are required to maintain a public float of $500,000, a minimum market capitalization of $1,000,000 and a minimum number of holders of our securities (generally 300 round lot shareholders). If Nasdaq delists our securities from trading on its exchange and we are not able to list its securities on another national securities exchange, we expect our securities could be quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including:
a.a limited availability of market quotations for our securities
b.reduced liquidity for our securities;
c.a determination that Class A Common Stock is a “penny stock” which will require brokers trading in Class A Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;
d.a limited amount of news and analyst coverage; and
e.a decreased ability to issue additional securities or obtain additional financing in the future.

The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as “covered securities.” Since Class A Common Stock and public warrants are listed on Nasdaq, they are covered securities. However, if our securities were no longer listed on Nasdaq, they would not be covered securities and we would be subject to regulation in each state in which we offer our securities.

Our warrants may never be in the money, and they may expire worthless.

The exercise price for our public warrants is $11.50 per share, and the exercise price for our private placement warrants is $11.50 per share (each as subject to adjustment as described herein), which exceeds the market price of Class A Common Stock, which was $5.89 per share based on the closing price of Class A Common Stock on Nasdaq on November 1, 2023. If all of our warrants were exercised in full for cash, we would receive an aggregate of approximately $166.2 million. We do not expect warrant holders to exercise their warrants and, therefore, we do not expect to receive cash proceeds from any such exercise, for so long as the warrants remain out-of-the money. There can be no assurance that the public warrants will ever be in the money prior to their expiration and, as such, the warrants may expire worthless.

We may redeem unexpired public warrants prior to their exercise at a time that is disadvantageous to the warrant holders, thereby making the warrants worthless.

57
We may redeem outstanding warrants (excluding any private placement warrants held by the Sponsor or its permitted transferees) at any time after they become exercisable and prior to their expiration, at $0.01 per warrant, provided that the last reported sales price (or the closing bid price of Class A Common Stock in the event Class A Common Stock is not traded on any specific trading day) of Class A Common Stock equals or exceeds $18.00 per-share for any 20 trading days within a 30 trading-day period ending on the third business day prior to the date we send proper notice of such redemption, provided that on the date we give notice of redemption and during the entire period thereafter until the time we redeem the warrants, there is an effective registration statement under the Securities Act covering the shares of Class A Common Stock issuable upon exercise of the warrants and a current prospectus relating to them is available. We also have the ability to redeem outstanding warrants (excluding any private placement warrants held by the Sponsor or its permitted transferees) at any time after they become exercisable and prior to their expiration, at $0.10; provided that (i) the last reported sales price of the Class A Common Stock equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, reorganizations and the like) on each of 20 trading days within the 30 trading-day period ending on the third business day prior to the date on which AON sends proper notice of such redemption and (ii) if the last reported sales price of the Class A Common Stock is less than $18.00 per share, the Private Placement Warrants are also concurrently exchanged at the same price (equal to a number of shares of Class A Common Stock) as the outstanding Public Warrants; provided that on the date AON gives notice of redemption and during the entire period thereafter until the time AON redeems the warrants, AON has an effective registration statement under the Securities Act covering the shares of Class A Common Stock issuable upon exercise of the warrants and a current prospectus relating to them is available. If and when the warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of the outstanding warrants could force a warrant holder: (i) to exercise its warrants and pay the exercise price therefore at a time when it may be disadvantageous for it to do so, (ii) to sell its warrants at the then-current market price when it might otherwise wish to hold its warrants or (iii) to accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, will be substantially less than the market value of its warrants.

When the registration statement covering the exercise of the warrants to purchase AON Class A Common Stock is effective, such warrants will become exercisable, which could increase the number of shares eligible for future resale in the public market and result in dilution to its stockholders.

As of the closing of the Business Combination, there were 8,337,500 public warrants and 6,113,333 private placement warrants outstanding, all of which will become exercisable when the registration statement covering the exercise of such warrants is effective. Each public warrant entitles its holder to purchase one share of Common Stock at an exercise price of $11.50 per share, and each private placement warrant entitles its holder to purchase one share of Common Stock at an exercise price of $11.50 per share (subject to adjustment as described herein). To the extent warrants are exercised, additional shares of Common Stock will be issued, which will result in dilution to our then existing stockholders and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market could depress the market price of Class A Common Stock.

Future offerings of debt or offerings or issuances of equity securities by us may adversely affect the market price of Class A Common Stock or otherwise dilute all other stockholders.

In the future, we may attempt to obtain financing or to further increase our capital resources by issuing additional shares of our Class A Common Stock or offering debt or other equity securities, including commercial paper, medium-term notes, senior or subordinated notes, debt securities convertible into equity or shares of preferred stock. We also expect to grant equity awards to employees, directors, and consultants under our stock incentive plans. Future acquisitions could require substantial additional capital in excess of cash from operations. We would expect to obtain the capital required for acquisitions through a combination of additional issuances of equity, corporate indebtedness and/or cash from operations.

Issuing additional shares of common stock or other equity securities or securities convertible into equity may dilute the economic and voting rights of our existing stockholders or reduce the market price of our Class A Common Stock or both. Upon liquidation, holders of such debt securities and preferred shares, if issued, and lenders with respect to other borrowings would receive a distribution of our available assets prior to the holders of our Class A Common Stock. Debt securities convertible into equity could be subject to adjustments in the conversion ratio pursuant to which certain events may increase the number of equity securities issuable upon conversion. Preferred shares, if issued, could have a preference with respect to liquidating distributions or a preference with respect to dividend payments that could limit the our ability to pay dividends to the holders of the Class A Common Stock. Our decision to issue securities in any future offering will
58
depend on market conditions and other factors beyond our control, which may adversely affect the amount, timing and nature of our future offerings.

The price of Class A Common Stock could decline if securities analysts do not publish research or if securities analysts or other third parties publish inaccurate or unfavorable research about us.

The trading market for Class A Common Stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few securities or industry analysts commence coverage of us, the trading price for Class A Common Stock could be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model or the performance of Class A Common Stock, or if our results of operations fail to meet the expectations of analysts, the price of Class A Common Stock would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline.
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities

None.
Item 3. Defaults Upon Senior Securities

None.
Item 4. Mine Safety Disclosures

Not applicable.
Item 5. Other Information

None.
Item 6. Exhibits
4.1
Form of Class B Warrant (incorporated by reference to exhibit 4.2 to the registration statement on Form S-1, filed with the SEC on October 13, 2023)
31.1
31.2
32.1
32.2
99.1
Form of Indemnification Agreement (incorporated by reference to exhibit 99.1 to the registration statement on Form S-1, filed with the SEC on October 13, 2023
101.INSInline XBRL Instance Document.*
101.SCHInline XBRL Taxonomy Extension Schema Document.*
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.*
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.*
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.*
104Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)
* Filed herewith
** Furnished herewith
59
Signatures

Pursuant to the requirements of the Securities and Exchange Act 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 14, 2023
AMERICAN ONCOLOGY NETWORK, INC.
By:/s/ Todd Schonherz
Name:Todd Schonherz
Title:Chief Executive Officer

Dated: November 14, 2023
AMERICAN ONCOLOGY NETWORK, INC.
By:/s/ David Gould
Name:David Gould
Title:Chief Financial Officer


60
 EX-31.1 2 aonc-302certceoexhibit311.htm EX-31.1 Document

Exhibit 31.1



CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002


I, Todd Schonherz, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of American Oncology Network, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined by Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting


November 14, 2023

By: /s/ Todd Schonherz        

Todd Schonherz
Chief Executive Officer

 EX-31.2 3 aonc-302certcfoexhibit312.htm EX-31.2 Document

Exhibit 31.2



CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002


I, David Gould, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of American Oncology Network, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined by Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting


November 14, 2023

By: /s/ David Gould        

David Gould
Chief Financial Officer

 EX-32.1 4 aonc-906certceoexhibit321.htm EX-32.1 Document

Exhibit 32.1


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I, Todd Schonherz, certify that:


To my knowledge, the Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of American Oncology Network, Inc.


November 14, 2023

By: /s/ Todd Schonherz            

Todd Schonherz
Chief Executive Officer


 EX-32.2 5 aonc-906certcfoexhibit322.htm EX-32.2 Document

Exhibit 32.2


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I, David Gould, certify that:


To my knowledge, the Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of American Oncology Network, Inc.


November 14, 2023

By: /s/ David Gould            

David Gould
Chief Financial Officer


 EX-101.SCH 6 aonc-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Mezzanine and Members’ Equity link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows - Parenthetical link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Business link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Reverse Capitalization link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Variable Interest Entities link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Supplemental Condensed Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Long-term Debt link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Related Parties link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Redeemable Noncontrolling Interest link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Business (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Reverse Capitalization (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Variable Interest Entities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Supplemental Condensed Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Long-term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Related Parties (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Redeemable Noncontrolling Interest (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Business (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Reverse Capitalization - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Reverse Capitalization - Schedule of Historical Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Variable Interest Entities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Variable Interest Entities - Schedule of Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Marketable Securities - Remaining Contractual Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Business Combinations (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Other Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Accrued Other (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Long-term Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Long-term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Leases - Right-of-use Assets And Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Leases - Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Leases - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Related Parties - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Related Parties - Notes Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Equity - Schedule of Changes in Units (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Net Loss Per Share - Calculation Of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Redeemable Noncontrolling Interest - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Redeemable Noncontrolling Interest - Schedule of Ownership (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 aonc-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 aonc-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 aonc-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Consolidated Entities [Axis] Consolidated Entities [Axis] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Oral pharmaceuticals Oral Pharmaceuticals [Member] Oral Pharmaceuticals Net loss attributable to noncontrolling interest Net loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Offering Costs Deferred Charges, Policy [Policy Text Block] Pay vs Performance Disclosure [Line Items] Proceeds from sales of marketable securities Proceeds from Sale of Debt Securities, Available-for-Sale Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Changes in operating assets and liabilities, net of reverse recapitalization: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Related Party Transaction [Line Items] Related Party Transaction [Line Items] Notes receivable - related parties Financing Receivable, after Allowance for Credit Loss, Noncurrent Note 9 2023 Notes Receivable, Note 9 [Member] 2023 Notes Receivable, Note 9 Redemption value of noncontrolling interest Redeemable Noncontrolling Interest, Equity, Redemption Value All Award Types Award Type [Domain] Units vested upon consummation of business combination (in units) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested Upon Consummation Of Business Combination Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested Upon Consummation Of Business Combination Directors and Officers Liability Insurance Directors and Officers Liability Insurance [Member] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Issuance of Class C Units, net of offering costs Temporary Equity, Stock Issued During Period, Value, New Issues Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Revolving Credit Facility Revolving Credit Facility [Member] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] DTOC Sponsor DTOC Sponsor [Member] DTOC Sponsor Reverse Recapitalization, net (in shares) Temporary Equity, Shares, Reverse Recapitalization Temporary Equity, Shares, Reverse Recapitalization MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Computer equipment Computer Equipment [Member] Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Accrued transaction costs Reverse Recapitalization, Accrued Transaction Costs Reverse Recapitalization, Accrued Transaction Costs Capital Unit, Class B-1 Capital Unit, Class B-1 [Member] Capital Unit, Class B-1 Operating 
Lease Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Measurement Input, Price Volatility Measurement Input, Price Volatility [Member] Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Finance lease not yet commenced, term of contract (in months) Lessee, Finance Lease, Lease Not yet Commenced, Term of Contract Supplier [Axis] Supplier [Axis] Finance lease not yet commenced, number of leases Lessee, Finance Lease, Lease Not yet Commenced, Number of Leases Lessee, Finance Lease, Lease Not yet Commenced, Number of Leases Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Unwind agreement, liability Business Acquisition, Unwind Agreement, Liability Business Acquisition, Unwind Agreement, Liability Equity Equity [Text Block] MIBA MIBA [Member] MIBA Professional Liability Malpractice Loss Contingency, Policy [Policy Text Block] Income Taxes Income Tax Disclosure [Text Block] Business Business Description and Basis of Presentation [Text Block] Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Ownership [Axis] Ownership [Axis] Physician Owned Physicians [Member] Physician Owned Property and equipment, gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Noncontrolling Interest [Abstract] Issuance of additional Class A-1 Units pursuant to the Anti-Dilution Feature (in shares) Stock Issued During Period, Shares, Derivative Feature Stock Issued During Period, Shares, Derivative Feature Current liabilities Liabilities, Current [Abstract] Noncontrolling Interest [Table] Noncontrolling Interest [Table] Stockholders' Equity, Conversion Right [Domain] Stockholders' Equity, Conversion Right [Domain] Stockholders' Equity, Conversion Right [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Issuance of notes receivable - related parties Payments to Acquire Notes Receivable Earnings (loss) per unit, diluted (in usd per share) Diluted loss per share of Class A Common Stock (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Patient accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Refund liability Customer Refund Liability, Current Threshold stock price, conversion price adjustment (in usd per share) Stockholders' Equity, Conversion, Stock Price Stockholders' Equity, Conversion, Stock Price Schedule of Reverse Recapitalization, Ownership Summary Schedule Of Reverse Recapitalization, Ownership Summary [Table Text Block] Schedule Of Reverse Recapitalization, Ownership Summary Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Line of Credit Line of Credit [Member] Malpractice insurance, coverage per claim Malpractice Insurance, Maximum Coverage Per Incident Other income (expense) Other Nonoperating Income (Expense) [Abstract] Bloomberg Short-Term Bank Yield Index Bloomberg Short-Term Bank Yield Index [Member] Bloomberg Short-Term Bank Yield Index Redeemable noncontrolling interest Beginning Balance Ending Balance Redeemable Noncontrolling Interest, Equity, Carrying Amount Trading Symbol Trading Symbol Reverse Recapitalization Reverse Recapitalization Disclosure [Text Block] Reverse Recapitalization Disclosure Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Common Units Member Units [Member] Net income (loss) before noncontrolling interest Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] 2025 Finance Lease, Liability, to be Paid, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Leases Lessee, Operating Leases [Text Block] Corporate bonds Corporate Bond Securities [Member] AON Central AON Central [Member] AON Central Property and equipment, net Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Stockholders' equity, conversion, threshold stock price (in dollars per share) (less than) (greater than) Stockholders' Equity, Conversion, Threshold Stock Price Stockholders' Equity, Conversion, Threshold Stock Price Liabilities, Mezzanine Equity, and Stockholders' Equity Liabilities and Equity [Abstract] Entity Ex Transition Period Entity Ex Transition Period Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Clinical Trials Clinical Trials [Member] Clinical Trials Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders' equity Equity, Attributable to Parent [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Gross Unrealized
Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax AON Inc. AON Inc. [Member] AON Inc. Number of oncology practices Number Of Oncology Practices Number Of Oncology Practices Schedule of Affiliation Agreements Schedule Of Affiliation Agreements [Table Text Block] Schedule Of Affiliation Agreements Executive Category: Executive Category [Axis] Common Class B Common Class B [Member] Dividends [Domain] Dividends [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Fair value adjustment to redeemable noncontrolling interest Fair value adjustment to redeemable noncontrolling interest Adjustments To Additional Paid In Capital, Fair Value Adjustment, Redeemable Noncontrolling Interest Adjustments To Additional Paid In Capital, Fair Value Adjustment, Redeemable Noncontrolling Interest Schedule of Property and Equipment, net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Class B Prefunded Warrants Class B Prefunded Warrants [Member] Class B Prefunded Warrants Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Number of board of managers designated by company Number Of Board Of Managers Designated By Company Number Of Board Of Managers Designated By Company Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Accrued compensation and benefits Employee-related Liabilities Local Phone Number Local Phone Number Patient accounts receivable, net Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Earnout period (in years) Derivative Instrument, Contingent Consideration, Liability, Earnout Period Derivative Instrument, Contingent Consideration, Liability, Earnout Period Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share Warrant [Member] Long-term operating lease liabilities Long-term lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Class B-1 Common Stock, Class B-1 [Member] Common Stock, Class B-1 Medical equipment Medical Equipment [Member] Medical Equipment Basis of Presentation and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Reverse Recapitalization [Abstract] Reverse Recapitalization Class A and A-1 preferred returns and tax distributions Payments Of Preferred Returns And Tax Distributions Payments Of Preferred Returns And Tax Distributions Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Undistributed net loss, dilutive Undistributed Earnings, Diluted Offering costs Offering costs Payments of Stock Issuance Costs Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Reverse Recapitalization, net Redeemable Noncontrolling Interest, Reverse Recapitalization Redeemable Noncontrolling Interest, Reverse Recapitalization Quarterly collateral released Debt Instrument, Collateral Released, Quarterly Debt Instrument, Collateral Released, Quarterly Schedule of Long-Term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Public Warrant Public Warrant [Member] Public Warrant Goodwill and intangibles, net Intangible Assets, Net (Including Goodwill) Lessee, Operating Lease, Liability, to be Paid, Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Reverse Recapitalization Schedule Of Reverse Recapitalization [Table Text Block] Schedule Of Reverse Recapitalization Cash and cash equivalents and marketable securities, aggregate fair value Cash, Cash Equivalents And Available-For-Sale Debt Securities Cash, Cash Equivalents And Available-For-Sale Debt Securities Measurement Input, Risk Free Interest Rate Measurement Input, Risk Free Interest Rate [Member] Product and Service [Domain] Product and Service [Domain] Series A convertible preferred stock; $0.0001 par value; 7,500,000 shares authorized; 6,651,610 issued and outstanding at September 30, 2023, with an aggregate liquidation preference of $66,649,130 at September 30, 2023. Beginning Balance Ending Balance Temporary Equity, Carrying Amount, Attributable to Parent Other Performance Measure, Amount Other Performance Measure, Amount Total Net Liabilities Reverse Recapitalization, Net Reverse Recapitalization, Net Debt Instrument, Threshold Limit, Period Two Debt Instrument, Threshold Limit, Period Two [Member] Debt Instrument, Threshold Limit, Period Two Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Lease, Cost Lease, Cost [Table Text Block] Inventories Inventories Increase (Decrease) in Inventories Unrealized gains (losses) on marketable securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Award Type Award Type [Axis] Antidilutive shares excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Grants in period (in units) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Common unit, value Beginning of Period End of Period Common Unit, Issuance Value Interest expense Interest Expense Changes in accounts payable for capital additions to property and equipment Capital Expenditures Incurred but Not yet Paid Reverse Recapitalization, net Stock Issued During Period, Value, Reverse Recapitalization Stock Issued During Period, Value, Reverse Recapitalization Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] ROU assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Trading Arrangement: Trading Arrangement [Axis] Related Parties Related Party Transactions Disclosure [Text Block] Note 8 2025 Notes Receivable, Note 8 [Member] 2025 Notes Receivable, Note 8 Less: amount representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Accounting Estimates and Assumptions Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Notes receivable, amortization period (in months) Financing Receivable, Amortization Period Financing Receivable, Amortization Period Leases Lessee, Finance Leases [Text Block] Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Current portion of operating lease liabilities Less: current portion of lease liabilities Operating Lease, Liability, Current Interest on finance lease liabilities (included in interest expense) Finance Lease, Interest Expense Deferred offering costs Deferred Offering Costs Reverse Recapitalization, Change In Units [Roll Forward] Reverse Recapitalization, Change In Units [Roll Forward] Reverse Recapitalization, Change In Units Total right-of-use assets Lease, Right-Of-Use Asset Lease, Right-Of-Use Asset Accounts payable Accounts Payable Medicare advance payments Increase (Decrease) In Advances Increase (Decrease) In Advances Description Of Business And Significant Accounting Policies [Line Items] Description Of Business And Significant Accounting Policies [Line Items] Description Of Business And Significant Accounting Policies [Line Items] Entity Shell Company Entity Shell Company 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recently Adopted Accounting Pronouncements  and Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date PNC Line of Credit PNC Line Of Credit [Member] PNC Line Of Credit Note 2 2024 Notes Receivable, Note 2 [Member] 2024 Notes Receivable, Note 2 Counterparty Name [Domain] Counterparty Name [Domain] Other long-term liabilities Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Beginning of period End of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Anti-Dilution Feature Anti-Dilution Feature [Member] Anti-Dilution Feature 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Equity, Attributable to Noncontrolling Interest [Roll Forward] Equity, Attributable to Noncontrolling Interest [Roll Forward] Measurement Input, Expected Term Measurement Input, Expected Term [Member] Public and Private Warrants Public And Private Warrants [Member] Public And Private Warrants Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Variable lease costs Variable Lease, Cost Operating lease costs Operating Lease, Cost Weighted average shares of Class A Common Stock Outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Dividends Paid, Event Prior to June 7, 2027, After June 7, 2026 Dividends Paid, Event Prior to June 7, 2027, After June 7, 2026 [Member] Dividends Paid, Event Prior to June 7, 2027, After June 7, 2026 Excise taxes payable Sales and Excise Tax Payable Common stock, shares issued (in shares) Common Stock, Shares, Issued Units vested (in units) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Purchase price (less than) Business Combination, Consideration Transferred Bank fee (in percent) Line of Credit Facility, Commitment Fee Percentage Par value (dollars per share) Temporary Equity, Par or Stated Value Per Share Security Exchange Name Security Exchange Name Option to purchase additional units (in shares) Temporary Equity, Option To Purchase Additional Units Temporary Equity, Option To Purchase Additional Units Total debt Long-Term Debt Current portion of notes receivable - related parties Less:  Current portion of notes receivable Financing Receivable, after Allowance for Credit Loss, Current Issuance of additional Class A-1 Units pursuant to the Anti-Dilution Feature Stock Issued During Period, Value, Derivative Feature Stock Issued During Period, Value, Derivative Feature Capital Unit, Class [Domain] Capital Unit, Class [Domain] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Employee Stock Option Employee Stock Option [Member] Adjustment to APIC, transaction costs Adjustments to Additional Paid in Capital, Recapitalization, Transaction Costs Adjustments to Additional Paid in Capital, Recapitalization, Transaction Costs Common Class A Common Class A Common Class A [Member] Redeemable Noncontrolling Interest Noncontrolling Interest Disclosure [Text Block] Total costs and expenses Costs and Expenses Redemption ratio Stockholders' Equity, Redemption Ratio Stockholders' Equity, Redemption Ratio Number of shares subject to vesting (in shares) Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Number Of Shares Subject To Vesting Conditions Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Number Of Shares Subject To Vesting Conditions Document Type Document Type Schedule of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] Tabular List, Table Tabular List [Table Text Block] Minimum funding threshold (in percent) Debt Instrument, Minimum Funding Threshold, Percentage Debt Instrument, Minimum Borrowing Threshold, Percentage Entity Address, Address Line One Entity Address, Address Line One Current Lease Liability, Current [Abstract] Lease Liability, Current Entity Address, Address Line Two Entity Address, Address Line Two 2026 Finance Lease, Liability, to be Paid, Year Three Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Tax distributions Stockholders' Equity, Tax distributions Stockholders' Equity, Tax distributions Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale 2024 Finance Lease, Liability, to be Paid, Year One Business Acquisition [Axis] Business Acquisition [Axis] Excise taxes payable Taxes Payable, Current Warrant, exercise period, after initial public offering Class Of Warrant Or Right, Exercise Period, After Initial Public Offering Class Of Warrant Or Right, Exercise Period, After Initial Public Offering Net loss Net Income (Loss), Portion Attributable to Parent, Before Recapitalization Net Income (Loss), Portion Attributable to Parent, Before Recapitalization Issuance of Class C Units, net of offering costs (in shares) Temporary Equity, Stock Issued During Period, Shares, New Issues Temporary Equity, Stock Issued During Period, Shares, New Issues Allocation of income to controlling and noncontrolling interests (in percent) Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Income Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Income Anti-dilution feature at fair value Derivative, Fair Value, Net Temporary equity, redeemable period Temporary Equity, Redeemable Period Temporary Equity, Redeemable Period Due to AON LLC and subsidiaries, net Other Liabilities, Current Mezzanine equity Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Variable Rate [Axis] Variable Rate [Axis] Temporary Equity Temporary Equity [Member] Temporary Equity Income Statement [Abstract] Inventory [Line Items] Inventory [Line Items] Impact of the Reverse Recapitalization Common Unit, Value, Impact Of The Reverse Recapitalization Common Unit, Value, Impact Of The Reverse Recapitalization Debt Instrument, Threshold Limit, Period [Domain] Debt Instrument, Threshold Limit, Period [Domain] Debt Instrument, Threshold Limit, Period [Domain] Shares issued (in shares) Stock Issued During Period, Shares, New Issues Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash and cash equivalents, aggregate fair value Cash and Cash Equivalents, Fair Value Disclosure Northern Arizona Hematology and Oncology Northern Arizona Hematology and Oncology [Member] Northern Arizona Hematology and Oncology Business Combinations Business Combination Disclosure [Text Block] Other comprehensive loss attributable to noncontrolling interests Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Related Party, Type [Domain] Related Party, Type [Domain] Number of securities called by each warrant (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Mezzanine Equity Stockholders' Equity, Policy [Policy Text Block] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Invested capital contributions Members' Capital Income Tax Disclosure [Abstract] Percentage of stock subject to vesting (in percent) Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Percentage Of Stock Subject To Vesting Conditions Derivative Instrument, Contingent Consideration, Liability, Earnout Period, PErcentage Of Stock Subject To Vesting Conditions Series A Preferred Cumulative Dividends Distributed Earnings Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Tax Identification Number Entity Tax Identification Number Class A and A-1 preferred returns Dividends, Preferred Stock Inventories Inventory, Net Total lease costs Lease, Cost Earnout period, threshold trading day period (in days) Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Consecutive Trading Days Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Consecutive Trading Days Financial Instrument [Axis] Financial Instrument [Axis] Noncontrolling Interests Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] Entity Interactive Data Current Entity Interactive Data Current Long-Term Debt Long-Term Debt [Text Block] Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Reverse Recapitalization, net Temporary Equity, Value, Reverse Recapitalization Temporary Equity, Value, Reverse Recapitalization Retained earnings (deficit) Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Name Outstanding Recovery, Individual Name Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Capital Unit, Class A Capital Unit, Class A [Member] Leases not yet commenced, future commitments Lessee, Finance Lease, Lease Not Yet Commenced, Liability Lessee, Finance Lease, Lease Not Yet Commenced, Liability Class A-1 distribution (in shares) Stock Dividends, Shares Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Note 3 2024 Notes Receivable, Note 3 [Member] 2024 Notes Receivable, Note 3 Current assets Assets, Current [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Stock price trigger (in usd per share) Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Stock Price Trigger Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Stock Price Trigger Counterparty Name [Axis] Counterparty Name [Axis] Warrant Liabilities Derivatives, Policy [Policy Text Block] Total lease payments Finance Lease, Liability, to be Paid Total Units Issued Limited Liability Company (LLC) Units, Issued Limited Liability Company (LLC) Units, Issued Patient service revenue, net Patient Service [Member] Patient Service Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Operating cash flows from operating leases Payments for operating leases Operating Lease, Payments Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Series A Deemed Dividend Dividends PEO PEO [Member] Sponsor Earnout Shares Sponsor Earnout Shares [Member] Sponsor Earnout Shares Other receivables Other Receivables Capital Unit, Class B Capital Unit, Class B [Member] Redeemable Preferred Stock Increase (Decrease) in Temporary Equity [Roll Forward] Schedule of Variable Interest Entities [Table] Schedule of Variable Interest Entities [Table] Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Alternate Base Rate Alternate Base Rate [Member] Alternate Base Rate Net income (loss) and noncontrolling interest attributable to Legacy AON Shareholders prior to the reverse recapitalization Net Income attributable to Legacy AON Shareholders Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Before Recapitalization Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Before Recapitalization Earnout shares not outstanding (in shares) Derivative Instrument, Contingent Consideration, Liability, Shares Derivative Instrument, Contingent Consideration, Liability, Shares Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Net loss attributable to Class A Common Stockholders, Basic Net loss attributable to Class A Common Stockholders for basic loss per share Net Income (Loss) Available to Common Stockholders, Basic Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective income tax rate (in percent) Effective Income Tax Rate Reconciliation, Percent Present value of lease liabilities Operating Lease, Liability Fair value adjustment to redeemable noncontrolling interest Redeemable Noncontrolling Interest, Equity, Fair Value Adjustment Redeemable Noncontrolling Interest, Equity, Fair Value Adjustment Impact of the Reverse Recapitalization (in units) Common Unit, Unit Impact Of The Reverse Recapitalization Common Unit, Unit Impact Of The Reverse Recapitalization 2023 (remainder of year after September 30, 2023) Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Measurement Input Type [Domain] Measurement Input Type [Domain] Capital contribution from noncontrolling interest member Noncontrolling Interest, Increase from Subsidiary Equity Issuance Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets AOCI AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Participating Threshold [Axis] Participating Threshold [Axis] Participating Threshold Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] All Executive Categories All Executive Categories [Member] Issuance of units (in units) Common Units issued (in units) Common Unit, Issued Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Accounts Payable Accounts Payable [Member] Warrant, exercise period, after business combination Class Of Warrant Or Right Outstanding, Exercise Period, After Business Combination Class Of Warrant Or Right Outstanding, Exercise Period, After Business Combination Rebates receivable Rebates Receivable, Current Rebates Receivable, Current Debt Disclosure [Abstract] Related Party Transaction [Domain] Related Party Transaction [Domain] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Number of reportable segments Number of Reportable Segments Loss per share of Class A Common Stock: Earnings Per Share [Abstract] Schedule of Variable Interest Entities Schedule of Variable Interest Entities [Table Text Block] AON LLC AON LLC [Member] AON LLC Short-term Marketable Securities Marketable Securities, Policy [Policy Text Block] Schedule of Other Receivables Schedule Of Other Receivables [Table Text Block] Schedule Of Other Receivables Common stock, value Common Stock, Value, Issued General and administrative expenses General and Administrative Expense Due in one to five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization of operating right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Reverse recapitalization, equity conversion ratio Reverse Recapitalization, Equity Conversion Ratio Reverse Recapitalization, Equity Conversion Ratio Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Accrued other Other Accrued Liabilities Deferred social security taxes - COVID Deferred Social Security Taxes, Current Deferred Social Security Taxes, Current Assets Lease, Right-Of-Use Asset [Abstract] Lease, Right-Of-Use Asset Furniture, fixtures and equipment Furniture, Fixtures and Equipment [Member] Furniture, Fixtures and Equipment Ownership interest Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest Segments Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current Repayments on finance lease liabilities Financing cash flows from finance leases Finance Lease, Principal Payments Finance Lease, Liability, to be Paid, Maturity Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Accounts receivable Accounts Receivable, after Allowance for Credit Loss All Individuals All Individuals [Member] Supplemental noncash investing and financing activities Supplemental Cash Flow Information [Abstract] Other (expense) income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category PNC Loan Facility PNC Loan Facility [Member] PNC Loan Facility Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Earnings Per Share Earnings Per Share, Policy [Policy Text Block] PEO Name PEO Name Concentration risk (in percentage) Concentration Risk, Percentage AON Common Unit AON Common Unitholders [Member] AON Common Unitholders Measurement Input, Expected Dividend Rate Measurement Input, Expected Dividend Rate [Member] Other Other Sundry Liabilities, Current Class of warrant outstanding (in warrants) Class of Warrant or Right, Outstanding Patient Visits Patient Visits [Member] Patient Visits And Shipments Of Prescriptions Series A Preferred Units Issued Preferred Units, Issued 2027 Finance Lease, Liability, to be Paid, Year Four Unpaid offering costs relating to the reverse recapitalization Reverse Recapitalization, Deferred Offering Costs Reverse Recapitalization, Deferred Offering Costs Net cash (used) provided by operating activities Net Cash Provided by (Used in) Operating Activities Number of days after redemption notice date that redemption must be settled Stockholders' Equity, Number Of Days After The Redemption Notice Date For Redemption To Be Settled Stockholders Equity, Number Of Days After The Redemption Notice Date For Redemption To Be Settled Class of Stock [Axis] Class of Stock [Axis] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Accrued other Accrued other Other Accrued Liabilities, Current Fair Value Adjustment of Warrants Fair Value Adjustment of Warrants Depreciation and amortization Depreciation, Depletion and Amortization Common unit, units outstanding (in units) Beginning balance (in units) Ending balance (in units) Common Unit, Outstanding Net income (loss) attributable to common shareholders Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Accrued compensation related costs Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Cash and cash equivalents and available-for-sale securities, amortized cost Cash, Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Cash, Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Business Combination and Asset Acquisition [Abstract] Total stockholders' equity Equity, Attributable to Parent Total notes receivables Financing Receivable, after Allowance for Credit Loss Participating Threshold [Domain] Participating Threshold [Domain] Participating Threshold [Domain] Current Liabilities Current Liabilities Assumed In Reverse Recapitalization Current Liabilities Assumed In Reverse Recapitalization Beginning balance (in units) Ending balance (in units) Limited Liability Company (LLC), Units, Outstanding Limited Liability Company (LLC), Units, Outstanding Dividends Paid, Event Prior to June 7, 2026, After June 7, 2025 Dividends Paid, Event Prior to June 7, 2026, After June 7, 2025 [Member] Dividends Paid, Event Prior to June 7, 2026, After June 7, 2025 Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Finance 
Leases Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Variable Interest Entities Variable Interest Entity Disclosure [Text Block] Warrants, measurement input Warrants and Rights Outstanding, Measurement Input Common unit authorized (in units) Common Unit, Authorized Long-term Lease Liability, Noncurrent [Abstract] Lease Liability, Noncurrent Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Level 2 Fair Value, Inputs, Level 2 [Member] Accumulated Other Comprehensive Income Other Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization Other Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization Entity Emerging Growth Company Entity Emerging Growth Company Unamortized debt issuance costs Debt Issuance Costs, Net Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Long Term Liabilities Noncurrent Liabilities Assumed In Reverse Recapitalization Noncurrent Liabilities Assumed In Reverse Recapitalization Gain (Loss) On Reverse Recapitalization Gain (Loss) On Reverse Recapitalization Gain (Loss) On Reverse Recapitalization OCP Management Arizona, LLP OCP Management Arizona, LLP [Member] OCP Management Arizona, LLP Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Issuance of Units Common Unit, Units Issued, Value Common Unit, Units Issued, Value 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Equity-based compensation Share-Based Payment Arrangement, Noncash Expense Other Other Miscellaneous Receivables, Net, Current Other Miscellaneous Receivables, Net, Current Earnout period, number of months after closing (in months) Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Number Of Months After Closing Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Number Of Months After Closing Changes in fair value adjustments of warrants and derivative liabilities Gain (Loss) On Warrant And Derivative, Net Gain (Loss) On Warrant And Derivative, Net Cash and cash equivalents Cash And Cash Equivalents Acquired Through Reverse Recapitalization Cash And Cash Equivalents Acquired Through Reverse Recapitalization Common Stock Common Stock [Member] Individual: Individual [Axis] Purchase price of additional units (in dollars per share) Temporary Equity, Purchase Price Of Additional Units Temporary Equity, Purchase Price Of Additional Units City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Dividends Paid, Event Prior to June 7, 2025, After June 7, 2024 Dividends Paid, Event Prior to June 7, 2025, After June 7, 2024 [Member] Dividends Paid, Event Prior to June 7, 2025, After June 7, 2024 Net Loss Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Equity method investment (in percent) Equity Method Investment, Ownership Percentage Document Fiscal Year Focus Document Fiscal Year Focus Reverse Recapitalization, net (in shares) Stock Issued During Period, Shares, Reverse Recapitalization Stock Issued During Period, Shares, Reverse Recapitalization Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Inventory [Domain] Inventory [Domain] Other comprehensive income (loss) attributable to Legacy AON Shareholders Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization LLC ownership threshold, percentage Limited Liability Company (LLC), Ownership Threshold, Percentage Limited Liability Company (LLC), Ownership Threshold, Percentage Supplier [Domain] Supplier [Domain] Software Software and Software Development Costs [Member] Exercise Price Award Exercise Price Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Borrowings on long-term debt Proceeds from Issuance of Long-Term Debt Available-for-Sale Securities, Debt Maturities [Abstract] Available-for-Sale Securities, Debt Maturities [Abstract] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Liabilities Liabilities [Abstract] Professional Malpractice Liability Insurance Professional Malpractice Liability Insurance [Member] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Other revenue Product and Service, Other [Member] Unamortized debt issuance costs Debt Issuance Costs, Gross Net income (loss) before noncontrolling interest Net income (loss) before noncontrolling interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest U.S. Treasury securities US Treasury Securities [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Proceeds from reverse recapitalization Business Combination to Reverse Recaptialization Business Combination to Reverse Recaptialization Deferred tax asset, net Deferred Income Tax Assets, Net Payments to acquire interest in subsidiary Payments to Acquire Interest in Subsidiaries and Affiliates Retained
Earnings (Deficit) Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities, mezzanine equity, and stockholders' equity Liabilities and Equity Amortized 
Cost Debt Securities, Available-for-Sale, Amortized Cost Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] Disposal of property and equipment in exchange for reduction in finance lease liability Disposal Of Property, Plant And Equipment In Exchange For Reduction Of Capital Lease Liability Disposal Of Property, Plant And Equipment In Exchange For Reduction Of Capital Lease Liability Earnings (loss) per unit, basic (in usd per share) Basic loss per share of Class A Common Stock (in dollars per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating lease right-of-use assets, net Operating Lease, Right-of-Use Asset Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Stock issuance costs Stock Issuance Expense Stock Issuance Expense Lessee, Assets And Liabilities Lessee, Assets And Liabilities [Table Text Block] Lessee, Assets And Liabilities Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Warrant, term Warrants and Rights Outstanding, Term Number of days after five year anniversary Stockholders' Equity, Conversion, Number Of Days After Five Year Anniversary Stockholders' Equity, Conversion, Number Of Days After Five Year Anniversary Reverse recapitalization costs Reverse Recapitalization Expenses Reverse Recapitalization Expenses Capital Units by Class [Axis] Capital Units by Class [Axis] Undistributed net earnings, basic Undistributed Earnings, Basic 2023 (remainder of year after September 30, 2023) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Net loss attributable to Class A Common Stockholders, Diluted Net loss attributable to Class A Common Stockholders for diluted loss per share Net Income (Loss) Available to Common Stockholders, Diluted Arrangement Duration Trading Arrangement Duration Total stockholders' equity Beginning balance Ending balance Members' Equity Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Related Party Related Party [Member] Inventory, Current [Table] Inventory, Current [Table] Class C Common Class C [Member] Principles of Consolidation Consolidation, Policy [Policy Text Block] Stockholders' Equity, Conversion Right [Axis] Stockholders' Equity, Conversion Rights [Axis] Stockholders' Equity, Conversion Rights Supplemental Condensed Balance Sheet Information Supplemental Balance Sheet Disclosures [Text Block] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Option Feature Option Feature [Member] Option Feature Accrued other Increase (Decrease) in Other Accrued Liabilities Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Termination Date Trading Arrangement Termination Date Cost of Goods and Service Benchmark Cost of Goods and Service Benchmark [Member] Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Digital Transformation Opportunities Corp. (“DTOC”) Digital Transformation Opportunities Corp. (“DTOC”) [Member] Digital Transformation Opportunities Corp. (“DTOC”) Collections on notes receivable - related parties Proceeds from Collection of Notes Receivable Short-term marketable securities Estimated Fair
Value Total Debt Securities, Available-for-Sale Document Information [Table] Document Information [Table] Contribution from noncontrolling interest Proceeds from Noncontrolling Interests Excess redeemable noncontrolling interest over carrying amount Redeemable Noncontrolling Interest, Equity, Excess Over Carrying Amount Redeemable Noncontrolling Interest, Equity, Excess Over Carrying Amount Gross Unrealized
Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Stockholders' equity, conversion, threshold volume weighted average price period Stockholders' Equity, Conversion, Threshold Volume Weighted Average Price Period Stockholders' Equity, Conversion, Threshold Volume Weighted Average Price Period Liquidation preference Temporary Equity, Liquidation Preference Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] ROU assets obtained in exchange for new lease liabilities Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Right-Of-Use Asset Obtained In Exchange For Lease Liability Derivative Instrument [Axis] Derivative Instrument [Axis] Total Long-Term Debt, Gross Adjustments to reconcile net income (loss) to net cash provided by operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] Supplier Concentration Risk Supplier Concentration Risk [Member] Allocation of income to controlling and noncontrolling interests Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Ownership Interest Accumulated depreciation and amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Automobiles Automobiles [Member] AEA Growth Management LP AEA Growth Management LP [Member] AEA Growth Management LP Other comprehensive loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Note 6 2023 Notes Receivable, Note 6 [Member] 2023 Notes Receivable, Note 6 Additional paid-in capital Additional Paid in Capital Intravenous drugs Intravenous Drugs [Member] Intravenous Drugs Inventory [Axis] Inventory [Axis] Deferred income taxes Deferred Income Tax Expense (Benefit) Document Information [Line Items] Document Information [Line Items] Incremental borrowing rate Financing Receivable, Borrowing Rate Financing Receivable, Borrowing Rate Dividends Paid, Event Prior to June 7, 2024 Dividends Paid, Event Prior to June 7, 2024 [Member] Dividends Paid, Event Prior to June 7, 2024 Gain on sale of property and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Net proceeds from issuance of redeemable convertible stock Proceeds From Issuance Of Redeemable Convertible Stock, Net Proceeds From Issuance Of Redeemable Convertible Stock, Net AON Inc. New AON (AON Inc.) [Member] New AON (AON Inc.) Other receivables Increase (Decrease) in Other Receivables Number of board of managers designated by majority common unit holders Number Of Board Of Managers Designated By Majority Common Unit Holders Number Of Board Of Managers Designated By Majority Common Unit Holders Present value of lease liabilities Finance Lease, Liability Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Equity Investment in Affiliate Equity Method Investments [Policy Text Block] Insider Trading Arrangements [Line Items] Stock price (in usd per share) Share Price Related Party, Type [Axis] Related Party, Type [Axis] Other assets Other Assets Issuance of redeemable convertible Class C Units Proceeds from issuance of redeemable preferred stock Proceeds from Issuance of Redeemable Convertible Preferred Stock Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Other assets Increase (Decrease) in Other Operating Assets Pledged collateral Debt Instrument, Collateral Amount Fair value of warrants Warrants and Rights Outstanding Adjustment to Compensation, Amount Adjustment to Compensation Amount Proceeds from disposals of property and equipment Proceeds from Sale of Property, Plant, and Equipment Noncontrolling interest Equity, Attributable to Noncontrolling Interest Document Period End Date Document Period End Date Common unit excluded from issuance (in units) Common Unit, Excluded From Issuance Common Unit, Excluded From Issuance Proceeds from lines of credit Proceeds from Lines of Credit Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Accrued dividend rate (in percent) Preferred Stock, Dividend Rate, Percentage London Interbank Offered Rate (LIBOR) 1 London Interbank Offered Rate (LIBOR) 1 [Member] London Interbank Offered Rate (LIBOR) 1 Weighted-average discount rate for finance leases (in percent) Finance Lease, Weighted Average Discount Rate, Percent Long-term finance lease liabilities (included in other long-term liabilities) Long-term lease liabilities, net of current portion Finance Lease, Liability, Noncurrent Entity Central Index Key Entity Central Index Key Dividends Paid, Event After June 7, 2028 Dividends Paid, Event After June 7, 2028 [Member] Dividends Paid, Event After June 7, 2028 Thereafter Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Changes in fair value adjustments of warrants and derivative liabilities Derivative, Gain (Loss) on Derivative, Net Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Stock compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax expense Income Tax Expense (Benefit) Shares authorized (shares) Temporary Equity, Shares Authorized Finance lease right-of-use assets, net (included in property and equipment, net) Finance Lease, Right-of-Use Asset, after Accumulated Amortization Accrued compensation related costs Employee-related Liabilities, Current Cash paid for debt financing costs Payments of Financing Costs Number of operating segments Number of Operating Segments Name Trading Arrangement, Individual Name Other comprehensive gain (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Capital Unit, Class A-1 Capital Unit, Class A-1 [Member] Capital Unit, Class A-1 Shares issued (in shares) Stock Issued During Period, Value, New Issues Schedule of Reverse Recapitalization, Changes in Units Schedule Of Reverse Recapitalization, Changes In Units [Table Text Block] Schedule Of Reverse Recapitalization, Changes In Units Equity [Abstract] Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Weighted-average remaining lease term for operating leases Operating Lease, Weighted Average Remaining Lease Term Total lease liabilities Lease, Liability Lease, Liability Private Placement Warrants Private Placement Warrants [Member] Private Placement Warrants Total revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Other receivables Other receivables Other Receivables, Net, Current Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Reverse Recapitalization, Change In Value Of Units [Roll Forward] Reverse Recapitalization, Change In Value Of Units [Roll Forward] Reverse Recapitalization, Change In Value Of Units Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Earnout period, trading days (in days) Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Trading Days Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Trading Days Amendment Flag Amendment Flag Recapitalization exchange ratio, units Recapitalization Exchange Ratio, Units Recapitalization Exchange Ratio, Shares Preferred Class A Preferred Class A [Member] Redeemable convertible preferred stock, shares outstanding (in shares) Beginning Balance (in shares) Ending Balance (in shares) Temporary Equity, Shares Outstanding Legal Entity [Axis] Legal Entity [Axis] Current portion of operating and finance lease liabilities Finance and Operating Lease Liability, Current Finance and Operating Lease Liability, Current Money market funds Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Increase (Decrease) In Noncontrolling Interest [Roll Forward] Increase (Decrease) In Redeemable Noncontrolling Interest [Roll Forward] Increase (Decrease) In Redeemable Noncontrolling Interest Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Weighted-average discount rate for operating leases (in percent) Operating Lease, Weighted Average Discount Rate, Percent Debt Instrument, Threshold Limit, Period One Debt Instrument, Threshold Limit, Period One [Member] Debt Instrument, Threshold Limit, Period One Legacy AON Shareholders Legacy AON Shareholders [Member] Legacy AON Shareholders DTOC Unredeemed Shareholders DTOC Unredeemed Shareholders [Member] DTOC Unredeemed Shareholders Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Equity based compensation (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Due in one year or less Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Credit Facility [Domain] Credit Facility [Domain] Shares issued (in shares) Temporary Equity, Shares Issued Signs Signs [Member] Signs Income (loss) before equity loss in affiliate and noncontrolling interest Income (Loss) From Continuing Operations Before Equity Method Investments, Net Of Tax Income (Loss) From Continuing Operations Before Equity Method Investments, Net Of Tax Business Combinations Business Combinations Policy [Policy Text Block] Basis spread (in percent) Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long-term debt, net Long-Term Debt, Excluding Current Maturities Weighted-average remaining lease term for finance leases Finance Lease, Weighted Average Remaining Lease Term Leasehold improvements Leasehold Improvements [Member] Noncash consideration of equity method investment Noncash Consideration, Fair Value Of Consideration For Equity Method Investment Noncash Consideration, Fair Value Of Consideration For Equity Method Investment Diluted weighted average common units outstanding (in shares) Weighted average shares for diluted loss per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Subsidiary Under Common Control of Class A-1 Member Subsidiary Under Common Control Of Class A-1 Member [Member] Subsidiary Under Common Control Of Class A-1 Member Malpractice insurance, limit per policy period Malpractice Insurance, Annual Coverage Limit ROU assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Costs and expenses Operating Expenses [Abstract] Less: amount representing interest Finance Lease, Liability, Undiscounted Excess Amount Transaction expenses Reverse Recapitalization Transaction Costs Reverse Recapitalization Transaction Costs Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Debt Instrument, Threshold Limit, Period [Axis] Debt Instrument, Threshold Limit, Period [Axis] Debt Instrument, Threshold Limit, Period Additional Paid in Capital Additional Paid-in Capital [Member] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Equity in loss of affiliate Equity in loss of affiliate Income (Loss) from Equity Method Investments Issuance of units (in units) Common Unit, Issued During Period Common Unit, Issued During Period Right-of-use assets and lease liabilities removed in termination of lease Lease, Right-Of-Use Asset And Liability Reduction From Lease Terminations Lease, Right-Of-Use Asset And Liability Reduction From Lease Terminations Cover [Abstract] Description Of Business And Significant Accounting Policies [Table] Description Of Business And Significant Accounting Policies [Table] Description Of Business And Significant Accounting Policies [Table] Number of states in which entity operates Number of States in which Entity Operates Equity based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amortization of debt issuance costs Amortization of Debt Issuance Costs Participating Threshold, 3 Participating Threshold, 3 [Member] Participating Threshold, 3 Number of offices with operating lease Number Of Offices With Operating Leases Number Of Offices With Operating Leases Preferred units, outstanding (in units) Preferred Units, Outstanding Series A Preferred Stock Series A Preferred Stock [Member] Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Class A and A-1 preferred returns and tax distributions Payments of Dividends Other long-term liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Total lease payments Lessee, Operating Lease, Liability, to be Paid Construction-in-progress Construction in Progress [Member] Thereafter Finance Lease, Liability, to be Paid, Due after Year Four Finance Lease, Liability, to be Paid, Due after Year Four Stockholders Stockholders [Member] Stockholders Amortization of finance lease right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Common Class A-1 Common Class A-1 [Member] Common Class A-1 Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Income (loss) before income taxes, equity loss in affiliate, and noncontrolling interest Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Comprehensive Income (Loss), Net Of Tax, Attributable To Common Stockholders Comprehensive Income (Loss), Net Of Tax, Attributable To Common Stockholders Comprehensive Income (Loss), Net Of Tax, Attributable To Common Stockholders Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Less: current portion of lease liabilities Current portion of finance lease liabilities (included in accrued other) Less: current portion of lease liabilities Finance Lease, Liability, Current Adjustment to Compensation: Adjustment to Compensation [Axis] Participating Threshold, 2 Participating Threshold, 2 [Member] Participating Threshold, 2 Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Original
Principal Financing Receivable, After allowance For Credit Loss, Original Principal Financing Receivable, After allowance For Credit Loss, Original Principal Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted average shares for basic loss per share (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Schedule of Other Accrued Liabilities, Current Schedule Of Other Accrued Liabilities, Current [Table Text Block] Schedule Of Other Accrued Liabilities, Current Income (loss) from operations Operating Income (Loss) Dividends Paid, Event Prior to June 7, 2028, After June 7, 2027 Dividends Paid, Event Prior to June 7, 2028, After June 7, 2027 [Member] Dividends Paid, Event Prior to June 7, 2028, After June 7, 2027 Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] AOCI AOCI Including Portion Attributable to Noncontrolling Interest [Member] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Overnight Repurchase Agreements Overnight Repurchase Agreements [Member] Overnight Repurchase Agreements Revenue Revenues [Abstract] Consolidated Entities [Domain] Consolidated Entities [Domain] Series C Preferred Stock Series C Preferred Stock [Member] Cost of revenue Cost of Revenue Prepaid expenses and other current assets Prepaid Expense and Other Assets Participating Threshold, 1 Participating Threshold, 1 [Member] Participating Threshold, 1 Other comprehensive income (loss): Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Gain (loss) on issuance of warrants Gain (Loss) On Issuance Of Warrants Gain (Loss) On Issuance Of Warrants Related Party Transaction [Axis] Related Party Transaction [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Allocation of losses to controlling and noncontrolling interests (in percent) Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Losses Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Losses Unused line fee (in percent) Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement [Line Items] Statement [Line Items] Dividends [Axis] Dividends [Axis] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale [Table Text Block] Proceeds from facility Proceeds from Long-Term Lines of Credit Liabilities Lease, Liability [Abstract] Lease, Liability Noncontrolling Interest Noncontrolling Interest [Member] EX-101.PRE 10 aonc-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 9 Months Ended
Sep. 30, 2023
Nov. 09, 2023
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-04321  
Entity Registrant Name American Oncology Network, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-3984427  
Entity Address, Address Line One 14543 Global Parkway  
Entity Address, Address Line Two Suite 110  
Entity Address, City or Town Fort Myers  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33913  
City Area Code 833  
Local Phone Number 886-1725  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Central Index Key 0001839998  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Current Fiscal Year End Date --12-31  
Amendment Flag false  
Common Class A    
Document Information [Line Items]    
Title of 12(b) Security Class A common stock, par value $0.0001, per share  
Trading Symbol AONC  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   9,550,099
Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share    
Document Information [Line Items]    
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share  
Trading Symbol AONCW  
Security Exchange Name NASDAQ  
Common Class B    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   25,109,551
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 51,653 $ 26,926
Short-term marketable securities 26,034 9,851
Patient accounts receivable, net 141,039 136,098
Inventories 37,844 36,476
Other receivables 36,747 28,201
Prepaid expenses and other current assets 3,445 2,670
Current portion of notes receivable - related parties 1,630 1,797
Total current assets 298,392 242,019
Property and equipment, net 36,240 31,980
Operating lease right-of-use assets [1] 46,138 43,724
Notes receivable - related parties 1,504 2,076
Other assets 7,055 5,199
Goodwill and intangibles, net 1,230 1,230
Deferred tax asset, net 3,455 0
Total assets 394,014 326,228
Current liabilities    
Accounts payable [2] 120,383 106,495
Accrued compensation related costs 16,210 7,466
Accrued other 22,977 17,800
Excise taxes payable 1,211 0
Current portion of operating lease liabilities [3] 7,123 9,177
Total current liabilities 167,904 140,938
Long-term debt, net 80,425 80,301
Long-term operating lease liabilities [4] 42,261 37,224
Other long-term liabilities 10,333 5,749
Total liabilities 300,923 264,212
Mezzanine equity    
Series A convertible preferred stock; $0.0001 par value; 7,500,000 shares authorized; 6,651,610 issued and outstanding at September 30, 2023, with an aggregate liquidation preference of $66,649,130 at September 30, 2023. 64,986  
Redeemable noncontrolling interest 369,329  
Stockholders' equity    
Additional paid-in capital 0  
Accumulated other comprehensive income (loss) 21 (117)
Retained earnings (deficit) (341,357) 25,828
Total stockholders' equity (341,332)  
Total stockholders' equity   62,016
Noncontrolling interest 108  
Total liabilities, mezzanine equity, and stockholders' equity 394,014 326,228
Capital Unit, Class A    
Stockholders' equity    
Common unit, value   7,725
Capital Unit, Class A-1    
Stockholders' equity    
Common unit, value   28,500
Capital Unit, Class B    
Stockholders' equity    
Common unit, value   $ 80
Common Class A    
Stockholders' equity    
Common stock, value 1  
Common Class B    
Stockholders' equity    
Common stock, value $ 3  
[1] Includes related party operating right-of-use assets, net of $11,476 and $13,077 at September 30, 2023 and December 31, 2022, respectively
[2] Includes amounts due to related party of $112,740 and $102,113 at September 30, 2023 and December 31, 2022, respectively
[3] Includes related party current portion of operating lease liabilities of $1,912 and $1,836 at September 30, 2023 and December 31, 2022, respectively
[4] Includes related party long-term operating lease liabilities of $9,994 and $11,631 at September 30, 2023 and December 31, 2022, respectively
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Redeemable convertible preferred stock, shares outstanding (in shares) 6,652,000  
Operating lease right-of-use assets [1] $ 46,138,000 $ 43,724,000
Accounts payable [2] 120,383,000 106,495,000
Current portion of operating lease liabilities [3] 7,123,000 9,177,000
Long-term operating lease liabilities [4] $ 42,261,000 $ 37,224,000
Capital Unit, Class A    
Common unit, units outstanding (in units) 0 19,495,376
Capital Unit, Class A-1    
Common unit, units outstanding (in units) 0 1,842,520
Capital Unit, Class B    
Common unit, units outstanding (in units) 0 4,703,628
Related Party    
Operating lease right-of-use assets $ 11,476,000 $ 13,077,000
Accounts payable 112,740,000 102,113,000
Current portion of operating lease liabilities 1,912,000 1,836,000
Long-term operating lease liabilities $ 9,994,000 $ 11,631,000
Series A Preferred Stock    
Par value (dollars per share) $ 0.0001  
Shares authorized (shares) 7,500,000  
Shares issued (in shares) 6,651,610  
Redeemable convertible preferred stock, shares outstanding (in shares) 6,651,610  
Liquidation preference $ 66,649,130  
Common Class A    
Common stock, par value (in usd per share) $ 0.0001  
Common stock, shares authorized (in shares) 200,000,000  
Common stock, shares issued (in shares) 9,453,604  
Common stock, shares outstanding (in shares) 9,453,604  
Common Class B    
Common stock, par value (in usd per share) $ 0.0001  
Common stock, shares authorized (in shares) 100,000,000  
Common stock, shares issued (in shares) 25,109,551  
Common stock, shares outstanding (in shares) 25,109,551  
[1] Includes related party operating right-of-use assets, net of $11,476 and $13,077 at September 30, 2023 and December 31, 2022, respectively
[2] Includes amounts due to related party of $112,740 and $102,113 at September 30, 2023 and December 31, 2022, respectively
[3] Includes related party current portion of operating lease liabilities of $1,912 and $1,836 at September 30, 2023 and December 31, 2022, respectively
[4] Includes related party long-term operating lease liabilities of $9,994 and $11,631 at September 30, 2023 and December 31, 2022, respectively
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue        
Total revenue $ 336,305,000 $ 297,324,000 $ 955,003,000 $ 849,272,000
Costs and expenses        
Cost of revenue 310,894,000 267,647,000 880,827,000 [1] 780,658,000 [1]
General and administrative expenses 25,199,000 23,432,000 72,831,000 [2] 66,155,000 [2]
Transaction expenses 24,603,000 151,000 29,886,000 151,000
Total costs and expenses 360,696,000 291,230,000 983,544,000 846,964,000
Income (loss) from operations (24,391,000) 6,094,000 (28,541,000) 2,308,000
Other income (expense)        
Interest expense (1,532,000) (924,000) (4,500,000) (2,034,000)
Interest income 373,000 49,000 499,000 104,000
Other (expense) income, net (3,309,000) 388,000 (7,689,000) 849,000
Income (loss) before income taxes, equity loss in affiliate, and noncontrolling interest (28,859,000) 5,607,000 (40,231,000) 1,227,000
Income tax expense 315,000 0 315,000 0
Income (loss) before equity loss in affiliate and noncontrolling interest (29,174,000) 5,607,000 (40,546,000) 1,227,000
Equity in loss of affiliate (31,000) 0 (251,000) 0
Net income (loss) before noncontrolling interest (29,205,000) 5,607,000 (40,797,000) 1,227,000
Net income (loss) and noncontrolling interest attributable to Legacy AON Shareholders prior to the reverse recapitalization (15,489,000) 5,607,000 (27,081,000) 1,227,000
Net loss attributable to noncontrolling interest (11,924,000) 0 (11,924,000) 0
Net loss attributable to Class A Common Stockholders, Diluted (1,792,000) 0 (1,792,000) 0
Net loss attributable to Class A Common Stockholders, Basic $ (1,792,000) $ 0 $ (1,792,000) $ 0
Loss per share of Class A Common Stock:        
Earnings (loss) per unit, basic (in usd per share) $ (0.61) $ 0 $ (0.61) $ 0
Earnings (loss) per unit, diluted (in usd per share) $ (0.61) $ 0 $ (0.61) $ 0
Weighted average shares of Class A Common Stock Outstanding:        
Weighted average shares for basic loss per share (in shares) 6,614,229 0 6,614,229 0
Diluted weighted average common units outstanding (in shares) 6,614,229 0 6,614,229 0
Other comprehensive income (loss):        
Unrealized gains (losses) on marketable securities $ 102,000 $ (77,000) $ 190,000 $ (161,000)
Other comprehensive gain (loss) 102,000 (77,000) 190,000 (161,000)
Comprehensive income (loss) (29,103,000) 5,530,000 (40,607,000) 1,066,000
Other comprehensive income (loss) attributable to Legacy AON Shareholders (15,398,000) 5,530,000 (26,902,000) 1,066,000
Other comprehensive loss attributable to noncontrolling interests (11,915,000) 0 (11,915,000) 0
Comprehensive Income (Loss), Net Of Tax, Attributable To Common Stockholders (1,790,000) 0 (1,790,000) 0
Patient service revenue, net        
Revenue        
Total revenue 332,195,000 293,612,000 945,681,000 840,507,000
Other revenue        
Revenue        
Total revenue $ 4,110,000 $ 3,712,000 $ 9,322,000 $ 8,765,000
[1] Includes related party inventory expense of $271,790 and $236,077 and $777,478 and $682,671 for the three and nine months ended September 30, 2023 and 2022, respectively.
[2] Includes related party rent of $679 and $655 and $2,037 and $2,037 for the three and nine months ended September 30, 2023 and 2022, respectively.
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Mezzanine and Members’ Equity - USD ($)
$ in Thousands
Total
Capital Unit, Class A
Capital Unit, Class A-1
Capital Unit, Class B
Common Class A
Common Class B
Common Stock
Common Class A
Common Stock
Common Class B
Common Units
Capital Unit, Class A
Common Units
Capital Unit, Class A-1
Common Units
Capital Unit, Class B
Common Units
Capital Unit, Class B-1
AOCI
Additional Paid in Capital
AOCI
Noncontrolling Interest
Retained
Earnings (Deficit)
Increase (Decrease) In Noncontrolling Interest [Roll Forward]                                  
Net loss attributable to noncontrolling interest $ 0                                
Beginning balance (in units) at Dec. 31, 2021                 19,495,000 1,843,000              
Beginning balance at Dec. 31, 2021 59,544               $ 7,725 $ 28,500 $ 80   $ 0       $ 23,239
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Accumulated Other Comprehensive Income (161)                       (161)        
Equity based compensation 15                   15            
Other comprehensive income (loss) (161)                                
Net Income attributable to Legacy AON Shareholders 1,227                               1,227
Ending balance (in units) at Sep. 30, 2022                 19,495,000 1,843,000              
Ending balance at Sep. 30, 2022 60,625               $ 7,725 $ 28,500 95   (161)       24,466
Increase (Decrease) In Noncontrolling Interest [Roll Forward]                                  
Net loss attributable to noncontrolling interest 0                                
Beginning balance (in units) at Jun. 30, 2022                 19,495,000 1,843,000              
Beginning balance at Jun. 30, 2022 55,090               $ 7,725 $ 28,500 90   (84)       18,859
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Accumulated Other Comprehensive Income (77)                       (77)        
Equity based compensation 5                   5            
Other comprehensive income (loss) (77)                                
Net Income attributable to Legacy AON Shareholders 5,607                               5,607
Ending balance (in units) at Sep. 30, 2022                 19,495,000 1,843,000              
Ending balance at Sep. 30, 2022 $ 60,625               $ 7,725 $ 28,500 $ 95   $ (161)       24,466
Ending Balance (in shares) at Sep. 30, 2023 6,652,000                                
Ending Balance at Sep. 30, 2023 $ 64,986                                
Increase (Decrease) In Noncontrolling Interest [Roll Forward]                                  
Net loss attributable to noncontrolling interest (11,924)                                
Ending Balance at Sep. 30, 2023 369,329                                
Beginning balance (in units) at Dec. 31, 2022   19,495,376 1,842,520 4,703,628         19,495,000 1,843,000 4,704,000            
Beginning balance at Dec. 31, 2022 62,016               $ 7,725 $ 28,500 $ 80       $ (117)   25,828
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Other comprehensive income (loss) 190                                
Net Income attributable to Legacy AON Shareholders (27,081)                                
Fair value adjustment to redeemable noncontrolling interest                           $ (17,600)     (326,700)
Ending balance (in shares) at Sep. 30, 2023         9,453,604 25,109,551 6,614,000 25,110,000                  
Ending balance (in units) at Sep. 30, 2023   0 0 0             0            
Ending balance at Sep. 30, 2023 $ (341,223)           $ 1 $ 3           0 21 $ 108 (341,356)
Redeemable Preferred Stock                                  
Issuance of Class C Units, net of offering costs (in shares) 6,500,000                                
Issuance of Class C Units, net of offering costs $ 62,897                                
Beginning balance (in units) at Dec. 31, 2022   19,495,376 1,842,520 4,703,628         19,495,000 1,843,000 4,704,000            
Beginning balance at Dec. 31, 2022 62,016               $ 7,725 $ 28,500 $ 80       (117)   25,828
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Class A and A-1 preferred returns (8,174)                               (8,174)
Issuance of additional Class A-1 Units pursuant to the Anti-Dilution Feature (in shares)                   1,158,000              
Issuance of additional Class A-1 Units pursuant to the Anti-Dilution Feature 9,725                 $ 9,725              
Tax distributions (1,305)                               (1,305)
Capital contribution from noncontrolling interest member 134                             134  
Accumulated Other Comprehensive Income 178                           178    
Equity based compensation (in shares)                     911,000 1,047,000          
Equity based compensation 4,874                   $ 10 $ 4,864          
Net loss (27,081)                             (26) (27,055)
Net Income attributable to Legacy AON Shareholders $ (27,000)                                
Beginning Balance (in shares) at Jun. 30, 2023 6,500,000                                
Beginning Balance at Jun. 30, 2023 $ 62,897                                
Ending Balance (in shares) at Sep. 30, 2023 6,652,000                                
Ending Balance at Sep. 30, 2023 $ 64,986                                
Increase (Decrease) In Noncontrolling Interest [Roll Forward]                                  
Net loss attributable to noncontrolling interest (11,924)                                
Ending Balance at Sep. 30, 2023 369,329                                
Beginning balance (in units) at Jun. 30, 2023                 19,495,000 2,282,000 4,704,000            
Beginning balance at Jun. 30, 2023 44,753               $ 7,725 $ 31,040 $ 80       (29) 134 5,803
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Issuance of additional Class A-1 Units pursuant to the Anti-Dilution Feature (in shares)                   719,000              
Issuance of additional Class A-1 Units pursuant to the Anti-Dilution Feature 7,185                 $ 7,185              
Tax distributions (1,045)                               (1,045)
Accumulated Other Comprehensive Income 90                           90    
Equity based compensation (in shares)                     911,000 1,047,000          
Equity based compensation 4,874                   $ 10 $ 4,864          
Net loss (15,490)                             (26) (15,464)
Other comprehensive income (loss) 102                                
Net Income attributable to Legacy AON Shareholders (15,489)                                
Ending balance (in shares) at Sep. 30, 2023         9,453,604 25,109,551 6,614,000 25,110,000                  
Ending balance (in units) at Sep. 30, 2023   0 0 0             0            
Ending balance at Sep. 30, 2023 $ (341,223)           $ 1 $ 3           0 21 108 (341,356)
Redeemable Preferred Stock                                  
Reverse Recapitalization, net (in shares) 152,000                                
Reverse Recapitalization, net $ 2,089                                
Ending Balance (in shares) at Sep. 30, 2023 6,652,000                                
Ending Balance at Sep. 30, 2023 $ 64,986                                
Increase (Decrease) In Noncontrolling Interest [Roll Forward]                                  
Reverse Recapitalization, net 36,873                                
Other comprehensive loss attributable to noncontrolling interests 9                                
Net loss attributable to noncontrolling interest (11,924)                                
Fair value adjustment to redeemable noncontrolling interest 344,371                                
Ending Balance at Sep. 30, 2023 369,329                                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Reverse Recapitalization, net (in shares)             6,614,000 25,110,000 (19,495,000) (3,000,000) (5,615,000) (1,047,000)          
Reverse Recapitalization, net (35,429)           $ 1 $ 3 $ (7,725) $ (38,225) $ (90) $ (4,864)   17,602 (42)   (2,089)
Other comprehensive income (loss) 2                           2    
Net income (loss) before noncontrolling interest (1,792)                               (1,792)
Fair value adjustment to redeemable noncontrolling interest (344,371)                         (17,602)     (326,769)
Ending balance (in shares) at Sep. 30, 2023         9,453,604 25,109,551 6,614,000 25,110,000                  
Ending balance (in units) at Sep. 30, 2023   0 0 0             0            
Ending balance at Sep. 30, 2023 $ (341,223)           $ 1 $ 3           $ 0 $ 21 $ 108 $ (341,356)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities    
Net income (loss) before noncontrolling interest $ (40,797) $ 1,227
Adjustments to reconcile net income (loss) to net cash provided by operating activities    
Depreciation and amortization 6,368 5,318
Amortization of debt issuance costs 570 458
Deferred income taxes 75 0
Amortization of operating right-of-use assets [1] 6,194 7,766
Changes in fair value adjustments of warrants and derivative liabilities 9,334 0
Equity-based compensation 4,875 15
Equity in loss of affiliate 251 0
Gain on sale of property and equipment (2) 0
Changes in operating assets and liabilities, net of reverse recapitalization:    
Patient accounts receivable, net (4,941) (15,223)
Inventories [2] (1,367) 876
Prepaid expenses and other current assets (775) 641
Other receivables (8,546) (211)
Other assets (2,107) (376)
Accounts payable [3] 13,889 9,586
Accrued compensation related costs 8,744 4,456
Accrued other 6,290 (1,563)
Operating lease liabilities [4] (5,625) (8,252)
Medicare advance payments 0 (3,742)
Other long-term liabilities 1,410 654
Net cash (used) provided by operating activities (6,160) 1,630
Cash flows from investing activities    
Purchase of property and equipment (9,527) (5,051)
Proceeds from disposals of property and equipment 5 1,137
Purchases of marketable securities (20,824) (11,949)
Proceeds from sales of marketable securities 4,933 1,956
Issuance of notes receivable - related parties 0 (243)
Collections on notes receivable - related parties 740 1,091
Net cash used in investing activities (24,673) (13,059)
Cash flows from financing activities    
Borrowings on long-term debt 0 16,250
Issuance of redeemable convertible Class C Units 64,996 0
Class A and A-1 preferred returns and tax distributions (9,481) 0
Repayments on finance lease liabilities (387) (321)
Contribution from noncontrolling interest 134 0
Cash paid for debt financing costs (446) (171)
Proceeds from reverse recapitalization 1,494 0
Net cash provided by financing activities 55,560 15,758
Net increase (decrease) in cash and cash equivalents 24,727 4,329
Beginning of period 26,926 32,354
End of period 51,653 36,683
Supplemental noncash investing and financing activities    
Unpaid offering costs relating to the reverse recapitalization 2,745 0
Right-of-use assets and lease liabilities removed in termination of lease 1,254 0
Changes in accounts payable for capital additions to property and equipment 0 159
Disposal of property and equipment in exchange for reduction in finance lease liability 0 72
Series A Preferred Stock    
Cash flows from financing activities    
Offering costs $ (750) $ 0
[1] Includes related party amortization of operating right-of-use assets of $1,601 and $1,536 for the nine months ended September 30, 2023 and 2022, respectively.
[2] Includes changes in related party balances of ($1,299) and $832 for the nine months ended September 30, 2023 and 2022, respectively.
[3] Includes changes in related party balances of $10,627 and $23,309 for the nine months ended September 30, 2023 and 2022, respectively.
[4] Includes changes in related party balances of ($1,835) and ($1,446) for the nine months ended September 30, 2023 and 2022, respectively.
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Cost of revenue $ 310,894 $ 267,647 $ 880,827 [1] $ 780,658 [1]
General and administrative expenses 25,199 23,432 72,831 [2] 66,155 [2]
Related Party        
Cost of revenue 271,790 236,077 777,478 682,671
General and administrative expenses $ 679 $ 655 $ 2,037 $ 2,037
[1] Includes related party inventory expense of $271,790 and $236,077 and $777,478 and $682,671 for the three and nine months ended September 30, 2023 and 2022, respectively.
[2] Includes related party rent of $679 and $655 and $2,037 and $2,037 for the three and nine months ended September 30, 2023 and 2022, respectively.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows - Parenthetical - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Amortization of operating right-of-use assets [1] $ 6,194 $ 7,766
Inventories [2] 1,367 (876)
Accounts payable [3] 13,889 9,586
Operating lease liabilities [4] (5,625) (8,252)
Related Party    
Amortization of operating right-of-use assets 1,601 1,536
Inventories (1,299) 832
Accounts payable 10,627 23,309
Operating lease liabilities $ (1,835) $ (1,446)
[1] Includes related party amortization of operating right-of-use assets of $1,601 and $1,536 for the nine months ended September 30, 2023 and 2022, respectively.
[2] Includes changes in related party balances of ($1,299) and $832 for the nine months ended September 30, 2023 and 2022, respectively.
[3] Includes changes in related party balances of $10,627 and $23,309 for the nine months ended September 30, 2023 and 2022, respectively.
[4] Includes changes in related party balances of ($1,835) and ($1,446) for the nine months ended September 30, 2023 and 2022, respectively.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Business
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Business
American Oncology Network, Inc. (“AON”, “New AON”, “AON Inc.”, or the “Company”), through its subsidiary companies and variable interest entities (together, “its subsidiaries”), is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services across 33 oncology practices located in nineteen states (Arizona, Arkansas, Florida, Georgia, Iowa, Idaho, Indiana, Louisiana, Maryland, Missouri, Michigan, North Carolina, Nevada, Nebraska, Ohio, South Carolina, Texas, Virginia and Washington). The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services, clinical research, radiation oncology, and imaging. During the nine months ended September 30, 2023 and 2022, the Company entered into affiliation agreements with or acquired the following oncology practices.
Nine Months Ended September 30, 2022Nine Months Ended September 30, 2023
StateState
Arizona
Texas(a)
Georgia(a)
Florida(a)
Louisiana(a)
Arkansas(a)
Georgia(a)
Georgia(a)
Georgia(a)
(a)The Company entered into affiliation agreements with the physicians for these respective practices. The Company evaluated each of the affiliation agreements and determined that the transactions did not represent a business combination.
The operations of the practices that were acquired have been included in the Company’s condensed consolidated financial statements since the date of acquisition. The Company intends to continue to pursue additional purchases of physician practices in addition to seeking out new affiliation relationships.
Business Combination Agreements

Digital Transformation Opportunities Corp. (“DTOC”), American Oncology Network, LLC (“AON LLC”), GEF AON Holdings Corp. (“AON Class C Preferred Investor”), and DTOC Merger Sub, Inc., a direct, wholly owned subsidiary of DTOC (“Merger Sub”) entered into a Business Combination Agreement (the “Business Combination Agreement”), dated as of June 14, 2023 (which further amended and restated the Business Combination Agreement entered into by DTOC and AON as of October 5, 2022, and amended and restated on January 6, 2023, and April 27, 2023), pursuant to which, among other transactions, on September 20, 2023 (the “Closing Date”), DTOC and AON undertook a series of transactions (the “Business Combination”) resulting in the organization of the combined post-business combination company as an umbrella partnership C corporation, in which substantially all of the assets and the business of the combined company are held by AON LLC, and DTOC became a member of AON LLC. In connection with the closing of the Business Combination (“the Closing”), DTOC changed its name to “American Oncology Network, Inc.”. The Business Combination was completed on September 20, 2023.

As a result of, and in connection with, the Closing, among other things, (i) AON LLC amended and restated its operating agreement (the “Amended and Restated AON LLC Agreement”) to reclassify its existing Class A units, Class A-1 units and Class B units into a single class of AON LLC common units (“AON LLC Common Units”) that can be exchanged on a one-to-one basis for shares of New AON Class A common stock (“New AON Class A Common Stock”) and its existing AON LLC Class C units into AON LLC Series A preferred units (AON LLC Series A Preferred Units”); (ii) AON LLC converted profit pool units of certain of AON LLC’s subsidiaries into an equal number of AON LLC Common Units and shares of New AON Class B common stock (“New AON Class B Common Stock”), which together are exchangeable into shares of New AON Class A Common Stock (together with the New AON Class B Common Stock, the “New AON Common Stock”); (iii) New AON amended and
restated its charter (the “Charter”) to provide for (a) the conversion of all existing shares of DTOC Class B common stock into shares of New AON Class A Common Stock on a one-to-one basis, (b) amendment of the terms
of New AON Class B Common Stock to provide holders voting rights but no economic rights and (c) designation of a new series of New AON preferred stock as Series A convertible preferred stock (the “New AON Series A
Preferred Stock” or “Series A Preferred Stock") with such rights and preferences as provided for in the certificate of designation of the New Aon Series A Preferred Stock (the “New AON Series A Certificate of Designation”); and (iv) among other things, (a) AON LLC issued common units to New AON in exchange for a combination of cash and shares of New AON Class B Common Stock and warrants to acquire shares of New AON Class B Common Stock (the “Class B Prefunded Warrants”), (b) New AON was admitted as a member of AON LLC, (c) AON LLC distributed shares of New AON Class B common stock or Class B Prefunded Warrants, as applicable, to AON LLC equity holders, (d) New AON reserved a specified number of additional shares of New AON Class A Common Stock after the Closing for issuance to eligible participants, (e) Merger Sub merged with and into the AON Class C Preferred Investor whereby the separate existence of Merger Sub ceased and New AON issued a number of shares of New AON Series A Preferred Stock equal to the number of AON LLC Series A preferred units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor (the “First Step”), (f) promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON LLC Series A preferred units and (g) from and after the Closing (but subject to lock-up restrictions), the AON LLC common equity holders (other than New AON), referred to herein as “Legacy AON Shareholders” (former AON LLC Class A, Class A-1, and Class B unit holders), will have the right (but not the obligation) to exchange AON LLC Common Units together with an equal number of shares of New AON Class B Common Stock (whether held directly or indirectly through Class B Prefunded Warrants) for shares of New AON Class A Common Stock.

In addition, in connection with the Closing, DTOC completed the offer to the holders of AON LLC Class B-1 units to exchange their AON LLC Class B-1 units for such number of newly issued shares of New AON Class A Common Stock equal to the ratio set forth in the Business Combination Agreement (such offer, the “Exchange Offer”). DTOC and AON LLC solicited consents from the holders of AON LLC Class B-1 units to make certain amendments to the terms of the awards and the unit grant agreements pursuant to which the AON LLC Class B-1 units were granted, which provided for the automatic exchange, as of immediately prior to the adoption of the Amended and Restated AON LLC Agreement, of all outstanding AON LLC Class B-1 units into shares of New AON Class A Common Stock (collectively, the “Proposed Amendments”). The requisite number of holders of Class B-1 units provided their consent to the Proposed Amendments, and as a result, in connection with the Closing, all AON LLC Class B-1 units were exchanged for an aggregate of 1,047,343 shares of New AON Class A Common Stock.

Upon the consummation of the Business Combination, the outstanding membership units in AON LLC and the outstanding shares in AON Inc. (New AON) are as follows:
•AON LLC Common Units held by the Legacy AON Shareholders - 28,109,796
•AON LLC Common Units held by New AON - 9,532,354
•AON LLC Series A Preferred Units held by New AON - 6,651,610

•Class A Common Stock held by the former AON LLC Class B-1 unit holders - 1,047,343
•Class A Common Stock held by the DTOC unredeemed shareholders - 147,511
•Class A Common Stock held by the DTOC Sponsor and their permitted transferees - 5,419,375(a)
•Class B Common Stock held by Legacy AON Shareholders - 25,109,551(b)
•New AON Series A Preferred Stock held by AEA Growth Management LP - 6,651,610

(a) Sponsor Earnout Shares of 2,839,375 are subject to vesting and forfeiture provisions and are not outstanding for GAAP purposes as of the Closing Date.

(b) Certain Legacy AON Shareholders hold 3,000,245 Class B Prefunded Warrants, which underlying shares of Class B common stock are not outstanding as of the Closing Date.


Accounting Treatment for the Business Combination

As AON LLC does not meet any of the characteristics of a VIE under ASC 810, the Business Combination was evaluated under ASC 805, Business Combinations. Notwithstanding the legal form of the Business Combination pursuant to the Business Combination Agreement, the Business Combination was accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, DTOC was treated as the acquired company and AON LLC was considered the acquirer for financial statement reporting purposes. AON LLC was determined to be the accounting acquirer based on, in summary, an evaluation of the following primary facts and circumstances:

•AON LLC’s directors will represent a majority of the board seats for New AON’s board of directors;

•AON LLC’s senior management will be the senior management of the combined company;

•AON LLC’s operations comprising the ongoing operations of the post-combination company; and

•AON LLC’s relative size (i.e., assets, revenues, and earnings) is significantly larger compared to DTOC.

Accordingly, for accounting purposes, the financial statements of the post-combination entity will represent a continuation of the financial statements of AON LLC with the acquisition being treated as the equivalent of AON LLC issuing stock for the net assets of DTOC, accompanied by a recapitalization. The net assets of DTOC are stated at historical cost, with no goodwill or other intangible assets recorded. Refer to Note 3 for additional information.

Accounting for the Earnout Shares

Following the Closing and for five years thereafter, the DTOC Sponsor agreed to subject 35%, or 2,839,375 shares of New AON Class A common stock held by it as of the Closing (the “Sponsor Earnout Shares”) to the following vesting and forfeiture provisions:

•the Sponsor Earnout Shares will vest when the volume-weighted average price of the New AON Class A common stock equals or exceeds $13.50 per share for any 20 trading days within any 30 trading day period beginning after the Closing and ending 60 months following the Closing;

•the Sponsor Earnout Shares will be released immediately upon the consummation of a change of control transaction within the 60-month period following the Closing; and

•if the Sponsor Earnout Shares are not released pursuant to the foregoing provisions on or before the date that is 60 months after the Closing, then the Sponsor Earnout Shares will be forfeited immediately following such date.

As the Business Combination was accounted for as a reverse recapitalization, the issuance of the Sponsor Earnout Shares to the Company’s existing shareholders will be accounted for as an equity transaction. The accounting for the Sponsor Earnout Shares was evaluated under ASC Topic 480, Distinguishing Liabilities from Equity, and ASC Subtopic 815-40, Derivatives and Hedging — Contracts in Entity’s Own Equity, to determine if the Sponsor Earnout Shares should be classified as a liability or within equity. As part of that analysis, it was determined that the Sponsor Earnout Shares are freestanding, do not meet the criteria within ASC 480 to be classified as a liability, and meet the criteria in ASC 815-40 to be considered indexed to the post-combination entity’s common stock and classified within equity.
Warrants

As of the Closing Date, New AON assumed the outstanding warrants (Public Warrants and Private Placement Warrants) that were issued by DTOC as part of DTOC’s IPO. Further, New AON issued the Class B Prefunded Warrants to former Class A-1 unit holders, in lieu of New AON Class B Common Stock. The accounting treatment for the Public Warrants, the Private Placement Warrants, and the Class B Prefunded Warrants, collectively referred to as “the Warrants”, is disclosed in Note 2.

Public Warrants

As of the Closing Date, New AON assumed 8,337,500 public warrants (the “Public Warrants”) issued by DTOC in its IPO. Each whole warrant entitles the holder to purchase one share of New AON Class A Common Stock at a price of $11.50 per share, subject to adjustment. The warrants will become exercisable on the later of 12 months from the closing of the DTOC Initial Public Offering or 30 days after the completion of its initial business combination and will expire five years after the Closing of the Business Combination, or earlier upon redemption or liquidation.

Private Warrants

As of the Closing Date, New AON assumed 6,113,333 Private Placement Warrants held by the DTOC Sponsor (the “Private Placement Warrants” or “Private Warrants”). The Private Placement Warrants will be non-redeemable in certain circumstances so long as they are held by the Sponsor or its permitted transferees. The Private Placement Warrants may also be exercised by the Sponsor and its permitted transferees for cash or on a cashless basis. Otherwise, the Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants, including as to exercise price, exercisability, and exercise period.

Class B Prefunded Warrants

As of the Closing Date, New AON issued 3,000,245 of Class B Prefunded Warrants to former AON Class A-1 unitholders. Because the Class B Warrants are prefunded, there was not any cash consideration exchanged as part of the Class B Warrant issuance. Each Class B Prefunded Warrant entitles the holder to purchase one share of New AON Class B common stock at a price of $0.01 per share. The exercise term of the Class B Warrant shall continue indefinitely so long as the holder of the Class B Warrant is also the holder of an AON LLC Common Unit, provided that the number of shares of Common Stock that this Warrant is exercisable for shall not exceed the number of AON LLC Common Units held by holder.


Transaction Expenses
In connection with the Reverse Recapitalization, AON LLC incurred costs of $24.6 million and $30.6 million during the three and nine months ended September 30, 2023, respectively. Of the total costs incurred during the three months ended September 30, 2023, $24.6 million were reported as transaction expenses in the condensed consolidated statements of operations and comprehensive loss. Of the total costs incurred during the nine months ended September 30, 2023, $29.8 million were reported as transaction expenses in the condensed consolidated statements of operations and comprehensive loss and $0.8 million were reported as a reduction of Series A Preferred Stock presented as mezzanine equity on the condensed consolidated balance sheet at September 30, 2023. At December 31, 2022, the Company had accrued $0.3 million of transaction costs related to the Reverse Recapitalization, which were reported as other assets on the condensed consolidated balance sheet. AON LLC recorded $0.2 million of transaction expenses in connection with the Reverse Recapitalization during the three and nine months September 30, 2022, which were reported as transaction expenses in the condensed consolidated statements of operations and comprehensive loss.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation and Significant Accounting Policies
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of the Company were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. Management believes the unaudited condensed consolidated financial statements for the interim periods presented contain all necessary adjustments, of a normal recurring nature, to state fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. These condensed consolidated financial statements were prepared on the same basis as and should be read in conjunction with the Company’s annual consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with such audited consolidated financial statements and related notes thereto of AON LLC and its wholly-owned subsidiaries, included in the proxy statement/prospectus of Digital Transformation Opportunities Corp., dated July 18, 2023 (the “Proxy Statement/Prospectus"). Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results the Company expects for the entire year.

For the three and nine months ended September 30, 2023, these unaudited condensed consolidated financial statements reflect the consolidated results of operations, comprehensive income (loss), cash flows and changes in equity of AON LLC and its wholly-owned subsidiaries for the period of January 1, 2023 through September 20, 2023, the Closing Date of the Reverse Recapitalization, and the consolidated results of operations, comprehensive income (loss), cash flows and changes in stockholders’ equity of AON Inc. and its consolidated subsidiaries, including AON LLC, for the period of September 21, 2023 through September 30, 2023. The condensed consolidated balance sheet at September 30, 2023 presents the financial condition of AON Inc. and its consolidated subsidiaries, including AON LLC, and reflects the initial recording of the assets and liabilities of AON Inc. at their historical cost (see Note 3). All intercompany balances and transactions of AON LLC prior to the Reverse Recapitalization have been eliminated. All intercompany balances and transactions of AON Inc. after the Reverse Recapitalization have been eliminated.

For the three and nine months ended September 30, 2022, these unaudited condensed consolidated financial statements present the consolidated results of operations, comprehensive income (loss), cash flows and changes in equity of AON LLC. The condensed consolidated balance sheet as of December 31, 2022 presents the financial condition of AON LLC and its wholly-owned subsidiaries. All intercompany balances and transactions of AON LLC have been eliminated.

In accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, the historical equity of AON LLC has been recasted in all periods up to the Closing Date, to reflect the number of shares of New AON’s Class A Common Stock and Class B Common Stock issued to Legacy AON Shareholders in connection with the Reverse Recapitalization. The Company recasted the units outstanding related to the historical AON LLC Class A, Class A-1, and Class B units prior to the Reverse Recapitalization (“Historical AON LLC Equity”) as common equity of New AON, equal to the Per Company Class Unit Exchange Ratio, pursuant to the Business Combination Agreement.

The Per Company Unit Exchange Ratio at which AON LLC Class A units and Class A-1 units were reclassified is equal to 2,524 AON Common Units. The Per Company Unit Exchange Ratio at which AON LLC Class B units were reclassified varied depending on participation threshold, and is equal to 2,524, 2,453, or 1,976, AON Common Units. The Per Company Unit Exchange Ratio at which Class C units were reclassified is equal to 2,705 AON LLC Series A Preferred Units.
The condensed consolidated financial statements and related notes thereto give effect to the conversion for all periods presented, without any change to par value or per unit amounts. The condensed consolidated financial statements do not necessarily represent the capital structure of New AON had the Reverse Recapitalization occurred in prior periods. The Company has not made retroactive adjustments related to the historical book values of Historical AON LLC Equity as the adjustments were considered immaterial.

For both the three and nine months ended September 30, 2023, $1.7 million of the consolidated net loss of AON LLC were attributable to the Class A Common Stockholders, and reflects the Class A Common Stockholders’ absorption of 19.0% of the consolidated net loss of AON LLC for the period of September 21, 2023 through September 30, 2023. For both the three and nine months ended September 30, 2023, $11.9 million of the consolidated net losses of AON LLC were attributable to the noncontrolling interest, and reflects the Legacy AON Shareholders’ absorption of 81.0% of the consolidated net losses of AON LLC for the period of September 21, 2023 through September 30, 2023. For the three and nine months ended September 30, 2023, $15.5 million and $27.0 million of the consolidated net losses of AON LLC were attributable to the Legacy AON Shareholders, respectively, to reflect their absorption of 100% of the consolidated net losses of AON LLC pertaining to the days prior to the Reverse Recapitalization. For the three and nine months ended September 30, 2022, net income of $5.6 million and $1.2 million were attributable to the Legacy AON Shareholders, respectively, to reflect their absorption of 100% of AON LLC’s net income pertaining to the periods prior to the Reverse Recapitalization.


Principles of Consolidation
For the period of September 21, 2023 through September 30, 2023, the condensed consolidated financial statements include the accounts of the Company, AON, Inc., American Oncology Network, LLC (“AON LLC”) and its wholly owned subsidiary American Oncology Management Company, LLC (“AOMC”), and its consolidated variable interest entities (“VIEs”) American Oncology Partners, P.A. (“AON Partners”), American Oncology Partners of Maryland, P.A. (“Partners of Maryland”), AON Central Services, LLC (“AON Central Services”), and Meaningful Insights Biotech Analytics, LLC (“MIBA”). All intercompany accounts and transactions between the entities have been eliminated in consolidation.

Refer to Note 1 for the accounting treatment of the Business Combination.

For the periods prior to the Reverse Recapitalization, the consolidated financial statements of the Company comprise the accounts of AON LLC and its wholly-owned subsidiaries. All intercompany accounts and transactions among AON LLC and its consolidated subsidiaries were eliminated.
The Company accounts for American Oncology Network, LLC, AON Partners, Partners of Maryland, AON Central Services, and MIBA in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, Consolidations. The Company determines whether it has a controlling financial interest in an entity by first evaluating whether the entity is a VIE. A VIE is broadly defined as an entity that has any of the following three characteristics: (i) the equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (ii) substantially all of the entity’s activities either involve or are conducted on behalf of an investor that has disproportionately few voting rights; or (iii) the equity investors as a group lack any of the following, the power through voting or similar rights to direct the activities of the entity that most significantly impact the entity’s economic performance, the obligation to absorb the expected losses of the entity, or the right to receive the expected residual returns of the entity. The Company consolidates a VIE if it has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and an obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively, if any.

AON LLC has contractual relationships with AON Partners, Partners of Maryland and AON Central Services and the physician owners through management service agreements (“MSAs”) and other contractual agreements to
provide all practice management services outside of medical services provided by the physicians. In addition, despite not being required by the contractual relationships, AON LLC regularly provides funding to support AON Partners and Partners of Maryland’s operations and acquisitions of physician practices. AON Central Services was formed July 15, 2022 and, effective January 1, 2023, entered into an agreement with AOMC to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. MIBA was established during the first quarter of 2023 for the purpose of developing intellectual property to synergize the collection, de-identification, and dissemination of the Company’s patient data for sale to external parties for research, development, and clinical decisions. In May 2023, the Company contributed $0.2 million for a 56% interest in the equity of MIBA. As of September 30, 2023, MIBA had no significant operating activity. The Company concluded that AON LLC had a controlling financial interest in MIBA and has consolidated the entity at September 30, 2023 and recorded the noncontrolling interest in equity. 
The Company has concluded that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all VIEs in which AON LLC has the characteristics of a controlling financial interest and is deemed to be the primary beneficiary. The variable interest subjects AON LLC to all potential losses in the entities and, therefore, requires AON LLC, and in turn AON Inc., to consolidate the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA in its condensed consolidated financial statements. 
Refer to Note 4 for further information on the VIEs. Refer to Note 1 for the accounting treatment of the Reverse Recapitalization.
Significant Accounting Policies
The accounting policies included below should be read in conjunction with the annual consolidated financial statements.
Accounting Estimates and Assumptions
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Segments
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the “CODM”). The Company’s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company’s performance. The Company has one operating segment and one reportable segment that are structured around the organizational management of oncology practice operations. All revenue and assets are in the United States. 
Revenue Recognition
Revenue is recognized under Accounting Standards Update (“ASU”) 2014-09 Revenue from Contracts with Customers (“Topic 606”). The Company determines the transaction price based upon standard charges for goods and services with anticipated consideration due from patients, third-party payors (including health insurers and government agencies) and others. The Company’s revenue is primarily derived from patient service revenues, which encompass oncology services provided during patient visits and shipments of pharmacy prescriptions. Performance obligations for the Company’s services provided to patients and most procedures, are satisfied over the time of visit which is the same day services are performed. Performance obligations relating to pharmacy revenue are considered fully satisfied at a point in time upon the customer receiving delivery of the prescription. Accordingly, the Company does not anticipate a significant amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods, and any such revenue recognized during the three and nine month periods ended September 30, 2023 and 2022 was immaterial. Additionally, the Company does not expect to recognize material revenue in the future related to performance obligations that are unsatisfied (or partially
satisfied) as of September 30, 2023 and December 31, 2022. Approximately $238.9 million and $213.8 million and $678.1 million and $606.0 million of the Company’s revenues are generated from services performed during patient visits with the remainder primarily generated from shipments of pharmacy prescriptions for the three and nine month periods ended September 30, 2023 and 2022, respectively.
As services are performed and prescriptions are shipped, timely billing occurs for services rendered and prescriptions shipped less discounts provided to uninsured patients and contractual adjustments to third-party payors based upon prospectively determined rates and discounted charges. Payment is requested at the time of service for self-paying patients and for patients covered by third-party payors that are responsible for paying deductibles and coinsurance.
The Company monitors revenue and receivables to prepare estimated contractual allowances for the anticipated differences between billed and reimbursed amounts. Payments from third-party payors and Government programs including Medicare and Medicaid may be subject to audit and other retrospective adjustments. Such amounts are considered on an estimated basis when net patient revenue is recorded and are adjusted as final adjustments are determined. For the three and nine month periods ended September 30, 2023 and 2022, such resulting historic adjustments have been immaterial to the condensed consolidated financial statements. 
In assessing who is the principal in providing patient services and pharmacy prescriptions, the Company considered who controls the provision of services and prescriptions. The Company has determined they are acting as a principal in these relationships. 
In April 2022, the Company entered into a long-term arrangement to sponsor and manage a clinical trial. The Company subsequently contracted with a third-party to provide the clinical research services and is the principal in this arrangement. The performance of clinical research services are considered a single performance obligation because the Company provides a highly-integrated service. Revenue is recognized for the single performance obligation over time due to the Company’s right to payment for work performed to date. The contract provides for invoices based on predetermined milestones. 

The Company uses the cost-to-cost measure of progress for the Company’s contract because it best depicts the transfer of control to the customer as the performance obligation is fulfilled. For this method, the Company compares the contract costs incurred to date to the estimated total contract costs through completion. As part of the client proposal and contract negotiation process, the Company develops a detailed project budget for the direct costs and reimbursable costs based on the scope of the work, the complexity of the study, the geographical location involved and the Company’s historical experience. The estimated total contract costs at the project level are reviewed and revised periodically throughout the life of the contract, with adjustments to revenue resulting from such revisions being recorded on a cumulative basis in the period in which the revisions are identified. Contract costs consist primarily of direct labor and other reimbursable project-related costs such as travel, third-party vendor costs and investigator fees. The Company establishes pricing based on the Company’s internal pricing guidelines, discount agreements, if any, and negotiations with the client. The transaction price is the contractually defined amount. Revenue related to the clinical trial, which is included within other revenue, was $2.2 million and $1.0 million and $3.7 million and $3.1 million for the three and nine months ended September 30, 2023 and 2022, respectively. 
The Company has a system and estimation process for recording Medicare net patient service revenue and estimated recoupments as it relates to value-based care (“VBC”) revenue included in patient service revenue in the condensed consolidated statements of operations and comprehensive loss. The Company’s VBC revenue is primarily generated through its participation in the CMS Oncology Care Model (“OCM”) which is an episode-based payment model to promote high-quality cancer care. Participants enter six-month episode periods, and the Company bills a monthly fee during the six-month period based on a fixed rate per participant per month and the total number of participants. Certain quality and compliance metrics are tracked as part of the program and submitted to CMS at the end of the episode period which may result in recoupment of funds. The Company estimates the recoupment amount by developing a recoupment percentage for each period based on historical known recoupment from CMS and applies the recoupment percentage against total fees for the period. Based on the
estimate, the Company accrues a liability representing the expected final recoupments based on historical settlement trends.
Short-term Marketable Securities 
Investments in marketable securities consist of corporate bonds and U.S. Treasury securities.
Management determines the appropriate classification of investments at the time of purchase and reevaluates such determination at each balance sheet date. Marketable securities are classified as available-for-sale and are carried at fair value in the consolidated balance sheets. The marketable securities are classified as short-term based on management’s intent to convert such securities within one year and the ability to convert them within two to three days.
Certain of our available-for-sale securities are debt securities. For an available-for-sale debt security with an amortized cost that exceeds its fair value, the Company first determines if it intends to sell or will more-likely-than-not be required to sell the security before the expected recovery of its amortized cost. If it intends to sell or will more-likely-than-not be required to sell the security, then the Company recognizes the impairment as a credit loss in the condensed consolidated statements of operations and comprehensive loss by writing down the security’s amortized cost to its fair value. If it does not intend to sell or it is not more-likely-than-not that it will be required to sell the security before the expected recovery of its amortized cost, the Company recognizes the portion of the impairment that is due to a credit loss, if any, in the condensed consolidated statements of operations and comprehensive loss through an allowance. The portion of the impairment that is due to factors other than a credit loss is recognized in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss as an unrealized loss.
Equity Investment in Affiliate
In January 2023, the Company contributed noncash consideration, with a fair value of approximately $2.3 million, in return for a 49% equity interest in OCP Management Arizona, LLP. Investments in entities over which the Company has the ability to exercise significant influence but does not control the entity are accounted for using the equity method. Equity method investments are included with other assets in the condensed consolidated balance sheets. The carrying amount of the investment is adjusted to reflect the Company’s proportionate share of the net earnings or losses and reduced by any dividends received. The Company’s share of income or loss related to this investment is reported as an equity in loss of affiliate in the condensed consolidated statements of operations and comprehensive loss.
Noncontrolling Interests
The Company consolidates the results of entities in which it has a controlling financial interest. Refer to Note 14 for additional considerations and presentation for noncontrolling interest.
Mezzanine Equity

New AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which is outside of the Company’s control). As a result, Management has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity. As of September 30, 2023, the Preferred Stock are recorded at their initial carrying value, net of offering costs of $0.8 million. The Series A Preferred Stock are not being accreted to redemption value, as the redemption is not probable. The Series A Preferred Stock are classified outside of members’ equity on the consolidated balance sheets. Refer to Note 14 for mezzanine equity presentation considerations for redeemable noncontrolling interest.
Business Combinations
The Company evaluates acquired practices in accordance with ASU 2017-01, Business Combinations (Topic 805)-Clarifying the Definition of a Business. This standard clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or
disposals of assets or businesses. Because substantially all of the value of each acquired practice did not relate to a similar group of assets and as each acquired practice contained both inputs and processes necessary to provide economic benefits to the Company, it was determined that each acquisition represents a business combination. Therefore, the transactions have been accounted for using the acquisition method of accounting, which requires, with limited exceptions, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Any excess of the consideration transferred over the estimated fair values of the net assets acquired is recorded as goodwill. Transaction costs related to business combinations are expensed in the period in which they are incurred.
Offering Costs
The Company defers specific incremental costs directly attributable to proposed offerings of securities. These costs consist of legal, accounting, and other similar expenses incurred through the balance sheet date that are directly related to a potential offering. If the offering is completed, these costs will be charged against the gross proceeds of the offering. These offering costs will be allocated to the separable financial instruments issued in the transaction on a relative fair value basis of the securities issued, compared to total proceeds received. Offering costs associated with any instruments classified as liabilities will be expensed as incurred, presented as non-operating expenses in the condensed consolidated statement of operations and comprehensive loss.
During the nine months ended September 30, 2023, the Company incurred additional deferred offering costs of approximately $0.8 million which were recorded as an offset to the net proceeds of the AON LLC Class C Units (discussed below) in mezzanine equity on the condensed consolidated balance sheet at September 30, 2023. At December 31, 2022, the Company had incurred approximately $0.3 million of offering costs, which are included in other assets in the accompanying condensed consolidated balance sheets.

As discussed in Note 1, on June 7, 2023, AON LLC issued Redeemable Convertible Preferred Class C Units (“Class C Units” or “AON LLC Class C Units”) for net proceeds of approximately $64.5 million ($65.0 million in gross proceeds, net of $0.5 million in offering costs). The Company determined that an additional $0.3 million of costs incurred through June 7, 2023 related to the process of raising the proceeds generated by the issuance of the Class C Units. Accordingly, these deferred offering costs have been reclassified from other assets to mezzanine equity, for a total of $0.8 million in Class C Unit offering costs. The Class C Units were subsequently converted to AON LLC Series A Preferred Units upon the Closing of the Business Combination, which were subsequently exchanged for Series A Preferred Stock.
Professional Liability
The Company maintains insurance policies for exposure to professional malpractice insurance risk. The limits of malpractice insurance provide each physician/advanced practice provider with a dedicated $1.0 million limit per claim and a $3.0 million limit in the aggregate per policy period – on a first dollar basis, as no deductible applies. The policy further then extends coverage to the Company, by providing a $2.0 million limit per claim and a $4.0 million limit in the aggregate per policy period - on a first dollar basis, additionally, as no deductible applies. Reserves are established for estimates of the loss that will ultimately be incurred on claims that have been reported but not paid and claims that have been incurred but not reported. These reserves are established based on consultation with a third-party actuary. The actuarial valuations consider a number of factors, including historical claims payment patterns, changes in case reserves and the assumed rate of increase in healthcare costs. Management believes the use of actuarial methods to account for these reserves provides a consistent and effective way to measure these subjective accruals. However, due to the sensitive nature of this estimation technique, recorded reserves could differ from ultimate costs related to these claims due to changes in claims reporting, claims payment and settlement practices and differences in assumed future cost increases. Accrued unpaid claims and expenses that are expected to be paid within the next twelve months are classified as current liabilities and included in accrued other. All other accrued unpaid claims and expenses are classified as long-term liabilities and included in other long-term liabilities. Insurance recoveries associated with the unpaid claims are classified as long-term assets included in other assets.
Fair Value of Financial Instruments
Fair value is the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.
Accounting guidance establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:
Level 1Inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.
Level 2Inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.
Level 3Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. 
Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement of assets and liabilities being measured within the fair value hierarchy.
Our financial instruments include cash, short-term marketable securities, accounts receivable, notes receivable, accounts payable, accrued expenses, long-term debt and contractual agreements that resulted in derivative liabilities. Our nonfinancial assets such as property and equipment are not measured at fair value on a recurring basis; however, they are subject to fair value adjustments in certain circumstances, such as when there is evidence that impairment may exist.
The carrying amounts of cash, accounts receivable, accounts payable, notes receivable, and accrued expenses approximate their fair value because of the short-term maturity and highly liquid nature of these instruments. We determine the fair value of long-term debt and marketable securities based on various factors including maturity schedules and current market rates.
See Note 6 for a discussion of the Company’s Level 1 and Level 2 Marketable Securities as of September 30, 2023. See below for a discussion of the Company’s Level 1 and Level 3 warrant liabilities as of September 30, 2023. As of December 31, 2022, there were no Level 3 financial instruments. There were no transfers between any levels of the hierarchy during any periods presented.

Warrant Liabilities

The Company evaluated the Public Warrants and Private Placement Warrants and the Class B Prefunded Warrants, collectively referred to herein as “Warrants”, in accordance with ASC 815-40, “Derivatives and Hedging —- Contracts in Entity’s Own Equity”, and concluded that a provision in the warrant agreements related to potential net cash settlement of the warrants upon an exchange or tender offer that may not result in a change in control of the entity precludes the warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as long term liabilities on the condensed consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive loss in the period of change.
As of September 30, 2023, the Public Warrants were trading separately from the Class A Common Stock and the quoted market price was used to establish fair value. As such, the Public Warrants fair value was determined using a Level 1 input. The fair value of the Public Warrants is $1.4 million and recorded in other long-term liabilities on the condensed consolidated balance sheets.

Management has utilized the public warrant price to value the private warrants and believes the public and private warrants have materially consistent fair values given the existence of the make-whole redemption feature. As of September 30, 2023, a valuation of the private warrants was performed which confirmed the private warrant value was materially consistent with the public warrants. The details of this valuation are included in the paragraph below.

The fair value of the Private Placement warrants was determined using Level 3 inputs. As of September 30, 2023, the fair value of the Private Placement Warrants was estimated to be $1.0 million and recorded in other long-term liabilities on the condensed consolidated balance sheets. The fair value was estimated at September 30, 2023, using the Black-Scholes Option Pricing model using the following assumptions:
Expected annual dividend yield – 0.0%
                Expected volatility – 0.75%
                Risk-free rate of return – 4.60%
                Expected Option Term – 5.0
                
The AON Class B Prefunded Warrants are exercisable into one share of New AON Class B Common Stock. A share of New AON Class B Common Stock, together with an AON LLC Common Unit, may be exchanged for one share of New AON Class A Common Stock. Considering New AON Class B Common Stock has no economic rights and limited liquidity or value if the holder does not also possess an AON LLC Common Unit, and because the AON Class B Prefunded Warrants are exercisable into New AON Class B Common Stock, the Company has estimated fair value of the Class B Prefunded Warrants to be immaterial.
Earnings Per Share

The Company recast Historical AON LLC Equity as AON Inc. common equity for all periods prior to the Reverse Recapitalization, refer to Note 2. However, as 100% of the net losses of AON LLC prior to the Reverse Recapitalization were absorbed by the Legacy AON Shareholders, basic and diluted earnings (loss) per share is zero for the three and nine months ended September 30, 2022 and basic and diluted earnings (loss) per share for the three and nine months ended September 30, 2023 represents only the period from September 21, 2023 to September 30, 2023, the period where the Company had earnings (loss) attributable to Class A Common Stockholders. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted earnings (loss) per share. As such, basic and diluted earnings (loss) per share of Class B Common Stock has not been presented.

As discussed in Note 1, the Company has issued and outstanding Sponsor Earnouts, which are subject to forfeiture if the achievement of certain stock price thresholds are not met. In accordance with ASC Topic 260, “Earnings Per Share,” the Sponsor Earnouts are excluded from weighted-average shares outstanding to calculate basic earnings (loss) per share as they are considered contingently issuable shares due to their potential forfeiture. Sponsor Earnouts will be included in weighted-average shares outstanding to calculate basic earnings (loss) per share as of the date of their stock price thresholds are met and they are no longer subject to forfeiture.

Basic and diluted earnings (loss) per share is computed by use of the two-class method as a result of outstanding Series A Preferred Stock, which accrue dividends at the annual rate of 8% of the original price per share, participate with common stock on all other dividends, and accordingly have participation rights in undistributed earnings as if all such earnings had been distributed during the period (see Note 12). Under such method income available to common shareholders is computed by deducting both dividends declared or, if not declared,
accumulated on Series A Preferred Stock from net income. Loss attributable to common shareholders is computed by increasing net loss by such dividends. Since the participating Series A Preferred Stock has no contractual obligation to share in the losses of the Company, there is no loss allocation between Class A Common Stock and Series A Preferred Stock.

Basic earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock used for the basic earnings (loss) per share calculation, adjusted for the dilutive effect of the Public and Private Warrants and Sponsor Earnout, if any, using the “treasury stock” method and the convertible Series A Preferred Stock and, exchangeable Class B Common Stock and Class B Prefunded Warrants, if any, using the “if-converted” method. Net earnings (loss) for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net earnings (loss), net of AON Inc. taxes, after giving effect to the Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock, to the extent it is dilutive.
Recently Adopted Accounting Pronouncements 
In June 2016, the FASB issued ASU 2016-13, ‘‘Financial instruments-Credit Losses’’ (“ASU 2016- 13”). ASU 2016-13 requires entities to report ‘‘expected’’ credit losses on financial instruments and other commitments to extend credit rather than the current ‘‘incurred loss’’ model. These expected credit losses for financial assets held at the reporting date are to be based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU will also require enhanced disclosures relating to significant estimates and judgments used in estimating credit losses, as well as the credit quality. ASU 2016-13 is effective for the Company for annual reporting periods beginning after December 15, 2022. ASU 2016-13 was adopted by the Company effective January 1, 2023 with no material impact on the Company’s consolidated financial statements and related disclosures. 
Recently Issued Accounting Pronouncements
In October 2021, the FASB issued ASU 2021-08, “Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”, which provides that an acquirer must recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606. The guidance is effective for the Company for annual reporting periods beginning after December 15, 2023, with early adoption permitted. The Company does not expect the adoption of this standard to have a material impact on the Company’s consolidated financial statements and related disclosures.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Reverse Capitalization
 9 Months Ended
Sep. 30, 2023
Reverse Recapitalization [Abstract]  
Reverse Recapitalization Reverse RecapitalizationAs discussed in Note 1, AON LLC merged with DTOC, with AON LLC surviving the Merger. AON LLC is governed by a board of managers composed of three (3) persons that were designated by New AON and two (2) persons that were designated by holders of a majority of the AON LLC Common Units, held by members of AON LLC other than New AON. Management determined AON LLC was not a variable interest entity (Refer to Note 2), and as result, identified AON LLC as the accounting acquirer of the Merger in accordance ASC Topic 805. Management concluded that AON LLC was the accounting acquirer due to (i) the Legacy AON Shareholders, defined as the former AON Class A, Class A-1, and Class B unit holders, receiving the largest portion of the voting rights in the combined company, New AON, (ii) significantly all of the Legacy AON Shareholders retained their equity interest as stockholders in New AON, (iii) AON LLC’s operations prior to the Reverse Recapitalization comprising the only ongoing operations of New AON, (iv) the Legacy AON Shareholders have the right to appoint a majority of the directors of New AON, (v) the executive management of AON LLC will become the executive management of New AON and (vi) AON LLC is significantly larger than New AON in terms of revenue, total assets, and employees. Therefore, the Merger was accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded, in accordance with ASC Topic 805. New AON was treated as the “acquired” company for financial reporting purposes, and for accounting purposes, the Reverse Recapitalization was treated as the equivalent of AON LLC issuing stock for the net assets of New AON, accompanied by a recapitalization. The net assets of New AON were recorded at historical cost on the condensed consolidated balance sheet as of
September 20, 2023, the Closing Date of the Reverse Recapitalization, with no goodwill or other intangible assets recorded. For additional information on the capitalization of New AON and AON LLC immediately following the Closing of the Reverse Recapitalization, see Note 1.

The following table provides the historical cost of assets and liabilities of AON Inc. as of September 20, 2023.

As of September 30,
2023
Cash and Cash Equivalents$1,493 
Current Liabilities(13,295)
Long Term Liabilities(6,791)
Total Net Liabilities$(18,593)
The Company recorded a Day 1 expense as of the Closing of the Business Combination equal to $18.2 million. Of that total amount, $13.0 million was recorded in transaction expenses on the condensed consolidated statement of operations and comprehensive loss. The remaining $5.2 million was recorded in other income (expense) net on the condensed consolidated statement of operations and comprehensive loss. This amount represented the loss on the issuance of Public and Private Warrants, as of the Closing, net of cash received. The Company also recorded a $4.3 million gain in other income (expense), net related to the change in the fair value of the Public and Private Warrants during the period of September 21, 2023 through September 30, 2023.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Variable Interest Entities
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Variable Interest Entities Variable Interest Entities
AOMC is a wholly owned subsidiary of AON LLC and neither AOMC nor AON LLC has ownership interest in AON Partners and Partners of Maryland. Both AON Partners and Partners of Maryland are fully owned by physicians. AON LLC operates its physician practices through the MSAs and other contractual agreements between AOMC, AON Partners, and Partners of Maryland. The responsibilities of AOMC include, but are not limited to, negotiating provider and payor contracts, employment and compensation decisions, billing and collections, furnishing all supplies and equipment necessary for the respective practice’s operations as well as, necessary real estate, contracting on behalf of AON Partners and Partners of Maryland, entering into leases, holding a power of attorney to perform the above activities, preparing, maintaining and administering all accounting records (including financial reporting), expense payment, and maintenance of all information systems/software. AON LLC is paid a management fee to compensate AOMC for the services provided. AON Central Services is 80% physician owned and 20% owned by AON LLC. AOMC entered into an agreement with AON Central Services, effective January 1, 2023, to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. AOMC pays a monthly management fee to AON Central Services equal to the aggregate cost of compensation, benefits and all other costs related to these employees. AON LLC invested $0.2 million in MIBA, a newly formed LLC, during the second quarter of 2023 in exchange for 56% equity ownership. The Company evaluated AON LLC’s relationship with MIBA under the VIE model and determined it was a VIE and the Company is the primary beneficiary based on its financial controlling interest.

Based on various quantitative and qualitative factors, including assessment of certain services performed and relationships held above, management has determined that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all variable interest entities and AOMC is the primary beneficiary who holds the decision-making rights over the activities that most significantly impact the economic performance of AON Partners, Partners of Maryland, AON Central Services, and MIBA through the MSAs and other contractual agreements. Accordingly, the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA have been consolidated with the Company for the three and nine month periods ended September 30, 2023 and 2022.
The assets of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of September 30, 2023 and December 31, 2022, are as follows:
As of September 30,
2023		As of December 31,
2022
Assets
Cash and cash equivalents$33,083 $26,844 
Accounts receivable141,039 136,098 
Inventories37,844 36,476 
Prepaid expenses and other current assets869 846 
Goodwill and intangibles, net180 180 
Other receivables36,294 28,139 
Other assets2,014 1,489 
Total assets$251,323 $230,072 
The liabilities of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of September 30, 2023 and December 31, 2022, are as follows:
As of September 30,
2023		As of December 31,
2022
Liabilities
Accounts payable$114,779 $102,783 
Accrued compensation and benefits22,747 6,021 
Accrued other16,038 15,926 
Other long-term liabilities137 452 
Due to AON LLC and subsidiaries, net134,344 128,204 
Total liabilities$288,045 $253,386 
All intercompany transactions and balances with the VIEs are eliminated in consolidation.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities
 9 Months Ended
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities Marketable Securities
The following table summarizes the Company’s marketable securities financial assets that are measured at fair value on a recurring basis:
As of September 30, 2023
Amortized
Cost		Gross Unrealized
Gains		Gross Unrealized
Losses		Estimated Fair
Value
Cash equivalents (1)
Level 1:
Overnight repurchase agreements (2)$28,272 $- $- $28,272 
Money market funds773 - - 773 
U.S. Treasury Bills18,606 - - 18,606 
Level 1 total$47,651 $— $— $47,651 
Marketable securities
Level 2:
Corporate bonds13,980 62 (38)14,004 
U.S. Treasury securities11,981 52 (4)12,029 
Level 2 total25,961 114 (42)26,033 
Total$73,612 $114 $(42)$73,684 
As of December 31, 2022
Amortized
Cost		Gross Unrealized
Gains		Gross Unrealized
Losses		Estimated Fair
Value
Cash equivalents (1)
Level 1:
Money market funds$109 $- $- $109 
Marketable securities
Level 2:
Corporate bonds7,742 6 (125)7,623 
U.S. Treasury securities2,226 6 (4)2,228 
Level 2 total9,968 12 (129)9,851 
Total$10,077 $12 $(129)$9,960 
(1)Included in cash and cash equivalents in the Consolidated Balance Sheets at September 30, 2023 and December 31, 2022.
(2)Cash equivalents as of September 30, 2023 included U.S. Treasury Bills with an initial maturity of 3 months or less and overnight repurchase agreements in which cash from the Company's main operating checking account is invested overnight in highly liquid, short-term investments sponsored by a large financial institution. The company had no such investments as of December 31, 2022.
The Company uses quoted prices in active markets for identical assets to determine the fair value of its Level 1 investments. The fair value of the Company’s Level 2 investments is determined using pricing based on quoted market prices or alternative market observable inputs. 
The fair value of the Company’s marketable securities as of September 30, 2023, by remaining contractual maturities, were as follows:
Corporate BondsU.S. TreasuriesTotal
Due in one year or less$4,805 $8,385 $13,190 
Due in one to five years9,199 3,644 12,843 
Total$14,004 $12,029 $26,033 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Business Combinations
 9 Months Ended
Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Business Combinations Business Combinations
2022 Acquisitions
During the nine months ended September 30, 2022, the Company entered into a purchase agreement acquiring control of Northern Arizona Hematology and Oncology on January 1, 2022 for an aggregate purchase price of less than $0.1 million. Because the acquisition of Northern Arizona Hematology and Oncology was on the first day of the fiscal period, the Company’s results for the three and nine months ended September 30, 2022 include the results of the acquired practice.
In connection with each of the Company’s business combinations (the “Transactions”), the Company executed employment agreements with the selling physicians to become employees of AON Partners and/or Partners of Maryland. Additionally, for each transaction the Company and selling physicians entered into a separate unwind agreement granting each other a unilateral option that may be exercised by either party and effectively returns the acquired business to the selling physicians if exercised. In the event the Company or seller exercise their unwind rights, the selling physicians are required to repay the original purchase price for the assets that were sold in the Transaction plus any assets that were acquired after the Transaction, less any accumulated depreciation or amortization with respect to the assets. The selling physicians are also required to assume all contracts associated with their practice. Additionally, in the event of unwind, the selling physicians are entitled to any severance
amounts that are due to them under their employment agreement with AON Partners and their employment is terminated on the unwind date. As of September 30, 2023 and December 31, 2022, no liability has been recorded related to the unwind agreements as neither the Company nor any selling physicians have exercised their unwind rights and therefore no payments are considered probable to the selling physicians.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Condensed Balance Sheet Information
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental Condensed Balance Sheet Information Supplemental Condensed Balance Sheet Information
Other receivables
Other receivables consisted of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December 31,
2022
Rebates receivable$36,556 $27,955 
Other191 246 
Total other receivables$36,747 $28,201 
Inventory
Inventory consisted of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December
31, 2022
Intravenous drugs$27,508 $25,674 
Oral pharmaceuticals10,336 10,802 
Total inventories$37,844 $36,476 
Property and Equipment, net
Property and equipment, net consisted of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December 31,
2022
Leasehold improvements$30,078 $26,076 
Furniture, fixtures and equipment2,722 2,669 
Medical equipment12,659 11,003 
Computer equipment3,325 3,115 
Signs147 129 
Automobiles59 69 
Software4,412 4,834 
Construction-in-progress6,150 1,433 
Property and equipment, gross59,552 49,328 
Accumulated depreciation and amortization(23,312)(17,348)
Property and equipment, net$36,240 $31,980 
Accrued Other
Accrued other consisted of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December 31,
2022
Refund liability$14,521 $14,544 
Deferred social security taxes - COVID- 378 
Excise taxes payable2,700 - 
Current portion of finance lease liabilities630 425 
Other5,126 2,453 
Total accrued other$22,977 $17,800 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Long-term Debt
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Long-Term Debt Long-term Debt
Debt consisted of the following at September 30, 2023 and December 31, 2022: 
As of September 30,
2023		As of December
31, 2022
PNC Facility$81,250 $81,250 
Total81,250 81,250 
Unamortized debt issuance costs(825)(949)
Total debt$80,425 $80,301 
Credit Facilities
On April 30, 2021, the Company entered into a Loan Facility with PNC (“PNC Loan Facility”) collateralized by the Company’s assets and outstanding patient accounts receivable. The PNC Loan Facility is guaranteed on a limited basis by the Company and shareholder of AON Partners and Partners of Maryland. $34.6 million of
proceeds from the PNC Loan Facility was used to pay off the Company’s previous term loans and revolver with Truist Bank. The remaining funds were made available for working capital and acquisition of additional physician practices.
The PNC Loan Facility is interest-only with total principal due at maturity on April 30, 2024. Interest originally accrued at one-month LIBOR or an alternate base rate plus 1.45%. The maximum balance of the PNC Loan Facility (“Borrowing Base”) is limited to the lesser of the Facility Limit ($65.0 million) or the fair value of the Company’s patient accounts receivable. The Company must maintain a balance of the lesser of the Borrowing Base or 65% of the Facility Limit in the first year and 75% of the Facility Limit in subsequent years (“minimum funding threshold”). The Company can repay the PNC Loan Facility up to the minimum funding threshold at any time without penalty. In accordance with the PNC Loan Facility, the Company pledged $10.0 million of collateral as restricted cash to be released quarterly in increments of $2.5 million. The restricted cash was fully released as of September 30, 2023 and December 31, 2022.
On April 30, 2021, the Company entered into a $5.0 million revolving line of credit agreement (“PNC Line of Credit”). The PNC Line of Credit has an expiration date of April 30, 2024 and originally bore interest at a rate per annum equal to the sum of the daily LIBOR rate plus 1.65% or an alternate base rate plus 0.65% and is due on the first day of each month beginning June 1, 2021. Any outstanding principal and accrued interest will be due on the expiration date. Beginning July 1, 2021, quarterly bank fees equal to 1.65% per day per annum are due in arrears and will continue on the first day of each quarter thereafter. All debt related to the PNC Line of Credit is collateralized by the Company’s assets. As of September 30, 2023 and December 31 2022, no draws had been made on the PNC Line of Credit. The Company is also subject to a 0.20% unused line fee calculated per annum on the unused balance of the PNC Line of Credit. 
On July 29, 2021, the Company amended the PNC Loan Facility increasing the Facility Limit to $75.0 million. On February 14, 2022, the Company further amended the PNC Loan Facility and Line of Credit agreements. The primary changes included an increase of the Facility limit from $75.0 million to $125.0 million, an increase of the PNC Line of Credit availability from $5.0 million to $10.0 million, interest charges to be calculated based on the Bloomberg Short-Term Bank Yield Index plus 1.65% and certain financial covenants. As part of the amendment, the Company drew an additional $16.3 million in proceeds under the Loan Facility. On August 15, 2022, the PNC Loan Facility and Line of Credit agreements were amended again to reduce the availability under the PNC Line of Credit from $10.0 million to $1.0 million. 
Effective November 23, 2022, the Company entered into Waiver and Amendment No. 6 (“Waiver and Amendment”) under its PNC Loan Facility as the Company was not in compliance with the Delinquency Ratio financial covenant for the period ending October 31, 2022 and the requirement to provide certain annual financial statements. The Waiver and Amendment waives each event of default and also revised future delinquency percentages and financial statement requirements. 
On June 30, 2023, the Company entered into Amendment No. 7 (“Amendment 7”) to its PNC Loan Facility which extended the maturity date from April 30, 2024 to June 30, 2026. In connection with Amendment 7, the Company paid additional debt issuance costs of $0.4 million which will be amortized over the revised remaining life of the Loan Facility. In addition, Amendment 7 revised the definition of the minimum funding threshold to limit the threshold multiplier to 65% of the Facility Limit. 
The PNC Loan Facility and PNC Line of Credit nonfinancial covenants include restrictions related to unpermitted property liens and the requirement of audited financial statements. Both agreements also contain several financial covenants, including the following ratios: accounts receivable default, delinquency, dilution, days sales outstanding, leverage, and fixed charge coverage. As of September 30, 2023, the Company was in compliance with all financial and nonfinancial debt covenants as required by both loan agreements.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes
 9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The Company is a member of American Oncology Network, LLC, which is treated as a partnership for U.S. federal and certain state and local income taxes. As a partnership, American Oncology Network, LLC is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by American Oncology Network, LLC is passed through to and included in the taxable income or loss of its members, including the Company, on a pro-rata basis.

The Company is subject to U.S. federal income taxes, in addition to state and local income taxes with respect to the allocable share of any taxable income of American Oncology Network, LLC. Additionally, other corporate entities within the Company's structure are subject to income taxes. These corporate entities continue to generate losses and continue to maintain a valuation allowance against their net deferred tax assets.

The Company’s effective income tax rate was (1.1)% and —% for the three months ended September 30, 2023 and 2022, respectively. The provision for income taxes was $315 and $0 for the three months ended September 30, 2023 and 2022, respectively.

The Company’s effective income tax rate was (0.8)% and —% for the nine months ended September 30, 2023 and 2022, respectively. The provision for income taxes was $315 and $0 for the nine ended September 30, 2023 and 2022, respectively.

The change to the income tax provision for the three and nine months ended September 30, 2023 compared to the income tax provision for the three and nine months ended September 30, 2022 was primarily a result of the transaction closing on September 20, 2023, resulting in a portion of the Company's consolidated pre-tax earnings, which were previously not subject to income taxes, flowing into a taxable corporation included in the Company's post transaction structure.

The effective income tax rate for the three and nine months ended September 30, 2023 and 2022 differed from the federal statutory rate primarily due to certain legal entities in the Company's structure being treated as partnerships for income tax purposes and, therefore, a significant portion of its income not being subject to income tax. Additionally, certain corporate entities within the Company's structure continue to maintain a full valuation allowance against their net deferred tax assets.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Leases
 9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Leases Leases
The Company currently leases office facilities and equipment for its practices under noncancelable operating and finance lease agreements expiring on various dates through 2038. Certain of the leases contain renewal options which are exercisable at the Company’s discretion. These renewal options are considered in determining the lease term if it is reasonably certain that the Company will exercise such options. Additionally, the Company leases certain other office and medical equipment under month-to-month lease agreements. 
Right-of-use assets and lease liabilities consist of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December 31,
2022
Assets
Operating lease right-of-use assets, net$46,138 $43,724 
Finance lease right-of-use assets, net (included in property and equipment, net)2,791 1,998 
Total right-of-use assets$48,929 $45,722 
Liabilities
Current
Current portion of operating lease liabilities$7,123 $9,177 
Current portion of finance lease liabilities (included in accrued other)630 425 
Long-term7,753 9,602 
Long-term operating lease liabilities42,261 37,224 
Long-term finance lease liabilities (included in other long-term liabilities)2,126 1,619 
Total lease liabilities$52,140 $48,445 
The components of lease costs recognized in the condensed consolidated statements of operations and comprehensive loss consist of the following for the three and nine month periods ended September 30, 2023 and 2022 and are included in selling, general, and administrative expenses unless otherwise noted:
Three Months Ended September 30,Nine Months Ended
September 30,
2023202220232022
Operating lease costs$2,820 $3,161 $8,361 $9,297 
Finance lease costs
Amortization of finance lease right-of-use assets122185354 413 
Interest on finance lease liabilities (included in interest expense)351979 60 
Variable lease costs5608621,742 2,232 
Total lease costs$3,537 $4,227 $10,536 $12,002 
The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of September 30, 2023:
Operating
Lease		Finance
Leases
2023 (remainder of year after September 30, 2023)$1,679 $188 
202410,940 753 
20259,830 731 
20269,413 492 
20278,194 428 
Thereafter24,154 528 
Total lease payments64,210 3,120 
Less: amount representing interest(14,826)(364)
Present value of lease liabilities49,384 2,756 
Less: current portion of lease liabilities(7,123)(630)
Long-term lease liabilities, net of current portion$42,261 $2,126 
The weighted-average remaining lease term as of September 30, 2023 and December 31, 2022 was 7.01 years and 5.68 years for operating leases and 5.00 years and 5.37 years for finance leases, respectively. The weighted-average discount rate as of September 30, 2023 and December 31, 2022 was 6.56% and 4.88% for operating leases and 5.12% and 3.60% for finance leases, respectively.
The cash paid for amounts included in the measurement of lease liabilities for the nine months ended September 30, 2023 and 2022 is as follows:
Nine Months Ended
September 30,
20232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$7,678 $9,788 
Operating cash flows from finance leases79 60 
Financing cash flows from finance leases387 321 
ROU assets obtained in exchange for new operating lease liabilities9,862 9,771 
ROU assets obtained in exchange for new finance lease liabilities1,103 - 
At September 30, 2023, the Company had entered into two sixty-month finance leases for medical equipment that had not yet commenced. The future commitments related to these leases are approximately $3.8 million and the Company expects to take control of the leased assets early in the fourth quarter.
Leases Leases
The Company currently leases office facilities and equipment for its practices under noncancelable operating and finance lease agreements expiring on various dates through 2038. Certain of the leases contain renewal options which are exercisable at the Company’s discretion. These renewal options are considered in determining the lease term if it is reasonably certain that the Company will exercise such options. Additionally, the Company leases certain other office and medical equipment under month-to-month lease agreements. 
Right-of-use assets and lease liabilities consist of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December 31,
2022
Assets
Operating lease right-of-use assets, net$46,138 $43,724 
Finance lease right-of-use assets, net (included in property and equipment, net)2,791 1,998 
Total right-of-use assets$48,929 $45,722 
Liabilities
Current
Current portion of operating lease liabilities$7,123 $9,177 
Current portion of finance lease liabilities (included in accrued other)630 425 
Long-term7,753 9,602 
Long-term operating lease liabilities42,261 37,224 
Long-term finance lease liabilities (included in other long-term liabilities)2,126 1,619 
Total lease liabilities$52,140 $48,445 
The components of lease costs recognized in the condensed consolidated statements of operations and comprehensive loss consist of the following for the three and nine month periods ended September 30, 2023 and 2022 and are included in selling, general, and administrative expenses unless otherwise noted:
Three Months Ended September 30,Nine Months Ended
September 30,
2023202220232022
Operating lease costs$2,820 $3,161 $8,361 $9,297 
Finance lease costs
Amortization of finance lease right-of-use assets122185354 413 
Interest on finance lease liabilities (included in interest expense)351979 60 
Variable lease costs5608621,742 2,232 
Total lease costs$3,537 $4,227 $10,536 $12,002 
The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of September 30, 2023:
Operating
Lease		Finance
Leases
2023 (remainder of year after September 30, 2023)$1,679 $188 
202410,940 753 
20259,830 731 
20269,413 492 
20278,194 428 
Thereafter24,154 528 
Total lease payments64,210 3,120 
Less: amount representing interest(14,826)(364)
Present value of lease liabilities49,384 2,756 
Less: current portion of lease liabilities(7,123)(630)
Long-term lease liabilities, net of current portion$42,261 $2,126 
The weighted-average remaining lease term as of September 30, 2023 and December 31, 2022 was 7.01 years and 5.68 years for operating leases and 5.00 years and 5.37 years for finance leases, respectively. The weighted-average discount rate as of September 30, 2023 and December 31, 2022 was 6.56% and 4.88% for operating leases and 5.12% and 3.60% for finance leases, respectively.
The cash paid for amounts included in the measurement of lease liabilities for the nine months ended September 30, 2023 and 2022 is as follows:
Nine Months Ended
September 30,
20232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$7,678 $9,788 
Operating cash flows from finance leases79 60 
Financing cash flows from finance leases387 321 
ROU assets obtained in exchange for new operating lease liabilities9,862 9,771 
ROU assets obtained in exchange for new finance lease liabilities1,103 - 
At September 30, 2023, the Company had entered into two sixty-month finance leases for medical equipment that had not yet commenced. The future commitments related to these leases are approximately $3.8 million and the Company expects to take control of the leased assets early in the fourth quarter.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Related Parties
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Related Parties Related Parties
Transactions Notes Receivable
The Company enters into promissory notes with physicians of the Company. The notes receivable balances are satisfied through cash payments or settlements through the physicians’ compensation as part of their employee agreement. The notes receivable are amortized over a 60-month period as a reduction of compensation. The notes bear interest at the Company’s incremental borrowing rate (7.14% at September 30, 2023 and 1.57% at December 31, 2022, respectively).
As of September 30,
2023		As of
December 31,
2022		Original
Principal		Issue
Date		Maturity
Date
Notes receivable
Note 2$1,027 $1,057 $5,355 5/1/20194/30/2024
Note 342 119 491 6/1/20195/31/2024
Note 6- 351 1,111 5/22/20205/22/2023
Note 82,065 2,221 2,816 5/1/20205/1/2025
Note 9- 125 125 1/24/20226/30/2023
Total notes receivables3,134 3,873 
Less:  Current portion of notes receivable$(1,630)(1,797)
Notes receivable, less current portion$1,504 $2,076 
Leases
The Company has operating leases for ten of the office facilities owned by employees of the Company. Total cash was approximately $0.6 million and $1.9 million paid for leases to related parties for the both the three and nine months ended September 30, 2023 and 2022, respectively.
Inventory Purchases/Concentration Risk
The Company purchases the majority of pharmaceuticals inventory from a subsidiary under common control of a Legacy AON Shareholder. During the three and nine months ended September 30, 2023 and 2022, the Company purchased from the related party approximately $268.0 million and $239.0 million and $774.0 million and $682.0 million, respectively. These purchases were approximately 86% and 89% and 88% and 86% as a percentage of cost of revenue for the three and nine months ended September 30, 2023 and 2022, respectively. At September 30, 2023 and December 31, 2022, the Company had $113.0 million and $102.1 million, respectively, included in accounts payable for invoices from the related party, representing 94% of accounts payable at each period-end.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Equity
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Equity Equity
Prior Period Presentation

For periods prior to the Reverse Recapitalization, AON LLC had equity and stock-based compensation described below authorized, issued and outstanding. As discussed in Note 1, upon the Closing of the Business Combination, Legacy AON Shareholders received Class A Common Stock, Class B Common Stock, or Class B Prefunded Warrants and AON LLC reclassified their existing Class A, Class A-1, and Class B Units into AON LLC Common Units, pursuant to the terms of the Business Combination Agreement.
The Company recasted Historical AON LLC Equity outstanding for the periods prior to the Reverse Recapitalization, equal to the Per Company Unit Exchange Ratio, pursuant to the Business Combination, that was applied to the Class A, Class A-1, and Class B Units. The historical AON LLC units disclosed in this note give effect to the conversion for all periods presented, as follows.

Class A Units

AON LLC had authorized 19,495,376 units of Class A Units, of which 19,495,376 units were issued and were outstanding as of December 31, 2022.

Class A-1 Units

AON LLC had authorized 3,000,245 units of Class A-1 Units, of which 1,842,520 units were issued and were outstanding as of December 31, 2022.

Class B Units (Profit Interest)

The Class B units were issued through the 2017 Profits Interest Plan adopted by the Company in October 2017. The Class B Units represented a non-voting equity interest in AON LLC that entitled the holder to appreciation in the equity value of AON LLC arising after the date of grant and after such time as an applicable hurdle amount is met. AON LLC recognized the cost of services received in exchange for Class B Units based on the grant-date fair value. That cost was recognized over the period during which the service provider is required to provide service in exchange for the award over the requisite service period or based on performance. AON LLC used the Black-Scholes-Merton pricing model to estimate the fair value of profits interest unit awards. On an as converted basis, as of December 31, 2022, AON LLC issued 5,614,176 Class B Units, of which 4,703,628 were vested and outstanding; the remaining 910,548 of Class B units vested upon consummation of the Business Combination. The stock compensation expense that was recognized for the vesting of the Class B Units was less than $0.1 million.

The following table summarizes the changes to AON LLC’s Class A, Class A-1, and Class B Units for the three and nine months ended September 30, 2023, and 2022.


in thousands, except for share and per share amountsThree Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Class A Units, value
Beginning of Period$7,725 $7,725 $7,725 $7,725 
Issuance of Units— — — — 
Impact of the Reverse Recapitalization(7,725)— (7,725)— 
End of Period$— $7,725 $— $7,725 
Class A Units, units
Beginning of Period19,495,376 19,495,376 19,495,376 19,495,376 
Issuance of Units— — — — 
Impact of the Reverse Recapitalization(19,495,376)— (19,495,376)— 
End of Period— 19,495,376 — 19,495,376 
in thousands, except for share and per share amountsThree Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Class A-1 Units, value
Beginning of Period$31,040 $28,500 $28,500 $28,500 
Issuance of Units7,185 — 9,725 — 
Impact of the Reverse Recapitalization(38,225)— (38,225)— 
End of Period$— $28,500 $— $28,500 
Class A-1 Units, units
Beginning of Period2,281,696 1,842,520 1,842,520 1,842,520 
Issuance of Units718,549 1,157,725 
Impact of the Reverse Recapitalization(3,000,245)(3,000,245)
End of Period— 1,842,520 — 1,842,520 
in thousands, except for share and per share amountsThree Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Class B Units, value
Beginning of Period$80 $90 $80 $80 
Equity based compensation10 5 10 15 
Impact of the Reverse Recapitalization(90)— (90)
End of Period$— $95 $— $95 
Class B Units, units
Beginning of Period4,703,628 4,703,628 4,703,628 4,703,628 
Units Vested910,548 — 910,548 — 
Impact of the Reverse Recapitalization(5,614,176)— (5,614,176)— 
End of Period— 4,703,628 — 4,703,628 

Class B-1 Units

In June and July of 2023, the Company granted a total of 415 AON LLC Class B-1 Units to certain employees under the 2017 Profits Interest Plan (the “Plan”). The Class B-1 Units vested upon the consummation of the Business Combination, therefore, $4.9 million of expense has been recognized in the condensed consolidated statement of operations and comprehensive loss for the three months ended September 30, 2023. Upon the closing of the Business Combination, the vested Class B-1 Units were reclassified to AON LLC Common Units and exchanged for newly issued shares of Class A Common Stock equal to the Per Company Unit Exchange Ratio, pursuant to the Business Combination Agreement, which resulted in the issuance of 1,047,343 shares of New AON Class A Common Stock.

Mezzanine Equity Class C Units
As described in Note 1, the AON LLC Class C Units were converted into AON LLC Series A Preferred Units as of the Closing Date. Concurrently, New AON issued a number of shares of New AON Series A Preferred Stock equal to the number of AON LLC Series A Preferred Units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor. Promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON LLC Series A Preferred Units. On an as converted basis, as of September 20, 2023, 6,651,610 Series A Preferred Stock were issued to AEA Growth Management LP.

The AON LLC Class C Units were contingently redeemable convertible preferred units and classified as mezzanine equity on the condensed consolidated balance sheet as of June 30, 2023 because the units were redeemable five years from the issuance date, at the option of the holder. As of June 30, 2023, the AON LLC Class C Units were recorded at their initial carrying value, net of offering costs. The Class C Units were not being accreted to redemption value, as the redemption was not probable due to the removal of the redemption right pursuant to the Business Combination. See discussion below.

The Class C Units had materially the same rights as the Series A Preferred Stock issued by the Company to AEA Growth Management LP, the parent of the AON Class C Preferred Investor, with the exception of the “AON LLC Class C Unit Redemption Right” and the “Class C Option to Purchase Additional Shares”, discussed below. Further, the Class C Units did not contain a mandatory conversion feature that allowed AON LLC to force the Class C Investor to convert the Class C Units into another equity unit in AON LLC and the Class C Units did not have a one time conversion price adjustment.

Class C Unit Redemption Right

After the fifth anniversary of the Effective Date (June 7, 2028), the holders of a majority of the Class C Units had the right to cause the Company to redeem all of the Class C Units. The redemption price per Class C Unit was equal to the greater of (i) the Class C Liquidation Preference and (ii) the Fair Market Value of a Class C Unit (the “Class C Redemption Price”). The Class C Liquidation Preference is defined as an amount equal to the sum of (a) the Class C Preferred Return of such Class C Member and (b) the amount of such Class C Member’s Net Invested Capital Contributions of $65.0 million. The Class C Unit Preferred Return is defined as the cumulative, semiannually-compounded return of 8% per annum based on the original Net Invested Capital Contributions of $65.0 million. The Class C Unit Redemption Right was removed as of the Closing of the Business Combination.

Class C Unit Option to Purchase Additional Units

In accordance with the terms of the Amended and Restated Class C Convertible Preferred Unit Purchase Agreement dated June 7, 2023, the Class C Preferred Investor had an option to purchase an additional 378 AON Class C Units until the Closing of the Business Combination at a purchase price of $26,423 per Unit (“Option Feature”). The Company determined that this Option Feature was required to be accounted for as a derivative in accordance with ASC 815. The fair value of the derivative was estimated to be $1.4 million as of June 30, 2023. The Class C Preferred Investor did not exercise this option prior to the Closing of the Business Combination. As a result, the Company recognized a gain of $1.4 million in other (expense) income, net in the condensed consolidated statements of operations and comprehensive loss for the three months ended September 30, 2023. The Class C Unit Option expired as of the Closing of the Business Combination.


Series A Preferred Stock (Mezzanine Equity)

New AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which outside of the Company’s control). As a result, the Company has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity. At the closing of the Business Combination, the Company exchanged existing AON LLC Class C Units for Series A Preferred Stock in the Company. Based on the qualitative changes to the instrument, this exchange is
considered an extinguishment for accounting purposes, with the Company recording a deemed dividend of $2.1 million to account for the difference between the carrying value of the Class C Units and the fair value of the Series A Preferred Stock at the transaction date. This amount is reflected in the condensed consolidated statements of mezzanine and stockholders’ equity as part of the reverse recapitalization, net. See further discussion on the PIK Dividend discussed below.

The Series A Preferred Stock are not being accreted to redemption value, as the Series A Preferred Stock are not redeemable, nor are they probable of becoming redeemable.

Dividends

The Series A Preferred Stock accrue dividends at a cumulative, semiannually-compounded return of 8% per annum based on the original Net Invested Capital Contributions from the Class C Units of $65.0 million. These dividends may be paid in cash or accumulate into the Accrued Value at the option of New AON. The accrual shall be calculated on June 30 and December 31 and with respect to the semiannually-compounded return, no interest is required to be paid on any present or future Series A Preferred Stock accrued dividends. The Series A Preferred Stock also participate in distributions with the Class A Common stockholders.

On September 20, 2023, the Company issued 6,651,610 Series A Preferred Stock to AEA Growth Management LP. The number of Series A Preferred Stock shares issued at the Closing of the Business Combination was equal to the aggregate Class C Liquidation Preference pursuant to the Business Combination Agreement. As a result, the issuance of the Series A Preferred Stock effectively included an in-kind payout (“PIK”) of the accrued dividend since the calculation of the amount issued was based on the Class C Liquidation Preference. As of the Closing, the Company recorded a dividend of 151,610 Series A Preferred Stock PIK shares with respect to the accrued dividends on the Series A Preferred Stock (the "PIK Dividend").

Voting

The holders of the Preferred Stock are entitled to elect and appoint one of the directors (“Series A Director”) to the Board of Directors. All other directors are appointed by the Class A and Class B Common stockholders. There are no restrictions on which matters the Series A Preferred stockholders are entitled to vote. The Series A Preferred stockholders are entitled to the number of votes equal to the number of shares of Common Stock into which the Series A Preferred Stock would be convertible on the record date of the vote.

Conversion Rights

The Series A Preferred Stock is convertible, at the option of the holder, at any time, and without the payment of additional consideration by the holder, into such number of fully-paid Class A Common Stock as is determined by dividing the Accrued Value by the Conversion Price in effect at the time of conversion (“Conversion Ratio”). The Accrued Value is the Original Issue Price (which is $10.00 per share of Preferred Stock, as adjusted for any stock split, stock dividend, combination, or other recapitalization) plus any unpaid dividends, compounded semi-annually. The Conversion Price is initially $10.00 per Preferred Share subject to adjustment for dilutive issuances of additional shares, dividends to common stockholders, stock splits, mergers, and a five-year anniversary special adjustment based on the volume weighted average price of the common stock. These dividends may be paid in cash or accumulate into the Accrued Value, at the option of New AON, on June 30 and December 31 of each year. The Conversion Rights shall terminate at the close of business on the day prior to the date of a Change of Control.

If at any time on or after the 30th day after the five-year anniversary of the issue date, any of the Series A Preferred Stock remain outstanding and the 30-Day VWAP of the Common Stock is less than $10.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification), then the Conversion Price shall be adjusted to the greater of (x) the 30-Day VWAP on such date of determination and (y) $5.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification).
New AON also has the right on or after the third-year anniversary of the date of issuance to cause all (but not less than all) of the outstanding shares of Series A Preferred Stock to be converted into shares of Class A Common Stock for each share of Series A Preferred Stock at the Conversion Ratio detailed above. The Company may only convert shares of Series A Preferred Stock into shares of Common Stock if the 30-Day VWAP of the Common Stock immediately prior to the Company Conversion Date is greater than $16.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization).

Liquidation Preferences

In the event of voluntary or involuntary liquidation, dissolution or winding up of the Company or an Initial Public Offering (IPO) or Exit Event, the Series A Preferred Stock have preferential liquidation rights. If a Deemed Liquidation Event were to occur, each Series A Preferred stockholder is entitled to be paid out of the assets of the Company available for distribution, equal to the greater of the following:

(i) The Original Issue Price of $10 per Series A Preferred Stock multiplied by the Applicable Percentage plus any Accrued Dividends on such share of Series A Preferred Stock; or

(ii) Such amount per share as would have been payable had all shares of Series A Preferred Stock been converted into Common Stock immediately prior to such Deemed Liquidation Event.

The Series A Preferred Stock Applicable Percentage is defined as a percentage equal to (a) one hundred twenty-five percent (125%) if an Exit Event, dissolution, liquidation, or winding-up occurs prior to June 7, 2024, (b) one hundred twenty percent (120%) if an Exit Event, dissolution, liquidation, or winding up occurs after June 7, 2024, but prior to June 7, 2025, (c) one hundred fifteen percent (115%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2025, but prior to June 7, 2026, (d) one hundred ten percent (110%) if an Exit Event, dissolution, liquidation, or winding up occurs after June 7, 2026, but prior to June 7, 2027, (e) one hundred five percent (105%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2027, but prior to June 7, 2028, (f) one hundred percent (100%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2028.

Distributions to Class A and Class A-1 Members

On March 4, 2020, the AON LLC entered into the Second Amended and Restated Limited Liability Agreement (“Second Operating Agreement”) which established another class of equity, Class A-1 Units. The Second Operating Agreement provided, among other things, that the Class A and A-1 Units would receive a cumulative, annually-compounded, preferred return of 8.0% and 4.0%, respectively, on capital contributions when and if distributions are declared by the Board of the Company.

Prior to the issuance of the Class C Units on June 7, 2023 as discussed above, the Class A and A-1 unitholders were paid a cash distribution of $4.0 million and $4.1 million, respectively, representing the cumulative accrued preferred return to June 7, 2023.

On June 7, 2023, in connection with the issuance of the Class C Units, AON LLC entered into the Third Amended and Restated Limited Liability Agreement (“Third Operating Agreement”) which, among other things, eliminated any provisions for future preferred returns on Class A and A-1 units.

Class A-1 Anti-Dilution Feature

Prior to the Closing, in the event AON LLC, prior to a Qualified IPO, issued additional membership equity (“Additional Issuance”) at a valuation that represents a purchase price that is less than the New Unit Purchase Price, as defined, AON LLC was obligated to issue additional Class A-1 Units, for no consideration, such that the Class A-1 unitholder maintains the same percentage ownership as prior to the Additional Issuance (“Anti-Dilution Feature”).
The Company determined that the Anti-Dilution Feature met the definition of a derivative in accordance with ASC 815. The total loss on derivatives for the three months and nine months ended September 30, 2023 relating to this feature is $4.7 million and $9.8 million, respectively, and was recorded in other (expense) income, net in the condensed consolidated statements of operations and comprehensive loss. As a result of the Anti-Dilution Feature, upon the issuance of the Class C Units on June 7, 2023 and the Closing of the Business Combination on September 20, 2023, the Company issued an additional 174 and 284 Class A-1 Units, that were subsequently converted into 439,176 and 718,549 AON Common Units using the Per Company Unit Exchange Ratio, pursuant to the Business Combination Agreement. The total fair value of the issuance of additional Class A-1 shares on June 7, 2023 and September 20, 2023 was $2.5 million and $7.2 million, respectively, for a cumulative $9.7 million recorded as Class A-1 member equity in the condensed consolidated statements of mezzanine and stockholders’ equity. Upon the Closing of the Business Combination, the Class A-1 Anti-dilution Feature was eliminated and the derivative liability was fully extinguished.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss Per Share
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Net Loss Per Share Net Loss Per Share
The following table sets forth the computation of basic and diluted net loss per share of Class A Common Stock and represents the period from September 21, 2023 to September 30, 2023, the period where the Company had Class A and Class B common stock outstanding. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted loss per share. As such, basic and diluted loss per share of Class B Common Stock has not been presented. Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As such, basic and diluted loss per share is computed using the two-class method. For additional information, see Notes 1 and 2.

Basic loss per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted loss per share is based on the weighted-average number of shares of Class A Common Stock used for the basic loss per share calculation, adjusted for the dilutive effect of Public and Private Warrants and Sponsor Earnouts, if any, using the “treasury stock” method and the convertible Series A Preferred Stock, Class B Common Stock, and Class B Prefunded Warrants, if any, using the “if-converted” method. Net loss for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net loss, net of AON Inc. taxes, after giving effect to Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock that accrue dividends, to the extent it is dilutive.


Net loss attributable to Class A Common Stockholders for basic and diluted loss per share $ (1,791,768)
Series A Deemed Dividend (2,089,000)
Series A Preferred Cumulative Dividends (133,032)
Undistributed Net Loss attributable to Class A Common Stockholders $ (4,013,000)

                        
Weighted-average shares for basic and diluted loss per share 6,614,229
Basic & Diluted loss per share of Class A Common Stock $ (0.61)


The following table details the securities that have been excluded from the calculation of weighted-average shares for diluted loss per share for the period presented as they were anti-dilutive. Note that the Sponsor Earnouts are excluded from the calculation of weighted-average shares for diluted loss per share as the contingency had not been met as of the period end.

Series A Preferred Stock                                  6,651,610
Class B Common Stock                             25,109,551
Class B Prefunded Warrants                         3,000,245
Public and Private Warrants                         14,450,883
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Redeemable Noncontrolling Interest
 9 Months Ended
Sep. 30, 2023
Noncontrolling Interest [Abstract]  
Redeemable Noncontrolling Interest Redeemable Noncontrolling Interest
Legacy AON Shareholders own 28,109,796 AON LLC Common Units, equal to a 67.9% of the economic interest in AON LLC. Legacy AON Shareholders also own 25,109,551 shares of Class B Common Stock and 3,000,245 Class B Prefunded Warrants, which, together with the AON LLC Common Units, may be redeemed at the option of the Legacy AON Shareholder on a one-for-one basis for shares of Class A Common Stock or the cash equivalent thereof (based on the market price of the shares of Class A Common Stock at the time of redemption) as determined by New AON. If New AON elects the redemption to be settled in cash, the cash used to settle the redemption must be funded through a private or public offering of Class A Common Stock no later than ten (10) business days after the redemption notice date. Upon the redemption of the AON LLC Common Units and Class B
Common Stock for shares of Class A Common Stock or the equivalent thereof, all redeemed shares of Class B Common Stock will be cancelled. The redemption value is determined based on a five-day volume weighted average price (”VWAP”) of the Class A common shares, subject to customary conversion rate adjustments for share splits, share dividends, and similar events affecting Class A Common Stock.

When applying SEC guidance concerning mezzanine classification, the Company understands that due to the NCI holders having control of the Board, if there is a sequence of remotely possible events that could trigger a redemption, this requires the instrument to be classified as temporary equity, without any regard to probability. Accordingly, though the redemption would require such a remotely possible sequence of events, and such remote sequence of events would also require, in management’s view, the Company to take extraordinary actions in order to allow such sequence of events to be remotely possible, the noncontrolling interest is currently classified as temporary equity. In the event that the Legacy AON Shareholders own less than 50% of the outstanding economic interest in AON LLC Common Units due to future redemptions, the noncontrolling interest will be presented as permanent equity.

The redeemable noncontrolling interest is recognized at the greater of (1) its initial fair value plus accumulated earnings/(losses) associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At September 30, 2023, the redeemable noncontrolling interest was recorded based on its redemption value of $369.3 million which exceeded its carrying value by $344.3 million. This measurement adjustment decreased additional paid in capital by $17.6 million and retained earnings (deficit) by $326.7 million.

The following table summarizes the economic ownership of AON LLC, for the period beginning September 20, 2023, the Closing Date of the Reverse Recapitalization, and ending September 30, 2023 (Refer to Note 1).
 Period beginning September 20, 2023 and ending September 30, 2023
AON LLC Units
AON Inc.Legacy AON ShareholdersTotal
Beginning of Period— — — 
Common Units Issued(1)
6,614,229 28,109,796 34,724,025 
Series A Preferred Units Issued6,651,610 — 6,651,610 
Total Units Issued13,265,839 28,109,796 41,375,635 
End of Period13,265,839 28,109,796 41,375,635 
Allocation of income to controlling and noncontrolling interests
32.1 %67.9 %100 %
Allocation of losses to controlling and noncontrolling interests(2)
19.0 %81.0 %100 %
(1) The 6,614,229 of AON Inc. Common Units excludes 2,839,375 units, which is equivalent to the number of Sponsor Earnout Shares, that do not participate in profits and losses and are not included in the controlling interest percentage.
(2) As discussed in Note 13, Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As a result, the consolidated net loss of AON LLC, during the period of September 21, 2023 through September 30, 2023, were allocated to the NCI to reflect the absorption of the Legacy AON Shareholders to a portion of the consolidated net loss of AON LLC. Net losses were not attributed to Series A Preferred Stock.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Pay vs Performance Disclosure
$ in Thousands
Sep. 30, 2023
USD ($)
Pay vs Performance Disclosure  
Net income (loss) before noncontrolling interest $ (1,792)
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation and Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of the Company were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. Management believes the unaudited condensed consolidated financial statements for the interim periods presented contain all necessary adjustments, of a normal recurring nature, to state fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. These condensed consolidated financial statements were prepared on the same basis as and should be read in conjunction with the Company’s annual consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with such audited consolidated financial statements and related notes thereto of AON LLC and its wholly-owned subsidiaries, included in the proxy statement/prospectus of Digital Transformation Opportunities Corp., dated July 18, 2023 (the “Proxy Statement/Prospectus"). Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results the Company expects for the entire year.

For the three and nine months ended September 30, 2023, these unaudited condensed consolidated financial statements reflect the consolidated results of operations, comprehensive income (loss), cash flows and changes in equity of AON LLC and its wholly-owned subsidiaries for the period of January 1, 2023 through September 20, 2023, the Closing Date of the Reverse Recapitalization, and the consolidated results of operations, comprehensive income (loss), cash flows and changes in stockholders’ equity of AON Inc. and its consolidated subsidiaries, including AON LLC, for the period of September 21, 2023 through September 30, 2023. The condensed consolidated balance sheet at September 30, 2023 presents the financial condition of AON Inc. and its consolidated subsidiaries, including AON LLC, and reflects the initial recording of the assets and liabilities of AON Inc. at their historical cost (see Note 3). All intercompany balances and transactions of AON LLC prior to the Reverse Recapitalization have been eliminated. All intercompany balances and transactions of AON Inc. after the Reverse Recapitalization have been eliminated.

For the three and nine months ended September 30, 2022, these unaudited condensed consolidated financial statements present the consolidated results of operations, comprehensive income (loss), cash flows and changes in equity of AON LLC. The condensed consolidated balance sheet as of December 31, 2022 presents the financial condition of AON LLC and its wholly-owned subsidiaries. All intercompany balances and transactions of AON LLC have been eliminated.

In accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, the historical equity of AON LLC has been recasted in all periods up to the Closing Date, to reflect the number of shares of New AON’s Class A Common Stock and Class B Common Stock issued to Legacy AON Shareholders in connection with the Reverse Recapitalization. The Company recasted the units outstanding related to the historical AON LLC Class A, Class A-1, and Class B units prior to the Reverse Recapitalization (“Historical AON LLC Equity”) as common equity of New AON, equal to the Per Company Class Unit Exchange Ratio, pursuant to the Business Combination Agreement.

The Per Company Unit Exchange Ratio at which AON LLC Class A units and Class A-1 units were reclassified is equal to 2,524 AON Common Units. The Per Company Unit Exchange Ratio at which AON LLC Class B units were reclassified varied depending on participation threshold, and is equal to 2,524, 2,453, or 1,976, AON Common Units. The Per Company Unit Exchange Ratio at which Class C units were reclassified is equal to 2,705 AON LLC Series A Preferred Units.
The condensed consolidated financial statements and related notes thereto give effect to the conversion for all periods presented, without any change to par value or per unit amounts. The condensed consolidated financial statements do not necessarily represent the capital structure of New AON had the Reverse Recapitalization occurred in prior periods. The Company has not made retroactive adjustments related to the historical book values of Historical AON LLC Equity as the adjustments were considered immaterial.

For both the three and nine months ended September 30, 2023, $1.7 million of the consolidated net loss of AON LLC were attributable to the Class A Common Stockholders, and reflects the Class A Common Stockholders’ absorption of 19.0% of the consolidated net loss of AON LLC for the period of September 21, 2023 through September 30, 2023. For both the three and nine months ended September 30, 2023, $11.9 million of the consolidated net losses of AON LLC were attributable to the noncontrolling interest, and reflects the Legacy AON Shareholders’ absorption of 81.0% of the consolidated net losses of AON LLC for the period of September 21, 2023 through September 30, 2023. For the three and nine months ended September 30, 2023, $15.5 million and $27.0 million of the consolidated net losses of AON LLC were attributable to the Legacy AON Shareholders, respectively, to reflect their absorption of 100% of the consolidated net losses of AON LLC pertaining to the days prior to the Reverse Recapitalization. For the three and nine months ended September 30, 2022, net income of $5.6 million and $1.2 million were attributable to the Legacy AON Shareholders, respectively, to reflect their absorption of 100% of AON LLC’s net income pertaining to the periods prior to the Reverse Recapitalization.
Principles of Consolidation
Principles of Consolidation
For the period of September 21, 2023 through September 30, 2023, the condensed consolidated financial statements include the accounts of the Company, AON, Inc., American Oncology Network, LLC (“AON LLC”) and its wholly owned subsidiary American Oncology Management Company, LLC (“AOMC”), and its consolidated variable interest entities (“VIEs”) American Oncology Partners, P.A. (“AON Partners”), American Oncology Partners of Maryland, P.A. (“Partners of Maryland”), AON Central Services, LLC (“AON Central Services”), and Meaningful Insights Biotech Analytics, LLC (“MIBA”). All intercompany accounts and transactions between the entities have been eliminated in consolidation.

Refer to Note 1 for the accounting treatment of the Business Combination.

For the periods prior to the Reverse Recapitalization, the consolidated financial statements of the Company comprise the accounts of AON LLC and its wholly-owned subsidiaries. All intercompany accounts and transactions among AON LLC and its consolidated subsidiaries were eliminated.
The Company accounts for American Oncology Network, LLC, AON Partners, Partners of Maryland, AON Central Services, and MIBA in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, Consolidations. The Company determines whether it has a controlling financial interest in an entity by first evaluating whether the entity is a VIE. A VIE is broadly defined as an entity that has any of the following three characteristics: (i) the equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (ii) substantially all of the entity’s activities either involve or are conducted on behalf of an investor that has disproportionately few voting rights; or (iii) the equity investors as a group lack any of the following, the power through voting or similar rights to direct the activities of the entity that most significantly impact the entity’s economic performance, the obligation to absorb the expected losses of the entity, or the right to receive the expected residual returns of the entity. The Company consolidates a VIE if it has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and an obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively, if any.

AON LLC has contractual relationships with AON Partners, Partners of Maryland and AON Central Services and the physician owners through management service agreements (“MSAs”) and other contractual agreements to
provide all practice management services outside of medical services provided by the physicians. In addition, despite not being required by the contractual relationships, AON LLC regularly provides funding to support AON Partners and Partners of Maryland’s operations and acquisitions of physician practices. AON Central Services was formed July 15, 2022 and, effective January 1, 2023, entered into an agreement with AOMC to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. MIBA was established during the first quarter of 2023 for the purpose of developing intellectual property to synergize the collection, de-identification, and dissemination of the Company’s patient data for sale to external parties for research, development, and clinical decisions. In May 2023, the Company contributed $0.2 million for a 56% interest in the equity of MIBA. As of September 30, 2023, MIBA had no significant operating activity. The Company concluded that AON LLC had a controlling financial interest in MIBA and has consolidated the entity at September 30, 2023 and recorded the noncontrolling interest in equity. The Company has concluded that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all VIEs in which AON LLC has the characteristics of a controlling financial interest and is deemed to be the primary beneficiary. The variable interest subjects AON LLC to all potential losses in the entities and, therefore, requires AON LLC, and in turn AON Inc., to consolidate the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA in its condensed consolidated financial statements.
Accounting Estimates and Assumptions
Accounting Estimates and Assumptions
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Segments Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the “CODM”). The Company’s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company’s performance. The Company has one operating segment and one reportable segment that are structured around the organizational management of oncology practice operations. All revenue and assets are in the United States.
Revenue Recognition
Revenue Recognition
Revenue is recognized under Accounting Standards Update (“ASU”) 2014-09 Revenue from Contracts with Customers (“Topic 606”). The Company determines the transaction price based upon standard charges for goods and services with anticipated consideration due from patients, third-party payors (including health insurers and government agencies) and others. The Company’s revenue is primarily derived from patient service revenues, which encompass oncology services provided during patient visits and shipments of pharmacy prescriptions. Performance obligations for the Company’s services provided to patients and most procedures, are satisfied over the time of visit which is the same day services are performed. Performance obligations relating to pharmacy revenue are considered fully satisfied at a point in time upon the customer receiving delivery of the prescription. Accordingly, the Company does not anticipate a significant amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods, and any such revenue recognized during the three and nine month periods ended September 30, 2023 and 2022 was immaterial. Additionally, the Company does not expect to recognize material revenue in the future related to performance obligations that are unsatisfied (or partially
satisfied) as of September 30, 2023 and December 31, 2022. Approximately $238.9 million and $213.8 million and $678.1 million and $606.0 million of the Company’s revenues are generated from services performed during patient visits with the remainder primarily generated from shipments of pharmacy prescriptions for the three and nine month periods ended September 30, 2023 and 2022, respectively.
As services are performed and prescriptions are shipped, timely billing occurs for services rendered and prescriptions shipped less discounts provided to uninsured patients and contractual adjustments to third-party payors based upon prospectively determined rates and discounted charges. Payment is requested at the time of service for self-paying patients and for patients covered by third-party payors that are responsible for paying deductibles and coinsurance.
The Company monitors revenue and receivables to prepare estimated contractual allowances for the anticipated differences between billed and reimbursed amounts. Payments from third-party payors and Government programs including Medicare and Medicaid may be subject to audit and other retrospective adjustments. Such amounts are considered on an estimated basis when net patient revenue is recorded and are adjusted as final adjustments are determined. For the three and nine month periods ended September 30, 2023 and 2022, such resulting historic adjustments have been immaterial to the condensed consolidated financial statements. 
In assessing who is the principal in providing patient services and pharmacy prescriptions, the Company considered who controls the provision of services and prescriptions. The Company has determined they are acting as a principal in these relationships. 
In April 2022, the Company entered into a long-term arrangement to sponsor and manage a clinical trial. The Company subsequently contracted with a third-party to provide the clinical research services and is the principal in this arrangement. The performance of clinical research services are considered a single performance obligation because the Company provides a highly-integrated service. Revenue is recognized for the single performance obligation over time due to the Company’s right to payment for work performed to date. The contract provides for invoices based on predetermined milestones. 

The Company uses the cost-to-cost measure of progress for the Company’s contract because it best depicts the transfer of control to the customer as the performance obligation is fulfilled. For this method, the Company compares the contract costs incurred to date to the estimated total contract costs through completion. As part of the client proposal and contract negotiation process, the Company develops a detailed project budget for the direct costs and reimbursable costs based on the scope of the work, the complexity of the study, the geographical location involved and the Company’s historical experience. The estimated total contract costs at the project level are reviewed and revised periodically throughout the life of the contract, with adjustments to revenue resulting from such revisions being recorded on a cumulative basis in the period in which the revisions are identified. Contract costs consist primarily of direct labor and other reimbursable project-related costs such as travel, third-party vendor costs and investigator fees. The Company establishes pricing based on the Company’s internal pricing guidelines, discount agreements, if any, and negotiations with the client. The transaction price is the contractually defined amount. Revenue related to the clinical trial, which is included within other revenue, was $2.2 million and $1.0 million and $3.7 million and $3.1 million for the three and nine months ended September 30, 2023 and 2022, respectively. 
The Company has a system and estimation process for recording Medicare net patient service revenue and estimated recoupments as it relates to value-based care (“VBC”) revenue included in patient service revenue in the condensed consolidated statements of operations and comprehensive loss. The Company’s VBC revenue is primarily generated through its participation in the CMS Oncology Care Model (“OCM”) which is an episode-based payment model to promote high-quality cancer care. Participants enter six-month episode periods, and the Company bills a monthly fee during the six-month period based on a fixed rate per participant per month and the total number of participants. Certain quality and compliance metrics are tracked as part of the program and submitted to CMS at the end of the episode period which may result in recoupment of funds. The Company estimates the recoupment amount by developing a recoupment percentage for each period based on historical known recoupment from CMS and applies the recoupment percentage against total fees for the period. Based on the
estimate, the Company accrues a liability representing the expected final recoupments based on historical settlement trends.
Short-term Marketable Securities
Short-term Marketable Securities 
Investments in marketable securities consist of corporate bonds and U.S. Treasury securities.
Management determines the appropriate classification of investments at the time of purchase and reevaluates such determination at each balance sheet date. Marketable securities are classified as available-for-sale and are carried at fair value in the consolidated balance sheets. The marketable securities are classified as short-term based on management’s intent to convert such securities within one year and the ability to convert them within two to three days.
Certain of our available-for-sale securities are debt securities. For an available-for-sale debt security with an amortized cost that exceeds its fair value, the Company first determines if it intends to sell or will more-likely-than-not be required to sell the security before the expected recovery of its amortized cost. If it intends to sell or will more-likely-than-not be required to sell the security, then the Company recognizes the impairment as a credit loss in the condensed consolidated statements of operations and comprehensive loss by writing down the security’s amortized cost to its fair value. If it does not intend to sell or it is not more-likely-than-not that it will be required to sell the security before the expected recovery of its amortized cost, the Company recognizes the portion of the impairment that is due to a credit loss, if any, in the condensed consolidated statements of operations and comprehensive loss through an allowance. The portion of the impairment that is due to factors other than a credit loss is recognized in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss as an unrealized loss.
Equity Investment in Affiliate
Equity Investment in Affiliate
In January 2023, the Company contributed noncash consideration, with a fair value of approximately $2.3 million, in return for a 49% equity interest in OCP Management Arizona, LLP. Investments in entities over which the Company has the ability to exercise significant influence but does not control the entity are accounted for using the equity method. Equity method investments are included with other assets in the condensed consolidated balance sheets. The carrying amount of the investment is adjusted to reflect the Company’s proportionate share of the net earnings or losses and reduced by any dividends received. The Company’s share of income or loss related to this investment is reported as an equity in loss of affiliate in the condensed consolidated statements of operations and comprehensive loss.
Noncontrolling Interests Noncontrolling InterestsThe Company consolidates the results of entities in which it has a controlling financial interest. Refer to Note 14 for additional considerations and presentation for noncontrolling interest.
Mezzanine Equity Mezzanine EquityNew AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which is outside of the Company’s control). As a result, Management has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity. As of September 30, 2023, the Preferred Stock are recorded at their initial carrying value, net of offering costs of $0.8 million. The Series A Preferred Stock are not being accreted to redemption value, as the redemption is not probable. The Series A Preferred Stock are classified outside of members’ equity on the consolidated balance sheets. Refer to Note 14 for mezzanine equity presentation considerations for redeemable noncontrolling interest.
Business Combinations
Business Combinations
The Company evaluates acquired practices in accordance with ASU 2017-01, Business Combinations (Topic 805)-Clarifying the Definition of a Business. This standard clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or
disposals of assets or businesses. Because substantially all of the value of each acquired practice did not relate to a similar group of assets and as each acquired practice contained both inputs and processes necessary to provide economic benefits to the Company, it was determined that each acquisition represents a business combination. Therefore, the transactions have been accounted for using the acquisition method of accounting, which requires, with limited exceptions, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Any excess of the consideration transferred over the estimated fair values of the net assets acquired is recorded as goodwill. Transaction costs related to business combinations are expensed in the period in which they are incurred.
Offering Costs
Offering Costs
The Company defers specific incremental costs directly attributable to proposed offerings of securities. These costs consist of legal, accounting, and other similar expenses incurred through the balance sheet date that are directly related to a potential offering. If the offering is completed, these costs will be charged against the gross proceeds of the offering. These offering costs will be allocated to the separable financial instruments issued in the transaction on a relative fair value basis of the securities issued, compared to total proceeds received. Offering costs associated with any instruments classified as liabilities will be expensed as incurred, presented as non-operating expenses in the condensed consolidated statement of operations and comprehensive loss.
During the nine months ended September 30, 2023, the Company incurred additional deferred offering costs of approximately $0.8 million which were recorded as an offset to the net proceeds of the AON LLC Class C Units (discussed below) in mezzanine equity on the condensed consolidated balance sheet at September 30, 2023. At December 31, 2022, the Company had incurred approximately $0.3 million of offering costs, which are included in other assets in the accompanying condensed consolidated balance sheets.
As discussed in Note 1, on June 7, 2023, AON LLC issued Redeemable Convertible Preferred Class C Units (“Class C Units” or “AON LLC Class C Units”) for net proceeds of approximately $64.5 million ($65.0 million in gross proceeds, net of $0.5 million in offering costs). The Company determined that an additional $0.3 million of costs incurred through June 7, 2023 related to the process of raising the proceeds generated by the issuance of the Class C Units. Accordingly, these deferred offering costs have been reclassified from other assets to mezzanine equity, for a total of $0.8 million in Class C Unit offering costs. The Class C Units were subsequently converted to AON LLC Series A Preferred Units upon the Closing of the Business Combination, which were subsequently exchanged for Series A Preferred Stock.
Professional Liability
Professional Liability
The Company maintains insurance policies for exposure to professional malpractice insurance risk. The limits of malpractice insurance provide each physician/advanced practice provider with a dedicated $1.0 million limit per claim and a $3.0 million limit in the aggregate per policy period – on a first dollar basis, as no deductible applies. The policy further then extends coverage to the Company, by providing a $2.0 million limit per claim and a $4.0 million limit in the aggregate per policy period - on a first dollar basis, additionally, as no deductible applies. Reserves are established for estimates of the loss that will ultimately be incurred on claims that have been reported but not paid and claims that have been incurred but not reported. These reserves are established based on consultation with a third-party actuary. The actuarial valuations consider a number of factors, including historical claims payment patterns, changes in case reserves and the assumed rate of increase in healthcare costs. Management believes the use of actuarial methods to account for these reserves provides a consistent and effective way to measure these subjective accruals. However, due to the sensitive nature of this estimation technique, recorded reserves could differ from ultimate costs related to these claims due to changes in claims reporting, claims payment and settlement practices and differences in assumed future cost increases. Accrued unpaid claims and expenses that are expected to be paid within the next twelve months are classified as current liabilities and included in accrued other. All other accrued unpaid claims and expenses are classified as long-term liabilities and included in other long-term liabilities. Insurance recoveries associated with the unpaid claims are classified as long-term assets included in other assets.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
Fair value is the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.
Accounting guidance establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:
Level 1Inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.
Level 2Inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.
Level 3Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. 
Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement of assets and liabilities being measured within the fair value hierarchy.
Our financial instruments include cash, short-term marketable securities, accounts receivable, notes receivable, accounts payable, accrued expenses, long-term debt and contractual agreements that resulted in derivative liabilities. Our nonfinancial assets such as property and equipment are not measured at fair value on a recurring basis; however, they are subject to fair value adjustments in certain circumstances, such as when there is evidence that impairment may exist.
The carrying amounts of cash, accounts receivable, accounts payable, notes receivable, and accrued expenses approximate their fair value because of the short-term maturity and highly liquid nature of these instruments. We determine the fair value of long-term debt and marketable securities based on various factors including maturity schedules and current market rates.
Warrant Liabilities
Warrant Liabilities

The Company evaluated the Public Warrants and Private Placement Warrants and the Class B Prefunded Warrants, collectively referred to herein as “Warrants”, in accordance with ASC 815-40, “Derivatives and Hedging —- Contracts in Entity’s Own Equity”, and concluded that a provision in the warrant agreements related to potential net cash settlement of the warrants upon an exchange or tender offer that may not result in a change in control of the entity precludes the warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as long term liabilities on the condensed consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive loss in the period of change.
As of September 30, 2023, the Public Warrants were trading separately from the Class A Common Stock and the quoted market price was used to establish fair value. As such, the Public Warrants fair value was determined using a Level 1 input. The fair value of the Public Warrants is $1.4 million and recorded in other long-term liabilities on the condensed consolidated balance sheets.

Management has utilized the public warrant price to value the private warrants and believes the public and private warrants have materially consistent fair values given the existence of the make-whole redemption feature. As of September 30, 2023, a valuation of the private warrants was performed which confirmed the private warrant value was materially consistent with the public warrants. The details of this valuation are included in the paragraph below.

The fair value of the Private Placement warrants was determined using Level 3 inputs. As of September 30, 2023, the fair value of the Private Placement Warrants was estimated to be $1.0 million and recorded in other long-term liabilities on the condensed consolidated balance sheets. The fair value was estimated at September 30, 2023, using the Black-Scholes Option Pricing model using the following assumptions:
Expected annual dividend yield – 0.0%
                Expected volatility – 0.75%
                Risk-free rate of return – 4.60%
                Expected Option Term – 5.0
                
The AON Class B Prefunded Warrants are exercisable into one share of New AON Class B Common Stock. A share of New AON Class B Common Stock, together with an AON LLC Common Unit, may be exchanged for one share of New AON Class A Common Stock. Considering New AON Class B Common Stock has no economic rights and limited liquidity or value if the holder does not also possess an AON LLC Common Unit, and because the AON Class B Prefunded Warrants are exercisable into New AON Class B Common Stock, the Company has estimated fair value of the Class B Prefunded Warrants to be immaterial.
Earnings Per Share
Earnings Per Share

The Company recast Historical AON LLC Equity as AON Inc. common equity for all periods prior to the Reverse Recapitalization, refer to Note 2. However, as 100% of the net losses of AON LLC prior to the Reverse Recapitalization were absorbed by the Legacy AON Shareholders, basic and diluted earnings (loss) per share is zero for the three and nine months ended September 30, 2022 and basic and diluted earnings (loss) per share for the three and nine months ended September 30, 2023 represents only the period from September 21, 2023 to September 30, 2023, the period where the Company had earnings (loss) attributable to Class A Common Stockholders. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted earnings (loss) per share. As such, basic and diluted earnings (loss) per share of Class B Common Stock has not been presented.

As discussed in Note 1, the Company has issued and outstanding Sponsor Earnouts, which are subject to forfeiture if the achievement of certain stock price thresholds are not met. In accordance with ASC Topic 260, “Earnings Per Share,” the Sponsor Earnouts are excluded from weighted-average shares outstanding to calculate basic earnings (loss) per share as they are considered contingently issuable shares due to their potential forfeiture. Sponsor Earnouts will be included in weighted-average shares outstanding to calculate basic earnings (loss) per share as of the date of their stock price thresholds are met and they are no longer subject to forfeiture.

Basic and diluted earnings (loss) per share is computed by use of the two-class method as a result of outstanding Series A Preferred Stock, which accrue dividends at the annual rate of 8% of the original price per share, participate with common stock on all other dividends, and accordingly have participation rights in undistributed earnings as if all such earnings had been distributed during the period (see Note 12). Under such method income available to common shareholders is computed by deducting both dividends declared or, if not declared,
accumulated on Series A Preferred Stock from net income. Loss attributable to common shareholders is computed by increasing net loss by such dividends. Since the participating Series A Preferred Stock has no contractual obligation to share in the losses of the Company, there is no loss allocation between Class A Common Stock and Series A Preferred Stock.

Basic earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock used for the basic earnings (loss) per share calculation, adjusted for the dilutive effect of the Public and Private Warrants and Sponsor Earnout, if any, using the “treasury stock” method and the convertible Series A Preferred Stock and, exchangeable Class B Common Stock and Class B Prefunded Warrants, if any, using the “if-converted” method. Net earnings (loss) for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net earnings (loss), net of AON Inc. taxes, after giving effect to the Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock, to the extent it is dilutive.
Recently Adopted Accounting Pronouncements  and Recently Issued Accounting Pronouncements
Recently Adopted Accounting Pronouncements 
In June 2016, the FASB issued ASU 2016-13, ‘‘Financial instruments-Credit Losses’’ (“ASU 2016- 13”). ASU 2016-13 requires entities to report ‘‘expected’’ credit losses on financial instruments and other commitments to extend credit rather than the current ‘‘incurred loss’’ model. These expected credit losses for financial assets held at the reporting date are to be based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU will also require enhanced disclosures relating to significant estimates and judgments used in estimating credit losses, as well as the credit quality. ASU 2016-13 is effective for the Company for annual reporting periods beginning after December 15, 2022. ASU 2016-13 was adopted by the Company effective January 1, 2023 with no material impact on the Company’s consolidated financial statements and related disclosures. 
Recently Issued Accounting Pronouncements
In October 2021, the FASB issued ASU 2021-08, “Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”, which provides that an acquirer must recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606. The guidance is effective for the Company for annual reporting periods beginning after December 15, 2023, with early adoption permitted. The Company does not expect the adoption of this standard to have a material impact on the Company’s consolidated financial statements and related disclosures.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Business (Tables)
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Affiliation Agreements During the nine months ended September 30, 2023 and 2022, the Company entered into affiliation agreements with or acquired the following oncology practices.
Nine Months Ended September 30, 2022Nine Months Ended September 30, 2023
StateState
Arizona
Texas(a)
Georgia(a)
Florida(a)
Louisiana(a)
Arkansas(a)
Georgia(a)
Georgia(a)
Georgia(a)
(a)The Company entered into affiliation agreements with the physicians for these respective practices. The Company evaluated each of the affiliation agreements and determined that the transactions did not represent a business combination.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Reverse Capitalization (Tables)
 9 Months Ended
Sep. 30, 2023
Reverse Recapitalization [Abstract]  
Schedule of Reverse Recapitalization
The following table provides the historical cost of assets and liabilities of AON Inc. as of September 20, 2023.

As of September 30,
2023
Cash and Cash Equivalents$1,493 
Current Liabilities(13,295)
Long Term Liabilities(6,791)
Total Net Liabilities$(18,593)
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Variable Interest Entities (Tables)
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Variable Interest Entities
The assets of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of September 30, 2023 and December 31, 2022, are as follows:
As of September 30,
2023		As of December 31,
2022
Assets
Cash and cash equivalents$33,083 $26,844 
Accounts receivable141,039 136,098 
Inventories37,844 36,476 
Prepaid expenses and other current assets869 846 
Goodwill and intangibles, net180 180 
Other receivables36,294 28,139 
Other assets2,014 1,489 
Total assets$251,323 $230,072 
The liabilities of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of September 30, 2023 and December 31, 2022, are as follows:
As of September 30,
2023		As of December 31,
2022
Liabilities
Accounts payable$114,779 $102,783 
Accrued compensation and benefits22,747 6,021 
Accrued other16,038 15,926 
Other long-term liabilities137 452 
Due to AON LLC and subsidiaries, net134,344 128,204 
Total liabilities$288,045 $253,386 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities (Tables)
 9 Months Ended
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Debt Securities, Available-for-Sale
The following table summarizes the Company’s marketable securities financial assets that are measured at fair value on a recurring basis:
As of September 30, 2023
Amortized
Cost		Gross Unrealized
Gains		Gross Unrealized
Losses		Estimated Fair
Value
Cash equivalents (1)
Level 1:
Overnight repurchase agreements (2)$28,272 $- $- $28,272 
Money market funds773 - - 773 
U.S. Treasury Bills18,606 - - 18,606 
Level 1 total$47,651 $— $— $47,651 
Marketable securities
Level 2:
Corporate bonds13,980 62 (38)14,004 
U.S. Treasury securities11,981 52 (4)12,029 
Level 2 total25,961 114 (42)26,033 
Total$73,612 $114 $(42)$73,684 
As of December 31, 2022
Amortized
Cost		Gross Unrealized
Gains		Gross Unrealized
Losses		Estimated Fair
Value
Cash equivalents (1)
Level 1:
Money market funds$109 $- $- $109 
Marketable securities
Level 2:
Corporate bonds7,742 6 (125)7,623 
U.S. Treasury securities2,226 6 (4)2,228 
Level 2 total9,968 12 (129)9,851 
Total$10,077 $12 $(129)$9,960 
(1)Included in cash and cash equivalents in the Consolidated Balance Sheets at September 30, 2023 and December 31, 2022.
(2)Cash equivalents as of September 30, 2023 included U.S. Treasury Bills with an initial maturity of 3 months or less and overnight repurchase agreements in which cash from the Company's main operating checking account is invested overnight in highly liquid, short-term investments sponsored by a large financial institution. The company had no such investments as of December 31, 2022.
The fair value of the Company’s marketable securities as of September 30, 2023, by remaining contractual maturities, were as follows:
Corporate BondsU.S. TreasuriesTotal
Due in one year or less$4,805 $8,385 $13,190 
Due in one to five years9,199 3,644 12,843 
Total$14,004 $12,029 $26,033 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Condensed Balance Sheet Information (Tables)
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Other Receivables
Other receivables consisted of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December 31,
2022
Rebates receivable$36,556 $27,955 
Other191 246 
Total other receivables$36,747 $28,201 
Schedule of Inventory
Inventory consisted of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December
31, 2022
Intravenous drugs$27,508 $25,674 
Oral pharmaceuticals10,336 10,802 
Total inventories$37,844 $36,476 
Schedule of Property and Equipment, net
Property and equipment, net consisted of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December 31,
2022
Leasehold improvements$30,078 $26,076 
Furniture, fixtures and equipment2,722 2,669 
Medical equipment12,659 11,003 
Computer equipment3,325 3,115 
Signs147 129 
Automobiles59 69 
Software4,412 4,834 
Construction-in-progress6,150 1,433 
Property and equipment, gross59,552 49,328 
Accumulated depreciation and amortization(23,312)(17,348)
Property and equipment, net$36,240 $31,980 
Schedule of Other Accrued Liabilities, Current
Accrued other consisted of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December 31,
2022
Refund liability$14,521 $14,544 
Deferred social security taxes - COVID- 378 
Excise taxes payable2,700 - 
Current portion of finance lease liabilities630 425 
Other5,126 2,453 
Total accrued other$22,977 $17,800 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Long-term Debt (Tables)
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt Instruments
Debt consisted of the following at September 30, 2023 and December 31, 2022: 
As of September 30,
2023		As of December
31, 2022
PNC Facility$81,250 $81,250 
Total81,250 81,250 
Unamortized debt issuance costs(825)(949)
Total debt$80,425 $80,301 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Tables)
 9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Lessee, Assets And Liabilities
Right-of-use assets and lease liabilities consist of the following at September 30, 2023 and December 31, 2022:
As of September 30,
2023		As of December 31,
2022
Assets
Operating lease right-of-use assets, net$46,138 $43,724 
Finance lease right-of-use assets, net (included in property and equipment, net)2,791 1,998 
Total right-of-use assets$48,929 $45,722 
Liabilities
Current
Current portion of operating lease liabilities$7,123 $9,177 
Current portion of finance lease liabilities (included in accrued other)630 425 
Long-term7,753 9,602 
Long-term operating lease liabilities42,261 37,224 
Long-term finance lease liabilities (included in other long-term liabilities)2,126 1,619 
Total lease liabilities$52,140 $48,445 
Lease, Cost
The components of lease costs recognized in the condensed consolidated statements of operations and comprehensive loss consist of the following for the three and nine month periods ended September 30, 2023 and 2022 and are included in selling, general, and administrative expenses unless otherwise noted:
Three Months Ended September 30,Nine Months Ended
September 30,
2023202220232022
Operating lease costs$2,820 $3,161 $8,361 $9,297 
Finance lease costs
Amortization of finance lease right-of-use assets122185354 413 
Interest on finance lease liabilities (included in interest expense)351979 60 
Variable lease costs5608621,742 2,232 
Total lease costs$3,537 $4,227 $10,536 $12,002 
The cash paid for amounts included in the measurement of lease liabilities for the nine months ended September 30, 2023 and 2022 is as follows:
Nine Months Ended
September 30,
20232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$7,678 $9,788 
Operating cash flows from finance leases79 60 
Financing cash flows from finance leases387 321 
ROU assets obtained in exchange for new operating lease liabilities9,862 9,771 
ROU assets obtained in exchange for new finance lease liabilities1,103 - 
Lessee, Operating Lease, Liability, to be Paid, Maturity
The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of September 30, 2023:
Operating
Lease		Finance
Leases
2023 (remainder of year after September 30, 2023)$1,679 $188 
202410,940 753 
20259,830 731 
20269,413 492 
20278,194 428 
Thereafter24,154 528 
Total lease payments64,210 3,120 
Less: amount representing interest(14,826)(364)
Present value of lease liabilities49,384 2,756 
Less: current portion of lease liabilities(7,123)(630)
Long-term lease liabilities, net of current portion$42,261 $2,126 
Finance Lease, Liability, to be Paid, Maturity
The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of September 30, 2023:
Operating
Lease		Finance
Leases
2023 (remainder of year after September 30, 2023)$1,679 $188 
202410,940 753 
20259,830 731 
20269,413 492 
20278,194 428 
Thereafter24,154 528 
Total lease payments64,210 3,120 
Less: amount representing interest(14,826)(364)
Present value of lease liabilities49,384 2,756 
Less: current portion of lease liabilities(7,123)(630)
Long-term lease liabilities, net of current portion$42,261 $2,126 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Related Parties (Tables)
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Schedule of Related Party Transactions
As of September 30,
2023		As of
December 31,
2022		Original
Principal		Issue
Date		Maturity
Date
Notes receivable
Note 2$1,027 $1,057 $5,355 5/1/20194/30/2024
Note 342 119 491 6/1/20195/31/2024
Note 6- 351 1,111 5/22/20205/22/2023
Note 82,065 2,221 2,816 5/1/20205/1/2025
Note 9- 125 125 1/24/20226/30/2023
Total notes receivables3,134 3,873 
Less:  Current portion of notes receivable$(1,630)(1,797)
Notes receivable, less current portion$1,504 $2,076 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Equity (Tables)
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of Reverse Recapitalization, Changes in Units
The following table summarizes the changes to AON LLC’s Class A, Class A-1, and Class B Units for the three and nine months ended September 30, 2023, and 2022.


in thousands, except for share and per share amountsThree Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Class A Units, value
Beginning of Period$7,725 $7,725 $7,725 $7,725 
Issuance of Units— — — — 
Impact of the Reverse Recapitalization(7,725)— (7,725)— 
End of Period$— $7,725 $— $7,725 
Class A Units, units
Beginning of Period19,495,376 19,495,376 19,495,376 19,495,376 
Issuance of Units— — — — 
Impact of the Reverse Recapitalization(19,495,376)— (19,495,376)— 
End of Period— 19,495,376 — 19,495,376 
in thousands, except for share and per share amountsThree Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Class A-1 Units, value
Beginning of Period$31,040 $28,500 $28,500 $28,500 
Issuance of Units7,185 — 9,725 — 
Impact of the Reverse Recapitalization(38,225)— (38,225)— 
End of Period$— $28,500 $— $28,500 
Class A-1 Units, units
Beginning of Period2,281,696 1,842,520 1,842,520 1,842,520 
Issuance of Units718,549 1,157,725 
Impact of the Reverse Recapitalization(3,000,245)(3,000,245)
End of Period— 1,842,520 — 1,842,520 
in thousands, except for share and per share amountsThree Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Class B Units, value
Beginning of Period$80 $90 $80 $80 
Equity based compensation10 5 10 15 
Impact of the Reverse Recapitalization(90)— (90)
End of Period$— $95 $— $95 
Class B Units, units
Beginning of Period4,703,628 4,703,628 4,703,628 4,703,628 
Units Vested910,548 — 910,548 — 
Impact of the Reverse Recapitalization(5,614,176)— (5,614,176)— 
End of Period— 4,703,628 — 4,703,628 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Redeemable Noncontrolling Interest (Tables)
 9 Months Ended
Sep. 30, 2023
Noncontrolling Interest [Abstract]  
Schedule of Reverse Recapitalization, Ownership Summary The following table summarizes the economic ownership of AON LLC, for the period beginning September 20, 2023, the Closing Date of the Reverse Recapitalization, and ending September 30, 2023 (Refer to Note 1).
 Period beginning September 20, 2023 and ending September 30, 2023
AON LLC Units
AON Inc.Legacy AON ShareholdersTotal
Beginning of Period— — — 
Common Units Issued(1)
6,614,229 28,109,796 34,724,025 
Series A Preferred Units Issued6,651,610 — 6,651,610 
Total Units Issued13,265,839 28,109,796 41,375,635 
End of Period13,265,839 28,109,796 41,375,635 
Allocation of income to controlling and noncontrolling interests
32.1 %67.9 %100 %
Allocation of losses to controlling and noncontrolling interests(2)
19.0 %81.0 %100 %
(1) The 6,614,229 of AON Inc. Common Units excludes 2,839,375 units, which is equivalent to the number of Sponsor Earnout Shares, that do not participate in profits and losses and are not included in the controlling interest percentage.
(2) As discussed in Note 13, Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As a result, the consolidated net loss of AON LLC, during the period of September 21, 2023 through September 30, 2023, were allocated to the NCI to reflect the absorption of the Legacy AON Shareholders to a portion of the consolidated net loss of AON LLC. Net losses were not attributed to Series A Preferred Stock.
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Business (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 20, 2023
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
practice
state
$ / shares
shares
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
practice
state
$ / shares
shares
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Business Acquisition [Line Items]            
Number of oncology practices | practice   33   33    
Number of states in which entity operates | state   19   19    
Reverse recapitalization, equity conversion ratio   1   1    
Number of securities called by each warrant (in shares)   1   1    
Transaction expenses | $ $ 13,000 $ 24,603 $ 151 $ 29,886 $ 151  
Sponsor Earnout Shares            
Business Acquisition [Line Items]            
Earnout period (in years) 5 years          
Percentage of stock subject to vesting (in percent) 0.35          
Number of shares subject to vesting (in shares) 2,839,375          
Stock price trigger (in usd per share) | $ / shares $ 13.50          
Earnout period, trading days (in days) 20 days          
Earnout period, threshold trading day period (in days) 30 days          
Earnout period, number of months after closing (in months) 60 months          
AON LLC            
Business Acquisition [Line Items]            
Reverse recapitalization costs | $   24,600   30,600    
Transaction expenses | $   $ 24,600 $ 200 29,800 $ 200  
Accrued transaction costs | $           $ 300
AON LLC | Temporary Equity            
Business Acquisition [Line Items]            
Adjustment to APIC, transaction costs | $       $ (800)    
Common Class A            
Business Acquisition [Line Items]            
Shares issued (in shares) 1,047,343          
Common stock, shares outstanding (in shares)   9,453,604   9,453,604    
Series A Preferred Stock            
Business Acquisition [Line Items]            
Stock price (in usd per share) | $ / shares   $ 10.00   $ 10.00    
Common Class B            
Business Acquisition [Line Items]            
Common stock, shares outstanding (in shares)   25,109,551   25,109,551    
Legacy AON Shareholders | Class B Prefunded Warrants            
Business Acquisition [Line Items]            
Class of warrant outstanding (in warrants) 3,000,245          
Legacy AON Shareholders | AON LLC            
Business Acquisition [Line Items]            
Common unit, units outstanding (in units) 28,109,796          
Legacy AON Shareholders | Common Class B            
Business Acquisition [Line Items]            
Common stock, shares outstanding (in shares) 25,109,551          
AON Inc. | AON LLC            
Business Acquisition [Line Items]            
Common unit, units outstanding (in units) 9,532,354          
AON Inc. | AON LLC | Series A Preferred Stock            
Business Acquisition [Line Items]            
Preferred units, outstanding (in units) 6,651,610          
Digital Transformation Opportunities Corp. (“DTOC”) | Common Class B            
Business Acquisition [Line Items]            
Reverse recapitalization, equity conversion ratio 1          
DTOC Unredeemed Shareholders | Common Class A            
Business Acquisition [Line Items]            
Common stock, shares outstanding (in shares) 147,511          
DTOC Sponsor | Private Placement Warrants            
Business Acquisition [Line Items]            
Class of warrant outstanding (in warrants) 6,113,333          
DTOC Sponsor | Public Warrant            
Business Acquisition [Line Items]            
Class of warrant outstanding (in warrants) 8,337,500          
Warrant, exercise period, after initial public offering 12 months          
Warrant, exercise period, after business combination 30 days          
Warrant, term 5 years          
DTOC Sponsor | Common Class A            
Business Acquisition [Line Items]            
Common stock, shares outstanding (in shares) 5,419,375          
Earnout shares not outstanding (in shares) 2,839,375          
Stock price (in usd per share) | $ / shares $ 11.50          
DTOC Sponsor | Common Class A | Public Warrant            
Business Acquisition [Line Items]            
Number of securities called by each warrant (in shares) 1          
AEA Growth Management LP | Series A Preferred Stock            
Business Acquisition [Line Items]            
Shares issued (in shares) 6,651,610          
Common stock, shares outstanding (in shares) 6,651,610          
AON LLC            
Business Acquisition [Line Items]            
Reverse recapitalization, equity conversion ratio 1          
AON LLC | Class B Prefunded Warrants            
Business Acquisition [Line Items]            
Class of warrant outstanding (in warrants) 3,000,245          
AON LLC | Common Class A            
Business Acquisition [Line Items]            
Common stock, shares outstanding (in shares) 1,047,343          
AON LLC | Common Class B            
Business Acquisition [Line Items]            
Stock price (in usd per share) | $ / shares $ 0.01          
AON LLC | Common Class B | Class B Prefunded Warrants            
Business Acquisition [Line Items]            
Number of securities called by each warrant (in shares) 1          
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation and Significant Accounting Policies (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
shares
Jun. 07, 2023
USD ($)
May 31, 2023
USD ($)
Jan. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
$ / shares
Sep. 30, 2023
USD ($)
segment
$ / shares
shares
Sep. 20, 2023
USD ($)
Sep. 30, 2022
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
Description Of Business And Significant Accounting Policies [Line Items]                      
Recapitalization exchange ratio, units | shares 2,524,000       2,524,000     2,524,000      
Net income (loss) attributable to common shareholders         $ (1,700)     $ (1,700)      
Net loss attributable to noncontrolling interest $ 11,924       11,924   $ 0 11,924   $ 0  
Net income (loss) and noncontrolling interest attributable to Legacy AON Shareholders prior to the reverse recapitalization         (15,489)   5,607 $ (27,081) $ (27,000) 1,227  
Number of operating segments | segment               1      
Number of reportable segments | segment               1      
Revenue         $ 336,305   $ 297,324 $ 955,003   849,272  
Stock issuance costs               800      
Deferred offering costs                     $ 300
Proceeds from issuance of redeemable preferred stock               $ 64,996   $ 0  
Number of securities called by each warrant (in shares) | shares 1       1     1      
Reverse recapitalization, equity conversion ratio 1       1     1      
Earnings (loss) per unit, diluted (in usd per share) | $ / shares         $ (0.61)   $ 0 $ (0.61)   $ 0  
Earnings (loss) per unit, basic (in usd per share) | $ / shares         $ (0.61)   $ 0 $ (0.61)   $ 0  
Accrued dividend rate (in percent)               8.00%      
Series C Preferred Stock                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Offering costs   $ 500           $ 800      
Deferred offering costs   300                  
Net proceeds from issuance of redeemable convertible stock   64,500                  
Proceeds from issuance of redeemable preferred stock   $ 65,000                  
Participating Threshold, 1                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Recapitalization exchange ratio, units | shares 2,524,000       2,524,000     2,524,000      
Participating Threshold, 2                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Recapitalization exchange ratio, units | shares 2,453,000       2,453,000     2,453,000      
Participating Threshold, 3                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Recapitalization exchange ratio, units | shares 1,976,000       1,976,000     1,976,000      
AON LLC                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Reverse recapitalization, equity conversion ratio                 1    
AON LLC | Series A Preferred Stock                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Recapitalization exchange ratio, units | shares 2,705,000       2,705,000     2,705,000      
Preferred Class A                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Offering costs               $ 800      
Accrued dividend rate (in percent)               8.00%      
Series A Preferred Stock                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Offering costs               $ 750   $ 0  
Public Warrant                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Fair value of warrants $ 1,400       $ 1,400     1,400      
Private Placement Warrants                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Fair value of warrants $ 1,000       $ 1,000     $ 1,000      
Private Placement Warrants | Measurement Input, Expected Dividend Rate                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Warrants, measurement input 0.000       0.000     0.000      
Private Placement Warrants | Measurement Input, Price Volatility                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Warrants, measurement input 0.0075       0.0075     0.0075      
Private Placement Warrants | Measurement Input, Risk Free Interest Rate                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Warrants, measurement input 0.0460       0.0460     0.0460      
Private Placement Warrants | Measurement Input, Expected Term                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Warrants, measurement input 5.0       5.0     5.0      
Professional Malpractice Liability Insurance                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Malpractice insurance, coverage per claim               $ 1,000      
Malpractice insurance, limit per policy period               3,000      
Directors and Officers Liability Insurance                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Malpractice insurance, coverage per claim               2,000      
Malpractice insurance, limit per policy period               4,000      
OCP Management Arizona, LLP                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Noncash consideration of equity method investment       $ 2,300              
Equity method investment (in percent)       49.00%              
Patient Visits                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Revenue         $ 238,900   $ 213,800 678,100   606,000  
Clinical Trials                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Revenue         $ 2,200   $ 1,000 $ 3,700   $ 3,100  
MIBA                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Payments to acquire interest in subsidiary     $ 200     $ 200          
Allocation of income to controlling and noncontrolling interests     56.00%                
AON LLC | Legacy AON Shareholders                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Allocation of income to controlling and noncontrolling interests 81.00%             67.90% 100.00% 100.00%  
AON LLC | AON Inc.                      
Description Of Business And Significant Accounting Policies [Line Items]                      
Allocation of income to controlling and noncontrolling interests 19.00%                    
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Reverse Capitalization - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
person
Sep. 20, 2023
USD ($)
Sep. 30, 2023
USD ($)
person
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
person
Sep. 30, 2022
USD ($)
Restructuring Cost and Reserve [Line Items]            
Gain (Loss) On Reverse Recapitalization         $ 18,200  
Transaction expenses   $ 13,000 $ 24,603 $ 151 $ 29,886 $ 151
Public and Private Warrants            
Restructuring Cost and Reserve [Line Items]            
Gain (loss) on issuance of warrants $ (5,200)          
Fair Value Adjustment of Warrants $ 4,300          
AON Inc.            
Restructuring Cost and Reserve [Line Items]            
Number of board of managers designated by company | person 3   3   3  
AON Common Unit            
Restructuring Cost and Reserve [Line Items]            
Number of board of managers designated by majority common unit holders | person 2   2   2  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Reverse Capitalization - Schedule of Historical Cost (Details)
Sep. 30, 2023
USD ($)
Reverse Recapitalization [Abstract]  
Cash and cash equivalents $ 1,493,000
Current Liabilities (13,295,000)
Long Term Liabilities (6,791,000)
Total Net Liabilities $ (18,593,000)
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Variable Interest Entities - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2023
Jun. 30, 2023
Sep. 30, 2023
AON Central      
Variable Interest Entity [Line Items]      
Ownership interest     20.00%
MIBA      
Variable Interest Entity [Line Items]      
Payments to acquire interest in subsidiary $ 0.2 $ 0.2  
Allocation of income to controlling and noncontrolling interests 56.00%    
MIBA | Variable Interest Entity, Primary Beneficiary      
Variable Interest Entity [Line Items]      
Allocation of income to controlling and noncontrolling interests   56.00%  
Physician Owned | AON Central      
Variable Interest Entity [Line Items]      
Ownership interest     80.00%
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Variable Interest Entities - Schedule of Assets and Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Assets    
Cash and cash equivalents $ 51,653 $ 26,926
Inventories 37,844 36,476
Goodwill and intangibles, net 1,230 1,230
Total assets 394,014 326,228
Liabilities    
Other long-term liabilities 10,333 5,749
Total liabilities 300,923 264,212
Variable Interest Entity, Primary Beneficiary    
Assets    
Cash and cash equivalents 33,083 26,844
Accounts receivable 141,039 136,098
Inventories 37,844 36,476
Prepaid expenses and other current assets 869 846
Goodwill and intangibles, net 180 180
Other receivables 36,294 28,139
Other assets 2,014 1,489
Total assets 251,323 230,072
Liabilities    
Accounts payable 114,779 102,783
Accrued compensation and benefits 22,747 6,021
Accrued other 16,038 15,926
Other long-term liabilities 137 452
Due to AON LLC and subsidiaries, net 134,344 128,204
Total liabilities $ 288,045 $ 253,386
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-Sale [Line Items]    
Cash and cash equivalents $ 51,653 $ 26,926
Gross Unrealized
Gains 114 12
Gross Unrealized
Losses (42) (129)
Estimated Fair
Value 26,034 9,851
Cash and cash equivalents and available-for-sale securities, amortized cost 73,612 10,077
Cash and cash equivalents and marketable securities, aggregate fair value 73,684 9,960
Level 1    
Debt Securities, Available-for-Sale [Line Items]    
Cash and cash equivalents 47,651  
Cash and cash equivalents, aggregate fair value 47,651  
Level 1 | U.S. Treasury securities    
Debt Securities, Available-for-Sale [Line Items]    
Cash and cash equivalents 18,606  
Cash and cash equivalents, aggregate fair value 18,606  
Level 1 | Overnight Repurchase Agreements    
Debt Securities, Available-for-Sale [Line Items]    
Cash and cash equivalents 28,272  
Cash and cash equivalents, aggregate fair value 28,272  
Level 1 | Money market funds    
Debt Securities, Available-for-Sale [Line Items]    
Cash and cash equivalents 773 109
Cash and cash equivalents, aggregate fair value 773 109
Level 2    
Debt Securities, Available-for-Sale [Line Items]    
Amortized 
Cost 25,961 9,968
Gross Unrealized
Gains 114 12
Gross Unrealized
Losses (42) (129)
Estimated Fair
Value 26,033 9,851
Level 2 | Corporate bonds    
Debt Securities, Available-for-Sale [Line Items]    
Amortized 
Cost 13,980 7,742
Gross Unrealized
Gains 62 6
Gross Unrealized
Losses (38) (125)
Estimated Fair
Value 14,004 7,623
Level 2 | U.S. Treasury securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized 
Cost 11,981 2,226
Gross Unrealized
Gains 52 6
Gross Unrealized
Losses (4) (4)
Estimated Fair
Value $ 12,029 $ 2,228
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities - Remaining Contractual Maturities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]    
Total $ 26,034 $ 9,851
Level 2    
Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]    
Due in one year or less 13,190  
Due in one to five years 12,843  
Total 26,033 9,851
Corporate bonds | Level 2    
Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]    
Due in one year or less 4,805  
Due in one to five years 9,199  
Total 14,004 7,623
U.S. Treasury securities | Level 2    
Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]    
Due in one year or less 8,385  
Due in one to five years 3,644  
Total $ 12,029 $ 2,228
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Business Combinations (Details) - Northern Arizona Hematology and Oncology - USD ($)
Jan. 01, 2022
Sep. 30, 2023
Dec. 31, 2022
Business Acquisition [Line Items]      
Purchase price (less than) $ 100,000    
Unwind agreement, liability   $ 0 $ 0
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Condensed Balance Sheet Information - Schedule of Other Receivables (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Rebates receivable $ 36,556 $ 27,955
Other 191 246
Other receivables $ 36,747 $ 28,201
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Condensed Balance Sheet Information - Schedule of Inventory (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Inventory [Line Items]    
Inventories $ 37,844 $ 36,476
Intravenous drugs    
Inventory [Line Items]    
Inventories 27,508 25,674
Oral pharmaceuticals    
Inventory [Line Items]    
Inventories $ 10,336 $ 10,802
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Condensed Balance Sheet Information - Schedule of Property and Equipment, net (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 59,552 $ 49,328
Accumulated depreciation and amortization (23,312) (17,348)
Property and equipment, net 36,240 31,980
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 30,078 26,076
Furniture, fixtures and equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 2,722 2,669
Medical equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 12,659 11,003
Computer equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 3,325 3,115
Signs    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 147 129
Automobiles    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 59 69
Software    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 4,412 4,834
Construction-in-progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 6,150 $ 1,433
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Condensed Balance Sheet Information - Schedule of Accrued Other (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Refund liability $ 14,521 $ 14,544
Deferred social security taxes - COVID 0 378
Excise taxes payable 2,700 0
Less: current portion of lease liabilities 630 425
Other 5,126 2,453
Accrued other $ 22,977 $ 17,800
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Accrued other Accrued other
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Long-term Debt - Schedule of Long-term Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Total $ 81,250 $ 81,250
Unamortized debt issuance costs (825) (949)
Total debt 80,425 80,301
PNC Loan Facility | Line of Credit    
Debt Instrument [Line Items]    
Total $ 81,250 $ 81,250
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Long-term Debt - Narrative (Details) - Line of Credit
 9 Months Ended 12 Months Ended
Sep. 30, 2023
USD ($)
Feb. 14, 2022
USD ($)
Apr. 30, 2021
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Aug. 15, 2022
USD ($)
Jul. 29, 2021
USD ($)
PNC Loan Facility              
Debt Instrument [Line Items]              
Proceeds from facility     $ 34,600,000        
Maximum borrowing capacity   $ 125,000,000 65,000,000       $ 75,000,000
Pledged collateral     10,000,000        
Quarterly collateral released     $ 2,500,000        
Proceeds from lines of credit   16,300,000          
Unamortized debt issuance costs $ 400,000     $ 400,000      
PNC Loan Facility | Debt Instrument, Threshold Limit, Period One              
Debt Instrument [Line Items]              
Minimum funding threshold (in percent) 0.65   0.65        
PNC Loan Facility | Debt Instrument, Threshold Limit, Period Two              
Debt Instrument [Line Items]              
Minimum funding threshold (in percent)     0.75        
PNC Loan Facility | Alternate Base Rate              
Debt Instrument [Line Items]              
Basis spread (in percent)     1.45%        
Revolving Credit Facility | PNC Line of Credit              
Debt Instrument [Line Items]              
Maximum borrowing capacity   $ 10,000,000 $ 5,000,000     $ 1,000,000  
Bank fee (in percent)     1.65%        
Unused line fee (in percent)     0.20%        
Proceeds from lines of credit       $ 0 $ 0    
Revolving Credit Facility | PNC Line of Credit | London Interbank Offered Rate (LIBOR) 1              
Debt Instrument [Line Items]              
Basis spread (in percent)     1.65%        
Revolving Credit Facility | PNC Line of Credit | Alternate Base Rate              
Debt Instrument [Line Items]              
Basis spread (in percent)     0.65%        
Revolving Credit Facility | PNC Line of Credit | Bloomberg Short-Term Bank Yield Index              
Debt Instrument [Line Items]              
Basis spread (in percent)   1.65%          
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Tax Disclosure [Abstract]        
Effective income tax rate (in percent) (1.10%) 0.00% (0.80%) 0.00%
Income tax expense $ 315,000 $ 0 $ 315,000 $ 0
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Right-of-use Assets And Lease Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Assets    
Operating lease right-of-use assets, net [1] $ 46,138 $ 43,724
Finance lease right-of-use assets, net (included in property and equipment, net) 2,791 1,998
Total right-of-use assets 48,929 45,722
Current    
Current portion of operating lease liabilities [2] 7,123 9,177
Current portion of finance lease liabilities (included in accrued other) 630 425
Current portion of operating and finance lease liabilities 7,753 9,602
Long-term    
Long-term operating lease liabilities [3] 42,261 37,224
Long-term finance lease liabilities (included in other long-term liabilities) 2,126 1,619
Total lease liabilities $ 52,140 $ 48,445
[1] Includes related party operating right-of-use assets, net of $11,476 and $13,077 at September 30, 2023 and December 31, 2022, respectively
[2] Includes related party current portion of operating lease liabilities of $1,912 and $1,836 at September 30, 2023 and December 31, 2022, respectively
[3] Includes related party long-term operating lease liabilities of $9,994 and $11,631 at September 30, 2023 and December 31, 2022, respectively
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Lease Costs (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Leases [Abstract]        
Operating lease costs $ 2,820 $ 3,161 $ 8,361 $ 9,297
Amortization of finance lease right-of-use assets 122 185 354 413
Interest on finance lease liabilities (included in interest expense) 35 19 79 60
Variable lease costs 560 862 1,742 2,232
Total lease costs $ 3,537 $ 4,227 $ 10,536 $ 12,002
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Maturities of Operating and Financing Lease Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Operating 
Lease    
2023 (remainder of year after September 30, 2023) $ 1,679  
2024 10,940  
2025 9,830  
2026 9,413  
2027 8,194  
Thereafter 24,154  
Total lease payments 64,210  
Less: amount representing interest (14,826)  
Present value of lease liabilities 49,384  
Less: current portion of lease liabilities [1] (7,123) $ (9,177)
Long-term lease liabilities, net of current portion [2] 42,261 37,224
Finance 
Leases    
2023 (remainder of year after September 30, 2023) 188  
2024 753  
2025 731  
2026 492  
2027 428  
Thereafter 528  
Total lease payments 3,120  
Less: amount representing interest (364)  
Present value of lease liabilities 2,756  
Less: current portion of lease liabilities (630) (425)
Long-term lease liabilities, net of current portion $ 2,126 $ 1,619
[1] Includes related party current portion of operating lease liabilities of $1,912 and $1,836 at September 30, 2023 and December 31, 2022, respectively
[2] Includes related party long-term operating lease liabilities of $9,994 and $11,631 at September 30, 2023 and December 31, 2022, respectively
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Narrative (Details)
$ in Millions
Sep. 30, 2023
USD ($)
lease
Dec. 31, 2022
Leases [Abstract]    
Weighted-average remaining lease term for operating leases 7 years 3 days 5 years 8 months 4 days
Weighted-average remaining lease term for finance leases 5 years 5 years 4 months 13 days
Weighted-average discount rate for operating leases (in percent) 6.56% 4.88%
Weighted-average discount rate for finance leases (in percent) 5.12% 3.60%
Finance lease not yet commenced, term of contract (in months) 60 months  
Finance lease not yet commenced, number of leases | lease 2  
Leases not yet commenced, future commitments | $ $ 3.8  
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 7,678 $ 9,788
Operating cash flows from finance leases 79 60
Financing cash flows from finance leases 387 321
ROU assets obtained in exchange for new lease liabilities    
ROU assets obtained in exchange for new operating lease liabilities 9,862 9,771
ROU assets obtained in exchange for new finance lease liabilities $ 1,103 $ 0
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Related Parties - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
USD ($)
office
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
office
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Related Party Transaction [Line Items]          
Notes receivable, amortization period (in months)     60 months    
Incremental borrowing rate 7.14%   7.14%   1.57%
Payments for operating leases     $ 7,678 $ 9,788  
Cost of revenue $ 310,894 $ 267,647 $ 880,827 [1] 780,658 [1]  
Related Party          
Related Party Transaction [Line Items]          
Number of offices with operating lease | office 10   10    
Payments for operating leases $ 600 600 $ 1,900 1,900  
Cost of revenue 271,790 236,077 777,478 682,671  
Related Party | Subsidiary Under Common Control of Class A-1 Member          
Related Party Transaction [Line Items]          
Cost of revenue 268,000 $ 239,000 774,000 $ 682,000  
Accounts payable $ 113,000   $ 113,000   $ 102,100
Related Party | Cost of Goods and Service Benchmark | Supplier Concentration Risk | Subsidiary Under Common Control of Class A-1 Member          
Related Party Transaction [Line Items]          
Concentration risk (in percentage) 86.00% 89.00% 88.00% 86.00%  
Related Party | Accounts Payable | Supplier Concentration Risk | Subsidiary Under Common Control of Class A-1 Member          
Related Party Transaction [Line Items]          
Concentration risk (in percentage)     94.00%   94.00%
[1] Includes related party inventory expense of $271,790 and $236,077 and $777,478 and $682,671 for the three and nine months ended September 30, 2023 and 2022, respectively.
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Related Parties - Notes Receivable (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Jan. 24, 2022
May 22, 2020
May 01, 2020
Jun. 01, 2019
May 01, 2019
Related Party Transaction [Line Items]              
Total notes receivables $ 3,134 $ 3,873          
Less:  Current portion of notes receivable (1,630) (1,797)          
Notes receivable - related parties 1,504 2,076          
Note 2              
Related Party Transaction [Line Items]              
Total notes receivables 1,027 1,057          
Original
Principal             $ 5,355
Note 3              
Related Party Transaction [Line Items]              
Total notes receivables 42 119          
Original
Principal           $ 491  
Note 6              
Related Party Transaction [Line Items]              
Total notes receivables 0 351          
Original
Principal       $ 1,111      
Note 8              
Related Party Transaction [Line Items]              
Total notes receivables 2,065 2,221          
Original
Principal         $ 2,816    
Note 9              
Related Party Transaction [Line Items]              
Total notes receivables $ 0 $ 125          
Original
Principal     $ 125        
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Equity - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 2 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 21, 2023
Sep. 20, 2023
Jun. 07, 2023
Mar. 04, 2020
Jul. 31, 2023
Sep. 30, 2023
Sep. 20, 2023
Sep. 30, 2023
Dec. 31, 2022
Jun. 30, 2023
Sep. 30, 2022
Jun. 30, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Invested capital contributions           $ 65.0   $ 65.0          
Accrued dividend rate (in percent)               8.00%          
Common Class A                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Common unit, units outstanding (in units)           0   0 19,495,376 19,495,376 19,495,376 19,495,376 19,495,376
Accrued dividend rate (in percent)       8.00%                  
Class A and A-1 preferred returns and tax distributions     $ 4.0                    
Common stock, shares issued (in shares) 718,549   439,176                    
Common Class A-1                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Common unit, units outstanding (in units)           0   0 1,842,520 2,281,696 1,842,520 1,842,520 1,842,520
Shares issued (in shares) 284   174                    
Accrued dividend rate (in percent)       4.00%                  
Class A and A-1 preferred returns and tax distributions     $ 4.1                    
Shares issued (in shares)   $ 7.2 $ 2.5       $ 9.7            
Common Class B                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Common unit, units outstanding (in units)           0   0 4,703,628 4,703,628 4,703,628 4,703,628 4,703,628
Class B-1                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Stock compensation expense           $ 4.9              
Grants in period (in units)         415                
Class C                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Temporary equity, redeemable period               5 years          
Option to purchase additional units (in shares)     378                    
Purchase price of additional units (in dollars per share)     $ 26,423                    
Anti-dilution feature at fair value                   $ 1.4      
Stockholders                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Number of days after five year anniversary           30 days   30 days          
AON Inc.                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Stockholders' equity, conversion, threshold volume weighted average price period           30 days   30 days          
Stockholders' equity, conversion, threshold stock price (in dollars per share) (less than) (greater than)               $ 16.00          
AON LLC                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Issuance of units (in units)           34,724,025   34,724,025          
Anti-Dilution Feature                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Changes in fair value adjustments of warrants and derivative liabilities           $ 4.7   $ 9.8          
Option Feature                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Changes in fair value adjustments of warrants and derivative liabilities           $ (1.4)              
AON LLC | Common Class A                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Common unit authorized (in units)                 19,495,376        
Issuance of units (in units)                 19,495,376        
Common unit, units outstanding (in units)                 19,495,376        
AON LLC | Common Class A-1                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Common unit authorized (in units)                 3,000,245        
Issuance of units (in units)                 1,842,520        
Common unit, units outstanding (in units)                 1,842,520        
AON LLC | Common Class B                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Issuance of units (in units)                 5,614,176        
Units vested (in units)                 4,703,628        
Units vested upon consummation of business combination (in units)                 910,548        
Stock compensation expense                 $ 0.1        
Common Class A                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Shares issued (in shares)   1,047,343                      
Stockholders' equity, conversion, threshold volume weighted average price period           5 days   5 days          
Common stock, shares issued (in shares)           9,453,604   9,453,604          
Series A Preferred Stock                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Class A-1 distribution (in shares)   151,610                      
Stock price (in usd per share)           $ 10.00   $ 10.00          
Series A Preferred Stock | Stockholders                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Stockholders' equity, conversion, threshold volume weighted average price period           30 days   30 days          
Stockholders' equity, conversion, threshold stock price (in dollars per share) (less than) (greater than)               $ 10.00          
Threshold stock price, conversion price adjustment (in usd per share)               $ 5.00          
Series A Preferred Stock | AEA Growth Management LP                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Shares issued (in shares)   6,651,610                      
Series A Preferred Stock | Dividends Paid, Event Prior to June 7, 2024                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Accrued dividend rate (in percent)               125.00%          
Series A Preferred Stock | Dividends Paid, Event Prior to June 7, 2025, After June 7, 2024                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Accrued dividend rate (in percent)               120.00%          
Series A Preferred Stock | Dividends Paid, Event Prior to June 7, 2026, After June 7, 2025                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Accrued dividend rate (in percent)               115.00%          
Series A Preferred Stock | Dividends Paid, Event Prior to June 7, 2027, After June 7, 2026                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Accrued dividend rate (in percent)               110.00%          
Series A Preferred Stock | Dividends Paid, Event Prior to June 7, 2028, After June 7, 2027                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Accrued dividend rate (in percent)               105.00%          
Series A Preferred Stock | Dividends Paid, Event After June 7, 2028                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Accrued dividend rate (in percent)               100.00%          
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Equity - Schedule of Changes in Units (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Common Class A        
Reverse Recapitalization, Change In Value Of Units [Roll Forward]        
Beginning of Period $ 7,725 $ 7,725 $ 7,725 $ 7,725
Issuance of Units 0 0 0 0
Impact of the Reverse Recapitalization (7,725) 0 (7,725) 0
End of Period $ 0 $ 7,725 $ 0 $ 7,725
Reverse Recapitalization, Change In Units [Roll Forward]        
Beginning balance (in units) 19,495,376 19,495,376 19,495,376 19,495,376
Issuance of units (in units) 0 0 0 0
Impact of the Reverse Recapitalization (in units) (19,495,376) 0 (19,495,376) 0
Ending balance (in units) 0 19,495,376 0 19,495,376
Common Class A-1        
Reverse Recapitalization, Change In Value Of Units [Roll Forward]        
Beginning of Period $ 31,040 $ 28,500 $ 28,500 $ 28,500
Issuance of Units 7,185 0 9,725 0
Impact of the Reverse Recapitalization (38,225) 0 (38,225) 0
End of Period $ 0 $ 28,500 $ 0 $ 28,500
Reverse Recapitalization, Change In Units [Roll Forward]        
Beginning balance (in units) 2,281,696 1,842,520 1,842,520 1,842,520
Issuance of units (in units) 718,549 1,157,725
Impact of the Reverse Recapitalization (in units) (3,000,245) (3,000,245)
Ending balance (in units) 0 1,842,520 0 1,842,520
Common Class B        
Reverse Recapitalization, Change In Value Of Units [Roll Forward]        
Beginning of Period $ 80 $ 90 $ 80 $ 80
Issuance of Units 10 5 10 15
Impact of the Reverse Recapitalization (90) 0 (90)
End of Period $ 0 $ 95 $ 0 $ 95
Reverse Recapitalization, Change In Units [Roll Forward]        
Beginning balance (in units) 4,703,628 4,703,628 4,703,628 4,703,628
Issuance of units (in units) 910,548 0 910,548 0
Impact of the Reverse Recapitalization (in units) (5,614,176) 0 (5,614,176) 0
Ending balance (in units) 0 4,703,628 0 4,703,628
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss Per Share - Calculation Of Earnings Per Share (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
Net loss attributable to Class A Common Stockholders for basic loss per share $ (1,792,000) $ 0 $ (1,792,000) $ 0
Net loss attributable to Class A Common Stockholders for diluted loss per share $ (1,792,000) $ 0 $ (1,792,000) $ 0
Weighted average shares for basic loss per share (in shares) 6,614,229 0 6,614,229 0
Weighted average shares for diluted loss per share (in shares) 6,614,229 0 6,614,229 0
Basic loss per share of Class A Common Stock (in dollars per share) $ (0.61) $ 0 $ (0.61) $ 0
Diluted loss per share of Class A Common Stock (in dollars per share) $ (0.61) $ 0 $ (0.61) $ 0
Common Class A        
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
Net loss attributable to Class A Common Stockholders for basic loss per share     $ 1,791,768  
Net loss attributable to Class A Common Stockholders for diluted loss per share     1,791,768  
Undistributed net loss, dilutive     4,013,000  
Undistributed net earnings, basic     4,013,000  
Series A Preferred Stock        
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
Series A Deemed Dividend     (2,089,000)  
Series A Preferred Cumulative Dividends     $ (133,032)  
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss Per Share - Antidilutive Securities (Details)
 9 Months Ended
Sep. 30, 2023
shares
Series A Preferred Stock  
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]  
Antidilutive shares excluded from computation of earnings per share (in shares) 6,651,610
Common Class B  
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]  
Antidilutive shares excluded from computation of earnings per share (in shares) 25,109,551
Class B Prefunded Warrants  
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]  
Antidilutive shares excluded from computation of earnings per share (in shares) 3,000,245
Public and Private Warrants  
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]  
Antidilutive shares excluded from computation of earnings per share (in shares) 14,450,883
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.23.3
Redeemable Noncontrolling Interest - Narrative (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2023
Sep. 20, 2023
Sep. 30, 2022
Noncontrolling Interest [Line Items]        
Redemption ratio   1    
Number of days after redemption notice date that redemption must be settled 10 years 10 years    
Redemption value of noncontrolling interest $ 369,300 $ 369,300    
Excess redeemable noncontrolling interest over carrying amount 344,300 344,300    
Fair value adjustment to redeemable noncontrolling interest 344,371      
Additional Paid in Capital        
Noncontrolling Interest [Line Items]        
Fair value adjustment to redeemable noncontrolling interest 17,602 17,600    
Retained
Earnings (Deficit)        
Noncontrolling Interest [Line Items]        
Fair value adjustment to redeemable noncontrolling interest $ 326,769 $ 326,700    
Common Class A        
Noncontrolling Interest [Line Items]        
Common stock, shares outstanding (in shares) 9,453,604 9,453,604    
Stockholders' equity, conversion, threshold volume weighted average price period 5 days 5 days    
Legacy AON Shareholders | AON LLC        
Noncontrolling Interest [Line Items]        
Common unit, units outstanding (in units) 28,109,796 28,109,796    
Allocation of income to controlling and noncontrolling interests 81.00% 67.90% 100.00% 100.00%
Common stock, shares outstanding (in shares) 25,109,551 25,109,551    
Class of warrant outstanding (in warrants) 3,000,245 3,000,245    
LLC ownership threshold, percentage 50.00% 50.00%    
AON Inc. | AON LLC        
Noncontrolling Interest [Line Items]        
Allocation of income to controlling and noncontrolling interests 19.00%      
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.23.3
Redeemable Noncontrolling Interest - Schedule of Ownership (Details) - AON LLC
Sep. 30, 2023
shares
Equity, Attributable to Noncontrolling Interest [Roll Forward]  
Beginning balance (in units) 0
Common Units issued (in units) 34,724,025
Series A Preferred Units Issued 6,651,610
Total Units Issued 41,375,635
Ending balance (in units) 41,375,635
Allocation of income to controlling and noncontrolling interests (in percent) 1
Allocation of losses to controlling and noncontrolling interests (in percent) 1
AON Inc.  
Equity, Attributable to Noncontrolling Interest [Roll Forward]  
Beginning balance (in units) 0
Common Units issued (in units) 6,614,229
Series A Preferred Units Issued 6,651,610
Total Units Issued 13,265,839
Ending balance (in units) 13,265,839
Allocation of income to controlling and noncontrolling interests (in percent) 0.321
Allocation of losses to controlling and noncontrolling interests (in percent) 0.190
Common unit excluded from issuance (in units) 2,839,375
Legacy AON Shareholders  
Equity, Attributable to Noncontrolling Interest [Roll Forward]  
Beginning balance (in units) 0
Common Units issued (in units) 28,109,796
Series A Preferred Units Issued 0
Total Units Issued 28,109,796
Ending balance (in units) 28,109,796
Allocation of income to controlling and noncontrolling interests (in percent) 0.679
Allocation of losses to controlling and noncontrolling interests (in percent) 0.810
XML 74 aonc-20230930_htm.xml IDEA: XBRL DOCUMENT 0001839998 2023-01-01 2023-09-30 0001839998 us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001839998 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001839998 us-gaap:CommonClassAMember 2023-11-09 0001839998 us-gaap:CommonClassBMember 2023-11-09 0001839998 2023-09-30 0001839998 2022-12-31 0001839998 us-gaap:SeriesAPreferredStockMember 2023-09-30 0001839998 us-gaap:CommonClassAMember 2023-09-30 0001839998 us-gaap:CommonClassBMember 2023-09-30 0001839998 us-gaap:CapitalUnitClassAMember 2023-09-30 0001839998 us-gaap:CapitalUnitClassAMember 2022-12-31 0001839998 aonc:CapitalUnitClassA1Member 2023-09-30 0001839998 aonc:CapitalUnitClassA1Member 2022-12-31 0001839998 us-gaap:CapitalUnitClassBMember 2023-09-30 0001839998 us-gaap:CapitalUnitClassBMember 2022-12-31 0001839998 us-gaap:RelatedPartyMember 2023-09-30 0001839998 us-gaap:RelatedPartyMember 2022-12-31 0001839998 aonc:PatientServiceMember 2023-07-01 2023-09-30 0001839998 aonc:PatientServiceMember 2022-07-01 2022-09-30 0001839998 aonc:PatientServiceMember 2023-01-01 2023-09-30 0001839998 aonc:PatientServiceMember 2022-01-01 2022-09-30 0001839998 us-gaap:ProductAndServiceOtherMember 2023-07-01 2023-09-30 0001839998 us-gaap:ProductAndServiceOtherMember 2022-07-01 2022-09-30 0001839998 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-09-30 0001839998 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-09-30 0001839998 2023-07-01 2023-09-30 0001839998 2022-07-01 2022-09-30 0001839998 2022-01-01 2022-09-30 0001839998 us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001839998 us-gaap:RelatedPartyMember 2022-07-01 2022-09-30 0001839998 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001839998 us-gaap:RelatedPartyMember 2022-01-01 2022-09-30 0001839998 2023-06-30 0001839998 us-gaap:CapitalUnitClassAMember us-gaap:MemberUnitsMember 2023-06-30 0001839998 aonc:CapitalUnitClassA1Member us-gaap:MemberUnitsMember 2023-06-30 0001839998 us-gaap:CapitalUnitClassBMember us-gaap:MemberUnitsMember 2023-06-30 0001839998 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0001839998 us-gaap:NoncontrollingInterestMember 2023-06-30 0001839998 us-gaap:RetainedEarningsMember 2023-06-30 0001839998 aonc:CapitalUnitClassA1Member us-gaap:MemberUnitsMember 2023-07-01 2023-09-30 0001839998 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001839998 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-07-01 2023-09-30 0001839998 us-gaap:CapitalUnitClassBMember us-gaap:MemberUnitsMember 2023-07-01 2023-09-30 0001839998 aonc:CapitalUnitClassB1Member us-gaap:MemberUnitsMember 2023-07-01 2023-09-30 0001839998 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001839998 2023-09-21 2023-09-30 0001839998 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-09-21 2023-09-30 0001839998 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-09-21 2023-09-30 0001839998 us-gaap:CapitalUnitClassAMember us-gaap:MemberUnitsMember 2023-09-21 2023-09-30 0001839998 aonc:CapitalUnitClassA1Member us-gaap:MemberUnitsMember 2023-09-21 2023-09-30 0001839998 us-gaap:CapitalUnitClassBMember us-gaap:MemberUnitsMember 2023-09-21 2023-09-30 0001839998 aonc:CapitalUnitClassB1Member us-gaap:MemberUnitsMember 2023-09-21 2023-09-30 0001839998 us-gaap:AdditionalPaidInCapitalMember 2023-09-21 2023-09-30 0001839998 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-09-21 2023-09-30 0001839998 us-gaap:RetainedEarningsMember 2023-09-21 2023-09-30 0001839998 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-09-30 0001839998 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-09-30 0001839998 us-gaap:CapitalUnitClassBMember us-gaap:MemberUnitsMember 2023-09-30 0001839998 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001839998 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-09-30 0001839998 us-gaap:NoncontrollingInterestMember 2023-09-30 0001839998 us-gaap:RetainedEarningsMember 2023-09-30 0001839998 us-gaap:CapitalUnitClassAMember us-gaap:MemberUnitsMember 2022-12-31 0001839998 aonc:CapitalUnitClassA1Member us-gaap:MemberUnitsMember 2022-12-31 0001839998 us-gaap:CapitalUnitClassBMember us-gaap:MemberUnitsMember 2022-12-31 0001839998 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001839998 us-gaap:RetainedEarningsMember 2022-12-31 0001839998 2023-01-01 2023-09-20 0001839998 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-20 0001839998 aonc:CapitalUnitClassA1Member us-gaap:MemberUnitsMember 2023-01-01 2023-09-20 0001839998 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-20 0001839998 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-09-20 0001839998 us-gaap:CapitalUnitClassBMember us-gaap:MemberUnitsMember 2023-01-01 2023-09-20 0001839998 aonc:CapitalUnitClassB1Member us-gaap:MemberUnitsMember 2023-01-01 2023-09-20 0001839998 us-gaap:CapitalUnitClassAMember us-gaap:MemberUnitsMember 2022-06-30 0001839998 aonc:CapitalUnitClassA1Member us-gaap:MemberUnitsMember 2022-06-30 0001839998 us-gaap:CapitalUnitClassBMember us-gaap:MemberUnitsMember 2022-06-30 0001839998 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001839998 us-gaap:RetainedEarningsMember 2022-06-30 0001839998 2022-06-30 0001839998 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001839998 us-gaap:CapitalUnitClassBMember us-gaap:MemberUnitsMember 2022-07-01 2022-09-30 0001839998 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001839998 us-gaap:CapitalUnitClassAMember us-gaap:MemberUnitsMember 2022-09-30 0001839998 aonc:CapitalUnitClassA1Member us-gaap:MemberUnitsMember 2022-09-30 0001839998 us-gaap:CapitalUnitClassBMember us-gaap:MemberUnitsMember 2022-09-30 0001839998 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001839998 us-gaap:RetainedEarningsMember 2022-09-30 0001839998 2022-09-30 0001839998 us-gaap:CapitalUnitClassAMember us-gaap:MemberUnitsMember 2021-12-31 0001839998 aonc:CapitalUnitClassA1Member us-gaap:MemberUnitsMember 2021-12-31 0001839998 us-gaap:CapitalUnitClassBMember us-gaap:MemberUnitsMember 2021-12-31 0001839998 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001839998 us-gaap:RetainedEarningsMember 2021-12-31 0001839998 2021-12-31 0001839998 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001839998 us-gaap:CapitalUnitClassBMember us-gaap:MemberUnitsMember 2022-01-01 2022-09-30 0001839998 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001839998 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-09-30 0001839998 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-09-30 0001839998 aonc:AONLLCMember 2023-09-20 0001839998 aonc:DigitalTransformationOpportunitiesCorpDTOCMember us-gaap:CommonClassBMember 2023-09-20 0001839998 us-gaap:CommonClassAMember 2023-09-20 2023-09-20 0001839998 aonc:LegacyAONShareholdersMember aonc:AONLLCMember 2023-09-20 0001839998 aonc:NewAONAONIncMember aonc:AONLLCMember 2023-09-20 0001839998 aonc:NewAONAONIncMember us-gaap:SeriesAPreferredStockMember aonc:AONLLCMember 2023-09-20 0001839998 aonc:AONLLCMember us-gaap:CommonClassAMember 2023-09-20 0001839998 aonc:DTOCUnredeemedShareholdersMember us-gaap:CommonClassAMember 2023-09-20 0001839998 aonc:DTOCSponsorMember us-gaap:CommonClassAMember 2023-09-20 0001839998 aonc:LegacyAONShareholdersMember us-gaap:CommonClassBMember 2023-09-20 0001839998 aonc:AEAGrowthManagementLPMember us-gaap:SeriesAPreferredStockMember 2023-09-20 0001839998 aonc:LegacyAONShareholdersMember aonc:ClassBPrefundedWarrantsMember 2023-09-20 0001839998 aonc:SponsorEarnoutSharesMember 2023-09-20 2023-09-20 0001839998 aonc:SponsorEarnoutSharesMember 2023-09-20 0001839998 aonc:DTOCSponsorMember aonc:PublicWarrantMember 2023-09-20 0001839998 aonc:DTOCSponsorMember aonc:PublicWarrantMember us-gaap:CommonClassAMember 2023-09-20 0001839998 aonc:DTOCSponsorMember aonc:PublicWarrantMember 2023-09-20 2023-09-20 0001839998 aonc:DTOCSponsorMember aonc:PrivatePlacementWarrantsMember 2023-09-20 0001839998 aonc:AONLLCMember aonc:ClassBPrefundedWarrantsMember 2023-09-20 0001839998 aonc:AONLLCMember aonc:ClassBPrefundedWarrantsMember us-gaap:CommonClassBMember 2023-09-20 0001839998 aonc:AONLLCMember us-gaap:CommonClassBMember 2023-09-20 0001839998 aonc:AONLLCMember 2023-07-01 2023-09-30 0001839998 aonc:AONLLCMember 2023-01-01 2023-09-30 0001839998 aonc:TemporaryEquityMember aonc:AONLLCMember 2023-01-01 2023-09-30 0001839998 aonc:AONLLCMember 2022-12-31 0001839998 aonc:AONLLCMember 2022-07-01 2022-09-30 0001839998 aonc:AONLLCMember 2022-01-01 2022-09-30 0001839998 aonc:ParticipatingThreshold1Member 2023-09-30 0001839998 aonc:ParticipatingThreshold2Member 2023-09-30 0001839998 aonc:ParticipatingThreshold3Member 2023-09-30 0001839998 aonc:AONLLCMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001839998 aonc:AONLLCMember aonc:NewAONAONIncMember 2023-09-21 2023-09-30 0001839998 aonc:AONLLCMember aonc:LegacyAONShareholdersMember 2023-09-21 2023-09-30 0001839998 aonc:AONLLCMember aonc:LegacyAONShareholdersMember 2023-01-01 2023-09-20 0001839998 aonc:AONLLCMember aonc:LegacyAONShareholdersMember 2022-01-01 2022-09-30 0001839998 aonc:MIBAMember 2023-05-01 2023-05-31 0001839998 aonc:PatientVisitsMember 2023-07-01 2023-09-30 0001839998 aonc:PatientVisitsMember 2022-07-01 2022-09-30 0001839998 aonc:PatientVisitsMember 2023-01-01 2023-09-30 0001839998 aonc:PatientVisitsMember 2022-01-01 2022-09-30 0001839998 aonc:ClinicalTrialsMember 2023-07-01 2023-09-30 0001839998 aonc:ClinicalTrialsMember 2022-07-01 2022-09-30 0001839998 aonc:ClinicalTrialsMember 2023-01-01 2023-09-30 0001839998 aonc:ClinicalTrialsMember 2022-01-01 2022-09-30 0001839998 aonc:OCPManagementArizonaLLPMember 2023-01-01 2023-01-31 0001839998 aonc:OCPManagementArizonaLLPMember 2023-01-31 0001839998 us-gaap:PreferredClassAMember 2023-01-01 2023-09-30 0001839998 us-gaap:SeriesCPreferredStockMember 2023-06-07 2023-06-07 0001839998 us-gaap:SeriesCPreferredStockMember 2023-06-07 0001839998 us-gaap:SeriesCPreferredStockMember 2023-01-01 2023-09-30 0001839998 us-gaap:ProfessionalMalpracticeLiabilityMember 2023-01-01 2023-09-30 0001839998 us-gaap:DirectorsAndOfficersLiabilityInsuranceMember 2023-01-01 2023-09-30 0001839998 aonc:PublicWarrantMember 2023-09-30 0001839998 aonc:PrivatePlacementWarrantsMember 2023-09-30 0001839998 aonc:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-09-30 0001839998 aonc:PrivatePlacementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-09-30 0001839998 aonc:PrivatePlacementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-09-30 0001839998 aonc:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2023-09-30 0001839998 aonc:AONIncMember 2023-09-30 0001839998 aonc:AONCommonUnitholdersMember 2023-09-30 0001839998 2023-09-20 2023-09-20 0001839998 aonc:PublicAndPrivateWarrantsMember 2023-09-21 2023-09-30 0001839998 aonc:AONCentralMember aonc:PhysiciansMember 2023-01-01 2023-09-30 0001839998 aonc:AONCentralMember 2023-01-01 2023-09-30 0001839998 aonc:MIBAMember 2023-04-01 2023-06-30 0001839998 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember aonc:MIBAMember 2023-04-01 2023-06-30 0001839998 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2023-09-30 0001839998 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2022-12-31 0001839998 aonc:NorthernArizonaHematologyAndOncologyMember 2022-01-01 2022-01-01 0001839998 aonc:NorthernArizonaHematologyAndOncologyMember 2023-09-30 0001839998 aonc:NorthernArizonaHematologyAndOncologyMember 2022-12-31 0001839998 aonc:OvernightRepurchaseAgreementsMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0001839998 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0001839998 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0001839998 us-gaap:FairValueInputsLevel1Member 2023-09-30 0001839998 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2023-09-30 0001839998 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2023-09-30 0001839998 us-gaap:FairValueInputsLevel2Member 2023-09-30 0001839998 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001839998 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001839998 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001839998 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001839998 aonc:IntravenousDrugsMember 2023-09-30 0001839998 aonc:IntravenousDrugsMember 2022-12-31 0001839998 aonc:OralPharmaceuticalsMember 2023-09-30 0001839998 aonc:OralPharmaceuticalsMember 2022-12-31 0001839998 us-gaap:LeaseholdImprovementsMember 2023-09-30 0001839998 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001839998 aonc:FurnitureFixturesAndEquipmentMember 2023-09-30 0001839998 aonc:FurnitureFixturesAndEquipmentMember 2022-12-31 0001839998 aonc:MedicalEquipmentMember 2023-09-30 0001839998 aonc:MedicalEquipmentMember 2022-12-31 0001839998 us-gaap:ComputerEquipmentMember 2023-09-30 0001839998 us-gaap:ComputerEquipmentMember 2022-12-31 0001839998 aonc:SignsMember 2023-09-30 0001839998 aonc:SignsMember 2022-12-31 0001839998 us-gaap:AutomobilesMember 2023-09-30 0001839998 us-gaap:AutomobilesMember 2022-12-31 0001839998 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-09-30 0001839998 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-12-31 0001839998 us-gaap:ConstructionInProgressMember 2023-09-30 0001839998 us-gaap:ConstructionInProgressMember 2022-12-31 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2023-09-30 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2021-04-30 2021-04-30 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember aonc:AlternateBaseRateMember 2021-04-30 2021-04-30 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2021-04-30 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember aonc:DebtInstrumentThresholdLimitPeriodOneMember 2021-04-30 2021-04-30 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember aonc:DebtInstrumentThresholdLimitPeriodTwoMember 2021-04-30 2021-04-30 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember 2021-04-30 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember aonc:LondonInterbankOfferedRateLIBOR1Member 2021-04-30 2021-04-30 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember aonc:AlternateBaseRateMember 2021-04-30 2021-04-30 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember 2021-04-30 2021-04-30 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember 2023-01-01 2023-09-30 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember 2022-01-01 2022-12-31 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2021-07-29 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2022-02-14 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember 2022-02-14 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember aonc:BloombergShortTermBankYieldIndexMember 2022-02-14 2022-02-14 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2022-02-14 2022-02-14 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember 2022-08-15 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember aonc:DebtInstrumentThresholdLimitPeriodOneMember 2023-09-30 2023-09-30 0001839998 aonc:A2024NotesReceivableNote2Member 2023-09-30 0001839998 aonc:A2024NotesReceivableNote2Member 2022-12-31 0001839998 aonc:A2024NotesReceivableNote2Member 2019-05-01 0001839998 aonc:A2024NotesReceivableNote3Member 2023-09-30 0001839998 aonc:A2024NotesReceivableNote3Member 2022-12-31 0001839998 aonc:A2024NotesReceivableNote3Member 2019-06-01 0001839998 aonc:A2023NotesReceivableNote6Member 2023-09-30 0001839998 aonc:A2023NotesReceivableNote6Member 2022-12-31 0001839998 aonc:A2023NotesReceivableNote6Member 2020-05-22 0001839998 aonc:A2025NotesReceivableNote8Member 2023-09-30 0001839998 aonc:A2025NotesReceivableNote8Member 2022-12-31 0001839998 aonc:A2025NotesReceivableNote8Member 2020-05-01 0001839998 aonc:A2023NotesReceivableNote9Member 2023-09-30 0001839998 aonc:A2023NotesReceivableNote9Member 2022-12-31 0001839998 aonc:A2023NotesReceivableNote9Member 2022-01-24 0001839998 us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2023-07-01 2023-09-30 0001839998 us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2022-07-01 2022-09-30 0001839998 us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2023-01-01 2023-09-30 0001839998 us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2022-01-01 2022-09-30 0001839998 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2023-07-01 2023-09-30 0001839998 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2022-07-01 2022-09-30 0001839998 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2023-01-01 2023-09-30 0001839998 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2022-01-01 2022-09-30 0001839998 us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2023-09-30 0001839998 us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2022-12-31 0001839998 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2022-01-01 2022-12-31 0001839998 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2023-01-01 2023-09-30 0001839998 us-gaap:CommonClassAMember aonc:AONLLCMember 2022-12-31 0001839998 aonc:CommonClassA1Member aonc:AONLLCMember 2022-12-31 0001839998 us-gaap:CommonClassBMember aonc:AONLLCMember 2022-12-31 0001839998 us-gaap:CommonClassBMember aonc:AONLLCMember 2022-01-01 2022-12-31 0001839998 us-gaap:CommonClassAMember 2023-06-30 0001839998 us-gaap:CommonClassAMember 2022-06-30 0001839998 us-gaap:CommonClassAMember 2022-12-31 0001839998 us-gaap:CommonClassAMember 2021-12-31 0001839998 us-gaap:CommonClassAMember 2023-07-01 2023-09-30 0001839998 us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001839998 us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001839998 us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001839998 us-gaap:CommonClassAMember 2023-09-30 0001839998 us-gaap:CommonClassAMember 2022-09-30 0001839998 aonc:CommonClassA1Member 2023-06-30 0001839998 aonc:CommonClassA1Member 2022-06-30 0001839998 aonc:CommonClassA1Member 2022-12-31 0001839998 aonc:CommonClassA1Member 2021-12-31 0001839998 aonc:CommonClassA1Member 2023-07-01 2023-09-30 0001839998 aonc:CommonClassA1Member 2022-07-01 2022-09-30 0001839998 aonc:CommonClassA1Member 2023-01-01 2023-09-30 0001839998 aonc:CommonClassA1Member 2022-01-01 2022-09-30 0001839998 aonc:CommonClassA1Member 2023-09-30 0001839998 aonc:CommonClassA1Member 2022-09-30 0001839998 us-gaap:CommonClassBMember 2023-06-30 0001839998 us-gaap:CommonClassBMember 2022-06-30 0001839998 us-gaap:CommonClassBMember 2022-12-31 0001839998 us-gaap:CommonClassBMember 2021-12-31 0001839998 us-gaap:CommonClassBMember 2023-07-01 2023-09-30 0001839998 us-gaap:CommonClassBMember 2022-07-01 2022-09-30 0001839998 us-gaap:CommonClassBMember 2023-01-01 2023-09-30 0001839998 us-gaap:CommonClassBMember 2022-01-01 2022-09-30 0001839998 us-gaap:CommonClassBMember 2023-09-30 0001839998 us-gaap:CommonClassBMember 2022-09-30 0001839998 aonc:CommonStockClassB1Member 2023-06-01 2023-07-31 0001839998 aonc:CommonStockClassB1Member 2023-07-01 2023-09-30 0001839998 aonc:AEAGrowthManagementLPMember us-gaap:SeriesAPreferredStockMember 2023-09-20 2023-09-20 0001839998 us-gaap:CommonClassCMember 2023-01-01 2023-09-30 0001839998 us-gaap:CommonClassCMember 2023-06-07 2023-06-07 0001839998 us-gaap:CommonClassCMember 2023-06-30 0001839998 aonc:OptionFeatureMember 2023-07-01 2023-09-30 0001839998 us-gaap:SeriesAPreferredStockMember 2023-09-20 2023-09-20 0001839998 aonc:StockholdersMember 2023-09-30 0001839998 us-gaap:SeriesAPreferredStockMember aonc:StockholdersMember 2023-09-30 0001839998 us-gaap:SeriesAPreferredStockMember aonc:StockholdersMember 2023-01-01 2023-09-30 0001839998 aonc:NewAONAONIncMember 2023-09-30 0001839998 aonc:NewAONAONIncMember 2023-01-01 2023-09-30 0001839998 aonc:DividendsPaidEventPriorToJune72024Member us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-09-30 0001839998 aonc:DividendsPaidEventPriorToJune72025AfterJune72024Member us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-09-30 0001839998 aonc:DividendsPaidEventPriorToJune72026AfterJune72025Member us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-09-30 0001839998 aonc:DividendsPaidEventPriorToJune72027AfterJune72026Member us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-09-30 0001839998 aonc:DividendsPaidEventPriorToJune72028AfterJune72027Member us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-09-30 0001839998 aonc:DividendsPaidEventAfterJune72028Member us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-09-30 0001839998 us-gaap:CommonClassAMember 2020-03-04 2020-03-04 0001839998 aonc:CommonClassA1Member 2020-03-04 2020-03-04 0001839998 us-gaap:CommonClassAMember 2023-06-07 2023-06-07 0001839998 aonc:CommonClassA1Member 2023-06-07 2023-06-07 0001839998 aonc:AntiDilutionFeatureMember 2023-07-01 2023-09-30 0001839998 aonc:AntiDilutionFeatureMember 2023-01-01 2023-09-30 0001839998 aonc:CommonClassA1Member 2023-09-21 2023-09-21 0001839998 us-gaap:CommonClassAMember 2023-06-07 0001839998 us-gaap:CommonClassAMember 2023-09-21 0001839998 aonc:CommonClassA1Member 2023-09-20 2023-09-20 0001839998 aonc:CommonClassA1Member 2023-06-07 2023-09-20 0001839998 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-09-30 0001839998 us-gaap:CommonClassBMember 2023-01-01 2023-09-30 0001839998 aonc:ClassBPrefundedWarrantsMember 2023-01-01 2023-09-30 0001839998 aonc:PublicAndPrivateWarrantsMember 2023-01-01 2023-09-30 0001839998 aonc:AONLLCMember aonc:LegacyAONShareholdersMember 2023-09-30 0001839998 aonc:AONLLCMember aonc:LegacyAONShareholdersMember 2023-01-01 2023-09-30 0001839998 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001839998 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001839998 aonc:AONLLCMember aonc:NewAONAONIncMember 2023-09-20 0001839998 aonc:AONLLCMember aonc:LegacyAONShareholdersMember 2023-09-20 0001839998 aonc:AONLLCMember 2023-09-20 0001839998 aonc:AONLLCMember aonc:NewAONAONIncMember 2023-09-30 0001839998 aonc:AONLLCMember 2023-09-30 0001839998 aonc:AONLLCMember 2023-09-21 2023-09-30 shares iso4217:USD iso4217:USD shares aonc:practice aonc:state pure aonc:segment aonc:person aonc:lease aonc:office 0001839998 2023 Q3 --12-31 false http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrent P60M P10Y P5D 10-Q true 2023-09-30 false 001-04321 American Oncology Network, Inc. DE 85-3984427 14543 Global Parkway Suite 110 Fort Myers FL 33913 833 886-1725 Class A common stock, par value $0.0001, per share AONC NASDAQ Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share AONCW NASDAQ Yes Yes Non-accelerated Filer true true false false 9550099 25109551 51653000 26926000 26034000 9851000 141039000 136098000 37844000 36476000 36747000 28201000 3445000 2670000 1630000 1797000 298392000 242019000 36240000 31980000 46138000 43724000 1504000 2076000 7055000 5199000 1230000 1230000 3455000 0 394014000 326228000 120383000 106495000 16210000 7466000 22977000 17800000 1211000 0 7123000 9177000 167904000 140938000 80425000 80301000 42261000 37224000 10333000 5749000 300923000 264212000 0.0001 7500000 6651610 6651610 66649130 64986000 369329000 0.0001 200000000 9453604 9453604 1000 0.0001 100000000 25109551 25109551 3000 0 19495376 7725000 0 1842520 28500000 0 4703628 80000 0 21000 -117000 -341357000 25828000 -341332000 62016000 108000 394014000 326228000 11476000 13077000 112740000 102113000 1912000 1836000 9994000 11631000 332195000 293612000 945681000 840507000 4110000 3712000 9322000 8765000 336305000 297324000 955003000 849272000 310894000 267647000 880827000 780658000 25199000 23432000 72831000 66155000 24603000 151000 29886000 151000 360696000 291230000 983544000 846964000 -24391000 6094000 -28541000 2308000 1532000 924000 4500000 2034000 373000 49000 499000 104000 -3309000 388000 -7689000 849000 -28859000 5607000 -40231000 1227000 315000 0 315000 0 -29174000 5607000 -40546000 1227000 -31000 0 -251000 0 -29205000 5607000 -40797000 1227000 -15489000 5607000 -27081000 1227000 -11924000 0 -11924000 0 -1792000 -1792000 0 0 -1792000 -1792000 0 0 -0.61 0 -0.61 0 -0.61 0 -0.61 0 6614229 0 6614229 0 6614229 0 6614229 0 102000 -77000 190000 -161000 102000 -77000 190000 -161000 -29103000 5530000 -40607000 1066000 -15398000 5530000 -26902000 1066000 -11915000 0 -11915000 0 -1790000 0 -1790000 0 271790000 236077000 777478000 682671000 679000 655000 2037000 2037000 6500000 62897000 19495000 7725000 2282000 31040000 4704000 80000 -29000 134000 5803000 44753000 719000 7185000 7185000 1045000 1045000 90000 90000 911000 10000 1047000 4864000 4874000 -26000 -15464000 -15490000 152000 2089000 36873000 6614000 1000 25110000 3000 -19495000 -7725000 -3000000 -38225000 -5615000 -90000 -1047000 -4864000 17602000 -42000 -2089000 -35429000 9000 2000 2000 -11924000 -1792000 -1792000 344371000 -17602000 -326769000 -344371000 6652000 64986000 369329000 6614000 1000 25110000 3000 0 0 21000 108000 -341356000 -341223000 19495000 7725000 1843000 28500000 4704000 80000 -117000 25828000 62016000 6500000 62897000 8174000 8174000 1158000 9725000 9725000 1305000 1305000 134000 134000 178000 178000 911000 10000 1047000 4864000 4874000 -26000 -27055000 -27081000 152000 2089000 36873000 6614000 1000 25110000 3000 -19495000 -7725000 -3000000 -38225000 -5615000 -90000 -1047000 -4864000 17602000 -42000 -2089000 -35429000 9000 2000 2000 -11924000 -1792000 -1792000 344371000 -17602000 -326769000 -344371000 6652000 64986000 369329000 6614000 1000 25110000 3000 0 0 21000 108000 -341356000 -341223000 19495000 7725000 1843000 28500000 90000 -84000 18859000 55090000 5607000 5607000 5000 5000 -77000 -77000 19495000 7725000 1843000 28500000 95000 -161000 24466000 60625000 19495000 7725000 1843000 28500000 80000 0 23239000 59544000 1227000 1227000 15000 15000 -161000 -161000 19495000 7725000 1843000 28500000 95000 -161000 24466000 60625000 -40797000 1227000 6368000 5318000 570000 458000 75000 0 6194000 7766000 -9334000 0 4875000 15000 -251000 0 2000 0 4941000 15223000 1367000 -876000 775000 -641000 8546000 211000 2107000 376000 13889000 9586000 8744000 4456000 6290000 -1563000 -5625000 -8252000 0 -3742000 1410000 654000 -6160000 1630000 9527000 5051000 5000 1137000 20824000 11949000 4933000 1956000 0 243000 740000 1091000 -24673000 -13059000 0 16250000 64996000 0 9481000 0 387000 321000 134000 0 446000 171000 750000 0 -1494000 0 55560000 15758000 24727000 4329000 26926000 32354000 51653000 36683000 2745000 0 -1254000 0 0 159000 0 72000 1601000 1536000 -1299000 832000 10627000 23309000 -1835000 -1446000 Business<div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Oncology Network, Inc. (“AON”, “New AON”, “AON Inc.”, or the “Company”), through its subsidiary companies and variable interest entities (together, “its subsidiaries”), is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services across 33 oncology practices located in nineteen states (Arizona, Arkansas, Florida, Georgia, Iowa, Idaho, Indiana, Louisiana, Maryland, Missouri, Michigan, North Carolina, Nevada, Nebraska, Ohio, South Carolina, Texas, Virginia and Washington). The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services, clinical research, radiation oncology, and imaging. During the nine months ended September 30, 2023 and 2022, the Company entered into affiliation agreements with or acquired the following oncology practices.</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.090%"><tr><td style="width:1.0%"></td><td style="width:48.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">State</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">State</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arizona</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Texas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Florida</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Louisiana</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arkansas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The Company entered into affiliation agreements with the physicians for these respective practices. The Company evaluated each of the affiliation agreements and determined that the transactions did not represent a business combination.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operations of the practices that were acquired have been included in the Company’s condensed consolidated financial statements since the date of acquisition. The Company intends to continue to pursue additional purchases of physician practices in addition to seeking out new affiliation relationships.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combination Agreements</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Digital Transformation Opportunities Corp. (“DTOC”), American Oncology Network, LLC (“AON LLC”), GEF AON Holdings Corp. (“AON Class C Preferred Investor”), and DTOC Merger Sub, Inc., a direct, wholly owned subsidiary of DTOC (“Merger Sub”) entered into a Business Combination Agreement (the “Business Combination Agreement”), dated as of June 14, 2023 (which further amended and restated the Business Combination Agreement entered into by DTOC and AON as of October 5, 2022, and amended and restated on January 6, 2023, and April 27, 2023), pursuant to which, among other transactions, on September 20, 2023 (the “Closing Date”), DTOC and AON undertook a series of transactions (the “Business Combination”) resulting in the organization of the combined post-business combination company as an umbrella partnership C corporation, in which substantially all of the assets and the business of the combined company are held by AON LLC, and DTOC became a member of AON LLC. In connection with the closing of the Business Combination (“the Closing”), DTOC changed its name to “American Oncology Network, Inc.”. The Business Combination was completed on September 20, 2023.</span></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of, and in connection with, the Closing, among other things, (i) AON LLC amended and restated its operating agreement (the “Amended and Restated AON LLC Agreement”) to reclassify its existing Class A units, Class A-1 units and Class B units into a single class of AON LLC common units (“AON LLC Common Units”) that can be exchanged on a one-to-one basis for shares of New AON Class A common stock (“New AON Class A Common Stock”) and its existing AON LLC Class C units into AON LLC Series A preferred units (AON LLC Series A Preferred Units”); (ii) AON LLC converted profit pool units of certain of AON LLC’s subsidiaries into an equal number of AON LLC Common Units and shares of New AON Class B common stock (“New AON Class B Common Stock”), which together are exchangeable into shares of New AON Class A Common Stock (together with the New AON Class B Common Stock, the “New AON Common Stock”); (iii) New AON amended and </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restated its charter (the “Charter”) to provide for (a) the conversion of all existing shares of DTOC Class B common stock into shares of New AON Class A Common Stock on a one-to-one basis, (b) amendment of the terms </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of New AON Class B Common Stock to provide holders voting rights but no economic rights and (c) designation of a new series of New AON preferred stock as Series A convertible preferred stock (the “New AON Series A </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Stock” or “Series A Preferred Stock") with such rights and preferences as provided for in the certificate of designation of the New Aon Series A Preferred Stock (the “New AON Series A Certificate of Designation”); and (iv) among other things, (a) AON LLC issued common units to New AON in exchange for a combination of cash and shares of New AON Class B Common Stock and warrants to acquire shares of New AON Class B Common Stock (the “Class B Prefunded Warrants”), (b) New AON was admitted as a member of AON LLC, (c) AON LLC distributed shares of New AON Class B common stock or Class B Prefunded Warrants, as applicable, to AON LLC equity holders, (d) New AON reserved a specified number of additional shares of New AON Class A Common Stock after the Closing for issuance to eligible participants, (e) Merger Sub merged with and into the AON Class C Preferred Investor whereby the separate existence of Merger Sub ceased and New AON issued a number of shares of New AON Series A Preferred Stock equal to the number of AON LLC Series A preferred units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor (the “First Step”), (f) promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON LLC Series A preferred units and (g) from and after the Closing (but subject to lock-up restrictions), the AON LLC common equity holders (other than New AON), referred to herein as “Legacy AON Shareholders” (former AON LLC Class A, Class A-1, and Class B unit holders), will have the right (but not the obligation) to exchange AON LLC Common Units together with an equal number of shares of New AON Class B Common Stock (whether held directly or indirectly through Class B Prefunded Warrants) for shares of New AON Class A Common Stock. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with the Closing, DTOC completed the offer to the holders of AON LLC Class B-1 units to exchange their AON LLC Class B-1 units for such number of newly issued shares of New AON Class A Common Stock equal to the ratio set forth in the Business Combination Agreement (such offer, the “Exchange Offer”). DTOC and AON LLC solicited consents from the holders of AON LLC Class B-1 units to make certain amendments to the terms of the awards and the unit grant agreements pursuant to which the AON LLC Class B-1 units were granted, which provided for the automatic exchange, as of immediately prior to the adoption of the Amended and Restated AON LLC Agreement, of all outstanding AON LLC Class B-1 units into shares of New AON Class A Common Stock (collectively, the “Proposed Amendments”). The requisite number of holders of Class B-1 units provided their consent to the Proposed Amendments, and as a result, in connection with the Closing, all AON LLC Class B-1 units were exchanged for an aggregate of 1,047,343 shares of New AON Class A Common Stock.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the consummation of the Business Combination, the outstanding membership units in AON LLC and the outstanding shares in AON Inc. (New AON) are as follows:</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AON LLC Common Units held by the Legacy AON Shareholders - 28,109,796</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AON LLC Common Units held by New AON - 9,532,354</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AON LLC Series A Preferred Units held by New AON - 6,651,610</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Class A Common Stock held by the former AON LLC Class B-1 unit holders - 1,047,343</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Class A Common Stock held by the DTOC unredeemed shareholders - 147,511</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Class A Common Stock held by the DTOC Sponsor and their permitted transferees - 5,419,375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Class B Common Stock held by Legacy AON Shareholders - 25,109,551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New AON Series A Preferred Stock held by AEA Growth Management LP - 6,651,610</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsor Earnout Shares of 2,839,375 are subject to vesting and forfeiture provisions and are not outstanding for GAAP purposes as of the Closing Date. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Legacy AON Shareholders hold 3,000,245 Class B Prefunded Warrants, which underlying shares of Class B common stock are not outstanding as of the Closing Date.</span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting Treatment for the Business Combination</span></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As AON LLC does not meet any of the characteristics of a VIE under ASC 810, the Business Combination was evaluated under ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding the legal form of the Business Combination pursuant to the Business Combination Agreement, the Business Combination was accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, DTOC was treated as the acquired company and AON LLC was considered the acquirer for financial statement reporting purposes. AON LLC was determined to be the accounting acquirer based on, in summary, an evaluation of the following primary facts and circumstances:</span></div><div><span><br/></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AON LLC’s directors will represent a majority of the board seats for New AON’s board of directors;</span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AON LLC’s senior management will be the senior management of the combined company;</span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AON LLC’s operations comprising the ongoing operations of the post-combination company; and</span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AON LLC’s relative size (i.e., assets, revenues, and earnings) is significantly larger compared to DTOC.</span></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, for accounting purposes, the financial statements of the post-combination entity will represent a continuation of the financial statements of AON LLC with the acquisition being treated as the equivalent of AON LLC issuing stock for the net assets of DTOC, accompanied by a recapitalization. The net assets of DTOC are stated at historical cost, with no goodwill or other intangible assets recorded. Refer to Note 3 for additional information. </span></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting for the Earnout Shares</span></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Closing and for five years thereafter, the DTOC Sponsor agreed to subject 35%, or 2,839,375 shares of New AON Class A common stock held by it as of the Closing (the “Sponsor Earnout Shares”) to the following vesting and forfeiture provisions:</span></div><div><span><br/></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Sponsor Earnout Shares will vest when the volume-weighted average price of the New AON Class A common stock equals or exceeds $13.50 per share for any 20 trading days within any 30 trading day period beginning after the Closing and ending 60 months following the Closing;</span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Sponsor Earnout Shares will be released immediately upon the consummation of a change of control transaction within the 60-month period following the Closing; and</span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if the Sponsor Earnout Shares are not released pursuant to the foregoing provisions on or before the date that is 60 months after the Closing, then the Sponsor Earnout Shares will be forfeited immediately following such date.</span></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Business Combination was accounted for as a reverse recapitalization, the issuance of the Sponsor Earnout Shares to the Company’s existing shareholders will be accounted for as an equity transaction. The accounting for the Sponsor Earnout Shares was evaluated under ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ASC Subtopic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging — Contracts in Entity’s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine if the Sponsor Earnout Shares should be classified as a liability or within equity. As part of that analysis, it was determined that the Sponsor Earnout Shares are freestanding, do not meet the criteria within ASC 480 to be classified as a liability, and meet the criteria in ASC 815-40 to be considered indexed to the post-combination entity’s common stock and classified within equity.</span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrants</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Closing Date, New AON assumed the outstanding warrants (Public Warrants and Private Placement Warrants) that were issued by DTOC as part of DTOC’s IPO. Further, New AON issued the Class B Prefunded Warrants to former Class A-1 unit holders, in lieu of New AON Class B Common Stock. The accounting treatment for the Public Warrants, the Private Placement Warrants, and the Class B Prefunded Warrants, collectively referred to as “the Warrants”, is disclosed in Note 2. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Public Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Closing Date, New AON assumed 8,337,500 public warrants (the “Public Warrants”) issued by DTOC in its IPO. Each whole warrant entitles the holder to purchase one share of New AON Class A Common Stock at a price of $11.50 per share, subject to adjustment. The warrants will become exercisable on the later of 12 months from the closing of the DTOC Initial Public Offering or 30 days after the completion of its initial business combination and will expire five years after the Closing of the Business Combination, or earlier upon redemption or liquidation.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Closing Date, New AON assumed 6,113,333 Private Placement Warrants held by the DTOC Sponsor (the “Private Placement Warrants” or “Private Warrants”). The Private Placement Warrants will be</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-redeemable in certain circumstances so long as they are held by the Sponsor or its permitted transferees. The Private Placement Warrants may also be exercised by the Sponsor and its permitted transferees for cash or on a cashless basis. Otherwise, the Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants, including as to exercise price, exercisability, and exercise period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Class B Prefunded Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Closing Date, New AON issued 3,000,245 of Class B Prefunded Warrants to former AON Class A-1 unitholders. Because the Class B Warrants are prefunded, there was not any cash consideration exchanged as part of the Class B Warrant issuance. Each Class B Prefunded Warrant entitles the holder to purchase one share of New AON Class B common stock at a price of $0.01 per share. The exercise term of the Class B Warrant shall continue indefinitely so long as the holder of the Class B Warrant is also the holder of an AON LLC Common Unit, provided that the number of shares of Common Stock that this Warrant is exercisable for shall not exceed the number of AON LLC Common Units held by holder. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction Expenses</span></div>In connection with the Reverse Recapitalization, AON LLC incurred costs of $24.6 million and $30.6 million during the three and nine months ended September 30, 2023, respectively. Of the total costs incurred during the three months ended September 30, 2023, $24.6 million were reported as transaction expenses in the condensed consolidated statements of operations and comprehensive loss. Of the total costs incurred during the nine months ended September 30, 2023, $29.8 million were reported as transaction expenses in the condensed consolidated statements of operations and comprehensive loss and $0.8 million were reported as a reduction of Series A Preferred Stock presented as mezzanine equity on the condensed consolidated balance sheet at September 30, 2023. At December 31, 2022, the Company had accrued $0.3 million of transaction costs related to the Reverse Recapitalization, which were reported as other assets on the condensed consolidated balance sheet. AON LLC recorded $0.2 million of transaction expenses in connection with the Reverse Recapitalization during the three and nine months September 30, 2022, which were reported as transaction expenses in the condensed consolidated statements of operations and comprehensive loss. 33 19 During the nine months ended September 30, 2023 and 2022, the Company entered into affiliation agreements with or acquired the following oncology practices.<div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.090%"><tr><td style="width:1.0%"></td><td style="width:48.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">State</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">State</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arizona</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Texas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Florida</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Louisiana</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arkansas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The Company entered into affiliation agreements with the physicians for these respective practices. The Company evaluated each of the affiliation agreements and determined that the transactions did not represent a business combination.</span></div> 1 1 1047343 28109796 9532354 6651610 1047343 147511 5419375 25109551 6651610 2839375 3000245 P5Y 0.35 2839375 13.50 P20D P30D P60M P60M P60M 8337500 1 11.50 P12M P30D P5Y 6113333 3000245 1 0.01 24600000 30600000 24600000 29800000 -800000 300000 200000 200000 Basis of Presentation and Significant Accounting Policies<div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of the Company were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. Management believes the unaudited condensed consolidated financial statements for the interim periods presented contain all necessary adjustments, of a normal recurring nature, to state fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed consolidated financial statements were prepared on the same basis as and should be read in conjunction with the Company’s annual consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with such audited consolidated financial statements and related notes thereto of AON LLC and its wholly-owned subsidiaries, included in the proxy statement/prospectus of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Digital Transformation Opportunities Corp., dated July 18, 2023 (the “Proxy Statement/Prospectus")</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results the Company expects for the entire year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, these unaudited condensed consolidated financial statements reflect the consolidated results of operations, comprehensive income (loss), cash flows and changes in equity of AON LLC and its wholly-owned subsidiaries for the period of January 1, 2023 through September 20, 2023, the Closing Date of the Reverse Recapitalization, and the consolidated results of operations, comprehensive income (loss), cash flows and changes in stockholders’ equity of AON Inc. and its consolidated subsidiaries, including AON LLC, for the period of September 21, 2023 through September 30, 2023. The condensed consolidated balance sheet at September 30, 2023 presents the financial condition of AON Inc. and its consolidated subsidiaries, including AON LLC, and reflects the initial recording of the assets and liabilities of AON Inc. at their historical cost (see Note 3). All intercompany balances and transactions of AON LLC prior to the Reverse Recapitalization have been eliminated. All intercompany balances and transactions of AON Inc. after the Reverse Recapitalization have been eliminated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, these unaudited condensed consolidated financial statements present the consolidated results of operations, comprehensive income (loss), cash flows and changes in equity of AON LLC. The condensed consolidated balance sheet as of December 31, 2022 presents the financial condition of AON LLC and its wholly-owned subsidiaries. All intercompany balances and transactions of AON LLC have been eliminated. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (“ASC”) Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the historical equity of AON LLC has been recasted in all periods up to the Closing Date, to reflect the number of shares of New AON’s Class A Common Stock and Class B Common Stock issued to Legacy AON Shareholders in connection with the Reverse Recapitalization. The Company recasted the units outstanding related to the historical AON LLC Class A, Class A-1, and Class B units prior to the Reverse Recapitalization (“Historical AON LLC Equity”) as common equity of New AON, equal to the Per Company Class Unit Exchange Ratio, pursuant to the Business Combination Agreement. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Per Company Unit Exchange Ratio at which AON LLC Class A units and Class A-1 units were reclassified is equal to 2,524 AON Common Units. The Per Company Unit Exchange Ratio at which AON LLC Class B units were reclassified varied depending on participation threshold, and is equal to 2,524, 2,453, or 1,976, AON Common Units. The Per Company Unit Exchange Ratio at which Class C units were reclassified is equal to 2,705 AON LLC Series A Preferred Units.</span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements and related notes thereto give effect to the conversion for all periods presented, without any change to par value or per unit amounts. The condensed consolidated financial statements do not necessarily represent the capital structure of New AON had the Reverse Recapitalization occurred in prior periods. The Company has not made retroactive adjustments related to the historical book values of Historical AON LLC Equity as the adjustments were considered immaterial.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the three and nine months ended September 30, 2023, $1.7 million of the consolidated net loss of AON LLC were attributable to the Class A Common Stockholders, and reflects the Class A Common Stockholders’ absorption of 19.0% of the consolidated net loss of AON LLC for the period of September 21, 2023 through September 30, 2023. For both the three and nine months ended September 30, 2023, $11.9 million of the consolidated net losses of AON LLC were attributable to the noncontrolling interest, and reflects the Legacy AON Shareholders’ absorption of 81.0% of the consolidated net losses of AON LLC for the period of September 21, 2023 through September 30, 2023. For the three and nine months ended September 30, 2023, $15.5 million and $27.0 million of the consolidated net losses of AON LLC were attributable to the Legacy AON Shareholders, respectively, to reflect their absorption of 100% of the consolidated net losses of AON LLC pertaining to the days prior to the Reverse Recapitalization. For the three and nine months ended September 30, 2022, net income of $5.6 million and $1.2 million were attributable to the Legacy AON Shareholders, respectively, to reflect their absorption of 100% of AON LLC’s net income pertaining to the periods prior to the Reverse Recapitalization.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the period of September 21, 2023 through September 30, 2023, the condensed consolidated financial statements include the accounts of the Company, AON, Inc., American Oncology Network, LLC (“AON LLC”) and its wholly owned subsidiary American Oncology Management Company, LLC (“AOMC”), and its consolidated variable interest entities (“VIEs”) American Oncology Partners, P.A. (“AON Partners”), American Oncology Partners of Maryland, P.A. (“Partners of Maryland”), AON Central Services, LLC (“AON Central Services”), and Meaningful Insights Biotech Analytics, LLC (“MIBA”). All intercompany accounts and transactions between the entities have been eliminated in consolidation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 for the accounting treatment of the Business Combination. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods prior to the Reverse Recapitalization, the consolidated financial statements of the Company comprise the accounts of AON LLC and its wholly-owned subsidiaries. All intercompany accounts and transactions among AON LLC and its consolidated subsidiaries were eliminated.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for American Oncology Network, LLC, AON Partners, Partners of Maryland, AON Central Services, and MIBA in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determines whether it has a controlling financial interest in an entity by first evaluating whether the entity is a VIE. A VIE is broadly defined as an entity that has any of the following three characteristics: (i) the equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (ii) substantially all of the entity’s activities either involve or are conducted on behalf of an investor that has disproportionately few voting rights; or (iii) the equity investors as a group lack any of the following, the power through voting or similar rights to direct the activities of the entity that most significantly impact the entity’s economic performance, the obligation to absorb the expected losses of the entity, or the right to receive the expected residual returns of the entity. The Company consolidates a VIE if it has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and an obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively, if any. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AON LLC has contractual relationships with AON Partners, Partners of Maryland and AON Central Services and the physician owners through management service agreements (“MSAs”) and other contractual agreements to </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide all practice management services outside of medical services provided by the physicians. In addition, despite not being required by the contractual relationships, AON LLC regularly provides funding to support AON Partners and Partners of Maryland’s operations and acquisitions of physician practices. AON Central Services was formed July 15, 2022 and, effective January 1, 2023, entered into an agreement with AOMC to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. MIBA was established during the first quarter of 2023 for the purpose of developing intellectual property to synergize the collection, de-identification, and dissemination of the Company’s patient data for sale to external parties for research, development, and clinical decisions. In May 2023, the Company contributed $0.2 million for a 56% interest in the equity of MIBA. As of September 30, 2023, MIBA had no significant operating activity. The Company concluded that AON LLC had a controlling financial interest in MIBA and has consolidated the entity at September 30, 2023 and recorded the noncontrolling interest in equity. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has concluded that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all VIEs in which AON LLC has the characteristics of a controlling financial interest and is deemed to be the primary beneficiary. The variable interest subjects AON LLC to all potential losses in the entities and, therefore, requires AON LLC, and in turn AON Inc., to consolidate the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA in its condensed consolidated financial statements. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4 for further information on the VIEs. Refer to Note 1 for the accounting treatment of the Reverse Recapitalization.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies included below should be read in conjunction with the annual consolidated financial statements.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Assumptions </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the “CODM”). The Company’s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company’s performance. The Company has one operating segment and one reportable segment that are structured around the organizational management of oncology practice operations. All revenue and assets are in the United States. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized under Accounting Standards Update (“ASU”) 2014-09 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“Topic 606”). The Company determines the transaction price based upon standard charges for goods and services with anticipated consideration due from patients, third-party payors (including health insurers and government agencies) and others. The Company’s revenue is primarily derived from patient service revenues, which encompass oncology services provided during patient visits and shipments of pharmacy prescriptions. Performance obligations for the Company’s services provided to patients and most procedures, are satisfied over the time of visit which is the same day services are performed. Performance obligations relating to pharmacy revenue are considered fully satisfied at a point in time upon the customer receiving delivery of the prescription. Accordingly, the Company does not anticipate a significant amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods, and any such revenue recognized during the three and nine month periods ended September 30, 2023 and 2022 was immaterial. Additionally, the Company does not expect to recognize material revenue in the future related to performance obligations that are unsatisfied (or partially </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">satisfied) as of September 30, 2023 and December 31, 2022. Approximately $238.9 million and $213.8 million and $678.1 million and $606.0 million of the Company’s revenues are generated from services performed during patient visits with the remainder primarily generated from shipments of pharmacy prescriptions for the three and nine month periods ended September 30, 2023 and 2022, respectively.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As services are performed and prescriptions are shipped, timely billing occurs for services rendered and prescriptions shipped less discounts provided to uninsured patients and contractual adjustments to third-party payors based upon prospectively determined rates and discounted charges. Payment is requested at the time of service for self-paying patients and for patients covered by third-party payors that are responsible for paying deductibles and coinsurance.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors revenue and receivables to prepare estimated contractual allowances for the anticipated differences between billed and reimbursed amounts. Payments from third-party payors and Government programs including Medicare and Medicaid may be subject to audit and other retrospective adjustments. Such amounts are considered on an estimated basis when net patient revenue is recorded and are adjusted as final adjustments are determined. For the three and nine month periods ended September 30, 2023 and 2022, such resulting historic adjustments have been immaterial to the condensed consolidated financial statements. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing who is the principal in providing patient services and pharmacy prescriptions, the Company considered who controls the provision of services and prescriptions. The Company has determined they are acting as a principal in these relationships. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company entered into a long-term arrangement to sponsor and manage a clinical trial. The Company subsequently contracted with a third-party to provide the clinical research services and is the principal in this arrangement. The performance of clinical research services are considered a single performance obligation because the Company provides a highly-integrated service. Revenue is recognized for the single performance obligation over time due to the Company’s right to payment for work performed to date. The contract provides for invoices based on predetermined milestones. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the cost-to-cost measure of progress for the Company’s contract because it best depicts the transfer of control to the customer as the performance obligation is fulfilled. For this method, the Company compares the contract costs incurred to date to the estimated total contract costs through completion. As part of the client proposal and contract negotiation process, the Company develops a detailed project budget for the direct costs and reimbursable costs based on the scope of the work, the complexity of the study, the geographical location involved and the Company’s historical experience. The estimated total contract costs at the project level are reviewed and revised periodically throughout the life of the contract, with adjustments to revenue resulting from such revisions being recorded on a cumulative basis in the period in which the revisions are identified. Contract costs consist primarily of direct labor and other reimbursable project-related costs such as travel, third-party vendor costs and investigator fees. The Company establishes pricing based on the Company’s internal pricing guidelines, discount agreements, if any, and negotiations with the client. The transaction price is the contractually defined amount. Revenue related to the clinical trial, which is included within other revenue, was $2.2 million and $1.0 million and $3.7 million and $3.1 million for the three and nine months ended September 30, 2023 and 2022, respectively. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a system and estimation process for recording Medicare net patient service revenue and estimated recoupments as it relates to value-based care (“VBC”) revenue included in patient service revenue in the condensed consolidated statements of operations and comprehensive loss. The Company’s VBC revenue is primarily generated through its participation in the CMS Oncology Care Model (“OCM”) which is an episode-based payment model to promote high-quality cancer care. Participants enter six-month episode periods, and the Company bills a monthly fee during the six-month period based on a fixed rate per participant per month and the total number of participants. Certain quality and compliance metrics are tracked as part of the program and submitted to CMS at the end of the episode period which may result in recoupment of funds. The Company estimates the recoupment amount by developing a recoupment percentage for each period based on historical known recoupment from CMS and applies the recoupment percentage against total fees for the period. Based on the </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimate, the Company accrues a liability representing the expected final recoupments based on historical settlement trends.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term Marketable Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of corporate bonds and U.S. Treasury securities.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management determines the appropriate classification of investments at the time of purchase and reevaluates such determination at each balance sheet date. Marketable securities are classified as available-for-sale and are carried at fair value in the consolidated balance sheets. The marketable securities are classified as short-term based on management’s intent to convert such securities within one year and the ability to convert them within two to three days.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our available-for-sale securities are debt securities. For an available-for-sale debt security with an amortized cost that exceeds its fair value, the Company first determines if it intends to sell or will more-likely-than-not be required to sell the security before the expected recovery of its amortized cost. If it intends to sell or will more-likely-than-not be required to sell the security, then the Company recognizes the impairment as a credit loss in the condensed consolidated statements of operations and comprehensive loss by writing down the security’s amortized cost to its fair value. If it does not intend to sell or it is not more-likely-than-not that it will be required to sell the security before the expected recovery of its amortized cost, the Company recognizes the portion of the impairment that is due to a credit loss, if any, in the condensed consolidated statements of operations and comprehensive loss through an allowance. The portion of the impairment that is due to factors other than a credit loss is recognized in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss as an unrealized loss.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Investment in Affiliate</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company contributed noncash consideration, with a fair value of approximately $2.3 million, in return for a 49% equity interest in OCP Management Arizona, LLP. Investments in entities over which the Company has the ability to exercise significant influence but does not control the entity are accounted for using the equity method. Equity method investments are included with other assets in the condensed consolidated balance sheets. The carrying amount of the investment is adjusted to reflect the Company’s proportionate share of the net earnings or losses and reduced by any dividends received. The Company’s share of income or loss related to this investment is reported as an equity in loss of affiliate in the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates the results of entities in which it has a controlling financial interest. Refer to Note 14 for additional considerations and presentation for noncontrolling interest. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#060606;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which is outside of the Company’s control). As a result, Management has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of September 30, 2023, the Preferred Stock are recorded at their initial carrying value, net of offering costs of $0.8 million. The Series A Preferred Stock are not being accreted to redemption value, as the redemption is not probable. The Series A Preferred Stock are classified outside of members’ equity on the consolidated balance sheets. Refer to Note 14 for mezzanine equity presentation considerations for redeemable noncontrolling interest. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates acquired practices in accordance with ASU 2017-01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Business Combinations (Topic 805)-Clarifying the Definition of a Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disposals of assets or businesses. Because substantially all of the value of each acquired practice did not relate to a similar group of assets and as each acquired practice contained both inputs and processes necessary to provide economic benefits to the Company, it was determined that each acquisition represents a business combination. Therefore, the transactions have been accounted for using the acquisition method of accounting, which requires, with limited exceptions, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Any excess of the consideration transferred over the estimated fair values of the net assets acquired is recorded as goodwill. Transaction costs related to business combinations are expensed in the period in which they are incurred.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Offering Costs</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defers specific incremental costs directly attributable to proposed offerings of securities. These costs consist of legal, accounting, and other similar expenses incurred through the balance sheet date that are directly related to a potential offering. If the offering is completed, these costs will be charged against the gross proceeds of the offering. These offering costs will be allocated to the separable financial instruments issued in the transaction on a relative fair value basis of the securities issued, compared to total proceeds received. Offering costs associated with any instruments classified as liabilities will be expensed as incurred, presented as non-operating expenses in the condensed consolidated statement of operations and comprehensive loss.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, the Company incurred additional deferred offering costs of approximately $0.8 million which were recorded as an offset to the net proceeds of the AON LLC Class C Units (discussed below) in mezzanine equity on the condensed consolidated balance sheet at September 30, 2023. At December 31, 2022, the Company had incurred approximately $0.3 million of offering costs, which are included in other assets in the accompanying condensed consolidated balance sheets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, on June 7, 2023, AON LLC issued Redeemable Convertible Preferred Class C Units (“Class C Units” or “AON LLC Class C Units”) for net proceeds of approximately $64.5 million ($65.0 million in gross proceeds, net of $0.5 million in offering costs). The Company determined that an additional $0.3 million of costs incurred through June 7, 2023 related to the process of raising the proceeds generated by the issuance of the Class C Units. Accordingly, these deferred offering costs have been reclassified from other assets to mezzanine equity, for a total of $0.8 million in Class C Unit offering costs. The Class C Units were subsequently converted to AON LLC Series A Preferred Units upon the Closing of the Business Combination, which were subsequently exchanged for Series A Preferred Stock. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Professional Liability</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains insurance policies for exposure to professional malpractice insurance risk. The limits of malpractice insurance provide each physician/advanced practice provider with a dedicated $1.0 million limit per claim and a $3.0 million limit in the aggregate per policy period – on a first dollar basis, as no deductible applies. The policy further then extends coverage to the Company, by providing a $2.0 million limit per claim and a $4.0 million limit in the aggregate per policy period - on a first dollar basis, additionally, as no deductible applies. Reserves are established for estimates of the loss that will ultimately be incurred on claims that have been reported but not paid and claims that have been incurred but not reported. These reserves are established based on consultation with a third-party actuary. The actuarial valuations consider a number of factors, including historical claims payment patterns, changes in case reserves and the assumed rate of increase in healthcare costs. Management believes the use of actuarial methods to account for these reserves provides a consistent and effective way to measure these subjective accruals. However, due to the sensitive nature of this estimation technique, recorded reserves could differ from ultimate costs related to these claims due to changes in claims reporting, claims payment and settlement practices and differences in assumed future cost increases. Accrued unpaid claims and expenses that are expected to be paid within the next twelve months are classified as current liabilities and included in accrued other. All other accrued unpaid claims and expenses are classified as long-term liabilities and included in other long-term liabilities. Insurance recoveries associated with the unpaid claims are classified as long-term assets included in other assets.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting guidance establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:6.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. </span></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement of assets and liabilities being measured within the fair value hierarchy.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash, short-term marketable securities, accounts receivable, notes receivable, accounts payable, accrued expenses, long-term debt and contractual agreements that resulted in derivative liabilities. Our nonfinancial assets such as property and equipment are not measured at fair value on a recurring basis; however, they are subject to fair value adjustments in certain circumstances, such as when there is evidence that impairment may exist.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash, accounts receivable, accounts payable, notes receivable, and accrued expenses approximate their fair value because of the short-term maturity and highly liquid nature of these instruments. We determine the fair value of long-term debt and marketable securities based on various factors including maturity schedules and current market rates.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for a discussion of the Company’s Level 1 and Level 2 Marketable Securities as of September 30, 2023. See below for a discussion of the Company’s Level 1 and Level 3 warrant liabilities as of September 30, 2023. As of December 31, 2022, there were no Level 3 financial instruments. There were no transfers between any levels of the hierarchy during any periods presented.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Public Warrants and Private Placement Warrants and the Class B Prefunded Warrants, collectively referred to herein as “Warrants”, in accordance with ASC 815-40, “Derivatives and Hedging —- Contracts in Entity’s Own Equity”, and concluded that a provision in the warrant agreements related to potential net cash settlement of the warrants upon an exchange or tender offer that may not result in a change in control of the entity precludes the warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as long term liabilities on the condensed consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive loss in the period of change.</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Public Warrants were trading separately from the Class A Common Stock and the quoted market price was used to establish fair value. As such, the Public Warrants fair value was determined using a Level 1 input. The fair value of the Public Warrants is $1.4 million and recorded in other long-term liabilities on the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has utilized the public warrant price to value the private warrants and believes the public and private warrants have materially consistent fair values given the existence of the make-whole redemption feature. As of September 30, 2023, a valuation of the private warrants was performed which confirmed the private warrant value was materially consistent with the public warrants. The details of this valuation are included in the paragraph below.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Private Placement warrants was determined using Level 3 inputs. As of September 30, 2023, the fair value of the Private Placement Warrants was estimated to be $1.0 million and recorded in other long-term liabilities on the condensed consolidated balance sheets. The fair value was estimated at September 30, 2023, using the Black-Scholes Option Pricing model using the following assumptions:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected annual dividend yield – 0.0% </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 Expected volatility – 0.75%</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 Risk-free rate of return – 4.60%</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 Expected Option Term – 5.0</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AON Class B Prefunded Warrants are exercisable into one share of New AON Class B Common Stock. A share of New AON Class B Common Stock, together with an AON LLC Common Unit, may be exchanged for one share of New AON Class A Common Stock. Considering New AON Class B Common Stock has no economic rights and limited liquidity or value if the holder does not also possess an AON LLC Common Unit, and because the AON Class B Prefunded Warrants are exercisable into New AON Class B Common Stock, the Company has estimated fair value of the Class B Prefunded Warrants to be immaterial.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings Per Share </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recast Historical AON LLC Equity as AON Inc. common equity for all periods prior to the Reverse Recapitalization, refer to Note 2. However, as 100% of the net losses of AON LLC prior to the Reverse Recapitalization were absorbed by the Legacy AON Shareholders, basic and diluted earnings (loss) per share is zero for the three and nine months ended September 30, 2022 and basic and diluted earnings (loss) per share for the three and nine months ended September 30, 2023 represents only the period from September 21, 2023 to September 30, 2023, the period where the Company had earnings (loss) attributable to Class A Common Stockholders. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted earnings (loss) per share. As such, basic and diluted earnings (loss) per share of Class B Common Stock has not been presented.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, the Company has issued and outstanding Sponsor Earnouts, which are subject to forfeiture if the achievement of certain stock price thresholds are not met. In accordance with ASC Topic 260, “Earnings Per Share,” the Sponsor Earnouts are excluded from weighted-average shares outstanding to calculate basic earnings (loss) per share as they are considered contingently issuable shares due to their potential forfeiture. Sponsor Earnouts will be included in weighted-average shares outstanding to calculate basic earnings (loss) per share as of the date of their stock price thresholds are met and they are no longer subject to forfeiture. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings (loss) per share is computed by use of the two-class method as a result of outstanding Series A Preferred Stock, which accrue dividends at the annual rate of 8% of the original price per share, participate with common stock on all other dividends, and accordingly have participation rights in undistributed earnings as if all such earnings had been distributed during the period (see Note 12). Under such method income available to common shareholders is computed by deducting both dividends declared or, if not declared, </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated on Series A Preferred Stock from net income. Loss attributable to common shareholders is computed by increasing net loss by such dividends. Since the participating Series A Preferred Stock has no contractual obligation to share in the losses of the Company, there is no loss allocation between Class A Common Stock and Series A Preferred Stock.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock used for the basic earnings (loss) per share calculation, adjusted for the dilutive effect of the Public and Private Warrants and Sponsor Earnout, if any, using the “treasury stock” method and the convertible Series A Preferred Stock and, exchangeable Class B Common Stock and Class B Prefunded Warrants, if any, using the “if-converted” method. Net earnings (loss) for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net earnings (loss), net of AON Inc. taxes, after giving effect to the Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock, to the extent it is dilutive.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">‘‘Financial instruments-Credit Losses’’ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2016- 13”). ASU 2016-13 requires entities to report ‘‘expected’’ credit losses on financial instruments and other commitments to extend credit rather than the current ‘‘incurred loss’’ model. These expected credit losses for financial assets held at the reporting date are to be based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU will also require enhanced disclosures relating to significant estimates and judgments used in estimating credit losses, as well as the credit quality. ASU 2016-13 is effective for the Company for annual reporting periods beginning after December 15, 2022. ASU 2016-13 was adopted by the Company effective January 1, 2023 with no material impact on the Company’s consolidated financial statements and related disclosures. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides that an acquirer must recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606. The guidance is effective for the Company for annual reporting periods beginning after December 15, 2023, with early adoption permitted. The Company does not expect the adoption of this standard to have a material impact on the Company’s consolidated financial statements and related disclosures.</span></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of the Company were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. Management believes the unaudited condensed consolidated financial statements for the interim periods presented contain all necessary adjustments, of a normal recurring nature, to state fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed consolidated financial statements were prepared on the same basis as and should be read in conjunction with the Company’s annual consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with such audited consolidated financial statements and related notes thereto of AON LLC and its wholly-owned subsidiaries, included in the proxy statement/prospectus of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Digital Transformation Opportunities Corp., dated July 18, 2023 (the “Proxy Statement/Prospectus")</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results the Company expects for the entire year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, these unaudited condensed consolidated financial statements reflect the consolidated results of operations, comprehensive income (loss), cash flows and changes in equity of AON LLC and its wholly-owned subsidiaries for the period of January 1, 2023 through September 20, 2023, the Closing Date of the Reverse Recapitalization, and the consolidated results of operations, comprehensive income (loss), cash flows and changes in stockholders’ equity of AON Inc. and its consolidated subsidiaries, including AON LLC, for the period of September 21, 2023 through September 30, 2023. The condensed consolidated balance sheet at September 30, 2023 presents the financial condition of AON Inc. and its consolidated subsidiaries, including AON LLC, and reflects the initial recording of the assets and liabilities of AON Inc. at their historical cost (see Note 3). All intercompany balances and transactions of AON LLC prior to the Reverse Recapitalization have been eliminated. All intercompany balances and transactions of AON Inc. after the Reverse Recapitalization have been eliminated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, these unaudited condensed consolidated financial statements present the consolidated results of operations, comprehensive income (loss), cash flows and changes in equity of AON LLC. The condensed consolidated balance sheet as of December 31, 2022 presents the financial condition of AON LLC and its wholly-owned subsidiaries. All intercompany balances and transactions of AON LLC have been eliminated. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (“ASC”) Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the historical equity of AON LLC has been recasted in all periods up to the Closing Date, to reflect the number of shares of New AON’s Class A Common Stock and Class B Common Stock issued to Legacy AON Shareholders in connection with the Reverse Recapitalization. The Company recasted the units outstanding related to the historical AON LLC Class A, Class A-1, and Class B units prior to the Reverse Recapitalization (“Historical AON LLC Equity”) as common equity of New AON, equal to the Per Company Class Unit Exchange Ratio, pursuant to the Business Combination Agreement. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Per Company Unit Exchange Ratio at which AON LLC Class A units and Class A-1 units were reclassified is equal to 2,524 AON Common Units. The Per Company Unit Exchange Ratio at which AON LLC Class B units were reclassified varied depending on participation threshold, and is equal to 2,524, 2,453, or 1,976, AON Common Units. The Per Company Unit Exchange Ratio at which Class C units were reclassified is equal to 2,705 AON LLC Series A Preferred Units.</span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements and related notes thereto give effect to the conversion for all periods presented, without any change to par value or per unit amounts. The condensed consolidated financial statements do not necessarily represent the capital structure of New AON had the Reverse Recapitalization occurred in prior periods. The Company has not made retroactive adjustments related to the historical book values of Historical AON LLC Equity as the adjustments were considered immaterial.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the three and nine months ended September 30, 2023, $1.7 million of the consolidated net loss of AON LLC were attributable to the Class A Common Stockholders, and reflects the Class A Common Stockholders’ absorption of 19.0% of the consolidated net loss of AON LLC for the period of September 21, 2023 through September 30, 2023. For both the three and nine months ended September 30, 2023, $11.9 million of the consolidated net losses of AON LLC were attributable to the noncontrolling interest, and reflects the Legacy AON Shareholders’ absorption of 81.0% of the consolidated net losses of AON LLC for the period of September 21, 2023 through September 30, 2023. For the three and nine months ended September 30, 2023, $15.5 million and $27.0 million of the consolidated net losses of AON LLC were attributable to the Legacy AON Shareholders, respectively, to reflect their absorption of 100% of the consolidated net losses of AON LLC pertaining to the days prior to the Reverse Recapitalization. For the three and nine months ended September 30, 2022, net income of $5.6 million and $1.2 million were attributable to the Legacy AON Shareholders, respectively, to reflect their absorption of 100% of AON LLC’s net income pertaining to the periods prior to the Reverse Recapitalization.</span></div> 2524000 2524000 2453000 1976000 2705000 -1700000 -1700000 0.190 -11900000 -11900000 0.810 -15500000 -27000000 1 5600000 1200000 1 <div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the period of September 21, 2023 through September 30, 2023, the condensed consolidated financial statements include the accounts of the Company, AON, Inc., American Oncology Network, LLC (“AON LLC”) and its wholly owned subsidiary American Oncology Management Company, LLC (“AOMC”), and its consolidated variable interest entities (“VIEs”) American Oncology Partners, P.A. (“AON Partners”), American Oncology Partners of Maryland, P.A. (“Partners of Maryland”), AON Central Services, LLC (“AON Central Services”), and Meaningful Insights Biotech Analytics, LLC (“MIBA”). All intercompany accounts and transactions between the entities have been eliminated in consolidation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 for the accounting treatment of the Business Combination. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods prior to the Reverse Recapitalization, the consolidated financial statements of the Company comprise the accounts of AON LLC and its wholly-owned subsidiaries. All intercompany accounts and transactions among AON LLC and its consolidated subsidiaries were eliminated.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for American Oncology Network, LLC, AON Partners, Partners of Maryland, AON Central Services, and MIBA in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determines whether it has a controlling financial interest in an entity by first evaluating whether the entity is a VIE. A VIE is broadly defined as an entity that has any of the following three characteristics: (i) the equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (ii) substantially all of the entity’s activities either involve or are conducted on behalf of an investor that has disproportionately few voting rights; or (iii) the equity investors as a group lack any of the following, the power through voting or similar rights to direct the activities of the entity that most significantly impact the entity’s economic performance, the obligation to absorb the expected losses of the entity, or the right to receive the expected residual returns of the entity. The Company consolidates a VIE if it has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and an obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively, if any. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AON LLC has contractual relationships with AON Partners, Partners of Maryland and AON Central Services and the physician owners through management service agreements (“MSAs”) and other contractual agreements to </span></div>provide all practice management services outside of medical services provided by the physicians. In addition, despite not being required by the contractual relationships, AON LLC regularly provides funding to support AON Partners and Partners of Maryland’s operations and acquisitions of physician practices. AON Central Services was formed July 15, 2022 and, effective January 1, 2023, entered into an agreement with AOMC to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. MIBA was established during the first quarter of 2023 for the purpose of developing intellectual property to synergize the collection, de-identification, and dissemination of the Company’s patient data for sale to external parties for research, development, and clinical decisions. In May 2023, the Company contributed $0.2 million for a 56% interest in the equity of MIBA. As of September 30, 2023, MIBA had no significant operating activity. The Company concluded that AON LLC had a controlling financial interest in MIBA and has consolidated the entity at September 30, 2023 and recorded the noncontrolling interest in equity. The Company has concluded that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all VIEs in which AON LLC has the characteristics of a controlling financial interest and is deemed to be the primary beneficiary. The variable interest subjects AON LLC to all potential losses in the entities and, therefore, requires AON LLC, and in turn AON Inc., to consolidate the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA in its condensed consolidated financial statements. 200000 0.56 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Assumptions </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></div> Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the “CODM”). The Company’s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company’s performance. The Company has one operating segment and one reportable segment that are structured around the organizational management of oncology practice operations. All revenue and assets are in the United States. 1 1 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized under Accounting Standards Update (“ASU”) 2014-09 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“Topic 606”). The Company determines the transaction price based upon standard charges for goods and services with anticipated consideration due from patients, third-party payors (including health insurers and government agencies) and others. The Company’s revenue is primarily derived from patient service revenues, which encompass oncology services provided during patient visits and shipments of pharmacy prescriptions. Performance obligations for the Company’s services provided to patients and most procedures, are satisfied over the time of visit which is the same day services are performed. Performance obligations relating to pharmacy revenue are considered fully satisfied at a point in time upon the customer receiving delivery of the prescription. Accordingly, the Company does not anticipate a significant amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods, and any such revenue recognized during the three and nine month periods ended September 30, 2023 and 2022 was immaterial. Additionally, the Company does not expect to recognize material revenue in the future related to performance obligations that are unsatisfied (or partially </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">satisfied) as of September 30, 2023 and December 31, 2022. Approximately $238.9 million and $213.8 million and $678.1 million and $606.0 million of the Company’s revenues are generated from services performed during patient visits with the remainder primarily generated from shipments of pharmacy prescriptions for the three and nine month periods ended September 30, 2023 and 2022, respectively.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As services are performed and prescriptions are shipped, timely billing occurs for services rendered and prescriptions shipped less discounts provided to uninsured patients and contractual adjustments to third-party payors based upon prospectively determined rates and discounted charges. Payment is requested at the time of service for self-paying patients and for patients covered by third-party payors that are responsible for paying deductibles and coinsurance.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors revenue and receivables to prepare estimated contractual allowances for the anticipated differences between billed and reimbursed amounts. Payments from third-party payors and Government programs including Medicare and Medicaid may be subject to audit and other retrospective adjustments. Such amounts are considered on an estimated basis when net patient revenue is recorded and are adjusted as final adjustments are determined. For the three and nine month periods ended September 30, 2023 and 2022, such resulting historic adjustments have been immaterial to the condensed consolidated financial statements. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing who is the principal in providing patient services and pharmacy prescriptions, the Company considered who controls the provision of services and prescriptions. The Company has determined they are acting as a principal in these relationships. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company entered into a long-term arrangement to sponsor and manage a clinical trial. The Company subsequently contracted with a third-party to provide the clinical research services and is the principal in this arrangement. The performance of clinical research services are considered a single performance obligation because the Company provides a highly-integrated service. Revenue is recognized for the single performance obligation over time due to the Company’s right to payment for work performed to date. The contract provides for invoices based on predetermined milestones. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the cost-to-cost measure of progress for the Company’s contract because it best depicts the transfer of control to the customer as the performance obligation is fulfilled. For this method, the Company compares the contract costs incurred to date to the estimated total contract costs through completion. As part of the client proposal and contract negotiation process, the Company develops a detailed project budget for the direct costs and reimbursable costs based on the scope of the work, the complexity of the study, the geographical location involved and the Company’s historical experience. The estimated total contract costs at the project level are reviewed and revised periodically throughout the life of the contract, with adjustments to revenue resulting from such revisions being recorded on a cumulative basis in the period in which the revisions are identified. Contract costs consist primarily of direct labor and other reimbursable project-related costs such as travel, third-party vendor costs and investigator fees. The Company establishes pricing based on the Company’s internal pricing guidelines, discount agreements, if any, and negotiations with the client. The transaction price is the contractually defined amount. Revenue related to the clinical trial, which is included within other revenue, was $2.2 million and $1.0 million and $3.7 million and $3.1 million for the three and nine months ended September 30, 2023 and 2022, respectively. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a system and estimation process for recording Medicare net patient service revenue and estimated recoupments as it relates to value-based care (“VBC”) revenue included in patient service revenue in the condensed consolidated statements of operations and comprehensive loss. The Company’s VBC revenue is primarily generated through its participation in the CMS Oncology Care Model (“OCM”) which is an episode-based payment model to promote high-quality cancer care. Participants enter six-month episode periods, and the Company bills a monthly fee during the six-month period based on a fixed rate per participant per month and the total number of participants. Certain quality and compliance metrics are tracked as part of the program and submitted to CMS at the end of the episode period which may result in recoupment of funds. The Company estimates the recoupment amount by developing a recoupment percentage for each period based on historical known recoupment from CMS and applies the recoupment percentage against total fees for the period. Based on the </span></div>estimate, the Company accrues a liability representing the expected final recoupments based on historical settlement trends. 238900000 213800000 678100000 606000000 2200000 1000000 3700000 3100000 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term Marketable Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of corporate bonds and U.S. Treasury securities.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management determines the appropriate classification of investments at the time of purchase and reevaluates such determination at each balance sheet date. Marketable securities are classified as available-for-sale and are carried at fair value in the consolidated balance sheets. The marketable securities are classified as short-term based on management’s intent to convert such securities within one year and the ability to convert them within two to three days.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our available-for-sale securities are debt securities. For an available-for-sale debt security with an amortized cost that exceeds its fair value, the Company first determines if it intends to sell or will more-likely-than-not be required to sell the security before the expected recovery of its amortized cost. If it intends to sell or will more-likely-than-not be required to sell the security, then the Company recognizes the impairment as a credit loss in the condensed consolidated statements of operations and comprehensive loss by writing down the security’s amortized cost to its fair value. If it does not intend to sell or it is not more-likely-than-not that it will be required to sell the security before the expected recovery of its amortized cost, the Company recognizes the portion of the impairment that is due to a credit loss, if any, in the condensed consolidated statements of operations and comprehensive loss through an allowance. The portion of the impairment that is due to factors other than a credit loss is recognized in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss as an unrealized loss.</span></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Investment in Affiliate</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company contributed noncash consideration, with a fair value of approximately $2.3 million, in return for a 49% equity interest in OCP Management Arizona, LLP. Investments in entities over which the Company has the ability to exercise significant influence but does not control the entity are accounted for using the equity method. Equity method investments are included with other assets in the condensed consolidated balance sheets. The carrying amount of the investment is adjusted to reflect the Company’s proportionate share of the net earnings or losses and reduced by any dividends received. The Company’s share of income or loss related to this investment is reported as an equity in loss of affiliate in the condensed consolidated statements of operations and comprehensive loss.</span></div> 2300000 0.49 Noncontrolling InterestsThe Company consolidates the results of entities in which it has a controlling financial interest. Refer to Note 14 for additional considerations and presentation for noncontrolling interest. Mezzanine EquityNew AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which is outside of the Company’s control). As a result, Management has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity. As of September 30, 2023, the Preferred Stock are recorded at their initial carrying value, net of offering costs of $0.8 million. The Series A Preferred Stock are not being accreted to redemption value, as the redemption is not probable. The Series A Preferred Stock are classified outside of members’ equity on the consolidated balance sheets. Refer to Note 14 for mezzanine equity presentation considerations for redeemable noncontrolling interest. 800000 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates acquired practices in accordance with ASU 2017-01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Business Combinations (Topic 805)-Clarifying the Definition of a Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or </span></div>disposals of assets or businesses. Because substantially all of the value of each acquired practice did not relate to a similar group of assets and as each acquired practice contained both inputs and processes necessary to provide economic benefits to the Company, it was determined that each acquisition represents a business combination. Therefore, the transactions have been accounted for using the acquisition method of accounting, which requires, with limited exceptions, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Any excess of the consideration transferred over the estimated fair values of the net assets acquired is recorded as goodwill. Transaction costs related to business combinations are expensed in the period in which they are incurred. <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Offering Costs</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defers specific incremental costs directly attributable to proposed offerings of securities. These costs consist of legal, accounting, and other similar expenses incurred through the balance sheet date that are directly related to a potential offering. If the offering is completed, these costs will be charged against the gross proceeds of the offering. These offering costs will be allocated to the separable financial instruments issued in the transaction on a relative fair value basis of the securities issued, compared to total proceeds received. Offering costs associated with any instruments classified as liabilities will be expensed as incurred, presented as non-operating expenses in the condensed consolidated statement of operations and comprehensive loss.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, the Company incurred additional deferred offering costs of approximately $0.8 million which were recorded as an offset to the net proceeds of the AON LLC Class C Units (discussed below) in mezzanine equity on the condensed consolidated balance sheet at September 30, 2023. At December 31, 2022, the Company had incurred approximately $0.3 million of offering costs, which are included in other assets in the accompanying condensed consolidated balance sheets. </span></div>As discussed in Note 1, on June 7, 2023, AON LLC issued Redeemable Convertible Preferred Class C Units (“Class C Units” or “AON LLC Class C Units”) for net proceeds of approximately $64.5 million ($65.0 million in gross proceeds, net of $0.5 million in offering costs). The Company determined that an additional $0.3 million of costs incurred through June 7, 2023 related to the process of raising the proceeds generated by the issuance of the Class C Units. Accordingly, these deferred offering costs have been reclassified from other assets to mezzanine equity, for a total of $0.8 million in Class C Unit offering costs. The Class C Units were subsequently converted to AON LLC Series A Preferred Units upon the Closing of the Business Combination, which were subsequently exchanged for Series A Preferred Stock. 800000 300000 64500000 65000000 500000 300000 800000 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Professional Liability</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains insurance policies for exposure to professional malpractice insurance risk. The limits of malpractice insurance provide each physician/advanced practice provider with a dedicated $1.0 million limit per claim and a $3.0 million limit in the aggregate per policy period – on a first dollar basis, as no deductible applies. The policy further then extends coverage to the Company, by providing a $2.0 million limit per claim and a $4.0 million limit in the aggregate per policy period - on a first dollar basis, additionally, as no deductible applies. Reserves are established for estimates of the loss that will ultimately be incurred on claims that have been reported but not paid and claims that have been incurred but not reported. These reserves are established based on consultation with a third-party actuary. The actuarial valuations consider a number of factors, including historical claims payment patterns, changes in case reserves and the assumed rate of increase in healthcare costs. Management believes the use of actuarial methods to account for these reserves provides a consistent and effective way to measure these subjective accruals. However, due to the sensitive nature of this estimation technique, recorded reserves could differ from ultimate costs related to these claims due to changes in claims reporting, claims payment and settlement practices and differences in assumed future cost increases. Accrued unpaid claims and expenses that are expected to be paid within the next twelve months are classified as current liabilities and included in accrued other. All other accrued unpaid claims and expenses are classified as long-term liabilities and included in other long-term liabilities. Insurance recoveries associated with the unpaid claims are classified as long-term assets included in other assets.</span></div> 1000000 3000000 2000000 4000000 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting guidance establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:6.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. </span></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement of assets and liabilities being measured within the fair value hierarchy.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash, short-term marketable securities, accounts receivable, notes receivable, accounts payable, accrued expenses, long-term debt and contractual agreements that resulted in derivative liabilities. Our nonfinancial assets such as property and equipment are not measured at fair value on a recurring basis; however, they are subject to fair value adjustments in certain circumstances, such as when there is evidence that impairment may exist.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash, accounts receivable, accounts payable, notes receivable, and accrued expenses approximate their fair value because of the short-term maturity and highly liquid nature of these instruments. We determine the fair value of long-term debt and marketable securities based on various factors including maturity schedules and current market rates.</span></div> <div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Public Warrants and Private Placement Warrants and the Class B Prefunded Warrants, collectively referred to herein as “Warrants”, in accordance with ASC 815-40, “Derivatives and Hedging —- Contracts in Entity’s Own Equity”, and concluded that a provision in the warrant agreements related to potential net cash settlement of the warrants upon an exchange or tender offer that may not result in a change in control of the entity precludes the warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as long term liabilities on the condensed consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive loss in the period of change.</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Public Warrants were trading separately from the Class A Common Stock and the quoted market price was used to establish fair value. As such, the Public Warrants fair value was determined using a Level 1 input. The fair value of the Public Warrants is $1.4 million and recorded in other long-term liabilities on the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has utilized the public warrant price to value the private warrants and believes the public and private warrants have materially consistent fair values given the existence of the make-whole redemption feature. As of September 30, 2023, a valuation of the private warrants was performed which confirmed the private warrant value was materially consistent with the public warrants. The details of this valuation are included in the paragraph below.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Private Placement warrants was determined using Level 3 inputs. As of September 30, 2023, the fair value of the Private Placement Warrants was estimated to be $1.0 million and recorded in other long-term liabilities on the condensed consolidated balance sheets. The fair value was estimated at September 30, 2023, using the Black-Scholes Option Pricing model using the following assumptions:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected annual dividend yield – 0.0% </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 Expected volatility – 0.75%</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 Risk-free rate of return – 4.60%</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 Expected Option Term – 5.0</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AON Class B Prefunded Warrants are exercisable into one share of New AON Class B Common Stock. A share of New AON Class B Common Stock, together with an AON LLC Common Unit, may be exchanged for one share of New AON Class A Common Stock. Considering New AON Class B Common Stock has no economic rights and limited liquidity or value if the holder does not also possess an AON LLC Common Unit, and because the AON Class B Prefunded Warrants are exercisable into New AON Class B Common Stock, the Company has estimated fair value of the Class B Prefunded Warrants to be immaterial.</span></div> 1400000 1000000 0.000 0.0075 0.0460 5.0 1 1 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings Per Share </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recast Historical AON LLC Equity as AON Inc. common equity for all periods prior to the Reverse Recapitalization, refer to Note 2. However, as 100% of the net losses of AON LLC prior to the Reverse Recapitalization were absorbed by the Legacy AON Shareholders, basic and diluted earnings (loss) per share is zero for the three and nine months ended September 30, 2022 and basic and diluted earnings (loss) per share for the three and nine months ended September 30, 2023 represents only the period from September 21, 2023 to September 30, 2023, the period where the Company had earnings (loss) attributable to Class A Common Stockholders. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted earnings (loss) per share. As such, basic and diluted earnings (loss) per share of Class B Common Stock has not been presented.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, the Company has issued and outstanding Sponsor Earnouts, which are subject to forfeiture if the achievement of certain stock price thresholds are not met. In accordance with ASC Topic 260, “Earnings Per Share,” the Sponsor Earnouts are excluded from weighted-average shares outstanding to calculate basic earnings (loss) per share as they are considered contingently issuable shares due to their potential forfeiture. Sponsor Earnouts will be included in weighted-average shares outstanding to calculate basic earnings (loss) per share as of the date of their stock price thresholds are met and they are no longer subject to forfeiture. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings (loss) per share is computed by use of the two-class method as a result of outstanding Series A Preferred Stock, which accrue dividends at the annual rate of 8% of the original price per share, participate with common stock on all other dividends, and accordingly have participation rights in undistributed earnings as if all such earnings had been distributed during the period (see Note 12). Under such method income available to common shareholders is computed by deducting both dividends declared or, if not declared, </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated on Series A Preferred Stock from net income. Loss attributable to common shareholders is computed by increasing net loss by such dividends. Since the participating Series A Preferred Stock has no contractual obligation to share in the losses of the Company, there is no loss allocation between Class A Common Stock and Series A Preferred Stock.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock used for the basic earnings (loss) per share calculation, adjusted for the dilutive effect of the Public and Private Warrants and Sponsor Earnout, if any, using the “treasury stock” method and the convertible Series A Preferred Stock and, exchangeable Class B Common Stock and Class B Prefunded Warrants, if any, using the “if-converted” method. Net earnings (loss) for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net earnings (loss), net of AON Inc. taxes, after giving effect to the Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock, to the extent it is dilutive.</span></div> 0 0 0 0 0.08 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">‘‘Financial instruments-Credit Losses’’ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2016- 13”). ASU 2016-13 requires entities to report ‘‘expected’’ credit losses on financial instruments and other commitments to extend credit rather than the current ‘‘incurred loss’’ model. These expected credit losses for financial assets held at the reporting date are to be based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU will also require enhanced disclosures relating to significant estimates and judgments used in estimating credit losses, as well as the credit quality. ASU 2016-13 is effective for the Company for annual reporting periods beginning after December 15, 2022. ASU 2016-13 was adopted by the Company effective January 1, 2023 with no material impact on the Company’s consolidated financial statements and related disclosures. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides that an acquirer must recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606. The guidance is effective for the Company for annual reporting periods beginning after December 15, 2023, with early adoption permitted. The Company does not expect the adoption of this standard to have a material impact on the Company’s consolidated financial statements and related disclosures.</span></div> Reverse RecapitalizationAs discussed in Note 1, AON LLC merged with DTOC, with AON LLC surviving the Merger. AON LLC is governed by a board of managers composed of three (3) persons that were designated by New AON and two (2) persons that were designated by holders of a majority of the AON LLC Common Units, held by members of AON LLC other than New AON. Management determined AON LLC was not a variable interest entity (Refer to Note 2), and as result, identified AON LLC as the accounting acquirer of the Merger in accordance ASC Topic 805. Management concluded that AON LLC was the accounting acquirer due to (i) the Legacy AON Shareholders, defined as the former AON Class A, Class A-1, and Class B unit holders, receiving the largest portion of the voting rights in the combined company, New AON, (ii) significantly all of the Legacy AON Shareholders retained their equity interest as stockholders in New AON, (iii) AON LLC’s operations prior to the Reverse Recapitalization comprising the only ongoing operations of New AON, (iv) the Legacy AON Shareholders have the right to appoint a majority of the directors of New AON, (v) the executive management of AON LLC will become the executive management of New AON and (vi) AON LLC is significantly larger than New AON in terms of revenue, total assets, and employees. Therefore, the Merger was accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded, in accordance with ASC Topic 805. New AON was treated as the “acquired” company for financial reporting purposes, and for accounting purposes, the Reverse Recapitalization was treated as the equivalent of AON LLC issuing stock for the net assets of New AON, accompanied by a recapitalization. The net assets of New AON were recorded at historical cost on the condensed consolidated balance sheet as of <div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 20, 2023, the Closing Date of the Reverse Recapitalization, with no goodwill or other intangible assets recorded. For additional information on the capitalization of New AON and AON LLC immediately following the Closing of the Reverse Recapitalization, see Note 1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the historical cost of assets and liabilities of AON Inc. as of September 20, 2023.</span></div><div style="text-indent:31.5pt"><span><br/></span></div><div style="text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.303%"><tr><td style="width:1.0%"></td><td style="width:77.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long Term Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Net Liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,593)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a Day 1 expense as of the Closing of the Business Combination equal to $18.2 million. Of that total amount, $13.0 million was recorded in transaction expenses on the condensed consolidated statement of operations and comprehensive loss. The remaining $5.2 million was recorded in other income (expense) net on the condensed consolidated statement of operations and comprehensive loss. This amount represented the loss on the issuance of Public and Private Warrants, as of the Closing, net of cash received. The Company also recorded a $4.3 million gain in other income (expense), net related to the change in the fair value of the Public and Private Warrants d</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uring the period of September 21, 2023 through September 30, 2023</span>. 3 2 <div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the historical cost of assets and liabilities of AON Inc. as of September 20, 2023.</span></div><div style="text-indent:31.5pt"><span><br/></span></div><div style="text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.303%"><tr><td style="width:1.0%"></td><td style="width:77.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long Term Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Net Liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,593)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1493000 13295000 6791000 -18593000 18200000 13000000 -5200000 4300000 Variable Interest Entities<div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AOMC is a wholly owned subsidiary of AON LLC and neither AOMC nor AON LLC has ownership interest in AON Partners and Partners of Maryland. Both AON Partners and Partners of Maryland are fully owned by physicians. AON LLC operates its physician practices through the MSAs and other contractual agreements between AOMC, AON Partners, and Partners of Maryland. The responsibilities of AOMC include, but are not limited to, negotiating provider and payor contracts, employment and compensation decisions, billing and collections, furnishing all supplies and equipment necessary for the respective practice’s operations as well as, necessary real estate, contracting on behalf of AON Partners and Partners of Maryland, entering into leases, holding a power of attorney to perform the above activities, preparing, maintaining and administering all accounting records (including financial reporting), expense payment, and maintenance of all information systems/software. AON LLC is paid a management fee to compensate AOMC for the services provided. AON Central Services is 80% physician owned and 20% owned by AON LLC. AOMC entered into an agreement with AON Central Services, effective January 1, 2023, to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. AOMC pays a monthly management fee to AON Central Services equal to the aggregate cost of compensation, benefits and all other costs related to these employees. AON LLC invested $0.2 million in MIBA, a newly formed LLC, during the second quarter of 2023 in exchange for 56% equity ownership. The Company evaluated AON LLC’s relationship with MIBA under the VIE model and determined it was a VIE and the Company is the primary beneficiary based on its financial controlling interest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on various quantitative and qualitative factors, including assessment of certain services performed and relationships held above, management has determined that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all variable interest entities and AOMC is the primary beneficiary who holds the decision-making rights over the activities that most significantly impact the economic performance of AON Partners, Partners of Maryland, AON Central Services, and MIBA through the MSAs and other contractual agreements. Accordingly, the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA have been consolidated with the Company for the three and nine month periods ended September 30, 2023 and 2022.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of September 30, 2023 and December 31, 2022, are as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:67.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,098 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">251,323 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230,072 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liabilities of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of September 30, 2023 and December 31, 2022, are as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:67.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,783 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to AON LLC and subsidiaries, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">288,045 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">253,386 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intercompany transactions and balances with the VIEs are eliminated in consolidation.</span></div> 0.80 0.20 200000 0.56 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of September 30, 2023 and December 31, 2022, are as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:67.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,098 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">251,323 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230,072 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liabilities of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of September 30, 2023 and December 31, 2022, are as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:67.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,783 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to AON LLC and subsidiaries, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">288,045 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">253,386 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 33083000 26844000 141039000 136098000 37844000 36476000 869000 846000 180000 180000 36294000 28139000 2014000 1489000 251323000 230072000 114779000 102783000 22747000 6021000 16038000 15926000 137000 452000 134344000 128204000 288045000 253386000 Business Combinations <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Acquisitions</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, the Company entered into a purchase agreement acquiring control of Northern Arizona Hematology and Oncology on January 1, 2022 for an aggregate purchase price of less than $0.1 million. Because the acquisition of Northern Arizona Hematology and Oncology was on the first day of the fiscal period, the Company’s results for the three and nine months ended September 30, 2022 include the results of the acquired practice.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with each of the Company’s business combinations (the “Transactions”), the Company executed employment agreements with the selling physicians to become employees of AON Partners and/or Partners of Maryland. Additionally, for each transaction the Company and selling physicians entered into a separate unwind agreement granting each other a unilateral option that may be exercised by either party and effectively returns the acquired business to the selling physicians if exercised. In the event the Company or seller exercise their unwind rights, the selling physicians are required to repay the original purchase price for the assets that were sold in the Transaction plus any assets that were acquired after the Transaction, less any accumulated depreciation or amortization with respect to the assets. The selling physicians are also required to assume all contracts associated with their practice. Additionally, in the event of unwind, the selling physicians are entitled to any severance </span></div>amounts that are due to them under their employment agreement with AON Partners and their employment is terminated on the unwind date. As of September 30, 2023 and December 31, 2022, no liability has been recorded related to the unwind agreements as neither the Company nor any selling physicians have exercised their unwind rights and therefore no payments are considered probable to the selling physicians. 100000 0 0 Marketable Securities<div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s marketable securities financial assets that are measured at fair value on a recurring basis:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:40.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents (1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overnight repurchase agreements (2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury Bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,651 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,651 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,961 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,033 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,612 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,684 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:40.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents (1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,968 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(129)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,851 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,077 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(129)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,960 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.84pt">Included in cash and cash equivalents in the Consolidated Balance Sheets at September 30, 2023 and December 31, 2022.</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.84pt">Cash equivalents as of September 30, 2023 included U.S. Treasury Bills with an initial maturity of 3 months or less and overnight repurchase agreements in which cash from the Company's main operating checking account is invested overnight in highly liquid, short-term investments sponsored by a large financial institution. The company had no such investments as of December 31, 2022.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses quoted prices in active markets for identical assets to determine the fair value of its Level 1 investments. The fair value of the Company’s Level 2 investments is determined using pricing based on quoted market prices or alternative market observable inputs. </span></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company’s marketable securities as of September 30, 2023, by remaining contractual maturities, were as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:55.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Bonds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,805 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 40pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,004 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,029 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,033 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s marketable securities financial assets that are measured at fair value on a recurring basis:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:40.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents (1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overnight repurchase agreements (2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury Bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,651 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,651 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,961 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,033 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,612 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,684 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:40.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents (1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,968 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(129)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,851 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,077 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(129)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,960 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.84pt">Included in cash and cash equivalents in the Consolidated Balance Sheets at September 30, 2023 and December 31, 2022.</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.84pt">Cash equivalents as of September 30, 2023 included U.S. Treasury Bills with an initial maturity of 3 months or less and overnight repurchase agreements in which cash from the Company's main operating checking account is invested overnight in highly liquid, short-term investments sponsored by a large financial institution. The company had no such investments as of December 31, 2022.</span></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company’s marketable securities as of September 30, 2023, by remaining contractual maturities, were as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:55.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Bonds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,805 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 40pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,004 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,029 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,033 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 28272000 28272000 773000 773000 18606000 18606000 47651000 47651000 13980000 62000 38000 14004000 11981000 52000 4000 12029000 25961000 114000 42000 26033000 73612000 114000 42000 73684000 109000 109000 7742000 6000 125000 7623000 2226000 6000 4000 2228000 9968000 12000 129000 9851000 10077000 12000 129000 9960000 4805000 8385000 13190000 9199000 3644000 12843000 14004000 12029000 26033000 Supplemental Condensed Balance Sheet Information<div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other receivables</span></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables consisted of the following at September 30, 2023 and December 31, 2022:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:68.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,955 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 40pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other receivables</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,747 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,201 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following at September 30, 2023 and December 31, 2022:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:67.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December <br/>31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intravenous drugs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,674 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral pharmaceuticals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,844 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,476 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following at September 30, 2023 and December 31, 2022:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.818%"><tr><td style="width:1.0%"></td><td style="width:67.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,078 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,076 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture, fixtures and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,659 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Automobiles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,552 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,240 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,980 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Other</span></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued other consisted of the following at September 30, 2023 and December 31, 2022:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.757%"><tr><td style="width:1.0%"></td><td style="width:55.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.687%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refund liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred social security taxes - COVID</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excise taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-804"><span style="-sec-ix-hidden:f-805">Current portion of finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued other</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,977 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,800 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables consisted of the following at September 30, 2023 and December 31, 2022:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:68.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,955 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 40pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other receivables</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,747 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,201 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 36556000 27955000 191000 246000 36747000 28201000 <div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following at September 30, 2023 and December 31, 2022:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:67.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December <br/>31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intravenous drugs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,674 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral pharmaceuticals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,844 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,476 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 27508000 25674000 10336000 10802000 37844000 36476000 <div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following at September 30, 2023 and December 31, 2022:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.818%"><tr><td style="width:1.0%"></td><td style="width:67.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,078 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,076 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture, fixtures and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,659 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Automobiles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,552 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,240 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,980 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 30078000 26076000 2722000 2669000 12659000 11003000 3325000 3115000 147000 129000 59000 69000 4412000 4834000 6150000 1433000 59552000 49328000 23312000 17348000 36240000 31980000 <div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued other consisted of the following at September 30, 2023 and December 31, 2022:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.757%"><tr><td style="width:1.0%"></td><td style="width:55.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.687%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refund liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred social security taxes - COVID</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excise taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-804"><span style="-sec-ix-hidden:f-805">Current portion of finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued other</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,977 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,800 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 14521000 14544000 0 378000 2700000 0 630000 425000 5126000 2453000 22977000 17800000 Long-term Debt<div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consisted of the following at September 30, 2023 and December 31, 2022: </span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:57.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December <br/>31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PNC Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,425 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,301 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2021, the Company entered into a Loan Facility with PNC (“PNC Loan Facility”) collateralized by the Company’s assets and outstanding patient accounts receivable. The PNC Loan Facility is guaranteed on a limited basis by the Company and shareholder of AON Partners and Partners of Maryland. $34.6 million of </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds from the PNC Loan Facility was used to pay off the Company’s previous term loans and revolver with Truist Bank. The remaining funds were made available for working capital and acquisition of additional physician practices.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PNC Loan Facility is interest-only with total principal due at maturity on April 30, 2024. Interest originally accrued at one-month LIBOR or an alternate base rate plus 1.45%. The maximum balance of the PNC Loan Facility (“Borrowing Base”) is limited to the lesser of the Facility Limit ($65.0 million) or the fair value of the Company’s patient accounts receivable. The Company must maintain a balance of the lesser of the Borrowing Base or 65% of the Facility Limit in the first year and 75% of the Facility Limit in subsequent years (“minimum funding threshold”). The Company can repay the PNC Loan Facility up to the minimum funding threshold at any time without penalty. In accordance with the PNC Loan Facility, the Company pledged $10.0 million of collateral as restricted cash to be released quarterly in increments of $2.5 million. The restricted cash was fully released as of September 30, 2023 and December 31, 2022.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2021, the Company entered into a $5.0 million revolving line of credit agreement (“PNC Line of Credit”). The PNC Line of Credit has an expiration date of April 30, 2024 and originally bore interest at a rate per annum equal to the sum of the daily LIBOR rate plus 1.65% or an alternate base rate plus 0.65% and is due on the first day of each month beginning June 1, 2021. Any outstanding principal and accrued interest will be due on the expiration date. Beginning July 1, 2021, quarterly bank fees equal to 1.65% per day per annum are due in arrears and will continue on the first day of each quarter thereafter. All debt related to the PNC Line of Credit is collateralized by the Company’s assets. As of September 30, 2023 and December 31 2022, no draws had been made on the PNC Line of Credit. The Company is also subject to a 0.20% unused line fee calculated per annum on the unused balance of the PNC Line of Credit. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2021, the Company amended the PNC Loan Facility increasing the Facility Limit to $75.0 million. On February 14, 2022, the Company further amended the PNC Loan Facility and Line of Credit agreements. The primary changes included an increase of the Facility limit from $75.0 million to $125.0 million, an increase of the PNC Line of Credit availability from $5.0 million to $10.0 million, interest charges to be calculated based on the Bloomberg Short-Term Bank Yield Index plus 1.65% and certain financial covenants. As part of the amendment, the Company drew an additional $16.3 million in proceeds under the Loan Facility. On August 15, 2022, the PNC Loan Facility and Line of Credit agreements were amended again to reduce the availability under the PNC Line of Credit from $10.0 million to $1.0 million. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective November 23, 2022, the Company entered into Waiver and Amendment No. 6 (“Waiver and Amendment”) under its PNC Loan Facility as the Company was not in compliance with the Delinquency Ratio financial covenant for the period ending October 31, 2022 and the requirement to provide certain annual financial statements. The Waiver and Amendment waives each event of default and also revised future delinquency percentages and financial statement requirements. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2023, the Company entered into Amendment No. 7 (“Amendment 7”) to its PNC Loan Facility which extended the maturity date from April 30, 2024 to June 30, 2026. In connection with Amendment 7, the Company paid additional debt issuance costs of $0.4 million which will be amortized over the revised remaining life of the Loan Facility. In addition, Amendment 7 revised the definition of the minimum funding threshold to limit the threshold multiplier to 65% of the Facility Limit. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PNC Loan Facility and PNC Line of Credit nonfinancial covenants include restrictions related to unpermitted property liens and the requirement of audited financial statements. Both agreements also contain several financial covenants, including the following ratios: accounts receivable default, delinquency, dilution, days sales outstanding, leverage, and fixed charge coverage. As of September 30, 2023, the Company was in compliance with all financial and nonfinancial debt covenants as required by both loan agreements.</span></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consisted of the following at September 30, 2023 and December 31, 2022: </span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:57.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December <br/>31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PNC Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,425 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,301 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 81250000 81250000 81250000 81250000 825000 949000 80425000 80301000 34600000 0.0145 65000000 0.65 0.75 10000000 2500000 5000000 0.0165 0.0065 0.0165 0 0 0.0020 75000000 75000000 125000000 5000000 10000000 0.0165 16300000 10000000 1000000 400000 0.65 Income Taxes<div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a member of American Oncology Network, LLC, which is treated as a partnership for U.S. federal and certain state and local income taxes. As a partnership, American Oncology Network, LLC is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by American Oncology Network, LLC is passed through to and included in the taxable income or loss of its members, including the Company, on a pro-rata basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income taxes, in addition to state and local income taxes with respect to the allocable share of any taxable income of American Oncology Network, LLC. Additionally, other corporate entities within the Company's structure are subject to income taxes. These corporate entities continue to generate losses and continue to maintain a valuation allowance against their net deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s effective income tax rate was (1.1)% and —% for the three months ended September 30, 2023 and 2022, respectively. The provision for income taxes was $315 and $0 for the three months ended September 30, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s effective income tax rate was (0.8)% and —% for the nine months ended September 30, 2023 and 2022, respectively. The provision for income taxes was $315 and $0 for the nine ended September 30, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change to the income tax provision for the three and nine months ended September 30, 2023 compared to the income tax provision for the three and nine months ended September 30, 2022 was primarily a result of the transaction closing on September 20, 2023, resulting in a portion of the Company's consolidated pre-tax earnings, which were previously not subject to income taxes, flowing into a taxable corporation included in the Company's post transaction structure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rate for the three and nine months ended September 30, 2023 and 2022 differed from the federal statutory rate primarily due to certain legal entities in the Company's structure being treated as partnerships for income tax purposes and, therefore, a significant portion of its income not being subject to income tax. Additionally, certain corporate entities within the Company's structure continue to maintain a full valuation allowance against their net deferred tax assets.</span></div> -0.011 0 315000 0 -0.008 0 315000 0 Leases<div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently leases office facilities and equipment for its practices under noncancelable operating and finance lease agreements expiring on various dates through 2038. Certain of the leases contain renewal options which are exercisable at the Company’s discretion. These renewal options are considered in determining the lease term if it is reasonably certain that the Company will exercise such options. Additionally, the Company leases certain other office and medical equipment under month-to-month lease agreements. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities consist of the following at September 30, 2023 and December 31, 2022:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:66.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease right-of-use assets, net (included in property and equipment, net)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total right-of-use assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,929 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,722 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities (included in accrued other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,602 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term finance lease liabilities (included in other long-term liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,140 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,445 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs recognized in the condensed consolidated statements of operations and comprehensive loss consist of the following for the three and nine month periods ended September 30, 2023 and 2022 and are included in selling, general, and administrative expenses unless otherwise noted:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.663%"><tr><td style="width:1.0%"></td><td style="width:45.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,820 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,297 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finance lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on finance lease liabilities (included in interest expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">560</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">862</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,537 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,227 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,536 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,002 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of September 30, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.261%"><tr><td style="width:1.0%"></td><td style="width:70.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating <br/>Lease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 (remainder of year after September 30, 2023)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">753 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,210 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: amount representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,384 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,756 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,261 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,126 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term as of September 30, 2023 and December 31, 2022 was 7.01 years and 5.68 years for operating leases and 5.00 years and 5.37 years for finance leases, respectively. The weighted-average discount rate as of September 30, 2023 and December 31, 2022 was 6.56% and 4.88% for operating leases and 5.12% and 3.60% for finance leases, respectively.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash paid for amounts included in the measurement of lease liabilities for the nine months ended September 30, 2023 and 2022 is as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.261%"><tr><td style="width:1.0%"></td><td style="width:70.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for new finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2023, the Company had entered into two <span style="-sec-ix-hidden:f-941">sixty</span>-month finance leases for medical equipment that had not yet commenced. The future commitments related to these leases are approximately $3.8 million and the Company expects to take control of the leased assets early in the fourth quarter.</span></div> Leases<div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently leases office facilities and equipment for its practices under noncancelable operating and finance lease agreements expiring on various dates through 2038. Certain of the leases contain renewal options which are exercisable at the Company’s discretion. These renewal options are considered in determining the lease term if it is reasonably certain that the Company will exercise such options. Additionally, the Company leases certain other office and medical equipment under month-to-month lease agreements. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities consist of the following at September 30, 2023 and December 31, 2022:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:66.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease right-of-use assets, net (included in property and equipment, net)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total right-of-use assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,929 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,722 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities (included in accrued other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,602 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term finance lease liabilities (included in other long-term liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,140 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,445 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs recognized in the condensed consolidated statements of operations and comprehensive loss consist of the following for the three and nine month periods ended September 30, 2023 and 2022 and are included in selling, general, and administrative expenses unless otherwise noted:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.663%"><tr><td style="width:1.0%"></td><td style="width:45.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,820 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,297 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finance lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on finance lease liabilities (included in interest expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">560</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">862</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,537 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,227 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,536 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,002 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of September 30, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.261%"><tr><td style="width:1.0%"></td><td style="width:70.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating <br/>Lease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 (remainder of year after September 30, 2023)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">753 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,210 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: amount representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,384 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,756 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,261 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,126 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term as of September 30, 2023 and December 31, 2022 was 7.01 years and 5.68 years for operating leases and 5.00 years and 5.37 years for finance leases, respectively. The weighted-average discount rate as of September 30, 2023 and December 31, 2022 was 6.56% and 4.88% for operating leases and 5.12% and 3.60% for finance leases, respectively.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash paid for amounts included in the measurement of lease liabilities for the nine months ended September 30, 2023 and 2022 is as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.261%"><tr><td style="width:1.0%"></td><td style="width:70.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for new finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2023, the Company had entered into two <span style="-sec-ix-hidden:f-941">sixty</span>-month finance leases for medical equipment that had not yet commenced. The future commitments related to these leases are approximately $3.8 million and the Company expects to take control of the leased assets early in the fourth quarter.</span></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities consist of the following at September 30, 2023 and December 31, 2022:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:66.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease right-of-use assets, net (included in property and equipment, net)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total right-of-use assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,929 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,722 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities (included in accrued other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,602 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term finance lease liabilities (included in other long-term liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,140 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,445 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 46138000 43724000 2791000 1998000 48929000 45722000 7123000 9177000 630000 425000 7753000 9602000 42261000 37224000 2126000 1619000 52140000 48445000 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs recognized in the condensed consolidated statements of operations and comprehensive loss consist of the following for the three and nine month periods ended September 30, 2023 and 2022 and are included in selling, general, and administrative expenses unless otherwise noted:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.663%"><tr><td style="width:1.0%"></td><td style="width:45.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,820 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,297 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finance lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on finance lease liabilities (included in interest expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">560</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">862</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,537 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,227 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,536 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,002 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash paid for amounts included in the measurement of lease liabilities for the nine months ended September 30, 2023 and 2022 is as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.261%"><tr><td style="width:1.0%"></td><td style="width:70.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for new finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2820000 3161000 8361000 9297000 122000 185000 354000 413000 35000 19000 79000 60000 560000 862000 1742000 2232000 3537000 4227000 10536000 12002000 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of September 30, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.261%"><tr><td style="width:1.0%"></td><td style="width:70.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating <br/>Lease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 (remainder of year after September 30, 2023)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">753 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,210 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: amount representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,384 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,756 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,261 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,126 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of September 30, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.261%"><tr><td style="width:1.0%"></td><td style="width:70.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating <br/>Lease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 (remainder of year after September 30, 2023)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">753 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,210 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: amount representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,384 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,756 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,261 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,126 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1679000 188000 10940000 753000 9830000 731000 9413000 492000 8194000 428000 24154000 528000 64210000 3120000 14826000 364000 49384000 2756000 7123000 630000 42261000 2126000 P7Y3D P5Y8M4D P5Y P5Y4M13D 0.0656 0.0488 0.0512 0.0360 7678000 9788000 79000 60000 387000 321000 9862000 9771000 1103000 0 2 3800000 Related Parties<div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions Notes Receivable</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into promissory notes with physicians of the Company. The notes receivable balances are satisfied through cash payments or settlements through the physicians’ compensation as part of their employee agreement. The notes receivable are amortized over a 60-month period as a reduction of compensation. The notes bear interest at the Company’s incremental borrowing rate (7.14% at September 30, 2023 and 1.57% at December 31, 2022, respectively).</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:24.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of <br/>December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original<br/>Principal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issue <br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity<br/>Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 2</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/1/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/30/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/1/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/31/2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 6</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/22/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/22/2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 8</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/1/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/1/2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 9</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/24/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/30/2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total notes receivables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,134 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,873 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:  Current portion of notes receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,797)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes receivable, less current portion</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,504 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,076 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for ten of the office facilities owned by employees of the Company. Total cash was approximately $0.6 million and $1.9 million paid for leases to related parties for the both the three and nine months ended September 30, 2023 and 2022, respectively.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory Purchases/Concentration Risk </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases the majority of pharmaceuticals inventory from a subsidiary under common control of a Legacy AON Shareholder. During the three and nine months ended September 30, 2023 and 2022, the Company purchased from the related party approximately $268.0 million and $239.0 million and $774.0 million and $682.0 million, respectively. These purchases were approximately 86% and 89% and 88% and 86% as a percentage of cost of revenue for the three and nine months ended September 30, 2023 and 2022, respectively. At September 30, 2023 and December 31, 2022, the Company had $113.0 million and $102.1 million, respectively, included in accounts payable for invoices from the related party, representing 94% of accounts payable at each period-end.</span></div> P60M 0.0714 0.0157 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:24.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of <br/>December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original<br/>Principal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issue <br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity<br/>Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 2</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/1/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/30/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/1/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/31/2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 6</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/22/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/22/2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 8</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/1/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/1/2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 9</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/24/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/30/2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total notes receivables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,134 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,873 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:  Current portion of notes receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,797)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes receivable, less current portion</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,504 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,076 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table> 1027000 1057000 5355000 42000 119000 491000 0 351000 1111000 2065000 2221000 2816000 0 125000 125000 3134000 3873000 1630000 1797000 1504000 2076000 10 600000 600000 1900000 1900000 268000000 239000000 774000000 682000000 0.86 0.89 0.88 0.86 113000000 102100000 0.94 0.94 Equity<div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prior Period Presentation</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods prior to the Reverse Recapitalization, AON LLC had equity and stock-based compensation described below authorized, issued and outstanding. As discussed in Note 1, upon the Closing of the Business Combination, Legacy AON Shareholders received Class A Common Stock, Class B Common Stock, or Class B Prefunded Warrants and AON LLC reclassified their existing Class A, Class A-1, and Class B Units into AON LLC Common Units, pursuant to the terms of the Business Combination Agreement.</span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recasted Historical AON LLC Equity outstanding for the periods prior to the Reverse Recapitalization, equal to the Per Company Unit Exchange Ratio, pursuant to the Business Combination, that was applied to the Class A, Class A-1, and Class B Units. The historical AON LLC units disclosed in this note give effect to the conversion for all periods presented, as follows. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Class A Units</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AON LLC had authorized 19,495,376 units of Class A Units, of which 19,495,376 units were issued and were outstanding as of December 31, 2022. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Class A-1 Units</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AON LLC had authorized 3,000,245 units of Class A-1 Units, of which 1,842,520 units were issued and were outstanding as of December 31, 2022. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Class B Units (Profit Interest)</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Class B units were issued through the 2017 Profits Interest Plan adopted by the Company in October 2017. The Class B Units represented a non-voting equity interest in AON LLC that entitled the holder to appreciation in the equity value of AON LLC arising after the date of grant and after such time as an applicable hurdle amount is met. AON LLC recognized the cost of services received in exchange for Class B Units based on the grant-date fair value. That cost was recognized over the period during which the service provider is required to provide service in exchange for the award over the requisite service period or based on performance. AON LLC used the Black-Scholes-Merton pricing model to estimate the fair value of profits interest unit awards. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an as converted basis,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of December 31, 2022, AON LLC issued 5,614,176 Class B Units, of which 4,703,628 were vested and outstanding; the remaining 910,548 of Class B units vested upon consummation of the Business Combination. The stock compensation expense that was recognized for the vesting of the Class B Units was less than $0.1 million. </span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes to AON LLC’s Class A, Class A-1, and Class B Units for the three and nine months ended September 30, 2023, and 2022. </span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:27.702%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in thousands, except for share and per share amounts</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A Units, value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,725)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,725)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A Units, units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,495,376)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,495,376)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:27.702%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.218%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in thousands, except for share and per share amounts</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A-1 Units, value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,040 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,185 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38,225)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38,225)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,500 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,500 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A-1 Units, units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,281,696 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,842,520 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,842,520 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,842,520 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">718,549 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,157,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,000,245)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,000,245)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,842,520 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,842,520 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in thousands, except for share and per share amounts</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class B Units, value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(90)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(90)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class B Units, units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Units Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">910,548 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">910,548 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,614,176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,614,176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Class B-1 Units </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June and July of 2023, the Company granted a total of 415 AON LLC Class B-1 Units to certain employees under the 2017 Profits Interest Plan (the “Plan”). The Class B-1 Units vested upon the consummation of the Business Combination, therefore, $4.9 million of expense has been recognized in the condensed consolidated statement of operations and comprehensive loss for the three months ended September 30, 2023. Upon the closing of the Business Combination, the vested Class B-1 Units were reclassified to AON LLC Common Units and exchanged for newly issued shares of Class A Common Stock equal to the Per Company Unit Exchange Ratio, pursuant to the Business Combination Agreement, which resulted in the issuance of 1,047,343 shares of New AON Class A Common Stock. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mezzanine Equity Class C Units</span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 1, the AON LLC Class C Units were converted into AON LLC Series A Preferred Units as of the Closing Date. Concurrently, New AON issued a number of shares of New AON Series A Preferred Stock equal to the number of AON LLC Series A Preferred Units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor. Promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON LLC Series A Preferred Units. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an as converted basis,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of September 20, 2023, 6,651,610 Series A Preferred Stock were issued to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AEA Growth Management LP</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AON LLC Class C Units were contingently redeemable convertible preferred units and classified as mezzanine equity on the condensed consolidated balance sheet as of June 30, 2023 because the units were redeemable five years from the issuance date, at the option of the holder. As of June 30, 2023, the AON LLC Class C Units were recorded at their initial carrying value, net of offering costs. The Class C Units were not being accreted to redemption value, as the redemption was not probable due to the removal of the redemption right pursuant to the Business Combination. See discussion below. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Class C Units had materially the same rights as the Series A Preferred Stock issued by the Company to AEA Growth Management LP, the parent of the AON Class C Preferred Investor, with the exception of the “AON LLC Class C Unit Redemption Right” and the “Class C Option to Purchase Additional Shares”, discussed below. Further, the Class C Units did not contain a mandatory conversion feature that allowed AON LLC to force the Class C Investor to convert the Class C Units into another equity unit in AON LLC and the Class C Units did not have a one time conversion price adjustment. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Class C Unit Redemption Right</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the fifth anniversary of the Effective Date (June 7, 2028), the holders of a majority of the Class C Units had the right to cause the Company to redeem all of the Class C Units. The redemption price per Class C Unit was equal to the greater of (i) the Class C Liquidation Preference and (ii) the Fair Market Value of a Class C Unit (the “Class C Redemption Price”). The Class C Liquidation Preference is defined as an amount equal to the sum of (a) the Class C Preferred Return of such Class C Member and (b) the amount of such Class C Member’s Net Invested Capital Contributions of $65.0 million. The Class C Unit Preferred Return is defined as the cumulative, semiannually-compounded return of 8% per annum based on the original Net Invested Capital Contributions of $65.0 million. The Class C Unit Redemption Right was removed as of the Closing of the Business Combination. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Class C Unit Option to Purchase Additional Units</span></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the terms of the Amended and Restated Class C Convertible Preferred Unit Purchase Agreement dated June 7, 2023, the Class C Preferred Investor had an option to purchase an additional 378 AON Class C Units until the Closing of the Business Combination at a purchase price of $26,423 per Unit (“Option Feature”). The Company determined that this Option Feature was required to be accounted for as a derivative in accordance with ASC 815. The fair value of the derivative was estimated to be $1.4 million as of June 30, 2023. The Class C Preferred Investor did not exercise this option prior to the Closing of the Business Combination. As a result, the Company recognized a gain of $1.4 million in other (expense) income, net in the condensed consolidated statements of operations and comprehensive loss for the three months ended September 30, 2023. The Class C Unit Option expired as of the Closing of the Business Combination.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Preferred Stock (Mezzanine Equity) </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#060606;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which outside of the Company’s control). As a result, the Company has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At the closing of the Business Combination, the Company exchanged existing AON LLC Class C Units for Series A Preferred Stock in the Company. Based on the qualitative changes to the instrument, this exchange is </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considered an extinguishment for accounting purposes, with the Company recording a deemed dividend of $2.1 million to account for the difference between the carrying value of the Class C Units and the fair value of the Series A Preferred Stock at the transaction date. This amount is reflected in the condensed consolidated statements of mezzanine and stockholders’ equity as part of the reverse recapitalization, net. See further discussion on the PIK Dividend discussed below. </span></div><div><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock are not being accreted to redemption value, as the Series A Preferred Stock are not redeemable, nor are they probable of becoming redeemable. </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock accrue dividends at a cumulative, semiannually-compounded return of 8% per annum based on the original Net Invested Capital Contributions from the Class C Units of $65.0 million. These dividends may be paid in cash or accumulate into the Accrued Value at the option of New AON. The accrual shall be calculated on June 30 and December 31 and with respect to the semiannually-compounded return, no interest is required to be paid on any present or future Series A Preferred Stock accrued dividends. The Series A Preferred Stock also participate in distributions with the Class A Common stockholders. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2023, the Company issued </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,651,610 Series A Preferred Stock to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AEA Growth Management LP. The number of Series A Preferred Stock shares issued at the Closing of the Business Combination was equal to the aggregate Class C Liquidation Preference pursuant to the Business Combination Agreement. As a result, the issuance of the Series A Preferred Stock effectively included an in-kind payout (“PIK”) of the accrued dividend since the calculation of the amount issued was based on the Class C Liquidation Preference. As of the Closing, the Company recorded a dividend of 151,610 Series A Preferred Stock PIK shares with respect to the accrued dividends on the Series A Preferred Stock (the "PIK Dividend"). </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Preferred Stock are entitled to elect and appoint one of the directors (“Series A Director”) to the Board of Directors. All other directors are appointed by the Class A and Class B Common stockholders. There are no restrictions on which matters the Series A Preferred stockholders are entitled to vote. The Series A Preferred stockholders are entitled to the number of votes equal to the number of shares of Common Stock into which the Series A Preferred Stock would be convertible on the record date of the vote.</span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion Rights</span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock is convertible, at the option of the holder, at any time, and without the payment of additional consideration by the holder, into such number of fully-paid Class A Common Stock as is determined by dividing the Accrued Value by the Conversion Price in effect at the time of conversion (“Conversion Ratio”). The Accrued Value is the Original Issue Price (which is $10.00 per share of Preferred Stock, as adjusted for any stock split, stock dividend, combination, or other recapitalization) plus any unpaid dividends, compounded semi-annually. The Conversion Price is initially $10.00 per Preferred Share subject to adjustment for dilutive issuances of additional shares, dividends to common stockholders, stock splits, mergers, and a five-year anniversary special adjustment based on the volume weighted average price of the common stock. These dividends may be paid in cash or accumulate into the Accrued Value, at the option of New AON, on June 30 and December 31 of each year. The Conversion Rights shall terminate at the close of business on the day prior to the date of a Change of Control.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If at any time on or after the 30th day after the five-year anniversary of the issue date, any of the Series A Preferred Stock remain outstanding and the 30-Day VWAP of the Common Stock is less than $10.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification), then the Conversion Price shall be adjusted to the greater of (x) the 30-Day VWAP on such date of determination and (y) $5.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification).</span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New AON also has the right on or after the third-year anniversary of the date of issuance to cause all (but not less than all) of the outstanding shares of Series A Preferred Stock to be converted into shares of Class A Common Stock for each share of Series A Preferred Stock at the Conversion Ratio detailed above. The Company may only convert shares of Series A Preferred Stock into shares of Common Stock if the 30-Day VWAP of the Common Stock immediately prior to the Company Conversion Date is greater than $16.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization).</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation Preferences</span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of voluntary or involuntary liquidation, dissolution or winding up of the Company or an Initial Public Offering (IPO) or Exit Event, the Series A Preferred Stock have preferential liquidation rights. If a Deemed Liquidation Event were to occur, each Series A Preferred stockholder is entitled to be paid out of the assets of the Company available for distribution, equal to the greater of the following: </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:49.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) The Original Issue Price of $10 per Series A Preferred Stock multiplied by the Applicable Percentage plus any Accrued Dividends on such share of Series A Preferred Stock; or</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:49.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Such amount per share as would have been payable had all shares of Series A Preferred Stock been converted into Common Stock immediately prior to such Deemed Liquidation Event.</span></div><div style="padding-left:49.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock Applicable Percentage is defined as a percentage equal to (a) one hundred twenty-five percent (125%) if an Exit Event, dissolution, liquidation, or winding-up occurs prior to June 7, 2024, (b) one hundred twenty percent (120%) if an Exit Event, dissolution, liquidation, or winding up occurs after June 7, 2024, but prior to June 7, 2025, (c) one hundred fifteen percent (115%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2025, but prior to June 7, 2026, (d) one hundred ten percent (110%) if an Exit Event, dissolution, liquidation, or winding up occurs after June 7, 2026, but prior to June 7, 2027, (e) one hundred five percent (105%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2027, but prior to June 7, 2028, (f) one hundred percent (100%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2028.</span></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Distributions to Class A and Class A-1 Members </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2020, the AON LLC entered into the Second Amended and Restated Limited Liability Agreement (“Second Operating Agreement”) which established another class of equity, Class A-1 Units. The Second Operating Agreement provided, among other things, that the Class A and A-1 Units would receive a cumulative, annually-compounded, preferred return of 8.0% and 4.0%, respectively, on capital contributions when and if distributions are declared by the Board of the Company. </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the issuance of the Class C Units on June 7, 2023 as discussed above, the Class A and A-1 unitholders were paid a cash distribution of $4.0 million and $4.1 million, respectively, representing the cumulative accrued preferred return to June 7, 2023. </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2023, in connection with the issuance of the Class C Units, AON LLC entered into the Third Amended and Restated Limited Liability Agreement (“Third Operating Agreement”) which, among other things, eliminated any provisions for future preferred returns on Class A and A-1 units.</span></div><div style="text-indent:28.8pt"><span><br/></span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Class A-1 Anti-Dilution Feature </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Closing, in the event AON LLC, prior to a Qualified IPO, issued additional membership equity (“Additional Issuance”) at a valuation that represents a purchase price that is less than the New Unit Purchase Price, as defined, AON LLC was obligated to issue additional Class A-1 Units, for no consideration, such that the Class A-1 unitholder maintains the same percentage ownership as prior to the Additional Issuance (“Anti-Dilution Feature”).</span></div>The Company determined that the Anti-Dilution Feature met the definition of a derivative in accordance with ASC 815. The total loss on derivatives for the three months and nine months ended September 30, 2023 relating to this feature is $4.7 million and $9.8 million, respectively, and was recorded in other (expense) income, net in the condensed consolidated statements of operations and comprehensive loss. As a result of the Anti-Dilution Feature, upon the issuance of the Class C Units on June 7, 2023 and the Closing of the Business Combination on September 20, 2023, the Company issued an additional 174 and 284 Class A-1 Units, that were subsequently converted into 439,176 and 718,549 AON Common Units using the Per Company Unit Exchange Ratio, pursuant to the Business Combination Agreement. The total fair value of the issuance of additional Class A-1 shares on June 7, 2023 and September 20, 2023 was $2.5 million and $7.2 million, respectively, for a cumulative $9.7 million recorded as Class A-1 member equity in the condensed consolidated statements of mezzanine and stockholders’ equity. Upon the Closing of the Business Combination, the Class A-1 Anti-dilution Feature was eliminated and the derivative liability was fully extinguished. 19495376 19495376 19495376 3000245 1842520 1842520 5614176 4703628 910548 100000 <div style="padding-left:31.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes to AON LLC’s Class A, Class A-1, and Class B Units for the three and nine months ended September 30, 2023, and 2022. </span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:27.702%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in thousands, except for share and per share amounts</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A Units, value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,725)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,725)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A Units, units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,495,376)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,495,376)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:27.702%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.218%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in thousands, except for share and per share amounts</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A-1 Units, value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,040 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,185 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38,225)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38,225)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,500 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,500 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A-1 Units, units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,281,696 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,842,520 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,842,520 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,842,520 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">718,549 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,157,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,000,245)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,000,245)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,842,520 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,842,520 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in thousands, except for share and per share amounts</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class B Units, value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(90)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(90)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class B Units, units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Units Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">910,548 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">910,548 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,614,176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,614,176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 7725000 7725000 7725000 7725000 0 0 0 0 -7725000 0 -7725000 0 0 7725000 0 7725000 19495376 19495376 19495376 19495376 0 0 0 0 -19495376 0 -19495376 0 0 19495376 0 19495376 31040000 28500000 28500000 28500000 7185000 0 9725000 0 -38225000 0 -38225000 0 0 28500000 0 28500000 2281696 1842520 1842520 1842520 718549 1157725 -3000245 -3000245 0 1842520 0 1842520 80000 90000 80000 80000 10000 5000 10000 15000 -90000 0 -90000 0 95000 0 95000 4703628 4703628 4703628 4703628 910548 0 910548 0 -5614176 0 -5614176 0 0 4703628 0 4703628 415 4900000 1047343 6651610 P5Y 65000000 0.08 65000000 378 26423 1400000 1400000 0.08 65000000 6651610 151610 10.00 10.00 P30D P30D 10.00 P30D 5.00 P30D 16.00 10 1.25 1.20 1.15 1.10 1.05 1 0.080 0.040 4000000 4100000 -4700000 -9800000 174 284 439176 718549 2500000 7200000 9700000 Net Loss Per Share<div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share of Class A Common Stock and represents the period from September 21, 2023 to September 30, 2023, the period where the Company had Class A and Class B common stock outstanding. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted loss per share. As such, basic and diluted loss per share of Class B Common Stock has not been presented. Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As such, basic and diluted loss per share is computed using the two-class method. For additional information, see Notes 1 and 2.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted loss per share is based on the weighted-average number of shares of Class A Common Stock used for the basic loss per share calculation, adjusted for the dilutive effect of Public and Private Warrants and Sponsor Earnouts, if any, using the “treasury stock” method and the convertible Series A Preferred Stock, Class B Common Stock, and Class B Prefunded Warrants, if any, using the “if-converted” method. Net loss for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net loss, net of AON Inc. taxes, after giving effect to Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock that accrue dividends, to the extent it is dilutive.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Class A Common Stockholders for basic and diluted loss per share $ (1,791,768)</span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A Deemed Dividend (2,089,000)</span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A Preferred Cumulative Dividends </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> (133,032)</span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Undistributed Net Loss attributable to Class A Common Stockholders $ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,013,000)</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                         </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares for basic and diluted loss per share 6,614,229 </span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic &amp; Diluted loss per share of Class A Common Stock $ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.61)</span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the securities that have been excluded from the calculation of weighted-average shares for diluted loss per share for the period presented as they were anti-dilutive. Note that the Sponsor Earnouts are excluded from the calculation of weighted-average shares for diluted loss per share as the contingency had not been met as of the period end.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A Preferred Stock                                  6,651,610 </span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B Common Stock                             25,109,551</span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B Prefunded Warrants                         3,000,245</span></div>Public and Private Warrants                         14,450,883 1791768 1791768 2089000 133032 4013000 4013000 6614229 6614229 -0.61 -0.61 6651610 25109551 3000245 14450883 Redeemable Noncontrolling Interest<div style="padding-left:31.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legacy AON Shareholders own 28,109,796 AON LLC Common Units, equal to a 67.9% of the economic interest in AON LLC. Legacy AON Shareholders also own 25,109,551 shares of Class B Common Stock and 3,000,245 Class B Prefunded Warrants, which, together with the AON LLC Common Units, may be redeemed at the option of the Legacy AON Shareholder on a one-for-one basis for shares of Class A Common Stock or the cash equivalent thereof (based on the market price of the shares of Class A Common Stock at the time of redemption) as determined by New AON. If New AON elects the redemption to be settled in cash, the cash used to settle the redemption must be funded through a private or public offering of Class A Common Stock no later than <span style="-sec-ix-hidden:f-1160">ten</span> (10) business days after the redemption notice date. Upon the redemption of the AON LLC Common Units and Class B </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Stock for shares of Class A Common Stock or the equivalent thereof, all redeemed shares of Class B Common Stock will be cancelled. The redemption value is determined based on a <span style="-sec-ix-hidden:f-1161">five</span>-day volume weighted average price (”VWAP”) of the Class A common shares, subject to customary conversion rate adjustments for share splits, share dividends, and similar events affecting Class A Common Stock.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When applying SEC guidance concerning mezzanine classification, the Company understands that due to the NCI holders having control of the Board, if there is a sequence of remotely possible events that could trigger a redemption, this requires the instrument to be classified as temporary equity, without any regard to probability. Accordingly, though the redemption would require such a remotely possible sequence of events, and such remote sequence of events would also require, in management’s view, the Company to take extraordinary actions in order to allow such sequence of events to be remotely possible, the noncontrolling interest is currently classified as temporary equity. In the event that the Legacy AON Shareholders own less than 50% of the outstanding economic interest in AON LLC Common Units due to future redemptions, the noncontrolling interest will be presented as permanent equity. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The redeemable noncontrolling interest is recognized at the greater of (1) its initial fair value plus accumulated earnings/(losses) associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At September 30, 2023, the redeemable noncontrolling interest was recorded based on its redemption value of $369.3 million which exceeded its carrying value by $344.3 million. This measurement adjustment decreased additional paid in capital by $17.6 million and retained earnings (deficit) by $326.7 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the economic ownership of AON LLC, for the period beginning September 20, 2023, the Closing Date of the Reverse Recapitalization, and ending September 30, 2023 (Refer to Note 1). </span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:40.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Period beginning September 20, 2023 and ending September 30, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AON LLC Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AON Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legacy AON Shareholders</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Beginning of Period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Units Issued</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,614,229 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,109,796 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,724,025 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A Preferred Units Issued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,651,610 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,651,610 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Units Issued</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,265,839 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,109,796 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,375,635 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,265,839 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,109,796 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,375,635 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation of income to controlling and noncontrolling interests</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67.9 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation of losses to controlling and noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.0 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.0 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 6,614,229 of AON Inc. Common Units excludes 2,839,375 units, which is equivalent to the number of Sponsor Earnout Shares, that do not participate in profits and losses and are not included in the controlling interest percentage.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As a result, </span>the consolidated net loss of AON LLC, during the period of September 21, 2023 through September 30, 2023, were allocated to the NCI to reflect the absorption of the Legacy AON Shareholders to a portion of the consolidated net loss of AON LLC. Net losses were not attributed to Series A Preferred Stock. 28109796 0.679 25109551 3000245 1 0.50 369300000 344300000 -17600000 -326700000 The following table summarizes the economic ownership of AON LLC, for the period beginning September 20, 2023, the Closing Date of the Reverse Recapitalization, and ending September 30, 2023 (Refer to Note 1). <div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:40.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Period beginning September 20, 2023 and ending September 30, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AON LLC Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AON Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legacy AON Shareholders</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Beginning of Period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Units Issued</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,614,229 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,109,796 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,724,025 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A Preferred Units Issued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,651,610 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,651,610 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Units Issued</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,265,839 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,109,796 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,375,635 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,265,839 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,109,796 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,375,635 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation of income to controlling and noncontrolling interests</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67.9 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation of losses to controlling and noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.0 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.0 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 6,614,229 of AON Inc. Common Units excludes 2,839,375 units, which is equivalent to the number of Sponsor Earnout Shares, that do not participate in profits and losses and are not included in the controlling interest percentage.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As a result, </span>the consolidated net loss of AON LLC, during the period of September 21, 2023 through September 30, 2023, were allocated to the NCI to reflect the absorption of the Legacy AON Shareholders to a portion of the consolidated net loss of AON LLC. Net losses were not attributed to Series A Preferred Stock. 0 0 0 6614229 28109796 34724025 6651610 0 6651610 13265839 28109796 41375635 13265839 28109796 41375635 0.321 0.679 1 0.190 0.810 1 6614229 2839375 Includes related party inventory expense of $271,790 and $236,077 and $777,478 and $682,671 for the three and nine months ended September 30, 2023 and 2022, respectively. Includes related party rent of $679 and $655 and $2,037 and $2,037 for the three and nine months ended September 30, 2023 and 2022, respectively. Includes related party amortization of operating right-of-use assets of $1,601 and $1,536 for the nine months ended September 30, 2023 and 2022, respectively. Includes changes in related party balances of ($1,299) and $832 for the nine months ended September 30, 2023 and 2022, respectively. Includes changes in related party balances of ($1,835) and ($1,446) for the nine months ended September 30, 2023 and 2022, respectively. Includes changes in related party balances of $10,627 and $23,309 for the nine months ended September 30, 2023 and 2022, respectively. Includes related party operating right-of-use assets, net of $11,476 and $13,077 at September 30, 2023 and December 31, 2022, respectively Includes amounts due to related party of $112,740 and $102,113 at September 30, 2023 and December 31, 2022, respectively Includes related party current portion of operating lease liabilities of $1,912 and $1,836 at September 30, 2023 and December 31, 2022, respectively Includes related party long-term operating lease liabilities of $9,994 and $11,631 at September 30, 2023 and December 31, 2022, respectively EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ླ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

&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "4BVY7[M7M&.8! #U) $P M @ &T! ( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1P!' + &@3 #+!@( ! end XML 76 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 328 388 1 true 111 0 false 10 false false R1.htm 0000001 - Document - Cover Sheet http://www.aoncology.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Mezzanine and Members??? Equity Sheet http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity Condensed Consolidated Statements of Mezzanine and Members??? Equity Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Sheet http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows - Parenthetical Sheet http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows - Parenthetical Statements 8 false false R9.htm 0000009 - Disclosure - Business Sheet http://www.aoncology.com/role/Business Business Notes 9 false false R10.htm 0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPolicies Basis of Presentation and Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Reverse Capitalization Sheet http://www.aoncology.com/role/ReverseCapitalization Reverse Capitalization Notes 11 false false R12.htm 0000012 - Disclosure - Variable Interest Entities Sheet http://www.aoncology.com/role/VariableInterestEntities Variable Interest Entities Notes 12 false false R13.htm 0000013 - Disclosure - Marketable Securities Sheet http://www.aoncology.com/role/MarketableSecurities Marketable Securities Notes 13 false false R14.htm 0000014 - Disclosure - Business Combinations Sheet http://www.aoncology.com/role/BusinessCombinations Business Combinations Notes 14 false false R15.htm 0000015 - Disclosure - Supplemental Condensed Balance Sheet Information Sheet http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformation Supplemental Condensed Balance Sheet Information Notes 15 false false R16.htm 0000016 - Disclosure - Long-term Debt Sheet http://www.aoncology.com/role/LongtermDebt Long-term Debt Notes 16 false false R17.htm 0000017 - Disclosure - Income Taxes Sheet http://www.aoncology.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 0000018 - Disclosure - Leases Sheet http://www.aoncology.com/role/Leases Leases Notes 18 false false R19.htm 0000019 - Disclosure - Related Parties Sheet http://www.aoncology.com/role/RelatedParties Related Parties Notes 19 false false R20.htm 0000020 - Disclosure - Equity Sheet http://www.aoncology.com/role/Equity Equity Notes 20 false false R21.htm 0000021 - Disclosure - Net Loss Per Share Sheet http://www.aoncology.com/role/NetLossPerShare Net Loss Per Share Notes 21 false false R22.htm 0000022 - Disclosure - Redeemable Noncontrolling Interest Sheet http://www.aoncology.com/role/RedeemableNoncontrollingInterest Redeemable Noncontrolling Interest Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPolicies 24 false false R25.htm 9954472 - Disclosure - Business (Tables) Sheet http://www.aoncology.com/role/BusinessTables Business (Tables) Tables http://www.aoncology.com/role/Business 25 false false R26.htm 9954473 - Disclosure - Reverse Capitalization (Tables) Sheet http://www.aoncology.com/role/ReverseCapitalizationTables Reverse Capitalization (Tables) Tables http://www.aoncology.com/role/ReverseCapitalization 26 false false R27.htm 9954474 - Disclosure - Variable Interest Entities (Tables) Sheet http://www.aoncology.com/role/VariableInterestEntitiesTables Variable Interest Entities (Tables) Tables http://www.aoncology.com/role/VariableInterestEntities 27 false false R28.htm 9954475 - Disclosure - Marketable Securities (Tables) Sheet http://www.aoncology.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.aoncology.com/role/MarketableSecurities 28 false false R29.htm 9954476 - Disclosure - Supplemental Condensed Balance Sheet Information (Tables) Sheet http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationTables Supplemental Condensed Balance Sheet Information (Tables) Tables http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformation 29 false false R30.htm 9954477 - Disclosure - Long-term Debt (Tables) Sheet http://www.aoncology.com/role/LongtermDebtTables Long-term Debt (Tables) Tables http://www.aoncology.com/role/LongtermDebt 30 false false R31.htm 9954478 - Disclosure - Leases (Tables) Sheet http://www.aoncology.com/role/LeasesTables Leases (Tables) Tables http://www.aoncology.com/role/Leases 31 false false R32.htm 9954479 - Disclosure - Related Parties (Tables) Sheet http://www.aoncology.com/role/RelatedPartiesTables Related Parties (Tables) Tables http://www.aoncology.com/role/RelatedParties 32 false false R33.htm 9954480 - Disclosure - Equity (Tables) Sheet http://www.aoncology.com/role/EquityTables Equity (Tables) Tables http://www.aoncology.com/role/Equity 33 false false R34.htm 9954481 - Disclosure - Redeemable Noncontrolling Interest (Tables) Sheet http://www.aoncology.com/role/RedeemableNoncontrollingInterestTables Redeemable Noncontrolling Interest (Tables) Tables http://www.aoncology.com/role/RedeemableNoncontrollingInterest 34 false false R35.htm 9954482 - Disclosure - Business (Details) Sheet http://www.aoncology.com/role/BusinessDetails Business (Details) Details http://www.aoncology.com/role/BusinessTables 35 false false R36.htm 9954483 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details) Sheet http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails Basis of Presentation and Significant Accounting Policies (Details) Details http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies 36 false false R37.htm 9954484 - Disclosure - Reverse Capitalization - Narrative (Details) Sheet http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails Reverse Capitalization - Narrative (Details) Details 37 false false R38.htm 9954485 - Disclosure - Reverse Capitalization - Schedule of Historical Cost (Details) Sheet http://www.aoncology.com/role/ReverseCapitalizationScheduleofHistoricalCostDetails Reverse Capitalization - Schedule of Historical Cost (Details) Details 38 false false R39.htm 9954486 - Disclosure - Variable Interest Entities - Narrative (Details) Sheet http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails Variable Interest Entities - Narrative (Details) Details 39 false false R40.htm 9954487 - Disclosure - Variable Interest Entities - Schedule of Assets and Liabilities (Details) Sheet http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails Variable Interest Entities - Schedule of Assets and Liabilities (Details) Details 40 false false R41.htm 9954488 - Disclosure - Marketable Securities (Details) Sheet http://www.aoncology.com/role/MarketableSecuritiesDetails Marketable Securities (Details) Details http://www.aoncology.com/role/MarketableSecuritiesTables 41 false false R42.htm 9954489 - Disclosure - Marketable Securities - Remaining Contractual Maturities (Details) Sheet http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails Marketable Securities - Remaining Contractual Maturities (Details) Details 42 false false R43.htm 9954490 - Disclosure - Business Combinations (Details) Sheet http://www.aoncology.com/role/BusinessCombinationsDetails Business Combinations (Details) Details http://www.aoncology.com/role/BusinessCombinations 43 false false R44.htm 9954491 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Other Receivables (Details) Sheet http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails Supplemental Condensed Balance Sheet Information - Schedule of Other Receivables (Details) Details 44 false false R45.htm 9954492 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Inventory (Details) Sheet http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails Supplemental Condensed Balance Sheet Information - Schedule of Inventory (Details) Details 45 false false R46.htm 9954493 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Property and Equipment, net (Details) Sheet http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails Supplemental Condensed Balance Sheet Information - Schedule of Property and Equipment, net (Details) Details 46 false false R47.htm 9954494 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Accrued Other (Details) Sheet http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails Supplemental Condensed Balance Sheet Information - Schedule of Accrued Other (Details) Details 47 false false R48.htm 9954495 - Disclosure - Long-term Debt - Schedule of Long-term Debt (Details) Sheet http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails Long-term Debt - Schedule of Long-term Debt (Details) Details 48 false false R49.htm 9954496 - Disclosure - Long-term Debt - Narrative (Details) Sheet http://www.aoncology.com/role/LongtermDebtNarrativeDetails Long-term Debt - Narrative (Details) Details 49 false false R50.htm 9954497 - Disclosure - Income Taxes (Details) Sheet http://www.aoncology.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.aoncology.com/role/IncomeTaxes 50 false false R51.htm 9954498 - Disclosure - Leases - Right-of-use Assets And Lease Liabilities (Details) Sheet http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails Leases - Right-of-use Assets And Lease Liabilities (Details) Details 51 false false R52.htm 9954499 - Disclosure - Leases - Lease Costs (Details) Sheet http://www.aoncology.com/role/LeasesLeaseCostsDetails Leases - Lease Costs (Details) Details 52 false false R53.htm 9954500 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details) Sheet http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails Leases - Maturities of Operating and Financing Lease Liabilities (Details) Details 53 false false R54.htm 9954501 - Disclosure - Leases - Narrative (Details) Sheet http://www.aoncology.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 54 false false R55.htm 9954502 - Disclosure - Leases - Supplemental Cash Flow Information (Details) Sheet http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails Leases - Supplemental Cash Flow Information (Details) Details 55 false false R56.htm 9954503 - Disclosure - Related Parties - Narrative (Details) Sheet http://www.aoncology.com/role/RelatedPartiesNarrativeDetails Related Parties - Narrative (Details) Details 56 false false R57.htm 9954504 - Disclosure - Related Parties - Notes Receivable (Details) Notes http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails Related Parties - Notes Receivable (Details) Details 57 false false R58.htm 9954505 - Disclosure - Equity - Narrative (Details) Sheet http://www.aoncology.com/role/EquityNarrativeDetails Equity - Narrative (Details) Details 58 false false R59.htm 9954506 - Disclosure - Equity - Schedule of Changes in Units (Details) Sheet http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails Equity - Schedule of Changes in Units (Details) Details 59 false false R60.htm 9954507 - Disclosure - Net Loss Per Share - Calculation Of Earnings Per Share (Details) Sheet http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails Net Loss Per Share - Calculation Of Earnings Per Share (Details) Details 60 false false R61.htm 9954508 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details) Sheet http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails Net Loss Per Share - Antidilutive Securities (Details) Details 61 false false R62.htm 9954509 - Disclosure - Redeemable Noncontrolling Interest - Narrative (Details) Sheet http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails Redeemable Noncontrolling Interest - Narrative (Details) Details 62 false false R63.htm 9954510 - Disclosure - Redeemable Noncontrolling Interest - Schedule of Ownership (Details) Sheet http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails Redeemable Noncontrolling Interest - Schedule of Ownership (Details) Details 63 false false All Reports Book All Reports aonc-20230930.htm aonc-20230930.xsd aonc-20230930_cal.xml aonc-20230930_def.xml aonc-20230930_lab.xml aonc-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "aonc-20230930.htm": { "nsprefix": "aonc", "nsuri": "http://www.aoncology.com/20230930", "dts": { "inline": { "local": [ "aonc-20230930.htm" ] }, "schema": { "local": [ "aonc-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "aonc-20230930_cal.xml" ] }, "definitionLink": { "local": [ "aonc-20230930_def.xml" ] }, "labelLink": { "local": [ "aonc-20230930_lab.xml" ] }, "presentationLink": { "local": [ "aonc-20230930_pre.xml" ] } }, "keyStandard": 288, "keyCustom": 100, "axisStandard": 30, "axisCustom": 3, "memberStandard": 40, "memberCustom": 58, "hidden": { "total": 10, "http://xbrl.sec.gov/dei/2023": 5, "http://www.aoncology.com/20230930": 2, "http://fasb.org/us-gaap/2023": 3 }, "contextCount": 328, "entityCount": 1, "segmentCount": 111, "elementCount": 724, "unitCount": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 876, "http://xbrl.sec.gov/dei/2023": 35 }, "report": { "R1": { "role": "http://www.aoncology.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R3": { "role": "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:TemporaryEquitySharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-17", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "link:footnote", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R4": { "role": "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-27", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-27", "name": "us-gaap:CostsAndExpenses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R5": { "role": "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "longName": "0000005 - Statement - Condensed Consolidated Statements of Mezzanine and Members\u2019 Equity", "shortName": "Condensed Consolidated Statements of Mezzanine and Members\u2019 Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-29", "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-91", "name": "us-gaap:CommonUnitOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R6": { "role": "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R7": { "role": "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical", "longName": "0000007 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-27", "name": "us-gaap:CostOfRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-30", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "link:footnote", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R8": { "role": "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows - Parenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows - Parenthetical", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-32", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "link:footnote", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R9": { "role": "http://www.aoncology.com/role/Business", "longName": "0000009 - Disclosure - Business", "shortName": "Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPolicies", "longName": "0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies", "shortName": "Basis of Presentation and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.aoncology.com/role/ReverseCapitalization", "longName": "0000011 - Disclosure - Reverse Capitalization", "shortName": "Reverse Capitalization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "aonc:ReverseRecapitalizationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:ReverseRecapitalizationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.aoncology.com/role/VariableInterestEntities", "longName": "0000012 - Disclosure - Variable Interest Entities", "shortName": "Variable Interest Entities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.aoncology.com/role/MarketableSecurities", "longName": "0000013 - Disclosure - Marketable Securities", "shortName": "Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.aoncology.com/role/BusinessCombinations", "longName": "0000014 - Disclosure - Business Combinations", "shortName": "Business Combinations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformation", "longName": "0000015 - Disclosure - Supplemental Condensed Balance Sheet Information", "shortName": "Supplemental Condensed Balance Sheet Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.aoncology.com/role/LongtermDebt", "longName": "0000016 - Disclosure - Long-term Debt", "shortName": "Long-term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.aoncology.com/role/IncomeTaxes", "longName": "0000017 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.aoncology.com/role/Leases", "longName": "0000018 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.aoncology.com/role/RelatedParties", "longName": "0000019 - Disclosure - Related Parties", "shortName": "Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.aoncology.com/role/Equity", "longName": "0000020 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.aoncology.com/role/NetLossPerShare", "longName": "0000021 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.aoncology.com/role/RedeemableNoncontrollingInterest", "longName": "0000022 - Disclosure - Redeemable Noncontrolling Interest", "shortName": "Redeemable Noncontrolling Interest", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-47", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.aoncology.com/role/BusinessTables", "longName": "9954472 - Disclosure - Business (Tables)", "shortName": "Business (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfAffiliationAgreementsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfAffiliationAgreementsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.aoncology.com/role/ReverseCapitalizationTables", "longName": "9954473 - Disclosure - Reverse Capitalization (Tables)", "shortName": "Reverse Capitalization (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfReverseRecapitalizationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfReverseRecapitalizationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.aoncology.com/role/VariableInterestEntitiesTables", "longName": "9954474 - Disclosure - Variable Interest Entities (Tables)", "shortName": "Variable Interest Entities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.aoncology.com/role/MarketableSecuritiesTables", "longName": "9954475 - Disclosure - Marketable Securities (Tables)", "shortName": "Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationTables", "longName": "9954476 - Disclosure - Supplemental Condensed Balance Sheet Information (Tables)", "shortName": "Supplemental Condensed Balance Sheet Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfOtherReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfOtherReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.aoncology.com/role/LongtermDebtTables", "longName": "9954477 - Disclosure - Long-term Debt (Tables)", "shortName": "Long-term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.aoncology.com/role/LeasesTables", "longName": "9954478 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "aonc:LesseeAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:LesseeAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.aoncology.com/role/RelatedPartiesTables", "longName": "9954479 - Disclosure - Related Parties (Tables)", "shortName": "Related Parties (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.aoncology.com/role/EquityTables", "longName": "9954480 - Disclosure - Equity (Tables)", "shortName": "Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfReverseRecapitalizationChangesInUnitsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfReverseRecapitalizationChangesInUnitsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.aoncology.com/role/RedeemableNoncontrollingInterestTables", "longName": "9954481 - Disclosure - Redeemable Noncontrolling Interest (Tables)", "shortName": "Redeemable Noncontrolling Interest (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfReverseRecapitalizationOwnershipSummaryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfReverseRecapitalizationOwnershipSummaryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.aoncology.com/role/BusinessDetails", "longName": "9954482 - Disclosure - Business (Details)", "shortName": "Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-6", "name": "aonc:NumberOfOncologyPractices", "unitRef": "practice", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-114", "name": "aonc:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R36": { "role": "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "longName": "9954483 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)", "shortName": "Basis of Presentation and Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-6", "name": "aonc:RecapitalizationExchangeRatioUnits", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-27", "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R37": { "role": "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails", "longName": "9954484 - Disclosure - Reverse Capitalization - Narrative (Details)", "shortName": "Reverse Capitalization - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "aonc:GainLossOnReverseRecapitalization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:GainLossOnReverseRecapitalization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.aoncology.com/role/ReverseCapitalizationScheduleofHistoricalCostDetails", "longName": "9954485 - Disclosure - Reverse Capitalization - Schedule of Historical Cost (Details)", "shortName": "Reverse Capitalization - Schedule of Historical Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-6", "name": "aonc:CashAndCashEquivalentsAcquiredThroughReverseRecapitalization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfReverseRecapitalizationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "aonc:CashAndCashEquivalentsAcquiredThroughReverseRecapitalization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfReverseRecapitalizationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails", "longName": "9954486 - Disclosure - Variable Interest Entities - Narrative (Details)", "shortName": "Variable Interest Entities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-165", "name": "us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-165", "name": "us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails", "longName": "9954487 - Disclosure - Variable Interest Entities - Schedule of Assets and Liabilities (Details)", "shortName": "Variable Interest Entities - Schedule of Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-168", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R41": { "role": "http://www.aoncology.com/role/MarketableSecuritiesDetails", "longName": "9954488 - Disclosure - Marketable Securities (Details)", "shortName": "Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R42": { "role": "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails", "longName": "9954489 - Disclosure - Marketable Securities - Remaining Contractual Maturities (Details)", "shortName": "Marketable Securities - Remaining Contractual Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-179", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R43": { "role": "http://www.aoncology.com/role/BusinessCombinationsDetails", "longName": "9954490 - Disclosure - Business Combinations (Details)", "shortName": "Business Combinations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-170", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-170", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails", "longName": "9954491 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Other Receivables (Details)", "shortName": "Supplemental Condensed Balance Sheet Information - Schedule of Other Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-6", "name": "aonc:RebatesReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfOtherReceivablesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "aonc:RebatesReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfOtherReceivablesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails", "longName": "9954492 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Inventory (Details)", "shortName": "Supplemental Condensed Balance Sheet Information - Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-184", "name": "us-gaap:InventoryNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R46": { "role": "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails", "longName": "9954493 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Property and Equipment, net (Details)", "shortName": "Supplemental Condensed Balance Sheet Information - Schedule of Property and Equipment, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails", "longName": "9954494 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Accrued Other (Details)", "shortName": "Supplemental Condensed Balance Sheet Information - Schedule of Accrued Other (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CustomerRefundLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfOtherAccruedLiabilitiesCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CustomerRefundLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfOtherAccruedLiabilitiesCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails", "longName": "9954495 - Disclosure - Long-term Debt - Schedule of Long-term Debt (Details)", "shortName": "Long-term Debt - Schedule of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "longName": "9954496 - Disclosure - Long-term Debt - Narrative (Details)", "shortName": "Long-term Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-206", "name": "us-gaap:ProceedsFromLongTermLinesOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-206", "name": "us-gaap:ProceedsFromLongTermLinesOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.aoncology.com/role/IncomeTaxesDetails", "longName": "9954497 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-27", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-27", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails", "longName": "9954498 - Disclosure - Leases - Right-of-use Assets And Lease Liabilities (Details)", "shortName": "Leases - Right-of-use Assets And Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:LesseeAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:LesseeAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R52": { "role": "http://www.aoncology.com/role/LeasesLeaseCostsDetails", "longName": "9954499 - Disclosure - Leases - Lease Costs (Details)", "shortName": "Leases - Lease Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-27", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-27", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails", "longName": "9954500 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details)", "shortName": "Leases - Maturities of Operating and Financing Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.aoncology.com/role/LeasesNarrativeDetails", "longName": "9954501 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails", "longName": "9954502 - Disclosure - Leases - Supplemental Cash Flow Information (Details)", "shortName": "Leases - Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinanceLeaseInterestPaymentOnLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R56": { "role": "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails", "longName": "9954503 - Disclosure - Related Parties - Narrative (Details)", "shortName": "Related Parties - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "aonc:FinancingReceivableAmortizationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:FinancingReceivableAmortizationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails", "longName": "9954504 - Disclosure - Related Parties - Notes Receivable (Details)", "shortName": "Related Parties - Notes Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:NotesReceivableNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:NotesReceivableNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.aoncology.com/role/EquityNarrativeDetails", "longName": "9954505 - Disclosure - Equity - Narrative (Details)", "shortName": "Equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:MembersCapital", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-304", "name": "us-gaap:PreferredStockDividendRatePercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R59": { "role": "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails", "longName": "9954506 - Disclosure - Equity - Schedule of Changes in Units (Details)", "shortName": "Equity - Schedule of Changes in Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-255", "name": "us-gaap:CommonUnitIssuanceValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfReverseRecapitalizationChangesInUnitsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-255", "name": "us-gaap:CommonUnitIssuanceValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfReverseRecapitalizationChangesInUnitsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails", "longName": "9954507 - Disclosure - Net Loss Per Share - Calculation Of Earnings Per Share (Details)", "shortName": "Net Loss Per Share - Calculation Of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-27", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "unique": true } }, "R61": { "role": "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails", "longName": "9954508 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details)", "shortName": "Net Loss Per Share - Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-315", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-315", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "longName": "9954509 - Disclosure - Redeemable Noncontrolling Interest - Narrative (Details)", "shortName": "Redeemable Noncontrolling Interest - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "aonc:StockholdersEquityRedemptionRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:StockholdersEquityRedemptionRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails", "longName": "9954510 - Disclosure - Redeemable Noncontrolling Interest - Schedule of Ownership (Details)", "shortName": "Redeemable Noncontrolling Interest - Schedule of Ownership (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-325", "name": "aonc:LimitedLiabilityCompanyLLCUnitsOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-325", "name": "aonc:LimitedLiabilityCompanyLLCUnitsOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20230930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r9" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r512" ] }, "us-gaap_ProfessionalMalpracticeLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalMalpracticeLiabilityMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional Malpractice Liability Insurance", "label": "Professional Malpractice Liability Insurance [Member]", "documentation": "Business insurance coverage for professionals, such as doctors, lawyers, insurance agents, accountants, real estate agents, veterinarians, and others. This liability coverage insures losses for claims arising from mistakes and errors or omissions in the course of professional activities." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant Liabilities", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r19", "r90", "r91", "r92", "r97", "r220" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss attributable to noncontrolling interests", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests." } } }, "auth_ref": [ "r7", "r16", "r153", "r197", "r200" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities, net of reverse recapitalization:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r17", "r37", "r854", "r855", "r856" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive gain (loss)", "verboseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r16", "r153", "r197", "r200" ] }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfStatesInWhichEntityOperates", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of states in which entity operates", "label": "Number of States in which Entity Operates", "documentation": "The number of states the entity operates in as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCollateralAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCollateralAmount", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pledged collateral", "label": "Debt Instrument, Collateral Amount", "documentation": "Amount of assets pledged to secure a debt instrument." } } }, "auth_ref": [ "r110" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r512" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Changes in fair value adjustments of warrants and derivative liabilities", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r904" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains (losses) on marketable securities", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r7", "r16", "r153" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r512" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Earnings (loss) per unit, diluted (in usd per share)", "terseLabel": "Diluted loss per share of Class A Common Stock (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r207", "r227", "r228", "r229", "r230", "r231", "r239", "r248", "r250", "r251", "r255", "r478", "r479", "r573", "r593", "r724" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r512" ] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredOfferingCosts", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred offering costs", "label": "Deferred Offering Costs", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": [ "r886" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r512" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r32", "r61" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 (remainder of year after September 30, 2023)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r911" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r133", "r264" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.aoncology.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Maturity", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r911" ] }, "us-gaap_DirectorsAndOfficersLiabilityInsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DirectorsAndOfficersLiabilityInsuranceMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Directors and Officers Liability Insurance", "label": "Directors and Officers Liability Insurance [Member]", "documentation": "Professional liability coverage for legal expenses and liability to shareholders, bondholders, creditors or others due to actions or omissions by a director or officer of a corporation or nonprofit organization." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset, net", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r444", "r445" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of securities called by each warrant (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r188" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investment (in percent)", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r323" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.aoncology.com/role/Business" ], "lang": { "en-us": { "role": { "terseLabel": "Business", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r111", "r140", "r141" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r134" ] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r80", "r722" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/MarketableSecuritiesDetails_1": { "parentTag": "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.aoncology.com/role/MarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/MarketableSecuritiesDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r45", "r185", "r717" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of operating right-of-use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r858" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r23", "r160", "r362", "r373", "r730", "r731", "r917" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of finance lease right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r500", "r505", "r742" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Earnings (loss) per unit, basic (in usd per share)", "terseLabel": "Basic loss per share of Class A Common Stock (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r207", "r227", "r228", "r229", "r230", "r231", "r236", "r239", "r248", "r250", "r251", "r255", "r478", "r479", "r573", "r593", "r724" ] }, "us-gaap_MemberUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MemberUnitsMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Units", "label": "Member Units [Member]", "documentation": "Ownership interest in limited liability company (LLC)." } } }, "auth_ref": [] }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilitiesInventoryTypeDomain", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Domain]", "label": "Inventory [Domain]", "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale." } } }, "auth_ref": [ "r852" ] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other receivables", "label": "Increase (Decrease) in Other Receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PublicUtilitiesInventoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilitiesInventoryAxis", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Axis]", "label": "Inventory [Axis]", "documentation": "Information by type of inventory held." } } }, "auth_ref": [ "r852" ] }, "us-gaap_MovementInMinorityInterestRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInMinorityInterestRollForward", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity, Attributable to Noncontrolling Interest [Roll Forward]", "label": "Equity, Attributable to Noncontrolling Interest [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued other", "label": "Increase (Decrease) in Other Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid." } } }, "auth_ref": [ "r9" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r363", "r401", "r406", "r480", "r526", "r735", "r736", "r737" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r221", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r495", "r729", "r730", "r731", "r732", "r733", "r860" ] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestTable", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Table]", "label": "Noncontrolling Interest [Table]", "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r35", "r78", "r81", "r130" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r363", "r401", "r406", "r480", "r527", "r730", "r731", "r735", "r736", "r737" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r23", "r112", "r113", "r159", "r160", "r221", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r495", "r729", "r730", "r731", "r732", "r733", "r860" ] }, "aonc_NorthernArizonaHematologyAndOncologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "NorthernArizonaHematologyAndOncologyMember", "presentation": [ "http://www.aoncology.com/role/BusinessCombinationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Northern Arizona Hematology and Oncology", "label": "Northern Arizona Hematology and Oncology [Member]", "documentation": "Northern Arizona Hematology and Oncology" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r32", "r67", "r68", "r101", "r102", "r104", "r109", "r146", "r147", "r221", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r495", "r729", "r730", "r731", "r732", "r733", "r860" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of marketable securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r39", "r209", "r289" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical", "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r216", "r217", "r517", "r518", "r519", "r520", "r636", "r637", "r638", "r639", "r640", "r661", "r663", "r696" ] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of marketable securities", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r38", "r209", "r289", "r321" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r903" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grants in period (in units)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r425" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity based compensation (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r71" ] }, "us-gaap_MembersCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MembersCapital", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Invested capital contributions", "label": "Members' Capital", "documentation": "Amount of member capital in limited liability company (LLC)." } } }, "auth_ref": [ "r148" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r23", "r160", "r372" ] }, "aonc_FinanceAndOperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "FinanceAndOperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": "aonc_LeaseLiability", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Current portion of operating and finance lease liabilities", "label": "Finance and Operating Lease Liability, Current", "documentation": "Finance and Operating Lease Liability, Current" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "aonc_BusinessCombinationToReverseRecaptialization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "BusinessCombinationToReverseRecaptialization", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from reverse recapitalization", "label": "Business Combination to Reverse Recaptialization", "documentation": "Business Combination to Reverse Recaptialization" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Mezzanine Equity", "label": "Stockholders' Equity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": [ "r12", "r692" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units vested (in units)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r426" ] }, "aonc_DividendsPaidEventPriorToJune72027AfterJune72026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DividendsPaidEventPriorToJune72027AfterJune72026Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Paid, Event Prior to June 7, 2027, After June 7, 2026", "label": "Dividends Paid, Event Prior to June 7, 2027, After June 7, 2026 [Member]", "documentation": "Dividends Paid, Event Prior to June 7, 2027, After June 7, 2026" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant, term", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r907" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental noncash investing and financing activities", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized debt issuance costs", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r103" ] }, "aonc_StockIssuedDuringPeriodValueDerivativeFeature": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockIssuedDuringPeriodValueDerivativeFeature", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of additional Class A-1 Units pursuant to the Anti-Dilution Feature", "label": "Stock Issued During Period, Value, Derivative Feature", "documentation": "Stock Issued During Period, Value, Derivative Feature" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "aonc_IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r169", "r176", "r233", "r234", "r268", "r446", "r454", "r595" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r797" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r10", "r266" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock price (in usd per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r756" ] }, "aonc_AONCentralMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "AONCentralMember", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AON Central", "label": "AON Central [Member]", "documentation": "AON Central" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r329", "r330", "r331", "r332", "r333", "r336", "r337", "r338", "r371", "r387", "r475", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r590", "r728", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r881", "r882", "r883", "r884" ] }, "us-gaap_SupplierConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplierConcentrationRiskMember", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Concentration Risk", "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": [ "r55" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r798" ] }, "aonc_DebtInstrumentThresholdLimitPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DebtInstrumentThresholdLimitPeriodTwoMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Threshold Limit, Period Two", "label": "Debt Instrument, Threshold Limit, Period Two [Member]", "documentation": "Debt Instrument, Threshold Limit, Period Two" } } }, "auth_ref": [] }, "us-gaap_PreferredClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredClassAMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Class A", "label": "Preferred Class A [Member]", "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer." } } }, "auth_ref": [] }, "aonc_NumberOfBoardOfManagersDesignatedByCompany": { "xbrltype": "integerItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "NumberOfBoardOfManagersDesignatedByCompany", "presentation": [ "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of board of managers designated by company", "label": "Number Of Board Of Managers Designated By Company", "documentation": "Number Of Board Of Managers Designated By Company" } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ReverseRecapitalizationNet", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/ReverseCapitalizationScheduleofHistoricalCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/ReverseCapitalizationScheduleofHistoricalCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Net Liabilities", "label": "Reverse Recapitalization, Net", "documentation": "Reverse Recapitalization, Net" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r438", "r439", "r440", "r621", "r864", "r865", "r866", "r905", "r923" ] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Preferred Stock", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "aonc_LeaseLiabilityCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LeaseLiabilityCurrentAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Lease Liability, Current [Abstract]", "documentation": "Lease Liability, Current" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Investment in Affiliate", "label": "Equity Method Investments [Policy Text Block]", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r8", "r100", "r324" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r723", "r735", "r737", "r915" ] }, "aonc_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnout period, threshold trading day period (in days)", "label": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Consecutive Trading Days", "documentation": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Consecutive Trading Days" } } }, "auth_ref": [] }, "aonc_ClassOfWarrantOrRightExercisePeriodAfterInitialPublicOffering": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ClassOfWarrantOrRightExercisePeriodAfterInitialPublicOffering", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant, exercise period, after initial public offering", "label": "Class Of Warrant Or Right, Exercise Period, After Initial Public Offering", "documentation": "Class Of Warrant Or Right, Exercise Period, After Initial Public Offering" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Marketable Securities", "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r108" ] }, "aonc_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerAllocationOfIncome": { "xbrltype": "pureItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerAllocationOfIncome", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allocation of income to controlling and noncontrolling interests (in percent)", "label": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Income", "documentation": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Income" } } }, "auth_ref": [] }, "aonc_DigitalTransformationOpportunitiesCorpDTOCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DigitalTransformationOpportunitiesCorpDTOCMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Digital Transformation Opportunities Corp. (\u201cDTOC\u201d)", "label": "Digital Transformation Opportunities Corp. (\u201cDTOC\u201d) [Member]", "documentation": "Digital Transformation Opportunities Corp. (\u201cDTOC\u201d)" } } }, "auth_ref": [] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductAndServiceOtherMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other revenue", "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": [ "r902" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation related costs", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r9" ] }, "us-gaap_TemporaryEquityLiquidationPreference": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityLiquidationPreference", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidation preference", "label": "Temporary Equity, Liquidation Preference", "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r18", "r34", "r180", "r201", "r202", "r203", "r222", "r223", "r224", "r226", "r232", "r234", "r256", "r327", "r328", "r390", "r438", "r439", "r440", "r451", "r452", "r469", "r470", "r471", "r472", "r473", "r474", "r477", "r487", "r488", "r489", "r490", "r491", "r492", "r513", "r602", "r603", "r604", "r621", "r688" ] }, "aonc_PublicWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "PublicWarrantMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public Warrant", "label": "Public Warrant [Member]", "documentation": "Public Warrant" } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationChangeInValueOfUnitsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ReverseRecapitalizationChangeInValueOfUnitsRollForward", "presentation": [ "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Recapitalization, Change In Value Of Units [Roll Forward]", "label": "Reverse Recapitalization, Change In Value Of Units [Roll Forward]", "documentation": "Reverse Recapitalization, Change In Value Of Units" } } }, "auth_ref": [] }, "aonc_PatientVisitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "PatientVisitsMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patient Visits", "label": "Patient Visits [Member]", "documentation": "Patient Visits And Shipments Of Prescriptions" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retained\u2028Earnings (Deficit)", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r180", "r222", "r223", "r224", "r226", "r232", "r234", "r327", "r328", "r438", "r439", "r440", "r451", "r452", "r469", "r471", "r472", "r474", "r477", "r602", "r604", "r621", "r923" ] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/MarketableSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r156", "r166", "r167", "r179", "r288", "r290", "r483", "r484" ] }, "aonc_StockIssuedDuringPeriodSharesReverseRecapitalization": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockIssuedDuringPeriodSharesReverseRecapitalization", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Recapitalization, net (in shares)", "label": "Stock Issued During Period, Shares, Reverse Recapitalization", "documentation": "Stock Issued During Period, Shares, Reverse Recapitalization" } } }, "auth_ref": [] }, "aonc_LeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total right-of-use assets", "label": "Lease, Right-Of-Use Asset", "documentation": "Lease, Right-Of-Use Asset" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Par value (dollars per share)", "label": "Temporary Equity, Par or Stated Value Per Share", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": [ "r22", "r62" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r186" ] }, "aonc_StockholdersEquityConversionRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockholdersEquityConversionRightDomain", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity, Conversion Right [Domain]", "label": "Stockholders' Equity, Conversion Right [Domain]", "documentation": "Stockholders' Equity, Conversion Right [Domain]" } } }, "auth_ref": [] }, "aonc_NoncashConsiderationFairValueOfConsiderationForEquityMethodInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "NoncashConsiderationFairValueOfConsiderationForEquityMethodInvestment", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash consideration of equity method investment", "label": "Noncash Consideration, Fair Value Of Consideration For Equity Method Investment", "documentation": "Noncash Consideration, Fair Value Of Consideration For Equity Method Investment" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "aonc_DebtInstrumentThresholdLimitPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DebtInstrumentThresholdLimitPeriodOneMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Threshold Limit, Period One", "label": "Debt Instrument, Threshold Limit, Period One [Member]", "documentation": "Debt Instrument, Threshold Limit, Period One" } } }, "auth_ref": [] }, "aonc_StockholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockholdersMember", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders", "label": "Stockholders [Member]", "documentation": "Stockholders" } } }, "auth_ref": [] }, "aonc_DividendsPaidEventPriorToJune72028AfterJune72027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DividendsPaidEventPriorToJune72028AfterJune72027Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Paid, Event Prior to June 7, 2028, After June 7, 2027", "label": "Dividends Paid, Event Prior to June 7, 2028, After June 7, 2027 [Member]", "documentation": "Dividends Paid, Event Prior to June 7, 2028, After June 7, 2027" } } }, "auth_ref": [] }, "aonc_LegacyAONShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LegacyAONShareholdersMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legacy AON Shareholders", "label": "Legacy AON Shareholders [Member]", "documentation": "Legacy AON Shareholders" } } }, "auth_ref": [] }, "aonc_GainLossOnIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "GainLossOnIssuanceOfWarrants", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gain (loss) on issuance of warrants", "label": "Gain (Loss) On Issuance Of Warrants", "documentation": "Gain (Loss) On Issuance Of Warrants" } } }, "auth_ref": [] }, "aonc_IncreaseDecreaseInRedeemableNoncontrollingInterestRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "IncreaseDecreaseInRedeemableNoncontrollingInterestRollForward", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) In Noncontrolling Interest [Roll Forward]", "label": "Increase (Decrease) In Redeemable Noncontrolling Interest [Roll Forward]", "documentation": "Increase (Decrease) In Redeemable Noncontrolling Interest" } } }, "auth_ref": [] }, "aonc_ClassBPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ClassBPrefundedWarrantsMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Prefunded Warrants", "label": "Class B Prefunded Warrants [Member]", "documentation": "Class B Prefunded Warrants" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r18", "r180", "r201", "r202", "r203", "r222", "r223", "r224", "r226", "r232", "r234", "r256", "r327", "r328", "r390", "r438", "r439", "r440", "r451", "r452", "r469", "r470", "r471", "r472", "r473", "r474", "r477", "r487", "r488", "r489", "r490", "r491", "r492", "r513", "r602", "r603", "r604", "r621", "r688" ] }, "aonc_DividendsPaidEventPriorToJune72025AfterJune72024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DividendsPaidEventPriorToJune72025AfterJune72024Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Paid, Event Prior to June 7, 2025, After June 7, 2024", "label": "Dividends Paid, Event Prior to June 7, 2025, After June 7, 2024 [Member]", "documentation": "Dividends Paid, Event Prior to June 7, 2025, After June 7, 2024" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r17", "r37", "r470", "r473", "r513", "r602", "r603", "r854", "r855", "r856", "r864", "r865", "r866" ] }, "aonc_TemporaryEquityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "TemporaryEquityMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary Equity", "label": "Temporary Equity [Member]", "documentation": "Temporary Equity" } } }, "auth_ref": [] }, "aonc_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnout period, trading days (in days)", "label": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Trading Days", "documentation": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Trading Days" } } }, "auth_ref": [] }, "aonc_LeaseRightOfUseAssetAndLiabilityReductionFromLeaseTerminations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LeaseRightOfUseAssetAndLiabilityReductionFromLeaseTerminations", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Right-of-use assets and lease liabilities removed in termination of lease", "label": "Lease, Right-Of-Use Asset And Liability Reduction From Lease Terminations", "documentation": "Lease, Right-Of-Use Asset And Liability Reduction From Lease Terminations" } } }, "auth_ref": [] }, "aonc_TemporaryEquityOptionToPurchaseAdditionalUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "TemporaryEquityOptionToPurchaseAdditionalUnits", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to purchase additional units (in shares)", "label": "Temporary Equity, Option To Purchase Additional Units", "documentation": "Temporary Equity, Option To Purchase Additional Units" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current finance lease liability." } } }, "auth_ref": [ "r499" ] }, "aonc_ReverseRecapitalizationChangeInUnitsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ReverseRecapitalizationChangeInUnitsRollForward", "presentation": [ "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Recapitalization, Change In Units [Roll Forward]", "label": "Reverse Recapitalization, Change In Units [Roll Forward]", "documentation": "Reverse Recapitalization, Change In Units" } } }, "auth_ref": [] }, "aonc_CommonClassA1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "CommonClassA1Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class A-1", "label": "Common Class A-1 [Member]", "documentation": "Common Class A-1" } } }, "auth_ref": [] }, "aonc_SignsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "SignsMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Signs", "label": "Signs [Member]", "documentation": "Signs" } } }, "auth_ref": [] }, "aonc_A2024NotesReceivableNote3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "A2024NotesReceivableNote3Member", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note 3", "label": "2024 Notes Receivable, Note 3 [Member]", "documentation": "2024 Notes Receivable, Note 3" } } }, "auth_ref": [] }, "us-gaap_AutomobilesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AutomobilesMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Automobiles", "label": "Automobiles [Member]", "documentation": "Vehicles that are used primarily for transporting people." } } }, "auth_ref": [] }, "aonc_NetIncomeLossPortionAttributableToParentBeforeRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "NetIncomeLossPortionAttributableToParentBeforeRecapitalization", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Net Income (Loss), Portion Attributable to Parent, Before Recapitalization", "documentation": "Net Income (Loss), Portion Attributable to Parent, Before Recapitalization" } } }, "auth_ref": [] }, "aonc_TemporaryEquityRedeemablePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "TemporaryEquityRedeemablePeriod", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary equity, redeemable period", "label": "Temporary Equity, Redeemable Period", "documentation": "Temporary Equity, Redeemable Period" } } }, "auth_ref": [] }, "aonc_DerivativeInstrumentContingentConsiderationLiabilityShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DerivativeInstrumentContingentConsiderationLiabilityShares", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnout shares not outstanding (in shares)", "label": "Derivative Instrument, Contingent Consideration, Liability, Shares", "documentation": "Derivative Instrument, Contingent Consideration, Liability, Shares" } } }, "auth_ref": [] }, "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.aoncology.com/role/MarketableSecuritiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash and cash equivalents and available-for-sale securities, amortized cost", "label": "Cash, Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost", "documentation": "Cash, Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost" } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ReverseRecapitalizationTransactionCosts", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction expenses", "label": "Reverse Recapitalization Transaction Costs", "documentation": "Reverse Recapitalization Transaction Costs" } } }, "auth_ref": [] }, "aonc_FinanceLeaseLiabilityToBePaidDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "FinanceLeaseLiabilityToBePaidDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, to be Paid, Due after Year Four", "documentation": "Finance Lease, Liability, to be Paid, Due after Year Four" } } }, "auth_ref": [] }, "us-gaap_CapitalUnitClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitClassDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Unit, Class [Domain]", "label": "Capital Unit, Class [Domain]", "documentation": "Description of the type or class of capital units or capital shares." } } }, "auth_ref": [] }, "aonc_StockIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockIssuanceExpense", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issuance costs", "label": "Stock Issuance Expense", "documentation": "Stock Issuance Expense" } } }, "auth_ref": [] }, "aonc_NewAONAONIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "NewAONAONIncMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AON Inc.", "label": "New AON (AON Inc.) [Member]", "documentation": "New AON (AON Inc.)" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r72", "r73", "r409" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "terseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r9" ] }, "aonc_CommonUnitIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "CommonUnitIssuedDuringPeriod", "presentation": [ "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of units (in units)", "label": "Common Unit, Issued During Period", "documentation": "Common Unit, Issued During Period" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r103", "r165", "r204", "r265", "r493", "r673", "r753", "r922" ] }, "us-gaap_CapitalUnitsByClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitsByClassAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Units by Class [Axis]", "label": "Capital Units by Class [Axis]", "documentation": "Information by type or class of the entity's capital units." } } }, "auth_ref": [] }, "aonc_IntravenousDrugsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "IntravenousDrugsMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intravenous drugs", "label": "Intravenous Drugs [Member]", "documentation": "Intravenous Drugs" } } }, "auth_ref": [] }, "aonc_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger": { "xbrltype": "perShareItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock price trigger (in usd per share)", "label": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Stock Price Trigger", "documentation": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Stock Price Trigger" } } }, "auth_ref": [] }, "aonc_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal of property and equipment in exchange for reduction in finance lease liability", "label": "Disposal Of Property, Plant And Equipment In Exchange For Reduction Of Capital Lease Liability", "documentation": "Disposal Of Property, Plant And Equipment In Exchange For Reduction Of Capital Lease Liability" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicLineItems", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r239", "r240", "r248" ] }, "aonc_StockholdersEquityConversionThresholdStockPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockholdersEquityConversionThresholdStockPrice", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity, conversion, threshold stock price (in dollars per share) (less than) (greater than)", "label": "Stockholders' Equity, Conversion, Threshold Stock Price", "documentation": "Stockholders' Equity, Conversion, Threshold Stock Price" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in accounts payable for capital additions to property and equipment", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r46", "r47", "r48" ] }, "aonc_CommonUnitUnitImpactOfTheReverseRecapitalization": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "CommonUnitUnitImpactOfTheReverseRecapitalization", "presentation": [ "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of the Reverse Recapitalization (in units)", "label": "Common Unit, Unit Impact Of The Reverse Recapitalization", "documentation": "Common Unit, Unit Impact Of The Reverse Recapitalization" } } }, "auth_ref": [] }, "aonc_DividendsPaidEventAfterJune72028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DividendsPaidEventAfterJune72028Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Paid, Event After June 7, 2028", "label": "Dividends Paid, Event After June 7, 2028 [Member]", "documentation": "Dividends Paid, Event After June 7, 2028" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "aonc_StockholdersEquityRedemptionRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockholdersEquityRedemptionRatio", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption ratio", "label": "Stockholders' Equity, Redemption Ratio", "documentation": "Stockholders' Equity, Redemption Ratio" } } }, "auth_ref": [] }, "aonc_AONCommonUnitholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "AONCommonUnitholdersMember", "presentation": [ "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AON Common Unit", "label": "AON Common Unitholders [Member]", "documentation": "AON Common Unitholders" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Adjustment of Warrants", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r10" ] }, "aonc_CapitalUnitClassB1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "CapitalUnitClassB1Member", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Unit, Class B-1", "label": "Capital Unit, Class B-1 [Member]", "documentation": "Capital Unit, Class B-1" } } }, "auth_ref": [] }, "aonc_StockholdersEquityNumberOfDaysAfterTheRedemptionNoticeDateForRedemptionToBeSettled": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockholdersEquityNumberOfDaysAfterTheRedemptionNoticeDateForRedemptionToBeSettled", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of days after redemption notice date that redemption must be settled", "label": "Stockholders' Equity, Number Of Days After The Redemption Notice Date For Redemption To Be Settled", "documentation": "Stockholders Equity, Number Of Days After The Redemption Notice Date For Redemption To Be Settled" } } }, "auth_ref": [] }, "aonc_DeferredSocialSecurityTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DeferredSocialSecurityTaxesCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred social security taxes - COVID", "label": "Deferred Social Security Taxes, Current", "documentation": "Deferred Social Security Taxes, Current" } } }, "auth_ref": [] }, "aonc_ParticipatingThresholdDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ParticipatingThresholdDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Participating Threshold [Domain]", "label": "Participating Threshold [Domain]", "documentation": "Participating Threshold [Domain]" } } }, "auth_ref": [] }, "aonc_IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNetOfTax", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before equity loss in affiliate and noncontrolling interest", "label": "Income (Loss) From Continuing Operations Before Equity Method Investments, Net Of Tax", "documentation": "Income (Loss) From Continuing Operations Before Equity Method Investments, Net Of Tax" } } }, "auth_ref": [] }, "aonc_A2024NotesReceivableNote2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "A2024NotesReceivableNote2Member", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note 2", "label": "2024 Notes Receivable, Note 2 [Member]", "documentation": "2024 Notes Receivable, Note 2" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r802" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r363", "r401", "r402", "r403", "r404", "r405", "r406", "r480", "r526", "r527", "r528", "r730", "r731", "r735", "r736", "r737" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r803" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU assets obtained in exchange for new finance lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r509", "r742" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r185" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r804" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r757" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r70" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r806" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r805" ] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r804" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU assets obtained in exchange for new operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r509", "r742" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_CapitalUnitClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitClassAMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Unit, Class A", "label": "Capital Unit, Class A [Member]", "documentation": "Class A of capital units, which are a type of ownership interest in a corporation." } } }, "auth_ref": [] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r794" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r103", "r899" ] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r839", "r857" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r757" ] }, "us-gaap_CapitalUnitClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitClassBMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Unit, Class B", "label": "Capital Unit, Class B [Member]", "documentation": "Class B of capital units, which are a type of ownership interest in a corporation." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "aonc_PNCLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "PNCLoanFacilityMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PNC Loan Facility", "label": "PNC Loan Facility [Member]", "documentation": "PNC Loan Facility" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due in one year or less", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r299", "r575" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due in one to five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r300", "r576" ] }, "aonc_StockIssuedDuringPeriodSharesDerivativeFeature": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockIssuedDuringPeriodSharesDerivativeFeature", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of additional Class A-1 Units pursuant to the Anti-Dilution Feature (in shares)", "label": "Stock Issued During Period, Shares, Derivative Feature", "documentation": "Stock Issued During Period, Shares, Derivative Feature" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread (in percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r806" ] }, "us-gaap_DividendsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsAxis", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends [Axis]", "label": "Dividends [Axis]", "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r25", "r122", "r123", "r124" ] }, "us-gaap_DividendsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsDomain", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends [Domain]", "label": "Dividends [Domain]", "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r793" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r806" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]", "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r806" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.aoncology.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate for operating leases (in percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r511", "r742" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r771", "r779", "r789", "r806", "r814", "r818", "r826" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r771", "r779", "r789", "r806", "r814", "r818", "r826" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 }, "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/MarketableSecuritiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term marketable securities", "verboseLabel": "Estimated Fair\u2028Value", "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r293", "r335", "r569", "r869" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r757" ] }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Capital contribution from noncontrolling interest member", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref": [ "r15", "r69", "r154" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.aoncology.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate for finance leases (in percent)", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r511", "r742" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.aoncology.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term for operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r510", "r742" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r137" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r408", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r800" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r158", "r187", "r214", "r261", "r277", "r281", "r326", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r463", "r467", "r486", "r579", "r656", "r743", "r755", "r895", "r896", "r913" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r408", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning of period", "periodEndLabel": "End of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r45", "r137", "r212" ] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Condensed Balance Sheet Information", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r848" ] }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails": { "parentTag": "us-gaap_NotesReceivableNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of notes receivable - related parties", "negatedLabel": "Less:\u00a0\u00a0Current portion of notes receivable", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease." } } }, "auth_ref": [ "r286", "r287", "r570" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r116" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r77", "r390", "r864", "r865", "r866", "r923" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/Cover", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails", "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class B", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r923" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r116" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Domain]", "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r798" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/BusinessCombinations" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r151", "r461" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r77", "r78", "r87", "r180", "r181", "r202", "r222", "r223", "r224", "r226", "r232", "r327", "r328", "r390", "r438", "r439", "r440", "r451", "r452", "r469", "r470", "r471", "r472", "r473", "r474", "r477", "r487", "r488", "r492", "r513", "r603", "r604", "r619", "r644", "r662", "r689", "r690", "r710", "r754", "r861", "r885", "r908", "r923" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "totalLabel": "Other receivables", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Axis]", "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expenses", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r132", "r667" ] }, "aonc_LimitedLiabilityCompanyLLCUnitsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LimitedLiabilityCompanyLLCUnitsIssued", "calculation": { "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Units Issued", "label": "Limited Liability Company (LLC) Units, Issued", "documentation": "Limited Liability Company (LLC) Units, Issued" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r798" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, value", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r116", "r580", "r743" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r116", "r642" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r18", "r116", "r642", "r662", "r923", "r924" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r798" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r339", "r340", "r341", "r342", "r343", "r344", "r345" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r798" ] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredChargesPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Offering Costs", "label": "Deferred Charges, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": [ "r186" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableNoncontrollingInterestEquityRedemptionValue", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption value of noncontrolling interest", "label": "Redeemable Noncontrolling Interest, Equity, Redemption Value", "documentation": "Redemption value, as if currently redeemable, of redeemable noncontrolling interest classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date." } } }, "auth_ref": [ "r24" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r799" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r54", "r56", "r98", "r99", "r285", "r713" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r801" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r799" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails", "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "verboseLabel": "Payments for operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r503", "r508" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNet", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r651", "r712", "r748", "r918" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r799" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r11" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Patient accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r286", "r287" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r799" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r799" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments on finance lease liabilities", "terseLabel": "Financing cash flows from finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r501", "r508" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r799" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r799" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest." } } }, "auth_ref": [ "r170" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease costs", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r507", "r742" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares of Class A Common Stock Outstanding:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance \u2028Leases", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r221", "r463", "r464", "r467", "r468", "r522", "r714", "r894", "r897", "r898" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails", "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r221", "r463", "r464", "r467", "r468", "r522", "r714", "r894", "r897", "r898" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/Cover", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r178", "r189", "r190", "r191", "r214", "r239", "r240", "r248", "r251", "r259", "r260", "r326", "r346", "r348", "r349", "r350", "r353", "r354", "r375", "r376", "r379", "r382", "r389", "r486", "r610", "r611", "r612", "r613", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r642", "r665", "r688", "r705", "r706", "r707", "r708", "r709", "r833", "r859", "r867" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r283", "r556", "r596", "r597", "r598", "r599", "r600", "r601", "r716", "r734", "r744", "r840", "r892", "r893", "r901", "r919" ] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails", "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r283", "r556", "r596", "r597", "r598", "r599", "r600", "r601", "r716", "r734", "r744", "r840", "r892", "r893", "r901", "r919" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.aoncology.com/role/LongtermDebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r32", "r67", "r68", "r101", "r102", "r104", "r109", "r146", "r147", "r730", "r732", "r863" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r797" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Offering costs", "terseLabel": "Offering costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r43" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Redeemable noncontrolling interest", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r63", "r64", "r65", "r66" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant outstanding (in warrants)", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r797" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r824" ] }, "aonc_AONIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "AONIncMember", "presentation": [ "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AON Inc.", "label": "AON Inc. [Member]", "documentation": "AON Inc." } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r821" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r758" ] }, "aonc_PaymentsOfPreferredReturnsAndTaxDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "PaymentsOfPreferredReturnsAndTaxDistributions", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Class A and A-1 preferred returns and tax distributions", "label": "Payments Of Preferred Returns And Tax Distributions", "documentation": "Payments Of Preferred Returns And Tax Distributions" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r819" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due to AON LLC and subsidiaries, net", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r30", "r743" ] }, "aonc_AntiDilutionFeatureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "AntiDilutionFeatureMember", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-Dilution Feature", "label": "Anti-Dilution Feature [Member]", "documentation": "Anti-Dilution Feature" } } }, "auth_ref": [] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r826" ] }, "us-gaap_MalpracticeInsuranceAnnualCoverageLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MalpracticeInsuranceAnnualCoverageLimit", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Malpractice insurance, limit per policy period", "label": "Malpractice Insurance, Annual Coverage Limit", "documentation": "Annual coverage limit provided by the insurance arrangement for malpractice claims." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails", "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r105", "r106", "r668", "r669", "r672" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r820" ] }, "us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MalpracticeInsuranceMaximumCoveragePerIncident", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Malpractice insurance, coverage per claim", "label": "Malpractice Insurance, Maximum Coverage Per Incident", "documentation": "Maximum coverage per malpractice claim provided by the insurance arrangement." } } }, "auth_ref": [ "r168" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r143" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r33" ] }, "aonc_FinancingReceivableAfterAllowanceForCreditLossOriginalPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "FinancingReceivableAfterAllowanceForCreditLossOriginalPrincipal", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Original\u2028Principal", "label": "Financing Receivable, After allowance For Credit Loss, Original Principal", "documentation": "Financing Receivable, After allowance For Credit Loss, Original Principal" } } }, "auth_ref": [] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateBondSecuritiesMember", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "aonc_MIBAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "MIBAMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MIBA", "label": "MIBA [Member]", "documentation": "MIBA" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r825" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) before noncontrolling interest", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r127", "r139", "r164", "r182", "r196", "r199", "r203", "r214", "r225", "r227", "r228", "r229", "r230", "r233", "r234", "r245", "r261", "r276", "r280", "r282", "r326", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r479", "r486", "r589", "r664", "r686", "r687", "r726", "r753", "r895" ] }, "aonc_PNCLineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "PNCLineOfCreditMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PNC Line of Credit", "label": "PNC Line Of Credit [Member]", "documentation": "PNC Line Of Credit" } } }, "auth_ref": [] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r822" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails": { "parentTag": "us-gaap_UndistributedEarnings", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Class A Common Stockholders, Basic", "verboseLabel": "Net loss attributable to Class A Common Stockholders for basic loss per share", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r208", "r227", "r228", "r229", "r230", "r236", "r237", "r247", "r251", "r261", "r276", "r280", "r282", "r726" ] }, "us-gaap_TypeAndTierIdentifierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeAndTierIdentifierDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type and Tier Identifier [Domain]", "label": "Type and Tier Identifier [Domain]", "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r168" ] }, "aonc_StockIssuedDuringPeriodValueReverseRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockIssuedDuringPeriodValueReverseRecapitalization", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Recapitalization, net", "label": "Stock Issued During Period, Value, Reverse Recapitalization", "documentation": "Stock Issued During Period, Value, Reverse Recapitalization" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r823" ] }, "aonc_RedeemableNoncontrollingInterestReverseRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "RedeemableNoncontrollingInterestReverseRecapitalization", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Recapitalization, net", "label": "Redeemable Noncontrolling Interest, Reverse Recapitalization", "documentation": "Redeemable Noncontrolling Interest, Reverse Recapitalization" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Type and Tier Identifier [Axis]", "label": "Insurance Type and Tier Identifier [Axis]", "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r168" ] }, "aonc_OvernightRepurchaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "OvernightRepurchaseAgreementsMember", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Overnight Repurchase Agreements", "label": "Overnight Repurchase Agreements [Member]", "documentation": "Overnight Repurchase Agreements" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r824" ] }, "aonc_StockholdersEquityTaxDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockholdersEquityTaxDistributions", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax distributions", "label": "Stockholders' Equity, Tax distributions", "documentation": "Stockholders' Equity, Tax distributions" } } }, "auth_ref": [] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "aonc_DescriptionOfBusinessAndSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DescriptionOfBusinessAndSignificantAccountingPoliciesTable", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description Of Business And Significant Accounting Policies [Table]", "label": "Description Of Business And Significant Accounting Policies [Table]", "documentation": "Description Of Business And Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "aonc_CommonStockClassB1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "CommonStockClassB1Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B-1", "label": "Common Stock, Class B-1 [Member]", "documentation": "Common Stock, Class B-1" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r54", "r56", "r98", "r99", "r285", "r713" ] }, "aonc_ScheduleOfReverseRecapitalizationChangesInUnitsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ScheduleOfReverseRecapitalizationChangesInUnitsTableTextBlock", "presentation": [ "http://www.aoncology.com/role/EquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reverse Recapitalization, Changes in Units", "label": "Schedule Of Reverse Recapitalization, Changes In Units [Table Text Block]", "documentation": "Schedule Of Reverse Recapitalization, Changes In Units" } } }, "auth_ref": [] }, "aonc_ScheduleOfAffiliationAgreementsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ScheduleOfAffiliationAgreementsTableTextBlock", "presentation": [ "http://www.aoncology.com/role/BusinessTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Affiliation Agreements", "label": "Schedule Of Affiliation Agreements [Table Text Block]", "documentation": "Schedule Of Affiliation Agreements" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r54", "r56", "r98", "r99", "r285", "r608", "r713" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r824" ] }, "aonc_ScheduleOfReverseRecapitalizationOwnershipSummaryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ScheduleOfReverseRecapitalizationOwnershipSummaryTableTextBlock", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reverse Recapitalization, Ownership Summary", "label": "Schedule Of Reverse Recapitalization, Ownership Summary [Table Text Block]", "documentation": "Schedule Of Reverse Recapitalization, Ownership Summary" } } }, "auth_ref": [] }, "aonc_FurnitureFixturesAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "FurnitureFixturesAndEquipmentMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture, fixtures and equipment", "label": "Furniture, Fixtures and Equipment [Member]", "documentation": "Furniture, Fixtures and Equipment" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r825" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r218", "r219", "r358", "r377", "r520", "r720", "r721" ] }, "aonc_StockholdersEquityConversionStockPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockholdersEquityConversionStockPrice", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold stock price, conversion price adjustment (in usd per share)", "label": "Stockholders' Equity, Conversion, Stock Price", "documentation": "Stockholders' Equity, Conversion, Stock Price" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r825" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r825" ] }, "us-gaap_MalpracticeLossContingencyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MalpracticeLossContingencyPolicy", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Professional Liability", "label": "Malpractice Loss Contingency, Policy [Policy Text Block]", "documentation": "Disclosure of the accounting policy for malpractice loss contingencies accrual (general and professional liability) which may include the method for calculating incurred but not reported (IBNR) claims, the use of actuarial and individual case-based assumptions, whether the accrual has been discounted, the types of costs included in the accrual (for example, legal costs) and other significant estimates used to determine the accrued liability." } } }, "auth_ref": [] }, "aonc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of Class C Units, net of offering costs (in shares)", "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues", "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues" } } }, "auth_ref": [] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r192", "r650" ] }, "aonc_LeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LeaseLiability", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease liabilities", "label": "Lease, Liability", "documentation": "Lease, Liability" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r825" ] }, "aonc_StockholdersEquityConversionThresholdVolumeWeightedAveragePricePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockholdersEquityConversionThresholdVolumeWeightedAveragePricePeriod", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity, conversion, threshold volume weighted average price period", "label": "Stockholders' Equity, Conversion, Threshold Volume Weighted Average Price Period", "documentation": "Stockholders' Equity, Conversion, Threshold Volume Weighted Average Price Period" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromCollectionOfNotesReceivable", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Collections on notes receivable - related parties", "label": "Proceeds from Collection of Notes Receivable", "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r38" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Unrealized\u2028Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r296" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r31", "r184", "r214", "r326", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r464", "r467", "r468", "r486", "r743", "r895", "r913", "r914" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/Cover", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Class A", "terseLabel": "Common Class A", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r923" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized\u2028Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r295" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.aoncology.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term for finance leases", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r510", "r742" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r36", "r37", "r125", "r193", "r582", "r606", "r607" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeaseLeaseNotYetCommencedTermOfContract1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeaseLeaseNotYetCommencedTermOfContract1", "presentation": [ "http://www.aoncology.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease not yet commenced, term of contract (in months)", "label": "Lessee, Finance Lease, Lease Not yet Commenced, Term of Contract", "documentation": "Term of lessee's finance lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r909" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r129" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r9" ] }, "aonc_GainLossOnWarrantAndDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "GainLossOnWarrantAndDerivativeNet", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Changes in fair value adjustments of warrants and derivative liabilities", "label": "Gain (Loss) On Warrant And Derivative, Net", "documentation": "Gain (Loss) On Warrant And Derivative, Net" } } }, "auth_ref": [] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r35", "r161", "r214", "r326", "r346", "r348", "r349", "r350", "r353", "r354", "r486", "r584", "r644" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r32", "r221", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r495", "r729", "r730", "r731", "r732", "r733", "r860" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from disposals of property and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r135" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r27" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterest" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Noncontrolling Interest", "label": "Noncontrolling Interest Disclosure [Text Block]", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r152" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestLineItems", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Line Items]", "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r757" ] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableNet", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total notes receivables", "label": "Financing Receivable, after Allowance for Credit Loss", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r286", "r334", "r651" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r757" ] }, "aonc_RecapitalizationExchangeRatioUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "RecapitalizationExchangeRatioUnits", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recapitalization exchange ratio, units", "label": "Recapitalization Exchange Ratio, Units", "documentation": "Recapitalization Exchange Ratio, Shares" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r757" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Significant Accounting Policies", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r111", "r140", "r141", "r152" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r832" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and benefits", "label": "Employee-related Liabilities", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r107", "r916" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r853" ] }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansReceivableNetNoncurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails": { "parentTag": "us-gaap_NotesReceivableNet", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes receivable - related parties", "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r437", "r442" ] }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued other", "label": "Other Accrued Liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other." } } }, "auth_ref": [ "r107" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions", "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r795" ] }, "us-gaap_DistributedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DistributedEarnings", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails": { "parentTag": "us-gaap_UndistributedEarningsDiluted", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Series A Preferred Cumulative Dividends", "label": "Distributed Earnings", "documentation": "The total amount of dividends declared in the period for each class of stock and the contractual amount of dividends (or interest on participating income bonds) that must be paid for the period (for example, unpaid cumulative dividends). Dividends declared in the current period do not include dividends declared in respect of prior-period unpaid cumulative dividends. Preferred dividends that are cumulative only if earned are deducted only to the extent that they are earned." } } }, "auth_ref": [ "r245" ] }, "us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesAndExciseTaxPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excise taxes payable", "label": "Sales and Excise Tax Payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax." } } }, "auth_ref": [ "r107" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "us-gaap_UndistributedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UndistributedEarnings", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Undistributed net earnings, basic", "label": "Undistributed Earnings, Basic", "documentation": "The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed." } } }, "auth_ref": [ "r246", "r249" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r798" ] }, "us-gaap_UndistributedEarningsDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UndistributedEarningsDiluted", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Undistributed net loss, dilutive", "label": "Undistributed Earnings, Diluted", "documentation": "The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed. Includes the adjustments resulting from the assumption that dilutive securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r18", "r115", "r116", "r148", "r621", "r688", "r706", "r754" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted weighted average common units outstanding (in shares)", "verboseLabel": "Weighted average shares for diluted loss per share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r238", "r251" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26", "r743" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares for basic loss per share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r236", "r251" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical", "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r131", "r214", "r326", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r486", "r895" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r222", "r223", "r224", "r256", "r556", "r609", "r632", "r635", "r636", "r637", "r638", "r639", "r640", "r642", "r645", "r646", "r647", "r648", "r649", "r652", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r663", "r666", "r667", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r688", "r748" ] }, "aonc_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestBeforeRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestBeforeRecapitalization", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "aonc_ComprehensiveIncomeLossNetOfTaxAttributableToCommonStockholders", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) attributable to Legacy AON Shareholders", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization", "documentation": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization" } } }, "auth_ref": [] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilution feature at fair value", "label": "Derivative, Fair Value, Net", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": [ "r485" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r18", "r115", "r116", "r148", "r610", "r688", "r706" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r769", "r780", "r790", "r815" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r762", "r773", "r783", "r808" ] }, "us-gaap_CustomerRefundLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRefundLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refund liability", "label": "Customer Refund Liability, Current", "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment." } } }, "auth_ref": [] }, "aonc_IncreaseDecreaseInAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "IncreaseDecreaseInAdvances", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare advance payments", "label": "Increase (Decrease) In Advances", "documentation": "Increase (Decrease) In Advances" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r761", "r772", "r782", "r807" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r50" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r763", "r774", "r784", "r809" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.aoncology.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r910" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r761", "r772", "r782", "r807" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Price Volatility", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r906" ] }, "aonc_DTOCSponsorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DTOCSponsorMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DTOC Sponsor", "label": "DTOC Sponsor [Member]", "documentation": "DTOC Sponsor" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive shares excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r252" ] }, "aonc_AlternateBaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "AlternateBaseRateMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alternate Base Rate", "label": "Alternate Base Rate [Member]", "documentation": "Alternate Base Rate" } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationEquityConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ReverseRecapitalizationEquityConversionRatio", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse recapitalization, equity conversion ratio", "label": "Reverse Recapitalization, Equity Conversion Ratio", "documentation": "Reverse Recapitalization, Equity Conversion Ratio" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share of Class A Common Stock:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r767", "r778", "r788", "r813" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r764", "r775", "r785", "r810" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Risk Free Interest Rate", "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r906" ] }, "aonc_StockholdersEquityConversionNumberOfDaysAfterFiveYearAnniversary": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockholdersEquityConversionNumberOfDaysAfterFiveYearAnniversary", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of days after five year anniversary", "label": "Stockholders' Equity, Conversion, Number Of Days After Five Year Anniversary", "documentation": "Stockholders' Equity, Conversion, Number Of Days After Five Year Anniversary" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ReverseRecapitalizationDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/ReverseCapitalization" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Recapitalization", "label": "Reverse Recapitalization Disclosure [Text Block]", "documentation": "Reverse Recapitalization Disclosure" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r136" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r116", "r119", "r120", "r142", "r644", "r662", "r689", "r690", "r743", "r755", "r861", "r885", "r908", "r923" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r323", "r324", "r325" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r764", "r775", "r785", "r810" ] }, "aonc_LondonInterbankOfferedRateLIBOR1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LondonInterbankOfferedRateLIBOR1Member", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "London Interbank Offered Rate (LIBOR) 1", "label": "London Interbank Offered Rate (LIBOR) 1 [Member]", "documentation": "London Interbank Offered Rate (LIBOR) 1" } } }, "auth_ref": [] }, "aonc_A2023NotesReceivableNote9Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "A2023NotesReceivableNote9Member", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note 9", "label": "2023 Notes Receivable, Note 9 [Member]", "documentation": "2023 Notes Receivable, Note 9" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r765", "r776", "r786", "r811" ] }, "us-gaap_PaymentsToAcquireNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireNotesReceivable", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Issuance of notes receivable - related parties", "label": "Payments to Acquire Notes Receivable", "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [ "r39" ] }, "aonc_CapitalUnitClassA1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "CapitalUnitClassA1Member", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Unit, Class A-1", "label": "Capital Unit, Class A-1 [Member]", "documentation": "Capital Unit, Class A-1" } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r766", "r777", "r787", "r812" ] }, "aonc_MedicalEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "MedicalEquipmentMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical equipment", "label": "Medical Equipment [Member]", "documentation": "Medical Equipment" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share." } } }, "auth_ref": [ "r49", "r52", "r239", "r240", "r248" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Equity in loss of affiliate", "negatedTerseLabel": "Equity in loss of affiliate", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r10", "r126", "r163", "r267", "r322", "r586" ] }, "aonc_ProceedsFromIssuanceOfRedeemableConvertibleStockNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ProceedsFromIssuanceOfRedeemableConvertibleStockNet", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance of redeemable convertible stock", "label": "Proceeds From Issuance Of Redeemable Convertible Stock, Net", "documentation": "Proceeds From Issuance Of Redeemable Convertible Stock, Net" } } }, "auth_ref": [] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r157", "r186", "r578", "r755" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r50" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r768", "r779", "r789", "r814" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r768", "r779", "r789", "r806", "r814" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r10", "r150", "r175", "r455", "r456", "r862" ] }, "aonc_A2025NotesReceivableNote8Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "A2025NotesReceivableNote8Member", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note 8", "label": "2025 Notes Receivable, Note 8 [Member]", "documentation": "2025 Notes Receivable, Note 8" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.aoncology.com/role/BusinessCombinationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r75", "r76", "r460", "r738", "r739" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r50", "r51" ] }, "aonc_DebtInstrumentCollateralReleasedQuarterly": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DebtInstrumentCollateralReleasedQuarterly", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quarterly collateral released", "label": "Debt Instrument, Collateral Released, Quarterly", "documentation": "Debt Instrument, Collateral Released, Quarterly" } } }, "auth_ref": [] }, "aonc_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodNumberOfMonthsAfterClosing": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodNumberOfMonthsAfterClosing", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnout period, number of months after closing (in months)", "label": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Number Of Months After Closing", "documentation": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Number Of Months After Closing" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesDetails": { "parentTag": "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents, aggregate fair value", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.aoncology.com/role/BusinessCombinationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r460", "r738", "r739" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11" ] }, "aonc_ScheduleOfOtherAccruedLiabilitiesCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ScheduleOfOtherAccruedLiabilitiesCurrentTableTextBlock", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Accrued Liabilities, Current", "label": "Schedule Of Other Accrued Liabilities, Current [Table Text Block]", "documentation": "Schedule Of Other Accrued Liabilities, Current" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.aoncology.com/role/LongtermDebt" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r144" ] }, "aonc_DebtInstrumentThresholdLimitPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DebtInstrumentThresholdLimitPeriodAxis", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Threshold Limit, Period [Axis]", "label": "Debt Instrument, Threshold Limit, Period [Axis]", "documentation": "Debt Instrument, Threshold Limit, Period" } } }, "auth_ref": [] }, "aonc_CommonUnitValueImpactOfTheReverseRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "CommonUnitValueImpactOfTheReverseRecapitalization", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of the Reverse Recapitalization", "label": "Common Unit, Value, Impact Of The Reverse Recapitalization", "documentation": "Common Unit, Value, Impact Of The Reverse Recapitalization" } } }, "auth_ref": [] }, "us-gaap_StockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockDividendsShares", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class A-1 distribution (in shares)", "label": "Stock Dividends, Shares", "documentation": "Number of shares of common and preferred stock issued as dividends during the period. Excludes stock splits." } } }, "auth_ref": [ "r18" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r768", "r779", "r789", "r814" ] }, "aonc_ReverseRecapitalizationDeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ReverseRecapitalizationDeferredOfferingCosts", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Unpaid offering costs relating to the reverse recapitalization", "label": "Reverse Recapitalization, Deferred Offering Costs", "documentation": "Reverse Recapitalization, Deferred Offering Costs" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.aoncology.com/role/BusinessCombinationsDetails", "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r75", "r76", "r460" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "aonc_ComprehensiveIncomeLossNetOfTaxAttributableToCommonStockholders", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r7", "r79", "r89", "r198", "r200", "r206", "r572", "r592" ] }, "aonc_NumberOfOfficesWithOperatingLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "NumberOfOfficesWithOperatingLeases", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of offices with operating lease", "label": "Number Of Offices With Operating Leases", "documentation": "Number Of Offices With Operating Leases" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.aoncology.com/role/BusinessCombinationsDetails", "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r460" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r768", "r779", "r789", "r814" ] }, "aonc_AdjustmentsToAdditionalPaidInCapitalRecapitalizationTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "AdjustmentsToAdditionalPaidInCapitalRecapitalizationTransactionCosts", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to APIC, transaction costs", "label": "Adjustments to Additional Paid in Capital, Recapitalization, Transaction Costs", "documentation": "Adjustments to Additional Paid in Capital, Recapitalization, Transaction Costs" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r363", "r401", "r402", "r403", "r404", "r405", "r406", "r526", "r527", "r528", "r730", "r731", "r735", "r736", "r737" ] }, "aonc_CashFlowLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "CashFlowLesseeAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:", "label": "Cash Flow, Lessee [Abstract]", "documentation": "Cash Flow, Lessee" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, measurement input", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r482" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r128", "r370", "r494", "r858" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r768", "r779", "r789", "r814" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.aoncology.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate (in percent)", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r447" ] }, "aonc_OCPManagementArizonaLLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "OCPManagementArizonaLLPMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OCP Management Arizona, LLP", "label": "OCP Management Arizona, LLP [Member]", "documentation": "OCP Management Arizona, LLP" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r768", "r779", "r789", "r814" ] }, "aonc_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodPercentageOfStockSubjectToVestingConditions": { "xbrltype": "pureItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodPercentageOfStockSubjectToVestingConditions", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of stock subject to vesting (in percent)", "label": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Percentage Of Stock Subject To Vesting Conditions", "documentation": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, PErcentage Of Stock Subject To Vesting Conditions" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "aonc_ComprehensiveIncomeLossNetOfTaxAttributableToCommonStockholders", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r89", "r153", "r198", "r200", "r205", "r571", "r591" ] }, "aonc_OtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestBeforeRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "OtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestBeforeRecapitalization", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Other Comprehensive Income", "label": "Other Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization", "documentation": "Other Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r74" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "aonc_PrivatePlacementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "PrivatePlacementWarrantsMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement Warrants", "label": "Private Placement Warrants [Member]", "documentation": "Private Placement Warrants" } } }, "auth_ref": [] }, "aonc_TemporaryEquityValueReverseRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "TemporaryEquityValueReverseRecapitalization", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Recapitalization, net", "label": "Temporary Equity, Value, Reverse Recapitalization", "documentation": "Temporary Equity, Value, Reverse Recapitalization" } } }, "auth_ref": [] }, "aonc_NumberOfBoardOfManagersDesignatedByMajorityCommonUnitHolders": { "xbrltype": "integerItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "NumberOfBoardOfManagersDesignatedByMajorityCommonUnitHolders", "presentation": [ "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of board of managers designated by majority common unit holders", "label": "Number Of Board Of Managers Designated By Majority Common Unit Holders", "documentation": "Number Of Board Of Managers Designated By Majority Common Unit Holders" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r50" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r759" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r222", "r223", "r224", "r256", "r556", "r609", "r632", "r635", "r636", "r637", "r638", "r639", "r640", "r642", "r645", "r646", "r647", "r648", "r649", "r652", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r663", "r666", "r667", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r688", "r748" ] }, "aonc_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnout period (in years)", "label": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period", "documentation": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "aonc_PublicAndPrivateWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "PublicAndPrivateWarrantsMember", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails", "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public and Private Warrants", "label": "Public And Private Warrants [Member]", "documentation": "Public And Private Warrants" } } }, "auth_ref": [] }, "aonc_LesseeFinanceLeaseLeaseNotYetCommencedLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LesseeFinanceLeaseLeaseNotYetCommencedLiability", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leases not yet commenced, future commitments", "label": "Lessee, Finance Lease, Lease Not Yet Commenced, Liability", "documentation": "Lessee, Finance Lease, Lease Not Yet Commenced, Liability" } } }, "auth_ref": [] }, "aonc_LimitedLiabilityCompanyLLCUnitsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LimitedLiabilityCompanyLLCUnitsOutstanding", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in units)", "periodEndLabel": "Ending balance (in units)", "label": "Limited Liability Company (LLC), Units, Outstanding", "documentation": "Limited Liability Company (LLC), Units, Outstanding" } } }, "auth_ref": [] }, "us-gaap_CommonUnitIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitIssued", "calculation": { "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails": { "parentTag": "aonc_LimitedLiabilityCompanyLLCUnitsIssued", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of units (in units)", "terseLabel": "Common Units issued (in units)", "label": "Common Unit, Issued", "documentation": "Number of common units issued of limited liability company (LLC)." } } }, "auth_ref": [ "r148" ] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Series A Deemed Dividend", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r6", "r148" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r792" ] }, "aonc_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMinorityShareholders", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Contribution from noncontrolling interest", "label": "Proceeds from Noncontrolling Interests", "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership." } } }, "auth_ref": [ "r41" ] }, "aonc_PhysiciansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "PhysiciansMember", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Physician Owned", "label": "Physicians [Member]", "documentation": "Physician Owned" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetIncludingGoodwill", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and intangibles, net", "label": "Intangible Assets, Net (Including Goodwill)", "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance." } } }, "auth_ref": [] }, "us-gaap_CommonUnitAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitAuthorized", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common unit authorized (in units)", "label": "Common Unit, Authorized", "documentation": "Maximum number of common units of ownership permitted to be issued by a limited liability company (LLC)." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r93", "r94", "r95", "r96", "r633", "r634", "r647", "r648", "r649", "r652", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r676", "r677", "r678", "r679", "r682", "r683", "r684", "r685", "r700", "r701", "r702", "r703", "r721", "r745", "r747" ] }, "aonc_SponsorEarnoutSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "SponsorEarnoutSharesMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sponsor Earnout Shares", "label": "Sponsor Earnout Shares [Member]", "documentation": "Sponsor Earnout Shares" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of redeemable convertible Class C Units", "verboseLabel": "Proceeds from issuance of redeemable preferred stock", "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock", "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder." } } }, "auth_ref": [ "r5" ] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesCPreferredStockMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series C Preferred Stock", "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": [ "r850", "r851", "r900" ] }, "aonc_OptionFeatureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "OptionFeatureMember", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Feature", "label": "Option Feature [Member]", "documentation": "Option Feature" } } }, "auth_ref": [] }, "us-gaap_CommonUnitOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitOutstanding", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common unit, units outstanding (in units)", "periodStartLabel": "Beginning balance (in units)", "periodEndLabel": "Ending balance (in units)", "label": "Common Unit, Outstanding", "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC)." } } }, "auth_ref": [] }, "aonc_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU assets obtained in exchange for new lease liabilities", "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r831" ] }, "aonc_OralPharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "OralPharmaceuticalsMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oral pharmaceuticals", "label": "Oral Pharmaceuticals [Member]", "documentation": "Oral Pharmaceuticals" } } }, "auth_ref": [] }, "us-gaap_CommonUnitIssuanceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitIssuanceValue", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_MembersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common unit, value", "periodStartLabel": "Beginning of Period", "periodEndLabel": "End of Period", "label": "Common Unit, Issuance Value", "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC)." } } }, "auth_ref": [] }, "aonc_AdjustmentsToAdditionalPaidInCapitalFairValueAdjustmentRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "AdjustmentsToAdditionalPaidInCapitalFairValueAdjustmentRedeemableNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value adjustment to redeemable noncontrolling interest", "negatedTerseLabel": "Fair value adjustment to redeemable noncontrolling interest", "label": "Adjustments To Additional Paid In Capital, Fair Value Adjustment, Redeemable Noncontrolling Interest", "documentation": "Adjustments To Additional Paid In Capital, Fair Value Adjustment, Redeemable Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings (deficit)", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r118", "r148", "r583", "r605", "r607", "r614", "r643", "r743" ] }, "aonc_ParticipatingThresholdAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ParticipatingThresholdAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Participating Threshold [Axis]", "label": "Participating Threshold [Axis]", "documentation": "Participating Threshold" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings on long-term debt", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r42", "r610" ] }, "aonc_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerAllocationOfLosses": { "xbrltype": "pureItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerAllocationOfLosses", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allocation of losses to controlling and noncontrolling interests (in percent)", "label": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Losses", "documentation": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Losses" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from lines of credit", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r42", "r860" ] }, "aonc_ParticipatingThreshold2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ParticipatingThreshold2Member", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Participating Threshold, 2", "label": "Participating Threshold, 2 [Member]", "documentation": "Participating Threshold, 2" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from facility", "label": "Proceeds from Long-Term Lines of Credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r42" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A Preferred Stock", "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r850", "r851", "r900" ] }, "aonc_BloombergShortTermBankYieldIndexMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "BloombergShortTermBankYieldIndexMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bloomberg Short-Term Bank Yield Index", "label": "Bloomberg Short-Term Bank Yield Index [Member]", "documentation": "Bloomberg Short-Term Bank Yield Index" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r54", "r56", "r98", "r99", "r285", "r713", "r837" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "aonc_ScheduleOfOtherReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ScheduleOfOtherReceivablesTableTextBlock", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Receivables", "label": "Schedule Of Other Receivables [Table Text Block]", "documentation": "Schedule Of Other Receivables" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire interest in subsidiary", "label": "Payments to Acquire Interest in Subsidiaries and Affiliates", "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity)." } } }, "auth_ref": [ "r40" ] }, "aonc_FinancingReceivableBorrowingRate": { "xbrltype": "percentItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "FinancingReceivableBorrowingRate", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental borrowing rate", "label": "Financing Receivable, Borrowing Rate", "documentation": "Financing Receivable, Borrowing Rate" } } }, "auth_ref": [] }, "aonc_TemporaryEquitySharesReverseRecapitalization": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "TemporaryEquitySharesReverseRecapitalization", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Recapitalization, net (in shares)", "label": "Temporary Equity, Shares, Reverse Recapitalization", "documentation": "Temporary Equity, Shares, Reverse Recapitalization" } } }, "auth_ref": [] }, "us-gaap_OtherSundryLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherSundryLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Sundry Liabilities, Current", "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date." } } }, "auth_ref": [ "r30", "r60" ] }, "aonc_DividendsPaidEventPriorToJune72026AfterJune72025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DividendsPaidEventPriorToJune72026AfterJune72025Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Paid, Event Prior to June 7, 2026, After June 7, 2025", "label": "Dividends Paid, Event Prior to June 7, 2026, After June 7, 2025 [Member]", "documentation": "Dividends Paid, Event Prior to June 7, 2026, After June 7, 2025" } } }, "auth_ref": [] }, "aonc_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodNumberOfSharesSubjectToVestingConditions": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodNumberOfSharesSubjectToVestingConditions", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares subject to vesting (in shares)", "label": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Number Of Shares Subject To Vesting Conditions", "documentation": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Number Of Shares Subject To Vesting Conditions" } } }, "auth_ref": [] }, "aonc_TemporaryEquityPurchasePriceOfAdditionalUnits": { "xbrltype": "perShareItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "TemporaryEquityPurchasePriceOfAdditionalUnits", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price of additional units (in dollars per share)", "label": "Temporary Equity, Purchase Price Of Additional Units", "documentation": "Temporary Equity, Purchase Price Of Additional Units" } } }, "auth_ref": [] }, "aonc_CommonUnitUnitsIssuedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "CommonUnitUnitsIssuedValue", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Units", "label": "Common Unit, Units Issued, Value", "documentation": "Common Unit, Units Issued, Value" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r371", "r387", "r475", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r590", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r881", "r882", "r883", "r884" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r826" ] }, "us-gaap_InventoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryLineItems", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Line Items]", "label": "Inventory [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.aoncology.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r496" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_InventoryCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryCurrentTable", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Current [Table]", "label": "Inventory, Current [Table]", "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash paid for debt financing costs", "label": "Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r43" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/BusinessCombinationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price (less than)", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r14" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r827" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical", "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party, Type [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r407", "r517", "r518", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r636", "r637", "r638", "r639", "r640", "r661", "r663", "r696", "r912" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r834", "r849", "r889" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r826" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated depreciation and amortization", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease." } } }, "auth_ref": [ "r835", "r838", "r890" ] }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Mezzanine equity", "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 }, "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r838", "r888" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r828" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r827" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r211" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r633", "r634", "r647", "r648", "r649", "r652", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r676", "r677", "r678", "r679", "r682", "r683", "r684", "r685", "r700", "r701", "r702", "r703", "r745", "r747" ] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.aoncology.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r496" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r211" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used) provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r137", "r138", "r139" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r323", "r324", "r325" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r29", "r214", "r326", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r464", "r467", "r468", "r486", "r641", "r725", "r755", "r895", "r913", "r914" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r829" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r760", "r830" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r760", "r830" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails": { "parentTag": "us-gaap_UndistributedEarningsDiluted", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Class A Common Stockholders, Diluted", "verboseLabel": "Net loss attributable to Class A Common Stockholders for diluted loss per share", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r208", "r238", "r241", "r242", "r243", "r244", "r247", "r251" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r517", "r518", "r912" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r760", "r830" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities, mezzanine equity, and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r121", "r162", "r585", "r743", "r861", "r885", "r908" ] }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r107", "r916" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, Mezzanine Equity, and Stockholders' Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class A and A-1 preferred returns and tax distributions", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r44" ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r481" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: amount representing interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r512" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r498" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 3.0 }, "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) before noncontrolling interest", "terseLabel": "Net income (loss) before noncontrolling interest", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r182", "r196", "r199", "r210", "r214", "r225", "r233", "r234", "r261", "r276", "r280", "r282", "r326", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r462", "r465", "r466", "r479", "r486", "r574", "r587", "r620", "r664", "r686", "r687", "r726", "r740", "r741", "r754", "r856", "r895" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.aoncology.com/role/NetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r235", "r252", "r253", "r254" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": "aonc_FinanceAndOperatingLeaseLiabilityCurrent", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails", "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liabilities", "negatedLabel": "Less: current portion of lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r498" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r794" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r215", "r443", "r448", "r449", "r450", "r453", "r457", "r458", "r459", "r615" ] }, "us-gaap_PreferredUnitsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredUnitsIssued", "calculation": { "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails": { "parentTag": "aonc_LimitedLiabilityCompanyLLCUnitsIssued", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A Preferred Units Issued", "label": "Preferred Units, Issued", "documentation": "The number of preferred units issued." } } }, "auth_ref": [ "r149" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r796" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": "aonc_LeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails", "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term operating lease liabilities", "terseLabel": "Long-term lease liabilities, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r498" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to noncontrolling interest", "negatedTerseLabel": "Net loss attributable to noncontrolling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r88", "r155", "r196", "r199", "r233", "r234", "r588", "r856" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r794" ] }, "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allocation of income to controlling and noncontrolling interests", "label": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Ownership Interest", "documentation": "Percentage investment held by the managing member or general partner of the limited liability company (LLC) or limited partnership (LP)." } } }, "auth_ref": [ "r53" ] }, "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest", "label": "Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest", "documentation": "Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP)." } } }, "auth_ref": [ "r53" ] }, "us-gaap_PreferredUnitsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredUnitsOutstanding", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred units, outstanding (in units)", "label": "Preferred Units, Outstanding", "documentation": "The number of preferred units outstanding." } } }, "auth_ref": [ "r149" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r757" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails", "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails", "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on sale of property and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": [ "r858", "r887", "r891" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Expected Term", "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r906" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Expected Dividend Rate", "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r906" ] }, "aonc_DTOCUnredeemedShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DTOCUnredeemedShareholdersMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DTOC Unredeemed Shareholders", "label": "DTOC Unredeemed Shareholders [Member]", "documentation": "DTOC Unredeemed Shareholders" } } }, "auth_ref": [] }, "aonc_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestBeforeRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestBeforeRecapitalization", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) and noncontrolling interest attributable to Legacy AON Shareholders prior to the reverse recapitalization", "verboseLabel": "Net Income attributable to Legacy AON Shareholders", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Before Recapitalization", "documentation": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Before Recapitalization" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation related costs", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r30" ] }, "aonc_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "CashAndCashEquivalentsAcquiredThroughReverseRecapitalization", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/ReverseCapitalizationScheduleofHistoricalCostDetails": { "parentTag": "aonc_ReverseRecapitalizationNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/ReverseCapitalizationScheduleofHistoricalCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash And Cash Equivalents Acquired Through Reverse Recapitalization", "documentation": "Cash And Cash Equivalents Acquired Through Reverse Recapitalization" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesIssued", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Temporary Equity, Shares Issued", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r114" ] }, "aonc_RebatesReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "RebatesReceivableCurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails": { "parentTag": "us-gaap_OtherReceivablesNetCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rebates receivable", "label": "Rebates Receivable, Current", "documentation": "Rebates Receivable, Current" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical", "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party, Type [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r407", "r517", "r518", "r636", "r637", "r638", "r639", "r640", "r661", "r663", "r696" ] }, "aonc_ReverseRecapitalizationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ReverseRecapitalizationAbstract", "lang": { "en-us": { "role": { "label": "Reverse Recapitalization [Abstract]", "documentation": "Reverse Recapitalization" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436" ] }, "aonc_NoncurrentLiabilitiesAssumedInReverseRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "NoncurrentLiabilitiesAssumedInReverseRecapitalization", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/ReverseCapitalizationScheduleofHistoricalCostDetails": { "parentTag": "aonc_ReverseRecapitalizationNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/ReverseCapitalizationScheduleofHistoricalCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Long Term Liabilities", "label": "Noncurrent Liabilities Assumed In Reverse Recapitalization", "documentation": "Noncurrent Liabilities Assumed In Reverse Recapitalization" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesDetails_1": { "parentTag": "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/MarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized \u2028Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r292", "r335", "r577" ] }, "us-gaap_TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesAuthorized", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares authorized (shares)", "label": "Temporary Equity, Shares Authorized", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r114" ] }, "aonc_LesseeFinanceLeaseLeaseNotYetCommencedNumberOfLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LesseeFinanceLeaseLeaseNotYetCommencedNumberOfLeases", "presentation": [ "http://www.aoncology.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease not yet commenced, number of leases", "label": "Lessee, Finance Lease, Lease Not yet Commenced, Number of Leases", "documentation": "Lessee, Finance Lease, Lease Not yet Commenced, Number of Leases" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable convertible preferred stock, shares outstanding (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "periodEndLabel": "Ending Balance (in shares)", "label": "Temporary Equity, Shares Outstanding", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r114" ] }, "aonc_DescriptionOfBusinessAndSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DescriptionOfBusinessAndSignificantAccountingPoliciesLineItems", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description Of Business And Significant Accounting Policies [Line Items]", "label": "Description Of Business And Significant Accounting Policies [Line Items]", "documentation": "Description Of Business And Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ReverseRecapitalizationExpenses", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse recapitalization costs", "label": "Reverse Recapitalization Expenses", "documentation": "Reverse Recapitalization Expenses" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) attributable to common shareholders", "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders." } } }, "auth_ref": [ "r237", "r251" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r339", "r340", "r341", "r342", "r343", "r344", "r345" ] }, "aonc_BusinessAcquisitionUnwindAgreementLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "BusinessAcquisitionUnwindAgreementLiability", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/BusinessCombinationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unwind agreement, liability", "label": "Business Acquisition, Unwind Agreement, Liability", "documentation": "Business Acquisition, Unwind Agreement, Liability" } } }, "auth_ref": [] }, "aonc_LesseeAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LesseeAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.aoncology.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Assets And Liabilities", "label": "Lessee, Assets And Liabilities [Table Text Block]", "documentation": "Lessee, Assets And Liabilities" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r185" ] }, "aonc_PatientServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "PatientServiceMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Patient service revenue, net", "label": "Patient Service [Member]", "documentation": "Patient Service" } } }, "auth_ref": [] }, "aonc_LeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LeaseLiabilityAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Lease, Liability [Abstract]", "documentation": "Lease, Liability" } } }, "auth_ref": [] }, "aonc_OtherMiscellaneousReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "OtherMiscellaneousReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails": { "parentTag": "us-gaap_OtherReceivablesNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Miscellaneous Receivables, Net, Current", "documentation": "Other Miscellaneous Receivables, Net, Current" } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r194", "r718", "r743" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r269", "r270", "r271", "r272", "r273", "r274", "r284", "r727" ] }, "aonc_AONLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "AONLLCMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AON LLC", "label": "AON LLC [Member]", "documentation": "AON LLC" } } }, "auth_ref": [] }, "aonc_RedeemableNoncontrollingInterestEquityFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "RedeemableNoncontrollingInterestEquityFairValueAdjustment", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value adjustment to redeemable noncontrolling interest", "label": "Redeemable Noncontrolling Interest, Equity, Fair Value Adjustment", "documentation": "Redeemable Noncontrolling Interest, Equity, Fair Value Adjustment" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Estimates and Assumptions", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r57", "r58", "r59", "r171", "r172", "r173", "r174" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued other", "totalLabel": "Accrued other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r30" ] }, "aonc_DebtInstrumentMinimumFundingThresholdPercentage": { "xbrltype": "pureItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DebtInstrumentMinimumFundingThresholdPercentage", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum funding threshold (in percent)", "label": "Debt Instrument, Minimum Funding Threshold, Percentage", "documentation": "Debt Instrument, Minimum Borrowing Threshold, Percentage" } } }, "auth_ref": [] }, "aonc_NumberOfOncologyPractices": { "xbrltype": "integerItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "NumberOfOncologyPractices", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of oncology practices", "label": "Number Of Oncology Practices", "documentation": "Number Of Oncology Practices" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-Sale Securities, Debt Maturities [Abstract]", "label": "Available-for-Sale Securities, Debt Maturities [Abstract]" } } }, "auth_ref": [] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r796" ] }, "aonc_ClinicalTrialsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ClinicalTrialsMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Trials", "label": "Clinical Trials [Member]", "documentation": "Clinical Trials" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unused line fee (in percent)", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Excise taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "aonc_AEAGrowthManagementLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "AEAGrowthManagementLPMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AEA Growth Management LP", "label": "AEA Growth Management LP [Member]", "documentation": "AEA Growth Management LP" } } }, "auth_ref": [] }, "aonc_ParticipatingThreshold3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ParticipatingThreshold3Member", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Participating Threshold, 3", "label": "Participating Threshold, 3 [Member]", "documentation": "Participating Threshold, 3" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesLeaseCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease costs", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r504", "r742" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "aonc_ScheduleOfReverseRecapitalizationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ScheduleOfReverseRecapitalizationTableTextBlock", "presentation": [ "http://www.aoncology.com/role/ReverseCapitalizationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reverse Recapitalization", "label": "Schedule Of Reverse Recapitalization [Table Text Block]", "documentation": "Schedule Of Reverse Recapitalization" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails", "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r668", "r669", "r672" ] }, "aonc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedUponConsummationOfBusinessCombination": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedUponConsummationOfBusinessCombination", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units vested upon consummation of business combination (in units)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested Upon Consummation Of Business Combination", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested Upon Consummation Of Business Combination" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bank fee (in percent)", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/RelatedParties" ], "lang": { "en-us": { "role": { "terseLabel": "Related Parties", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r514", "r515", "r516", "r518", "r521", "r616", "r617", "r618", "r670", "r671", "r672", "r693", "r695" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r797" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r506", "r742" ] }, "aonc_ComprehensiveIncomeLossNetOfTaxAttributableToCommonStockholders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ComprehensiveIncomeLossNetOfTaxAttributableToCommonStockholders", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive Income (Loss), Net Of Tax, Attributable To Common Stockholders", "label": "Comprehensive Income (Loss), Net Of Tax, Attributable To Common Stockholders", "documentation": "Comprehensive Income (Loss), Net Of Tax, Attributable To Common Stockholders" } } }, "auth_ref": [] }, "aonc_ClassOfWarrantOrRightOutstandingExercisePeriodAfterBusinessCombination": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ClassOfWarrantOrRightOutstandingExercisePeriodAfterBusinessCombination", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant, exercise period, after business combination", "label": "Class Of Warrant Or Right Outstanding, Exercise Period, After Business Combination", "documentation": "Class Of Warrant Or Right Outstanding, Exercise Period, After Business Combination" } } }, "auth_ref": [] }, "aonc_LeaseRightOfUseAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LeaseRightOfUseAssetAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Lease, Right-Of-Use Asset [Abstract]", "documentation": "Lease, Right-Of-Use Asset" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Accounting Pronouncements\u00a0 and Recently Issued Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/Equity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r145", "r213", "r374", "r376", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r388", "r390", "r476", "r691", "r694", "r711" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r13", "r20" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "aonc_IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before income taxes, equity loss in affiliate, and noncontrolling interest", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r261", "r276", "r280", "r282", "r594", "r726" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Total revenue", "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r262", "r263", "r275", "r278", "r279", "r283", "r284", "r285", "r399", "r400", "r556" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity", "http://www.aoncology.com/role/Cover", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r178", "r189", "r190", "r191", "r214", "r239", "r240", "r248", "r251", "r259", "r260", "r326", "r346", "r348", "r349", "r350", "r353", "r354", "r375", "r376", "r379", "r382", "r389", "r486", "r610", "r611", "r612", "r613", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r642", "r665", "r688", "r705", "r706", "r707", "r708", "r709", "r833", "r859", "r867" ] }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Variable Interest Entities", "label": "Schedule of Variable Interest Entities [Table Text Block]", "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": [ "r82", "r83", "r84", "r85", "r86" ] }, "us-gaap_VariableInterestEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityLineItems", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity [Line Items]", "label": "Variable Interest Entity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r463", "r464", "r467", "r468", "r537", "r538", "r539" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r795" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r261", "r276", "r280", "r282", "r726" ] }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Variable Interest Entities [Table]", "label": "Schedule of Variable Interest Entities [Table]", "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": [ "r82", "r83", "r84", "r85", "r86", "r463", "r464", "r467", "r468", "r537", "r538", "r539" ] }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity, Primary Beneficiary", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": [ "r82", "r463", "r464", "r467", "r468" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntities" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Variable Interest Entity Disclosure [Text Block]", "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss." } } }, "auth_ref": [ "r152" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r218", "r219", "r358", "r377", "r520", "r719", "r721" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": "aonc_LeaseRightOfUseAsset", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Operating lease right-of-use assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r497" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r183", "r195", "r214", "r326", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r463", "r467", "r486", "r743", "r895", "r896", "r913" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Patient accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r9" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableMember", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable", "label": "Accounts Payable [Member]", "documentation": "Obligations incurred and payable to vendors for goods and services received." } } }, "auth_ref": [ "r21" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": "aonc_LeaseRightOfUseAsset", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease right-of-use assets, net (included in property and equipment, net)", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r497" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r745", "r746", "r749", "r750", "r751", "r752" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "aonc_CurrentLiabilitiesAssumedInReverseRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "CurrentLiabilitiesAssumedInReverseRecapitalization", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/ReverseCapitalizationScheduleofHistoricalCostDetails": { "parentTag": "aonc_ReverseRecapitalizationNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/ReverseCapitalizationScheduleofHistoricalCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Current Liabilities", "label": "Current Liabilities Assumed In Reverse Recapitalization", "documentation": "Current Liabilities Assumed In Reverse Recapitalization" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (in percentage)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r54", "r56", "r98", "r99", "r285" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "aonc_A2023NotesReceivableNote6Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "A2023NotesReceivableNote6Member", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note 6", "label": "2023 Notes Receivable, Note 6 [Member]", "documentation": "2023 Notes Receivable, Note 6" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r32" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r117", "r743", "r921" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating \u2028Lease", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r769", "r780", "r790", "r815" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r177", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r715" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r817" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r770", "r781", "r791", "r816" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: amount representing interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r512" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Present value of lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r498", "r512" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class C Units, net of offering costs", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "documentation": "Value of new stock classified as temporary equity issued during the period." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": "aonc_FinanceAndOperatingLeaseLiabilityCurrent", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails", "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails", "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: current portion of lease liabilities", "verboseLabel": "Current portion of finance lease liabilities (included in accrued other)", "negatedTerseLabel": "Less: current portion of lease liabilities", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r498" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r745", "r746", "r747", "r749", "r750", "r751", "r752", "r864", "r865", "r905", "r920", "r923" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction-in-progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r512" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r817" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsTotalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsTotalMember", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Goods and Service Benchmark", "label": "Cost of Goods and Service Benchmark [Member]", "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r836" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r817" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": "aonc_LeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails", "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term finance lease liabilities (included in other long-term liabilities)", "terseLabel": "Long-term lease liabilities, net of current portion", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r498" ] }, "us-gaap_CommonClassCMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassCMember", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class C", "label": "Common Class C [Member]", "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation." } } }, "auth_ref": [] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r817" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r868" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r817" ] }, "us-gaap_MembersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MembersEquity", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Members' Equity", "documentation": "Amount of ownership interest in limited liability company (LLC), attributable to the parent entity." } } }, "auth_ref": [ "r148", "r257", "r258", "r259", "r260" ] }, "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "CashCashEquivalentsAndAvailableForSaleDebtSecurities", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesDetails": { "parentTag": "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash and cash equivalents and marketable securities, aggregate fair value", "label": "Cash, Cash Equivalents And Available-For-Sale Debt Securities", "documentation": "Cash, Cash Equivalents And Available-For-Sale Debt Securities" } } }, "auth_ref": [] }, "aonc_RedeemableNoncontrollingInterestEquityExcessOverCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "RedeemableNoncontrollingInterestEquityExcessOverCarryingAmount", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess redeemable noncontrolling interest over carrying amount", "label": "Redeemable Noncontrolling Interest, Equity, Excess Over Carrying Amount", "documentation": "Redeemable Noncontrolling Interest, Equity, Excess Over Carrying Amount" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r512" ] }, "aonc_CommonUnitExcludedFromIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "CommonUnitExcludedFromIssuance", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common unit excluded from issuance (in units)", "label": "Common Unit, Excluded From Issuance", "documentation": "Common Unit, Excluded From Issuance" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r512" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r817" ] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Series A convertible preferred stock; $0.0001 par value; 7,500,000 shares authorized; 6,651,610 issued and outstanding at September 30, 2023, with an aggregate liquidation preference of $66,649,130 at September 30, 2023.", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r346", "r348", "r349", "r350", "r353", "r354", "r441", "r581" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r512" ] }, "us-gaap_DividendsPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPreferredStock", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandMembersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Class A and A-1 preferred returns", "label": "Dividends, Preferred Stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r6", "r148" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r512" ] }, "aonc_LimitedLiabilityCompanyLLCOwnershipThresholdPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LimitedLiabilityCompanyLLCOwnershipThresholdPercentage", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LLC ownership threshold, percentage", "label": "Limited Liability Company (LLC), Ownership Threshold, Percentage", "documentation": "Limited Liability Company (LLC), Ownership Threshold, Percentage" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 (remainder of year after September 30, 2023)", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r911" ] }, "aonc_LeaseLiabilityNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "LeaseLiabilityNoncurrentAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term", "label": "Lease Liability, Noncurrent [Abstract]", "documentation": "Lease Liability, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.aoncology.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, to be Paid, Maturity", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r911" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r868" ] }, "aonc_FinancingReceivableAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "FinancingReceivableAmortizationPeriod", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes receivable, amortization period (in months)", "label": "Financing Receivable, Amortization Period", "documentation": "Financing Receivable, Amortization Period" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r818" ] }, "aonc_DividendsPaidEventPriorToJune72024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DividendsPaidEventPriorToJune72024Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Paid, Event Prior to June 7, 2024", "label": "Dividends Paid, Event Prior to June 7, 2024 [Member]", "documentation": "Dividends Paid, Event Prior to June 7, 2024" } } }, "auth_ref": [] }, "aonc_SubsidiaryUnderCommonControlOfClassA1MemberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "SubsidiaryUnderCommonControlOfClassA1MemberMember", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary Under Common Control of Class A-1 Member", "label": "Subsidiary Under Common Control Of Class A-1 Member [Member]", "documentation": "Subsidiary Under Common Control Of Class A-1 Member" } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationAccruedTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ReverseRecapitalizationAccruedTransactionCosts", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued transaction costs", "label": "Reverse Recapitalization, Accrued Transaction Costs", "documentation": "Reverse Recapitalization, Accrued Transaction Costs" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r143" ] }, "aonc_GainLossOnReverseRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "GainLossOnReverseRecapitalization", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/ReverseCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (Loss) On Reverse Recapitalization", "label": "Gain (Loss) On Reverse Recapitalization", "documentation": "Gain (Loss) On Reverse Recapitalization" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from finance leases", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r502", "r508" ] }, "aonc_StockholdersEquityConversionRightsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "StockholdersEquityConversionRightsAxis", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity, Conversion Right [Axis]", "label": "Stockholders' Equity, Conversion Rights [Axis]", "documentation": "Stockholders' Equity, Conversion Rights" } } }, "auth_ref": [] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r817" ] }, "aonc_DebtInstrumentThresholdLimitPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "DebtInstrumentThresholdLimitPeriodDomain", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Threshold Limit, Period [Domain]", "label": "Debt Instrument, Threshold Limit, Period [Domain]", "documentation": "Debt Instrument, Threshold Limit, Period [Domain]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued dividend rate (in percent)", "label": "Preferred Stock, Dividend Rate, Percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r376", "r697", "r698", "r699", "r704" ] }, "aonc_ParticipatingThreshold1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20230930", "localname": "ParticipatingThreshold1Member", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Participating Threshold, 1", "label": "Participating Threshold, 1 [Member]", "documentation": "Participating Threshold, 1" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r818" ] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on finance lease liabilities (included in interest expense)", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r500", "r505", "r742" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(19)", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(27)", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "24(b)", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "272", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(12)(c)", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(16)(c)", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "14", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "15", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-9" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "66", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-66" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r833": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 82 0001839998-23-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001839998-23-000007-xbrl.zip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�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�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end